0001555280-24-000332.txt : 20241104 0001555280-24-000332.hdr.sgml : 20241104 20241104135213 ACCESSION NUMBER: 0001555280-24-000332 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 96 CONFORMED PERIOD OF REPORT: 20240930 FILED AS OF DATE: 20241104 DATE AS OF CHANGE: 20241104 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Zoetis Inc. CENTRAL INDEX KEY: 0001555280 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 460696167 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-35797 FILM NUMBER: 241422419 BUSINESS ADDRESS: STREET 1: 10 SYLVAN WAY CITY: PARSIPPANY STATE: NJ ZIP: 07054 BUSINESS PHONE: 973-822-7000 MAIL ADDRESS: STREET 1: 10 SYLVAN WAY CITY: PARSIPPANY STATE: NJ ZIP: 07054 10-Q 1 zts-20240930.htm 10-Q zts-20240930
false2024Q3000155528012/31383365308xbrli:sharesiso4217:USDiso4217:USDxbrli:shareszts:geographicRegionzts:countryzts:speciezts:productCategoryzts:product_categoryxbrli:pureiso4217:EURiso4217:DKKiso4217:CHFzts:defendantzts:segment00015552802024-01-012024-09-3000015552802024-10-3100015552802024-07-012024-09-3000015552802023-07-012023-09-3000015552802023-01-012023-09-300001555280us-gaap:CashFlowHedgingMember2024-07-012024-09-300001555280us-gaap:CashFlowHedgingMember2023-07-012023-09-300001555280us-gaap:CashFlowHedgingMember2024-01-012024-09-300001555280us-gaap:CashFlowHedgingMember2023-01-012023-09-300001555280us-gaap:NetInvestmentHedgingMember2024-07-012024-09-300001555280us-gaap:NetInvestmentHedgingMember2023-07-012023-09-300001555280us-gaap:NetInvestmentHedgingMember2024-01-012024-09-300001555280us-gaap:NetInvestmentHedgingMember2023-01-012023-09-3000015552802024-09-3000015552802023-12-310001555280us-gaap:CommonStockMember2024-06-300001555280us-gaap:TreasuryStockCommonMember2024-06-300001555280us-gaap:AdditionalPaidInCapitalMember2024-06-300001555280us-gaap:RetainedEarningsMember2024-06-300001555280us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300001555280us-gaap:NoncontrollingInterestMember2024-06-3000015552802024-06-300001555280us-gaap:RetainedEarningsMember2024-07-012024-09-300001555280us-gaap:NoncontrollingInterestMember2024-07-012024-09-300001555280us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300001555280us-gaap:TreasuryStockCommonMemberzts:ShareRepurchaseProgramMember2024-07-012024-09-300001555280us-gaap:TreasuryStockCommonMember2024-07-012024-09-300001555280us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300001555280us-gaap:CommonStockMember2024-09-300001555280us-gaap:TreasuryStockCommonMember2024-09-300001555280us-gaap:AdditionalPaidInCapitalMember2024-09-300001555280us-gaap:RetainedEarningsMember2024-09-300001555280us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-300001555280us-gaap:NoncontrollingInterestMember2024-09-300001555280us-gaap:CommonStockMember2023-06-300001555280us-gaap:TreasuryStockCommonMember2023-06-300001555280us-gaap:AdditionalPaidInCapitalMember2023-06-300001555280us-gaap:RetainedEarningsMember2023-06-300001555280us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300001555280us-gaap:NoncontrollingInterestMember2023-06-3000015552802023-06-300001555280us-gaap:RetainedEarningsMember2023-07-012023-09-300001555280us-gaap:NoncontrollingInterestMember2023-07-012023-09-300001555280us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300001555280us-gaap:TreasuryStockCommonMemberzts:ShareRepurchaseProgramMember2023-07-012023-09-300001555280us-gaap:TreasuryStockCommonMember2023-07-012023-09-300001555280us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001555280us-gaap:CommonStockMember2023-09-300001555280us-gaap:TreasuryStockCommonMember2023-09-300001555280us-gaap:AdditionalPaidInCapitalMember2023-09-300001555280us-gaap:RetainedEarningsMember2023-09-300001555280us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300001555280us-gaap:NoncontrollingInterestMember2023-09-3000015552802023-09-300001555280us-gaap:CommonStockMember2023-12-310001555280us-gaap:TreasuryStockCommonMember2023-12-310001555280us-gaap:AdditionalPaidInCapitalMember2023-12-310001555280us-gaap:RetainedEarningsMember2023-12-310001555280us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001555280us-gaap:NoncontrollingInterestMember2023-12-310001555280us-gaap:RetainedEarningsMember2024-01-012024-09-300001555280us-gaap:NoncontrollingInterestMember2024-01-012024-09-300001555280us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-09-300001555280us-gaap:TreasuryStockCommonMemberzts:ShareRepurchaseProgramMember2024-01-012024-09-300001555280us-gaap:TreasuryStockCommonMember2024-01-012024-09-300001555280us-gaap:AdditionalPaidInCapitalMember2024-01-012024-09-300001555280us-gaap:CommonStockMember2022-12-310001555280us-gaap:TreasuryStockCommonMember2022-12-310001555280us-gaap:AdditionalPaidInCapitalMember2022-12-310001555280us-gaap:RetainedEarningsMember2022-12-310001555280us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001555280us-gaap:NoncontrollingInterestMember2022-12-3100015552802022-12-310001555280us-gaap:RetainedEarningsMember2023-01-012023-09-300001555280us-gaap:NoncontrollingInterestMember2023-01-012023-09-300001555280us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-09-300001555280us-gaap:TreasuryStockCommonMemberzts:ShareRepurchaseProgramMember2023-01-012023-09-300001555280us-gaap:TreasuryStockCommonMember2023-01-012023-09-300001555280us-gaap:AdditionalPaidInCapitalMember2023-01-012023-09-300001555280us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember2024-01-012024-09-300001555280us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember2023-01-012023-09-300001555280us-gaap:ProductMember2024-09-300001555280country:US2024-07-012024-09-300001555280country:US2023-07-012023-09-300001555280country:US2024-01-012024-09-300001555280country:US2023-01-012023-09-300001555280country:AU2024-07-012024-09-300001555280country:AU2023-07-012023-09-300001555280country:AU2024-01-012024-09-300001555280country:AU2023-01-012023-09-300001555280country:BR2024-07-012024-09-300001555280country:BR2023-07-012023-09-300001555280country:BR2024-01-012024-09-300001555280country:BR2023-01-012023-09-300001555280country:CA2024-07-012024-09-300001555280country:CA2023-07-012023-09-300001555280country:CA2024-01-012024-09-300001555280country:CA2023-01-012023-09-300001555280country:CL2024-07-012024-09-300001555280country:CL2023-07-012023-09-300001555280country:CL2024-01-012024-09-300001555280country:CL2023-01-012023-09-300001555280country:CN2024-07-012024-09-300001555280country:CN2023-07-012023-09-300001555280country:CN2024-01-012024-09-300001555280country:CN2023-01-012023-09-300001555280country:FR2024-07-012024-09-300001555280country:FR2023-07-012023-09-300001555280country:FR2024-01-012024-09-300001555280country:FR2023-01-012023-09-300001555280country:DE2024-07-012024-09-300001555280country:DE2023-07-012023-09-300001555280country:DE2024-01-012024-09-300001555280country:DE2023-01-012023-09-300001555280country:IT2024-07-012024-09-300001555280country:IT2023-07-012023-09-300001555280country:IT2024-01-012024-09-300001555280country:IT2023-01-012023-09-300001555280country:JP2024-07-012024-09-300001555280country:JP2023-07-012023-09-300001555280country:JP2024-01-012024-09-300001555280country:JP2023-01-012023-09-300001555280country:MX2024-07-012024-09-300001555280country:MX2023-07-012023-09-300001555280country:MX2024-01-012024-09-300001555280country:MX2023-01-012023-09-300001555280country:ES2024-07-012024-09-300001555280country:ES2023-07-012023-09-300001555280country:ES2024-01-012024-09-300001555280country:ES2023-01-012023-09-300001555280country:GB2024-07-012024-09-300001555280country:GB2023-07-012023-09-300001555280country:GB2024-01-012024-09-300001555280country:GB2023-01-012023-09-300001555280zts:OtherDevelopedMarketsMember2024-07-012024-09-300001555280zts:OtherDevelopedMarketsMember2023-07-012023-09-300001555280zts:OtherDevelopedMarketsMember2024-01-012024-09-300001555280zts:OtherDevelopedMarketsMember2023-01-012023-09-300001555280zts:OtherEmergingMarketsMember2024-07-012024-09-300001555280zts:OtherEmergingMarketsMember2023-07-012023-09-300001555280zts:OtherEmergingMarketsMember2024-01-012024-09-300001555280zts:OtherEmergingMarketsMember2023-01-012023-09-300001555280zts:TotalGeographicalAreaMember2024-07-012024-09-300001555280zts:TotalGeographicalAreaMember2023-07-012023-09-300001555280zts:TotalGeographicalAreaMember2024-01-012024-09-300001555280zts:TotalGeographicalAreaMember2023-01-012023-09-300001555280zts:ContractManufacturingandHumanHealthDiagnosticsMember2024-07-012024-09-300001555280zts:ContractManufacturingandHumanHealthDiagnosticsMember2023-07-012023-09-300001555280zts:ContractManufacturingandHumanHealthDiagnosticsMember2024-01-012024-09-300001555280zts:ContractManufacturingandHumanHealthDiagnosticsMember2023-01-012023-09-300001555280zts:CompanionAnimalMemberzts:UnitedStatesSegmentMember2024-07-012024-09-300001555280zts:CompanionAnimalMemberzts:UnitedStatesSegmentMember2023-07-012023-09-300001555280zts:CompanionAnimalMemberzts:UnitedStatesSegmentMember2024-01-012024-09-300001555280zts:CompanionAnimalMemberzts:UnitedStatesSegmentMember2023-01-012023-09-300001555280zts:LivestockMemberzts:UnitedStatesSegmentMember2024-07-012024-09-300001555280zts:LivestockMemberzts:UnitedStatesSegmentMember2023-07-012023-09-300001555280zts:LivestockMemberzts:UnitedStatesSegmentMember2024-01-012024-09-300001555280zts:LivestockMemberzts:UnitedStatesSegmentMember2023-01-012023-09-300001555280us-gaap:OperatingSegmentsMemberzts:UnitedStatesSegmentMember2024-07-012024-09-300001555280us-gaap:OperatingSegmentsMemberzts:UnitedStatesSegmentMember2023-07-012023-09-300001555280us-gaap:OperatingSegmentsMemberzts:UnitedStatesSegmentMember2024-01-012024-09-300001555280us-gaap:OperatingSegmentsMemberzts:UnitedStatesSegmentMember2023-01-012023-09-300001555280zts:CompanionAnimalMemberzts:InternationalSegmentMember2024-07-012024-09-300001555280zts:CompanionAnimalMemberzts:InternationalSegmentMember2023-07-012023-09-300001555280zts:CompanionAnimalMemberzts:InternationalSegmentMember2024-01-012024-09-300001555280zts:CompanionAnimalMemberzts:InternationalSegmentMember2023-01-012023-09-300001555280zts:LivestockMemberzts:InternationalSegmentMember2024-07-012024-09-300001555280zts:LivestockMemberzts:InternationalSegmentMember2023-07-012023-09-300001555280zts:LivestockMemberzts:InternationalSegmentMember2024-01-012024-09-300001555280zts:LivestockMemberzts:InternationalSegmentMember2023-01-012023-09-300001555280us-gaap:OperatingSegmentsMemberzts:InternationalSegmentMember2024-07-012024-09-300001555280us-gaap:OperatingSegmentsMemberzts:InternationalSegmentMember2023-07-012023-09-300001555280us-gaap:OperatingSegmentsMemberzts:InternationalSegmentMember2024-01-012024-09-300001555280us-gaap:OperatingSegmentsMemberzts:InternationalSegmentMember2023-01-012023-09-300001555280zts:CompanionAnimalMember2024-07-012024-09-300001555280zts:CompanionAnimalMember2023-07-012023-09-300001555280zts:CompanionAnimalMember2024-01-012024-09-300001555280zts:CompanionAnimalMember2023-01-012023-09-300001555280zts:LivestockMember2024-07-012024-09-300001555280zts:LivestockMember2023-07-012023-09-300001555280zts:LivestockMember2024-01-012024-09-300001555280zts:LivestockMember2023-01-012023-09-300001555280zts:DogsAndCatsMember2024-07-012024-09-300001555280zts:DogsAndCatsMember2023-07-012023-09-300001555280zts:DogsAndCatsMember2024-01-012024-09-300001555280zts:DogsAndCatsMember2023-01-012023-09-300001555280zts:HorsesMember2024-07-012024-09-300001555280zts:HorsesMember2023-07-012023-09-300001555280zts:HorsesMember2024-01-012024-09-300001555280zts:HorsesMember2023-01-012023-09-300001555280zts:CattleMember2024-07-012024-09-300001555280zts:CattleMember2023-07-012023-09-300001555280zts:CattleMember2024-01-012024-09-300001555280zts:CattleMember2023-01-012023-09-300001555280zts:PoultryMember2024-07-012024-09-300001555280zts:PoultryMember2023-07-012023-09-300001555280zts:PoultryMember2024-01-012024-09-300001555280zts:PoultryMember2023-01-012023-09-300001555280zts:SwineMember2024-07-012024-09-300001555280zts:SwineMember2023-07-012023-09-300001555280zts:SwineMember2024-01-012024-09-300001555280zts:SwineMember2023-01-012023-09-300001555280zts:FishMember2024-07-012024-09-300001555280zts:FishMember2023-07-012023-09-300001555280zts:FishMember2024-01-012024-09-300001555280zts:FishMember2023-01-012023-09-300001555280us-gaap:ManufacturedProductOtherMember2024-07-012024-09-300001555280us-gaap:ManufacturedProductOtherMember2023-07-012023-09-300001555280us-gaap:ManufacturedProductOtherMember2024-01-012024-09-300001555280us-gaap:ManufacturedProductOtherMember2023-01-012023-09-300001555280zts:ParasiticidesMember2024-07-012024-09-300001555280zts:ParasiticidesMember2023-07-012023-09-300001555280zts:ParasiticidesMember2024-01-012024-09-300001555280zts:ParasiticidesMember2023-01-012023-09-300001555280zts:VaccinesMember2024-07-012024-09-300001555280zts:VaccinesMember2023-07-012023-09-300001555280zts:VaccinesMember2024-01-012024-09-300001555280zts:VaccinesMember2023-01-012023-09-300001555280zts:DermatologyMember2024-07-012024-09-300001555280zts:DermatologyMember2023-07-012023-09-300001555280zts:DermatologyMember2024-01-012024-09-300001555280zts:DermatologyMember2023-01-012023-09-300001555280zts:AntiInfectiveProductsMember2024-07-012024-09-300001555280zts:AntiInfectiveProductsMember2023-07-012023-09-300001555280zts:AntiInfectiveProductsMember2024-01-012024-09-300001555280zts:AntiInfectiveProductsMember2023-01-012023-09-300001555280zts:PainSedationMember2024-07-012024-09-300001555280zts:PainSedationMember2023-07-012023-09-300001555280zts:PainSedationMember2024-01-012024-09-300001555280zts:PainSedationMember2023-01-012023-09-300001555280zts:OtherPharmaceuticalsMember2024-07-012024-09-300001555280zts:OtherPharmaceuticalsMember2023-07-012023-09-300001555280zts:OtherPharmaceuticalsMember2024-01-012024-09-300001555280zts:OtherPharmaceuticalsMember2023-01-012023-09-300001555280zts:AnimalHealthDiagnosticsMember2024-07-012024-09-300001555280zts:AnimalHealthDiagnosticsMember2023-07-012023-09-300001555280zts:AnimalHealthDiagnosticsMember2024-01-012024-09-300001555280zts:AnimalHealthDiagnosticsMember2023-01-012023-09-300001555280zts:MedicatedFeedAdditivesMember2024-07-012024-09-300001555280zts:MedicatedFeedAdditivesMember2023-07-012023-09-300001555280zts:MedicatedFeedAdditivesMember2024-01-012024-09-300001555280zts:MedicatedFeedAdditivesMember2023-01-012023-09-300001555280zts:OtherNonPharmaceuticalsMember2024-07-012024-09-300001555280zts:OtherNonPharmaceuticalsMember2023-07-012023-09-300001555280zts:OtherNonPharmaceuticalsMember2024-01-012024-09-300001555280zts:OtherNonPharmaceuticalsMember2023-01-012023-09-300001555280zts:TotalProductsandServicesMember2024-07-012024-09-300001555280zts:TotalProductsandServicesMember2023-07-012023-09-300001555280zts:TotalProductsandServicesMember2024-01-012024-09-300001555280zts:TotalProductsandServicesMember2023-01-012023-09-300001555280zts:PetMedixLtdMember2024-09-300001555280zts:PetMedixLtdMember2023-08-032023-08-0300015552802024-04-280001555280us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember2024-09-300001555280zts:PumpkinInsuranceServicesMember2024-01-012024-06-300001555280zts:PumpkinInsuranceServicesMember2024-04-012024-06-300001555280us-gaap:AcquisitionRelatedCostsMember2024-07-012024-09-300001555280us-gaap:AcquisitionRelatedCostsMember2023-07-012023-09-300001555280us-gaap:AcquisitionRelatedCostsMember2024-01-012024-09-300001555280us-gaap:AcquisitionRelatedCostsMember2023-01-012023-09-300001555280us-gaap:EmployeeSeveranceMember2024-07-012024-09-300001555280us-gaap:EmployeeSeveranceMember2023-07-012023-09-300001555280us-gaap:EmployeeSeveranceMember2024-01-012024-09-300001555280us-gaap:EmployeeSeveranceMember2023-01-012023-09-300001555280us-gaap:FacilityClosingMember2024-07-012024-09-300001555280us-gaap:FacilityClosingMember2023-07-012023-09-300001555280us-gaap:FacilityClosingMember2024-01-012024-09-300001555280us-gaap:FacilityClosingMember2023-01-012023-09-300001555280us-gaap:OtherCurrentLiabilitiesMember2024-09-300001555280us-gaap:OtherCurrentLiabilitiesMember2023-12-310001555280us-gaap:OtherNoncurrentLiabilitiesMember2024-09-300001555280us-gaap:OtherNoncurrentLiabilitiesMember2023-12-310001555280us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember2024-07-012024-09-300001555280us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember2023-07-012023-09-300001555280us-gaap:InternalRevenueServiceIRSMember2024-07-012024-07-310001555280us-gaap:RevolvingCreditFacilityMember2024-09-300001555280zts:OperationalEfficiencyMember2024-09-300001555280us-gaap:RevolvingCreditFacilityMember2023-12-310001555280zts:LineOfCreditForGeneralCorporatePurposeMember2024-09-300001555280zts:LineOfCreditForGeneralCorporatePurposeMember2023-12-310001555280us-gaap:CommercialPaperMember2013-02-280001555280zts:A2022SeniorNotesMemberus-gaap:SeniorNotesMember2022-11-080001555280zts:A5400SeniorNotesDue2025Memberus-gaap:SeniorNotesMember2024-09-300001555280zts:A5400SeniorNotesDue2025Memberus-gaap:SeniorNotesMember2022-11-080001555280zts:A5600SeniorNotesDue2032Memberus-gaap:SeniorNotesMember2024-09-300001555280zts:A5600SeniorNotesDue2032Memberus-gaap:SeniorNotesMember2022-11-080001555280zts:SeniorNotesDue2023Memberus-gaap:SeniorNotesMember2023-02-010001555280zts:SeniorNotesDue2023Memberus-gaap:SeniorNotesMember2024-09-300001555280us-gaap:SeniorNotesMember2013-01-280001555280zts:SeniorNotes4.500Due2025Memberus-gaap:SeniorNotesMember2024-09-300001555280zts:SeniorNotes4.500Due2025Memberus-gaap:SeniorNotesMember2023-12-310001555280zts:A5400SeniorNotesDue2025Memberus-gaap:SeniorNotesMember2023-12-310001555280zts:SeniorNotes3.000Due2027Memberus-gaap:SeniorNotesMember2024-09-300001555280zts:SeniorNotes3.000Due2027Memberus-gaap:SeniorNotesMember2023-12-310001555280zts:SeniorNotes3.900Due2028Memberus-gaap:SeniorNotesMember2024-09-300001555280zts:SeniorNotes3.900Due2028Memberus-gaap:SeniorNotesMember2023-12-310001555280zts:SeniorNotes2000Due2030Memberus-gaap:SeniorNotesMember2024-09-300001555280zts:SeniorNotes2000Due2030Memberus-gaap:SeniorNotesMember2023-12-310001555280zts:A5600SeniorNotesDue2032Memberus-gaap:SeniorNotesMember2023-12-310001555280zts:SeniorNotesDue2043Memberus-gaap:SeniorNotesMember2024-09-300001555280zts:SeniorNotesDue2043Memberus-gaap:SeniorNotesMember2023-12-310001555280zts:SeniorNotes3.950Due2047Memberus-gaap:SeniorNotesMember2024-09-300001555280zts:SeniorNotes3.950Due2047Memberus-gaap:SeniorNotesMember2023-12-310001555280zts:SeniorNotes4.450Due2048Memberus-gaap:SeniorNotesMember2024-09-300001555280zts:SeniorNotes4.450Due2048Memberus-gaap:SeniorNotesMember2023-12-310001555280zts:SeniorNotes3000Due2050Memberus-gaap:SeniorNotesMember2024-09-300001555280zts:SeniorNotes3000Due2050Memberus-gaap:SeniorNotesMember2023-12-310001555280us-gaap:FairValueInputsLevel2Memberus-gaap:SeniorNotesMember2024-09-300001555280us-gaap:FairValueInputsLevel2Memberus-gaap:SeniorNotesMember2023-12-310001555280us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2024-01-012024-09-300001555280us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMembersrt:MaximumMember2024-01-012024-09-300001555280us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMembersrt:MaximumMember2024-01-012024-09-300001555280us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:SeniorNotesMember2023-12-310001555280us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2024-09-300001555280us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2023-12-310001555280us-gaap:CrossCurrencyInterestRateContractMember2024-09-300001555280us-gaap:CrossCurrencyInterestRateContractMember2023-12-310001555280us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-09-300001555280us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310001555280us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMemberus-gaap:OtherCurrentAssetsMember2024-09-300001555280us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMemberus-gaap:OtherCurrentAssetsMember2023-12-310001555280us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMemberus-gaap:OtherCurrentLiabilitiesMember2024-09-300001555280us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMemberus-gaap:OtherCurrentLiabilitiesMember2023-12-310001555280zts:Zts_ForwardStartingInterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentAssetsMember2024-09-300001555280zts:Zts_ForwardStartingInterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentAssetsMember2023-12-310001555280us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherCurrentAssetsMember2024-09-300001555280us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherCurrentAssetsMember2023-12-310001555280us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentAssetsMember2024-09-300001555280us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentAssetsMember2023-12-310001555280us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherCurrentLiabilitiesMember2024-09-300001555280us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherCurrentLiabilitiesMember2023-12-310001555280us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentLiabilitiesMember2024-09-300001555280us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentLiabilitiesMember2023-12-310001555280zts:Zts_FixedtoFloatInterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentLiabilitiesMember2024-09-300001555280zts:Zts_FixedtoFloatInterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentLiabilitiesMember2023-12-310001555280us-gaap:DesignatedAsHedgingInstrumentMember2024-09-300001555280us-gaap:DesignatedAsHedgingInstrumentMember2023-12-310001555280us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-09-300001555280us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310001555280us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2024-07-012024-09-300001555280us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2023-07-012023-09-300001555280us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2023-01-012023-09-300001555280zts:Zts_ForwardStartingInterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-07-012024-09-300001555280zts:Zts_ForwardStartingInterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-07-012023-09-300001555280zts:Zts_ForwardStartingInterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-01-012024-09-300001555280zts:Zts_ForwardStartingInterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-01-012023-09-300001555280us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-07-012024-09-300001555280us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-07-012023-09-300001555280us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-01-012024-09-300001555280us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-01-012023-09-300001555280country:US2023-12-310001555280zts:InternationalMember2023-12-310001555280zts:InternationalMember2024-01-012024-09-300001555280country:US2024-09-300001555280zts:InternationalMember2024-09-300001555280us-gaap:DevelopedTechnologyRightsMember2024-09-300001555280us-gaap:DevelopedTechnologyRightsMember2023-12-310001555280us-gaap:TrademarksAndTradeNamesMember2024-09-300001555280us-gaap:TrademarksAndTradeNamesMember2023-12-310001555280us-gaap:OtherIntangibleAssetsMember2024-09-300001555280us-gaap:OtherIntangibleAssetsMember2023-12-310001555280us-gaap:TrademarksAndTradeNamesMember2024-09-300001555280us-gaap:TrademarksAndTradeNamesMember2023-12-310001555280us-gaap:InProcessResearchAndDevelopmentMember2024-09-300001555280us-gaap:InProcessResearchAndDevelopmentMember2023-12-310001555280zts:ProductRightsMember2024-09-300001555280zts:ProductRightsMember2023-12-310001555280us-gaap:EmployeeStockOptionMember2024-07-012024-09-300001555280us-gaap:EmployeeStockOptionMember2023-07-012023-09-300001555280us-gaap:EmployeeStockOptionMember2024-01-012024-09-300001555280us-gaap:EmployeeStockOptionMember2023-01-012023-09-300001555280us-gaap:RestrictedStockUnitsRSUMember2024-07-012024-09-300001555280us-gaap:RestrictedStockUnitsRSUMember2023-07-012023-09-300001555280us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-09-300001555280us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-09-300001555280us-gaap:PerformanceSharesMember2024-07-012024-09-300001555280us-gaap:PerformanceSharesMember2023-07-012023-09-300001555280us-gaap:PerformanceSharesMember2024-01-012024-09-300001555280us-gaap:PerformanceSharesMember2023-01-012023-09-300001555280us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-12-310001555280us-gaap:PerformanceSharesMemberzts:PeerCompaniesMember2024-01-012024-09-300001555280us-gaap:PerformanceSharesMembersrt:MinimumMember2024-01-012024-09-300001555280us-gaap:PerformanceSharesMembersrt:MaximumMember2024-01-012024-09-300001555280zts:December2021ShareRepurchaseProgramMember2022-12-310001555280zts:December2021ShareRepurchaseProgramMember2024-09-300001555280zts:August2024ShareRepurchaseProgramMember2024-09-300001555280us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2023-12-310001555280us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-12-310001555280us-gaap:AccumulatedTranslationAdjustmentMember2023-12-310001555280us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-12-310001555280us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2024-01-012024-09-300001555280us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-01-012024-09-300001555280us-gaap:AccumulatedTranslationAdjustmentMember2024-01-012024-09-300001555280us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-01-012024-09-300001555280us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2024-09-300001555280us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-09-300001555280us-gaap:AccumulatedTranslationAdjustmentMember2024-09-300001555280us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-09-300001555280us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2022-12-310001555280us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-12-310001555280us-gaap:AccumulatedTranslationAdjustmentMember2022-12-310001555280us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-12-310001555280us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2023-01-012023-09-300001555280us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-01-012023-09-300001555280us-gaap:AccumulatedTranslationAdjustmentMember2023-01-012023-09-300001555280us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-01-012023-09-300001555280us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2023-09-300001555280us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-09-300001555280us-gaap:AccumulatedTranslationAdjustmentMember2023-09-300001555280us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-09-300001555280zts:UlianopolisBrazilMember2012-02-290001555280zts:UlianopolisBrazilMember2012-04-012012-04-300001555280us-gaap:OperatingSegmentsMember2024-07-012024-09-300001555280us-gaap:OperatingSegmentsMember2023-07-012023-09-300001555280us-gaap:AllOtherSegmentsMember2024-07-012024-09-300001555280us-gaap:AllOtherSegmentsMember2023-07-012023-09-300001555280us-gaap:CorporateNonSegmentMember2024-07-012024-09-300001555280us-gaap:CorporateNonSegmentMember2023-07-012023-09-300001555280us-gaap:MaterialReconcilingItemsMember2024-07-012024-09-300001555280us-gaap:MaterialReconcilingItemsMember2023-07-012023-09-300001555280us-gaap:OperatingSegmentsMembercurrency:EURzts:InternationalSegmentMember2024-07-012024-09-300001555280us-gaap:OperatingSegmentsMembercurrency:EURzts:InternationalSegmentMember2023-07-012023-09-300001555280us-gaap:OperatingSegmentsMember2024-01-012024-09-300001555280us-gaap:OperatingSegmentsMember2023-01-012023-09-300001555280us-gaap:AllOtherSegmentsMember2024-01-012024-09-300001555280us-gaap:AllOtherSegmentsMember2023-01-012023-09-300001555280us-gaap:CorporateNonSegmentMember2024-01-012024-09-300001555280us-gaap:CorporateNonSegmentMember2023-01-012023-09-300001555280us-gaap:MaterialReconcilingItemsMember2024-01-012024-09-300001555280us-gaap:MaterialReconcilingItemsMember2023-01-012023-09-300001555280us-gaap:OperatingSegmentsMembercurrency:EURzts:InternationalSegmentMember2024-01-012024-09-300001555280us-gaap:OperatingSegmentsMembercurrency:EURzts:InternationalSegmentMember2023-01-012023-09-300001555280zts:KristinPeckMember2024-01-012024-09-300001555280zts:KristinPeckMember2024-07-012024-09-300001555280zts:KristinPeckMember2024-09-300001555280zts:RoxanneLaganoMember2024-01-012024-09-300001555280zts:RoxanneLaganoMember2024-07-012024-09-300001555280zts:RoxanneLaganoTradingArrangementCommonStockMemberzts:RoxanneLaganoMember2024-07-012024-09-300001555280zts:RoxanneLaganoTradingArrangementCommonStockMemberzts:RoxanneLaganoMember2024-09-300001555280zts:RoxanneLaganoTradingArrangementEquityAwardsMemberzts:RoxanneLaganoMember2024-07-012024-09-300001555280zts:RoxanneLaganoTradingArrangementEquityAwardsMemberzts:RoxanneLaganoMember2024-09-30
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended
September 30, 2024
or
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from __________ to __________
Commission File Number:001-35797
Zoetis Inc.
(Exact name of registrant as specified in its charter)
 
Delaware
46-0696167
(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)
10 Sylvan Way,
Parsippany,
New Jersey
07054
(Address of principal executive offices)(Zip Code)
(973) 822-7000
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.01 per shareZTSNew York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities and Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes ☐ No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer☒Accelerated filer☐Non-accelerated filer☐Smaller reporting company☐Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☒ No
As of October 31, 2024, there were 451,165,011 shares of common stock outstanding.


TABLE OF CONTENTS
Page
Item 1.
Condensed Consolidated Statements of Income (Unaudited)
Condensed Consolidated Statements of Comprehensive Income (Unaudited)
Condensed Consolidated Balance Sheets (Unaudited)
Condensed Consolidated Statements of Equity (Unaudited)
Condensed Consolidated Statements of Cash Flows (Unaudited)
Notes to Condensed Consolidated Financial Statements (Unaudited)
Item 2.
Item 3.
Item 4.
Item 1.
Item 1A.
Item 2.
Item 3.Defaults Upon Senior Securities
Item 4.Mine Safety Disclosures
Item 5.Other Information
Item 6.



PART I – FINANCIAL INFORMATION
Item 1.    Financial Statements
ZOETIS INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(UNAUDITED)
Three Months EndedNine Months Ended
September 30,September 30,
(MILLIONS OF DOLLARS AND SHARES, EXCEPT PER SHARE DATA)2024202320242023
Revenue$2,388 $2,151 $6,939 $6,331 
Costs and expenses:
Cost of sales
701 638 2,012 1,833 
Selling, general and administrative expenses
565 525 1,693 1,586 
Research and development expenses
167 152 500 440 
Amortization of intangible assets
35 38 107 112 
Restructuring charges and certain acquisition and divestiture-related costs5 16 51 45 
Interest expense, net of capitalized interest
57 59 174 180 
Other (income)/deductions—net
(16)6 1 (151)
Income before provision for taxes on income874 717 2,401 2,286 
Provision for taxes on income182 121 486 469 
Net income before allocation to noncontrolling interests692 596 1,915 1,817 
Less: Net income/(loss) attributable to noncontrolling interests10 — 10 (2)
Net income attributable to Zoetis Inc.$682 $596 $1,905 $1,819 
Earnings per share attributable to Zoetis Inc. stockholders:
 Basic$1.51 $1.29 $4.18 $3.94 
 Diluted$1.50 $1.29 $4.18 $3.93 
Weighted-average common shares outstanding:
 Basic452.9 460.3 455.4 461.9 
 Diluted453.5 461.4 456.1 463.0 
Dividends declared per common share$— $— $0.864 $0.750 

See notes to condensed consolidated financial statements.
1 |
ZOETIS INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(UNAUDITED)
Three Months EndedNine Months Ended
September 30,September 30,
(MILLIONS OF DOLLARS)2024202320242023
Net income before allocation to noncontrolling interests$692 $596 $1,915 $1,817 
Other comprehensive (loss)/income, net of tax(a):
Unrealized (losses)/gains on derivatives for cash flow hedges, net of tax of $(1) and $1 for the three months ended September 30, 2024 and 2023, respectively, and $(1) and $0 for the nine months ended September 30, 2024 and 2023, respectively
(4)3 (5)— 
Unrealized (losses)/gains on derivatives for net investment hedges, net of tax of $(7) and $5 for the three months ended September 30, 2024 and 2023, respectively, and $(2) and $1 for the nine months ended September 30, 2024 and 2023, respectively
(23)18 (5)5 
Foreign currency translation adjustments21 60 (2)(6)
Benefit plans: Actuarial gains, net of tax of $0 and $0 for the three months ended September 30, 2024 and 2023, respectively, and $0 and $1 for the nine months ended September 30, 2024 and 2023, respectively
— — — 4 
Total other comprehensive (loss)/income, net of tax(6)81 (12)3 
Comprehensive income before allocation to noncontrolling interests686 677 1,903 1,820 
Less: Comprehensive income/(loss) attributable to noncontrolling interests10 — 10 (2)
Comprehensive income attributable to Zoetis Inc.$676 $677 $1,893 $1,822 
(a) Presented net of reclassification adjustments, which are not material in any period presented.



See notes to condensed consolidated financial statements.
2 |
ZOETIS INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
September 30,December 31,
20242023
(MILLIONS OF DOLLARS, EXCEPT SHARE AND PER SHARE DATA)(Unaudited)
Assets
Cash and cash equivalents(a)
$1,714 $2,041 
Accounts receivable, less allowance for doubtful accounts of $19 in 2024 and $18 in 2023
1,411 1,304 
Inventories2,416 2,564 
Assets held for sale314 — 
Other current assets427 434 
Total current assets6,282 6,343 
Property, plant and equipment, less accumulated depreciation of $2,657 in 2024 and $2,594 in 2023
3,298 3,204 
Operating lease right-of-use assets223 230 
Goodwill2,744 2,759 
Identifiable intangible assets, less accumulated amortization1,186 1,338 
Noncurrent deferred tax assets409 206 
Other noncurrent assets215 206 
Total assets$14,357 $14,286 
Liabilities and Equity
Short-term borrowings$— $3 
Accounts payable404 411 
Dividends payable— 198 
Accrued expenses725 683 
Accrued compensation and related items335 382 
Income taxes payable97 110 
Liabilities associated with assets held for sale26 — 
Other current liabilities115 102 
Total current liabilities1,702 1,889 
Long-term debt, net of discount and issuance costs6,574 6,564 
Noncurrent deferred tax liabilities172 146 
Operating lease liabilities181 188 
Other taxes payable274 271 
Other noncurrent liabilities220 237 
Total liabilities9,123 9,295 
Commitments and contingencies (Note 15)
Stockholders’ equity:
Common stock, $0.01 par value: 6,000,000,000 authorized; 501,891,243 and 501,891,243 shares issued; 451,549,789 and 458,367,358 shares outstanding at September 30, 2024, and December 31, 2023, respectively
5 5 
Treasury stock, at cost, 50,341,454 and 43,523,885 shares of common stock at September 30, 2024 and December 31, 2023, respectively
(6,889)(5,597)
Additional paid-in capital1,163 1,133 
Retained earnings11,806 10,295 
Accumulated other comprehensive loss(851)(839)
Total Zoetis Inc. equity5,234 4,997 
Equity attributable to noncontrolling interests— (6)
Total equity5,234 4,991 
Total liabilities and equity$14,357 $14,286 
(a)    As of September 30, 2024 and December 31, 2023, includes $4 million and $2 million of restricted cash, respectively.
See notes to condensed consolidated financial statements.
3 |
ZOETIS INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF EQUITY
(UNAUDITED)
Three months ended September 30, 2024
Zoetis
Accumulated
AdditionalOther
Common StockTreasury StockPaid-inRetainedComprehensiveNoncontrollingTotal
(MILLIONS OF DOLLARS AND SHARES)
SharesAmountSharesAmountCapitalEarningsLossInterestsEquity
Balance, June 30, 2024501.9 $5 48.0 $(6,464)$1,146 $11,124 $(845)$(6)$4,960 
Net income— — — — — 682 — 10 692 
Other comprehensive loss— — — — — — (6)— (6)
Deconsolidation of noncontrolling interests— — — — — — — (4)(4)
Share-based compensation awards (a)
— — — 2 17 — — — 19 
Treasury stock acquired (b)
— — 2.3 (427)— — — — (427)
Balance, September 30, 2024501.9 $5 50.3 $(6,889)$1,163 $11,806 $(851)$— $5,234 
Three months ended September 30, 2023
Zoetis
Accumulated
AdditionalOther
Common StockTreasury StockPaid-inRetainedComprehensiveNoncontrollingTotal
(MILLIONS OF DOLLARS AND SHARES)
SharesAmountSharesAmountCapitalEarningsLossInterestsEquity
Balance, June 30, 2023501.9 $5 41.2 $(5,126)$1,098 $9,543 $(895)$(4)$4,621 
Net income— — — — — 596 — — 596 
Other comprehensive income— — — — — — 81 — 81 
Share-based compensation awards (a)
— — (0.2)9 18 1 — — 28 
Treasury stock acquired (b)
— — 1.4 (252)— — — — (252)
Balance, September 30, 2023501.9 $5 42.4 $(5,369)$1,116 $10,140 $(814)$(4)$5,074 
Shares may not add due to rounding.
(a)    Includes the issuance of shares of Zoetis Inc. common stock and the reacquisition of shares of treasury stock associated with exercises of employee share-based awards. Also includes the reacquisition of shares of treasury stock associated with the vesting of employee share-based awards to satisfy tax withholding requirements. For additional information, see Note 12. Share-based Payments and Note 13. Stockholders’ Equity.
(b)    Reflects the acquisition of treasury shares in connection with the share repurchase program and includes excise tax accrued on net share repurchases. For additional information, see Note 13. Stockholders’ Equity.













See notes to condensed consolidated financial statements.
4 |
ZOETIS INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF EQUITY
(UNAUDITED) - Continued
Nine months ended September 30, 2024
Zoetis
Accumulated
AdditionalOther
Common StockTreasury StockPaid-inRetainedComprehensiveNoncontrollingTotal
(MILLIONS OF DOLLARS AND SHARES)
SharesAmountSharesAmountCapitalEarningsLossInterestsEquity
Balance, December 31, 2023501.9 $5 43.5 $(5,597)$1,133 $10,295 $(839)$(6)$4,991 
Net income— — — — — 1,905 — 10 1,915 
Other comprehensive loss— — — — — — (12)— (12)
Deconsolidation of noncontrolling interests— — — — — — — (4)(4)
Share-based compensation awards (a)
— — (0.5)15 30 — — — 45 
Treasury stock acquired (b)
— — 7.3 (1,307)— — — — (1,307)
Dividends declared— — — — — (394)— — (394)
Balance, September 30, 2024501.9 $5 50.3 $(6,889)$1,163 $11,806 $(851)$— $5,234 
Nine months ended September 30, 2023
Zoetis
Accumulated
AdditionalOther
Common StockTreasury StockPaid-inRetainedComprehensiveNoncontrollingTotal
(MILLIONS OF DOLLARS AND SHARES)
SharesAmountSharesAmountCapitalEarningsLossInterestsEquity
Balance, December 31, 2022501.9 $5 38.1 $(4,539)$1,088 $8,668 $(817)$(2)$4,403 
Net income/(loss)— — — — — 1,819 — (2)1,817 
Other comprehensive income— — — — — — 3 — 3 
Share-based compensation awards (a)
— — (0.7)34 28 (1)— — 61 
Treasury stock acquired (b)
— — 5.0 (864)— — — — (864)
Dividends declared— — — — — (346)— — (346)
Balance, September 30, 2023501.9 $5 42.4 $(5,369)$1,116 $10,140 $(814)$(4)$5,074 
Shares may not add due to rounding.
(a)    Includes the issuance of shares of Zoetis Inc. common stock and the reacquisition of shares of treasury stock associated with exercises of employee share-based awards. Also includes the reacquisition of shares of treasury stock associated with the vesting of employee share-based awards to satisfy tax withholding requirements. For additional information, see Note 12. Share-based Payments and Note 13. Stockholders’ Equity.
(b)    Reflects the acquisition of treasury shares in connection with the share repurchase program and includes excise tax accrued on net share repurchases. For additional information, see Note 13. Stockholders’ Equity.

See notes to condensed consolidated financial statements.
5 |
ZOETIS INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
Nine Months Ended
September 30,
(MILLIONS OF DOLLARS)20242023
Operating Activities
Net income before allocation to noncontrolling interests$1,915 $1,817 
Adjustments to reconcile net income before noncontrolling interests to net cash provided by operating activities:
Depreciation and amortization expense374 365 
Share-based compensation expense55 43 
Asset write-offs and asset impairments16 27 
Loss on assets held for sale22 — 
Net gain on sale of businesses, excluding transaction costs— (118)
Provision for losses on inventory71 82 
Deferred taxes(186)(40)
Other non-cash adjustments11 (6)
Other changes in assets and liabilities, net of acquisitions and divestitures:
    Accounts receivable(134)(54)
    Inventories(113)(497)
    Other assets(14)(119)
    Accounts payable5 (9)
    Other liabilities36 (27)
    Other tax accounts, net(10)(8)
Net cash provided by operating activities2,048 1,456 
Investing Activities
Capital expenditures(439)(534)
Acquisitions, net of cash acquired(8)(155)
Purchase of investments(4)(3)
Proceeds from derivative instrument activity, net11 23 
Proceeds from sale of businesses, net of cash sold— 96 
Net proceeds from sale of assets1 4 
Other investing activities(2)2 
Net cash used in investing activities(441)(567)
Financing Activities
Decrease in short-term borrowings, net(3)— 
Principal payments on long-term debt— (1,350)
Payment of consideration related to previous acquisitions(5)(3)
Share-based compensation-related proceeds, net of taxes paid on withholding shares(10)18 
Purchases of treasury stock, including excise taxes paid(1,305)(857)
Cash dividends paid(592)(520)
Net cash used in financing activities(1,915)(2,712)
Effect of exchange-rate changes on cash and cash equivalents(19)(4)
Net decrease in cash and cash equivalents(327)(1,827)
Cash and cash equivalents at beginning of period2,041 3,581 
Cash and cash equivalents at end of period$1,714 $1,754 
Supplemental cash flow information
Cash paid during the period for:
Income taxes$657 $586 
Interest, net of capitalized interest205 225 
Amounts included in the measurement of lease liabilities:
        Operating cash flows - operating leases46 42 
        Financing cash flows - finance leases1 — 
Non-cash transactions:
Capital expenditures4 4 
Excise tax accrued on net share repurchases, not paid12 7 
Lease obligations obtained in exchange for right-of-use assets - operating39 74 
See notes to condensed consolidated financial statements.
6 |
ZOETIS INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
1. Organization
Zoetis Inc. (including its subsidiaries, collectively, Zoetis, the company, we, us or our) is a global leader in the animal health industry, focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. We organize and operate our business in two geographic regions: the United States (U.S.) and International.
We directly market our products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. Our products are sold in more than 100 countries, including developed and emerging markets. We have a diversified business, commercializing products across eight core species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock); and within eight major product categories: parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, animal health diagnostics and medicated feed additives.
2. Basis of Presentation
The accompanying unaudited condensed consolidated financial statements were prepared following the requirements of the Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by accounting principles generally accepted in the United States of America (U.S. GAAP) can be condensed or omitted. Balance sheet amounts and operating results for subsidiaries operating outside the U.S. are as of and for the three and nine months ended August 31, 2024 and August 31, 2023.
Revenue, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.
Certain reclassifications of prior year information have been made to conform to the current year's presentation.
We are responsible for the unaudited condensed consolidated financial statements included in this Form 10-Q. The condensed consolidated financial statements include all normal and recurring adjustments that are considered necessary for the fair presentation of our financial position and operating results. The information included in this interim report should be read in conjunction with the financial statements and accompanying notes included in our 2023 Annual Report on Form 10-K.
In the third quarter of 2024, we concluded that we were no longer the primary beneficiary of a variable interest entity (VIE) that was previously consolidated. The effects of the deconsolidation were not material to the condensed consolidated financial statements.
3. Accounting Standards
Recently Issued Accounting Standards
In December 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The new guidance requires expanded annual and interim disclosures for significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss. This update is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. The update is to be applied retrospectively to all periods presented in the financial statements. Early adoption is permitted. The adoption of this guidance will impact our disclosures only and we do not expect it to have an impact on our consolidated financial statements.
In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax disclosures. The new guidance requires standardized categories for the effective tax rate reconciliation, disaggregation of income taxes paid and other income tax-related disclosures. This update is effective for fiscal years beginning after December 15, 2024. We are currently evaluating the impact that the new guidance will have on our notes to the consolidated financial statements.
4. Revenue
A. Revenue from Product Sales
We offer a diversified portfolio of products which allows us to capitalize on local and regional customer needs. Generally, our products are promoted to veterinarians and livestock producers by our sales organization which includes sales representatives and technical and veterinary operations specialists, and then sold directly by us or through distributors, retailers or e-commerce outlets. The depth of our product portfolio enables us to address the varying needs of customers in different species and geographies. Many of our top-selling product lines are distributed across both of our operating segments, leveraging our research and development (R&D) operations and manufacturing and supply chain network.
Over the course of our history, we have focused on developing a diverse portfolio of animal health products, including medicines, vaccines and diagnostics, complemented by biodevices, genetic tests and a range of services. We refer to all different brands of a particular product, or its dosage forms for all species, as a product line. We have approximately 300 comprehensive product lines, including products for both companion animals and livestock, within our major product categories.
In the first quarter of 2024, we modified the list of major product categories to include a category for pain and sedation products, which were previously included within other pharmaceutical products. The prior period presentation has been revised to reflect the new product category.
Our major product categories are:
•parasiticides: products that prevent or eliminate external and internal parasites such as fleas, ticks and worms;
7 |
•vaccines: biological preparations that help prevent diseases of the respiratory, gastrointestinal and reproductive tracts or induce a specific immune response;
•dermatology: products that relieve itch associated with allergic conditions and atopic dermatitis;
•anti-infectives: products that prevent, kill or slow the growth of bacteria, fungi or protozoa;
•pain and sedation: products that alleviate pain, primarily associated with osteoarthritis and postoperative pain;
•other pharmaceutical: antiemetic, reproductive and oncology products;
•animal health diagnostics: testing and analysis of blood, urine and other animal samples and related products and services, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services and blood glucose monitors; and
•medicated feed additives: products added to animal feed that provide medicines to livestock.
Our remaining revenue is derived from other non-pharmaceutical product categories, such as nutritionals, as well as products and services in biodevices, genetic tests and precision animal health.
Our companion animal products help extend and improve the quality of life for pets; increase convenience and compliance for pet owners; and help veterinarians improve the quality of their care and the efficiency of their businesses. Growth in the companion animal medicines, vaccines and diagnostics sector is driven by economic development, related increases in disposable income and increases in pet ownership and spending on pet care. Companion animals are also living longer, deepening the human-animal bond, receiving increased medical treatment and benefiting from advances in animal health medicine, vaccines and diagnostics.
Our livestock products primarily help prevent or treat diseases and conditions to allow veterinarians and producers to care for their animals and to enable the cost-effective production of safe, high-quality animal protein. Human population growth and increasing standards of living are important long-term growth drivers for our livestock products in three major ways. First, population growth and increasing standards of living drive demand for improved nutrition, particularly through increased consumption of animal protein. Second, population growth leads to greater natural resource constraints driving a need for enhanced productivity. Finally, as standards of living improve and the global food chain faces increased scrutiny, there is more focus on food quality, safety and reliability of supply.
The following tables present our revenue disaggregated by geographic area, species and major product category:
Revenue by geographic area
Three Months EndedNine Months Ended
September 30,September 30,
(MILLIONS OF DOLLARS)2024202320242023
United States$1,346 $1,174 $3,817 $3,344 
Australia83 84 239 248 
Brazil101 101 301 276 
Canada66 63 202 183 
Chile31 31 93 109 
China61 69 205 255 
France36 34 111 102 
Germany57 50 166 148 
Italy31 26 95 87 
Japan33 34 109 120 
Mexico39 42 129 119 
Spain35 30 100 94 
United Kingdom80 78 230 209 
Other developed markets148 127 413 374 
Other emerging markets220 187 670 605 
2,367 2,130 6,880 6,273 
Contract manufacturing & human health21 21 59 58 
Total Revenue$2,388 $2,151 $6,939 $6,331 

8 |
Revenue by major species
Three Months EndedNine Months Ended
September 30,September 30,
(MILLIONS OF DOLLARS)2024202320242023
U.S.
Companion animal$1,068 $908 $3,046 $2,588 
Livestock278 266 771 756 
1,346 1,174 3,817 3,344 
International
Companion animal541 506 1,662 1,540 
Livestock480 450 1,401 1,389 
1,021 956 3,063 2,929 
Total
Companion animal1,609 1,414 4,708 4,128 
Livestock758 716 2,172 2,145 
Contract manufacturing & human health21 21 59 58 
Total Revenue$2,388 $2,151 $6,939 $6,331 
Revenue by species
Three Months EndedNine Months Ended
September 30,September 30,
(MILLIONS OF DOLLARS)2024202320242023
Companion Animal:
Dogs and Cats$1,551 $1,354 $4,516 $3,931 
Horses58 60 192 197 
1,609 1,414 4,708 4,128 
Livestock:
Cattle391 374 1,132 1,102 
Poultry139 127 410 397 
Swine131 129 388 404 
Fish70 57 177 158 
Sheep and other27 29 65 84 
758 716 2,172 2,145 
Contract manufacturing & human health21 21 59 58 
Total Revenue$2,388 $2,151 $6,939 $6,331 
Revenue by major product category
Three Months EndedNine Months Ended
September 30,September 30,
(MILLIONS OF DOLLARS)2024202320242023
Parasiticides$530 $465 $1,634 $1,465 
Vaccines468 449 1,365 1,308 
Dermatology453 397 1,234 1,048 
Anti-infectives274 264 819 796 
Pain and sedation219 147 634 408 
Other pharmaceutical169 166 478 514 
Animal health diagnostics101 95 286 284 
Medicated feed additives91 86 242 257 
Other non-pharmaceutical62 61 188 193 
2,367 2,130 6,880 6,273 
Contract manufacturing & human health21 21 59 58 
Total Revenue$2,388 $2,151 $6,939 $6,331 
B. Revenue from Contracts with Customers
Contract liabilities reflected within Other current liabilities as of December 31, 2023 and 2022, and subsequently recognized as revenue during each of the first nine months of 2024 and 2023 were $4 million. Contract liabilities as of September 30, 2024 and December 31, 2023 were $21 million and $11 million, respectively.
Estimated future revenue expected to be generated from long-term contracts with unsatisfied performance obligations as of September 30, 2024 is not material.

9 |
5. Acquisitions and Divestitures
A. Acquisitions
During the third quarter of 2023, we acquired 100% of the issued share capital of PetMedix Ltd. (PetMedix), a privately held research and development stage animal health biopharmaceutical company based in the United Kingdom, which develops antibody-based therapeutics for companion animals. The purchase price included upfront cash consideration of $111 million, excluding $19 million of cash acquired, $5 million in cash withheld for customary post-closing adjustments, and contingent consideration up to $100 million based on the achievement of certain milestones. There are additional contingent payments to be made to the seller upon receipt of payments from a third party related to a preexisting collaboration arrangement between PetMedix and the third party. The initial fair value assessment of the contingent consideration and additional contingent payments is not material and the transaction did not have a material impact on our condensed consolidated financial statements.
During the third quarter of 2023, we also completed the acquisition of adivo GmbH (adivo), a privately held research and development stage animal health biopharmaceutical company based in Germany. The transaction did not have a material impact on our condensed consolidated financial statements.
B. Divestitures
During the second quarter of 2024, we entered into a definitive agreement where Phibro Animal Health will acquire Zoetis’ medicated feed additive product portfolio, certain water soluble products and related assets for $350 million, subject to customary closing adjustments. Net assets and liabilities related to the sale met all the criteria to be classified as held for sale during the second quarter of 2024. We have determined that this future divestiture does not qualify for reporting as a discontinued operation, as it does not represent a strategic shift that has or will have a major effect on our operations and/or financial results. Proceeds upon the closing of this transaction were received in the fourth quarter of 2024. See Note 17. Subsequent Event for additional information.
As of September 30, 2024, major classes of assets held for sale and liabilities associated with assets held for sale are summarized below:
September 30,
(MILLIONS OF DOLLARS)2024
Assets held for sale
Accounts receivable, less allowance for doubtful accounts$1 
Inventories162 
Other current assets2 
Property, plant and equipment, less accumulated depreciation108 
Operating lease right-of-use assets2 
Goodwill(a)
12 
Identifiable intangible assets, less accumulated amortization26 
Noncurrent deferred tax assets2 
Other noncurrent assets9 
Loss on assets held for sale(a)
(10)
  Total Assets Held for Sale$314 
Liabilities associated with assets held for sale
Accounts payable$11 
Accrued expenses8 
Accrued compensation and related items1 
Other noncurrent liabilities6 
  Total Liabilities Associated with Assets Held for Sale$26 
(a) We recorded a loss on assets held for sale of $22 million in the Condensed Consolidated Statements of Income during the nine months ended September 30, 2024. Of the loss on assets held for sale, $12 million is allocated to goodwill and the remaining $10 million relates to selling costs to be recognized upon closing and foreign currency translation losses to be reclassified out of accumulated other comprehensive income into earnings upon closing of the transaction.
During the second quarter of 2023, we received net cash proceeds of $93 million ($99 million sales proceeds, net of cash sold of $6 million) for the sale of a majority interest in our pet insurance business, Pumpkin Insurance Services. We recorded a net pre-tax gain of $101 million within Other (income)/deductions—net, which includes $24 million related to the remeasurement of our retained noncontrolling investment to fair value. We also completed the divestiture of Performance Livestock Analytics, part of our precision animal health business in the third quarter of 2023. The transaction did not have a material impact on our condensed consolidated financial statements.
6. Restructuring Charges and Other Costs Associated with Acquisitions and Divestitures
In connection with our cost-reduction/productivity initiatives, we typically incur restructuring charges associated with workforce reductions and site closings. In connection with our acquisition and divestiture activities, we typically incur costs associated with executing the transactions. Acquisition activity may also include integrating the acquired operations, which may include expenditures for consulting and the integration of systems and processes, product transfers and restructuring the company, which may include charges related to employees, assets and activities that will not continue in the company. Divestiture activity may also include costs to separate the divested operations, which may include expenditures for consulting and the disintegration of systems and processes, transfer costs, and restructuring charges which may include charges related to employees, assets and activities that will not continue in the company's ongoing operations. All operating functions can be impacted by these actions, including sales and marketing, manufacturing and R&D, as well as functions such as business technology, shared services and corporate operations.

10 |
The components of costs incurred in connection with restructuring initiatives, acquisitions and divestitures are as follows:
Three Months EndedNine Months Ended
September 30,September 30,
(MILLIONS OF DOLLARS)2024202320242023
Restructuring charges and certain acquisition and divestiture-related costs:
Acquisition-related costs$— $3 $1 $7 
Divestiture-related costs(a)
7 — 11 — 
Restructuring charges, net(b):
Employee termination costs, net(2)8 39 33 
Asset impairment charges— 1 — 1 
Exit costs— 4 — 4 
Total Restructuring charges and certain acquisition and divestiture-related costs
$5 $16 $51 $45 
(a)    Divestiture-related costs consisted of costs related to the planned sale of our medicated feed additive product portfolio, certain water soluble products and related assets.
(b) The restructuring charges for the nine months ended September 30, 2024 primarily consisted of employee termination costs related to organizational structure refinements, partially offset by a reversal of certain employee termination costs as a result of a change in strategy from our 2015 operational efficiency initiative.
The restructuring charges for the three and nine months ended September 30, 2023 primarily consisted of employee termination and exit costs related to organizational structure refinements and other cost-reduction and productivity initiatives.
The change in our restructuring accrual is as follows:
(MILLIONS OF DOLLARS)
Accrual
Balance, December 31, 2023(a)
$35 
Provision46 
Reserve adjustment(7)
Utilization and other(b)
(28)
Balance, September 30, 2024(a)
$46 
(a)     At September 30, 2024 and December 31, 2023, included in Accrued expenses ($44 million and $26 million, respectively) and Other noncurrent liabilities ($2 million and $9 million, respectively).
(b)     Includes adjustments for foreign currency translation.
7. Other (Income)/Deductions—Net
The components of Other (income)/deductions—net are as follows:
Three Months EndedNine Months Ended
September 30,September 30,
(MILLIONS OF DOLLARS)2024202320242023
Royalty-related income(a)
$(2)$(1)$(5)$(36)
Interest income(23)(23)(79)(79)
Identifiable intangible asset impairment charges(b)
— 6 11 17 
Loss on assets held for sale(c)
— — 22 — 
Other asset impairment charges— 1 — 1 
Net gain on sale of business(d)
— — — (101)
Foreign currency loss(e)
5 19 42 41 
Other, net4 4 10 6 
Other (income)/deductions—net$(16)$6 $1 $(151)
(a)     For the nine months ended September 30, 2023, predominantly associated with a settlement for underpayment of royalties in prior periods.
(b)    For the nine months ended September 30, 2024, represents asset impairment charges related to our aquaculture business.
For the three months ended September 30, 2023, primarily represents asset impairment charges related to our diagnostics business.
For the nine months ended September 30, 2023, primarily represents asset impairment charges related to our precision animal health and diagnostics businesses.
(c)    Represents a loss on assets held for sale related to the planned sale of our medicated feed additive product portfolio, certain water soluble products and related assets. For additional information, see Note 5. Acquisitions and Divestitures.
(d)    Relates to the gain on sale of a majority interest in our pet insurance business. For additional information, see Note 5. Acquisitions and Divestitures.
(e)    Primarily driven by costs related to hedging and exposures to certain emerging and developed market currencies.

11 |
8. Income Taxes
A. Taxes on Income
Our effective tax rate was 20.8% and 16.9% for the three months ended September 30, 2024 and 2023, respectively. The higher effective tax rate for the three months ended September 30, 2024, compared with the three months ended September 30, 2023, was primarily attributable to a benefit from the tax loss on the divestiture of Performance Livestock Analytics recorded in the third quarter of 2023, higher net discrete tax expenses and a less favorable jurisdictional mix of earnings (which includes the impact of the location of earnings and repatriation costs), partially offset by a higher benefit in the U.S. related to foreign-derived intangible income. Jurisdictional mix of earnings can vary depending on repatriation decisions, operating fluctuations in the normal course of business and the impact of non-deductible items and non-taxable items.
Our effective tax rate was 20.2% and 20.5% for the nine months ended September 30, 2024 and 2023, respectively. The lower effective tax rate for the nine months ended September 30, 2024, compared with the nine months ended September 30, 2023, was primarily attributable to a higher benefit in the U.S. related to foreign-derived intangible income, lower net discrete tax expenses and a more favorable jurisdictional mix of earnings (which includes the impact of the location of earnings and repatriation costs), partially offset by a benefit from the tax loss on the divestiture of Performance Livestock Analytics recorded in the third quarter of 2023. Jurisdictional mix of earnings can vary depending on repatriation decisions, operating fluctuations in the normal course of business and the impact of non-deductible items and non-taxable items.
In 2022, the company implemented an initiative to maximize its cash position in the U.S. This initiative resulted in a tax benefit in the U.S. in connection with a prepayment from a related foreign entity in Belgium which qualifies as foreign-derived intangible income; however, this income tax benefit was deferred to 2023 and 2024. A portion of this benefit was recognized during the three and nine months ended September 30, 2024 and 2023.
The global minimum tax provisions (Pillar Two) resulting from the Organisation for Economic Co-operation and Development (OECD) Base Erosion and Profit Shifting project are effective beginning in 2024 and the impact of these provisions is included in our effective tax rate for the three and nine months ended September 30, 2024.
B. Deferred Taxes
As of September 30, 2024, the total net deferred income tax asset of $237 million is included in Noncurrent deferred tax assets ($409 million) and Noncurrent deferred tax liabilities ($172 million).
As of December 31, 2023, the total net deferred income tax asset of $60 million is included in Noncurrent deferred tax assets ($206 million) and Noncurrent deferred tax liabilities ($146 million).
C. Tax Contingencies
Uncertain Tax Positions
As of September 30, 2024, the net tax liabilities associated with uncertain tax positions of $217 million (exclusive of interest and penalties related to uncertain tax positions of $36 million) are included in Other taxes payable.
As of December 31, 2023, the net tax liabilities associated with uncertain tax positions of $209 million (exclusive of interest and penalties related to uncertain tax positions of $27 million) are included in Other taxes payable.
Our tax liabilities for uncertain tax positions relate primarily to issues common among multinational corporations. Any settlements or statute of limitations expirations could result in a significant decrease in our uncertain tax positions. Substantially all of these unrecognized tax benefits, if recognized, would impact our effective income tax rate. We do not expect that within the next twelve months any of our uncertain tax positions could significantly decrease as a result of settlements with taxing authorities or the expiration of the statutes of limitations. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but our estimates of uncertain tax positions and potential tax benefits may not be representative of actual outcomes, and any variation from such estimates could materially affect our financial statements in the period of settlement or when the statutes of limitations expire, as we treat these events as discrete items in the period of resolution. Finalizing audits with the relevant taxing authorities can include formal administrative and legal proceedings, and, as a result, it is difficult to estimate the timing and range of possible changes related to our uncertain tax positions, and such changes could be significant.
Status of Tax Audits and Potential Impact on Accrual for Uncertain Tax Positions
We are currently under income tax audit by the U.S. Internal Revenue Service (IRS) for tax years 2017 and 2018. In July 2024, the IRS issued Notices of Proposed Adjustment (NOPA) related to the one-time mandatory deemed repatriation tax incurred on the 2018 U.S. Federal Income Tax return. In September 2024, the IRS issued a Revenue Agent Report for the adjustments identified in the NOPA. As of September 30, 2024, the additional tax liability, based on the income adjustment proposed by the IRS under the NOPA, is approximately $450 million, excluding interest and penalties.
Based on current facts and circumstances, we disagree with the IRS’ position and will defend our position taken on the 2018 U.S. Federal Income Tax return. We believe the amount previously accrued related to this uncertain tax position remains appropriate, but we will continue to evaluate the adequacy of our tax reserve as the audit progresses. However, the outcome of tax audits cannot be predicted with certainty. If any issues addressed in our tax audits are not consistent with management’s expectations, we could be required to adjust our provision for income taxes and this amount could be material to our financial statements.

12 |
9. Financial Instruments
A. Debt
Credit Facilities
In December 2022, we entered into an amended and restated revolving credit agreement with a syndicate of banks providing for a multi-year $1.0 billion senior unsecured revolving credit facility (the credit facility), which expires in December 2027. Subject to certain conditions, we have the right to increase the credit facility to up to $1.5 billion. The credit facility contains a financial covenant requiring us to not exceed a maximum total leverage ratio (the ratio of consolidated net debt as of the end of the period to consolidated Earnings Before Interest, Income Taxes, Depreciation and Amortization (EBITDA) for such period) of 3.50:1. Upon entering into a material acquisition, the maximum total leverage ratio increases to 4.00:1, and extends until the fourth full consecutive fiscal quarter ended immediately following the consummation of a material acquisition. In addition, the credit facility contains other customary covenants.
We were in compliance with all financial covenants as of September 30, 2024 and December 31, 2023. There were no amounts drawn under the credit facility as of September 30, 2024 or December 31, 2023.
We have additional lines of credit and other credit arrangements with a group of banks and other financial intermediaries for general corporate purposes. We maintain cash and cash equivalent balances in excess of our outstanding short-term borrowings. As of September 30, 2024, we had access to $56 million of lines of credit which expire at various times and are generally renewed annually. There were no borrowings outstanding related to these facilities as of September 30, 2024 and $3 million of borrowings outstanding related to these facilities as of December 31, 2023.
Commercial Paper Program
In February 2013, we entered into a commercial paper program with a capacity of up to $1.0 billion. As of September 30, 2024 and December 31, 2023, there was no commercial paper outstanding under this program.
Senior Notes and Other Long-Term Debt
On November 8, 2022, we issued $1.35 billion aggregate principal amount of our senior notes (2022 senior notes), with an original issue discount of $2 million. These notes are comprised of $600 million aggregate principal amount of 5.400% senior notes due 2025 and $750 million aggregate principal amount of 5.600% senior notes due 2032. On February 1, 2023, the net proceeds were used to redeem in full, upon maturity, the $1.35 billion aggregate principal amount of our 3.250% 2013 senior notes due 2023.
Our senior notes are governed by an indenture and supplemental indentures (collectively, the indenture) between us and Deutsche Bank Trust Company Americas, as trustee. The indenture contains certain covenants, including limitations on our and certain of our subsidiaries’ ability to incur liens or engage in sale-leaseback transactions. The indenture also contains restrictions on our ability to consolidate, merge or sell substantially all of our assets. In addition, the indenture contains other customary terms, including certain events of default, upon the occurrence of which the senior notes may be declared immediately due and payable.
Pursuant to the indenture, we are able to redeem the senior notes of any series, in whole or in part, at any time by paying a “make whole” premium, plus accrued and unpaid interest to, but excluding, the date of redemption. Upon the occurrence of a change of control of us and a downgrade of the senior notes below an investment grade rating by each of Moody’s Investors Service, Inc. and Standard & Poor’s Ratings Services, we are, in certain circumstances, required to make an offer to repurchase all of the outstanding senior notes at a price equal to 101% of the aggregate principal amount of the senior notes together with accrued and unpaid interest to, but excluding, the date of repurchase.
The components of our long-term debt are as follows:
September 30,December 31,
(MILLIONS OF DOLLARS)20242023
4.500% 2015 senior notes due 2025
$750 $750 
5.400% 2022 senior notes due 2025
600 600 
3.000% 2017 senior notes due 2027
750 750 
3.900% 2018 senior notes due 2028
500 500 
2.000% 2020 senior notes due 2030
750 750 
5.600% 2022 senior notes due 2032
750 750 
4.700% 2013 senior notes due 2043
1,150 1,150 
3.950% 2017 senior notes due 2047
500 500 
4.450% 2018 senior notes due 2048
400 400 
3.000% 2020 senior notes due 2050
500 500 
6,650 6,650 
Unamortized debt discount / debt issuance costs(56)(60)
Cumulative fair value adjustment for interest rate swap contracts(20)(26)
Long-term debt, net of discount and issuance costs$6,574 $6,564 
The fair value of our long-term debt was $6,334 million and $6,319 million as of September 30, 2024 and December 31, 2023, respectively, and has been determined using a third-party model that uses significant inputs derived from, or corroborated by, observable market data, including benchmark security prices and Zoetis’ credit spreads (Level 2 inputs).

13 |
The following table provides the principal amount of debt outstanding, as of September 30, 2024, by scheduled maturity date:
After
(MILLIONS OF DOLLARS)202420252026202720282028Total
Maturities$— $1,350 $— $750 $500 $4,050 $6,650 
Interest Expense
Interest expense, net of capitalized interest, was $57 million and $174 million for the three and nine months ended September 30, 2024, respectively, and $59 million and $180 million for the three and nine months ended September 30, 2023, respectively. Capitalized interest expense was $9 million and $26 million for the three and nine months ended September 30, 2024, respectively, and $7 million and $19 million for the three and nine months ended September 30, 2023, respectively.
B. Derivative Financial Instruments
Foreign Exchange Risk
A significant portion of our revenue, earnings and net investment in foreign affiliates is exposed to changes in foreign exchange rates. We seek to manage our foreign exchange risk, in part, through operational means, including managing same-currency revenue in relation to same-currency costs and same-currency assets in relation to same-currency liabilities. Depending on market conditions, foreign exchange risk is also managed through the use of various derivative financial instruments. These derivative financial instruments serve to manage the exposure of our net investment in certain foreign operations to changes in foreign exchange rates and protect net income against the impact of translation into U.S. dollars of certain foreign exchange-denominated transactions.
All derivative financial instruments used to manage foreign currency risk are measured at fair value and are reported as assets or liabilities on the Condensed Consolidated Balance Sheets. The derivative financial instruments primarily offset exposures in the Australian dollar, British pound, Canadian dollar, Chinese renminbi, euro and Norwegian krone. Changes in fair value are reported in earnings or in Accumulated other comprehensive loss, depending on the nature and purpose of the financial instrument, as follows:
•For foreign currency forward-exchange contracts not designated as hedging instruments, we recognize the gains and losses that are used to offset the same foreign currency assets or liabilities immediately into earnings along with the earnings impact of the items they generally offset. These contracts essentially take the opposite currency position of that reflected in the month-end balance sheet to counterbalance the effect of any currency movement. The vast majority of the foreign currency forward-exchange contracts mature within 60 days and all mature within four years.
•For foreign exchange derivative instruments that are designated as hedging instruments against our net investment in foreign operations, changes in the fair value are recorded as a component of cumulative translation adjustment within Accumulated other comprehensive loss and reclassified into earnings when the foreign investment is sold or substantially liquidated. These instruments include cross-currency interest rate swaps and foreign currency forward-exchange contracts. Gains and losses excluded from the assessment of hedge effectiveness are recognized in earnings (Interest expense, net of capitalized interest). The cash flows from these contracts are reflected within the investing section of our Condensed Consolidated Statements of Cash Flows. These contracts have varying maturities and all mature within one year.
Interest Rate Risk
The company may use interest rate swap contracts on certain investing and borrowing transactions to manage its net exposure to interest rates and to reduce its overall cost of borrowing.
•In anticipation of issuing fixed-rate debt, we may use forward-starting interest rate swaps that are designated as cash flow hedges to hedge against changes in interest rates that could impact expected future issuances of debt. Unrealized gains or losses on the forward-starting interest rate swaps are reported in Accumulated other comprehensive loss and are recognized in earnings over the life of the future fixed rate notes. When the company discontinues hedge accounting because it is no longer probable that an anticipated transaction will occur within the originally expected period of execution, or within an additional two-month period thereafter, changes to fair value accumulated in other comprehensive income are recognized immediately in earnings.
•During the period from 2019 to 2022, we entered into forward-starting interest rate swaps with an aggregate notional value of $650 million. We designated these swaps as cash flow hedges against interest rate exposure related principally to the issuance of fixed-rate debt to refinance our 3.250% 2013 senior notes due 2023. Upon issuance of our 2022 senior notes, we terminated these contracts and received $114 million in cash from the counterparties for settlement. The settlement amount, which represented the fair value of the contracts at the time of termination, was recorded in Accumulated other comprehensive loss, and will be amortized into income (offset to Interest expense, net of capitalized interest) over the life of the 5.600% 2022 senior notes due 2032.
•As of September 30, 2024, we had outstanding forward-starting interest rate swaps, having an effective date and mandatory termination date in March 2026, to hedge against interest rate exposure related principally to the anticipated future issuance of fixed-rate debt to be used primarily to refinance our 4.500% 2015 senior notes due 2025.
•We may use fixed-to-floating interest rate swaps that are designated as fair value hedges to hedge against changes in the fair value of certain fixed-rate debt attributable to changes in the benchmark of the Secured Overnight Financing Rate (SOFR). These derivative instruments effectively convert a portion of the company’s long-term debt from fixed-rate to floating-rate debt based on the daily SOFR rate plus a spread. Gains or losses on the fixed-to-floating interest rate swaps due to changes in SOFR are recorded in Interest expense, net of capitalized interest. Changes in the fair value of the fixed-to-floating interest rate swaps are offset by changes in the fair value of the underlying fixed-rate debt. As of September 30, 2024, we had outstanding fixed-to-floating interest rate swaps that correspond to a portion of the 3.900% 2018 senior notes due 2028 and the 2.000% 2020 senior notes due 2030. The amounts recorded during the three and nine

14 |
months ended September 30, 2024 for changes in the fair value of these hedges are not material to our condensed consolidated financial statements.
During the first quarter of 2023, we executed amendments to certain of our interest rate swap contracts, which changed the floating rate index from LIBOR to SOFR. These amendments did not have a material impact on our condensed consolidated financial statements.
Outstanding Positions
The aggregate notional amount of derivative instruments are as follows:
Notional
September 30,December 31,
(MILLIONS)20242023
Derivatives not Designated as Hedging Instruments:
     Foreign currency forward-exchange contracts $1,965 $1,948 
Derivatives Designated as Hedging Instruments:
     Foreign exchange derivative instruments (in foreign currency):
          Euro 750 650 
          Danish krone475 600 
          Swiss franc25 25 
     Forward-starting interest rate swaps $200 $100 
     Fixed-to-floating interest rate swap contracts$250 $250 
Fair Value of Derivative Instruments
The classification and fair values of derivative instruments are as follows:
Fair Value of Derivatives
September 30,December 31,
(MILLIONS OF DOLLARS)Balance Sheet Location20242023
Derivatives Not Designated as Hedging Instruments:
   Foreign currency forward-exchange contractsOther current assets$17 $11 
   Foreign currency forward-exchange contracts
Other current liabilities
(14)(11)
Total derivatives not designated as hedging instruments$3 $— 
Derivatives Designated as Hedging Instruments:
   Forward-starting interest rate swap contractsOther noncurrent assets$12 $12 
   Foreign exchange derivative instruments Other current assets17 5 
   Foreign exchange derivative instruments Other noncurrent assets— 11 
   Foreign exchange derivative instruments Other current liabilities(17)(20)
   Foreign exchange derivative instruments Other noncurrent liabilities— (1)
   Fixed-to-floating interest rate swap contractsOther noncurrent liabilities(20)(26)
Total derivatives designated as hedging instruments(8)(19)
Total derivatives$(5)$(19)
The company’s derivative transactions are subject to master netting agreements that mitigate credit risk by permitting net settlement of transactions with the same counterparty. The company also has collateral security agreements with certain of its counterparties. Under these collateral security agreements each party is required to post cash collateral when the net fair value of derivative instruments covered by the collateral agreement exceeds contractually established thresholds. At September 30, 2024, there was $12 million of collateral received and $22 million of collateral posted related to derivative instruments recorded in Other current liabilities and Other current assets, respectively. At December 31, 2023, there was $13 million of collateral received and $33 million of collateral posted related to derivative instruments recorded in Other current liabilities and Other current assets, respectively.
We use a market approach in valuing financial instruments on a recurring basis. Our derivative financial instruments are measured at fair value on a recurring basis using Level 2 inputs in the calculation of fair value.
The amounts of net gains/(losses) on derivative instruments not designated as hedging instruments, recorded in Other (income)/deductions—net, are as follows:
Three Months EndedNine Months Ended
September 30,September 30,
(MILLIONS OF DOLLARS)2024202320242023
Foreign currency forward-exchange contracts$11 $16 $12 $(20)

15 |
These amounts were substantially offset in Other (income)/deductions—net by the effect of changing exchange rates on the underlying foreign currency exposures.
The amounts of unrecognized net (losses)/gains on interest rate swap contracts, recorded, net of tax, in Accumulated other comprehensive loss, are as follows:
Three Months EndedNine Months Ended
September 30,September 30,
(MILLIONS OF DOLLARS)2024202320242023
Forward-starting interest rate swap contracts$(3)$5 $— $5 
Foreign exchange derivative instruments$(23)$18 $(5)$5 
Gains on interest rate swap contracts, recognized within Interest expense, net of capitalized interest, are as follows:
Three Months EndedNine Months Ended
September 30,September 30,
(MILLIONS OF DOLLARS)2024202320242023
Foreign exchange derivative instruments$4 $4 $12 $14 
The net amount of deferred gains related to derivative instruments designated as cash flow hedges that is expected to be reclassified from Accumulated other comprehensive loss into earnings over the next 12 months is not material.
10. Inventories
The components of inventory are as follows:
September 30,December 31,
(MILLIONS OF DOLLARS)20242023
Finished goods$1,049 $1,147 
Work-in-process951 966 
Raw materials and supplies416 451 
Inventories$2,416 $2,564 
11. Goodwill and Other Intangible Assets
A. Goodwill
The components of, and changes in, the carrying amount of goodwill are as follows:
(MILLIONS OF DOLLARS)U.S.InternationalTotal
Balance, December 31, 2023$1,532 $1,227 $2,759 
Other(a)
(17)2 (15)
Balance, September 30, 2024$1,515 $1,229 $2,744 
(a)     Includes adjustments for the reclassification of goodwill of $24 million to Assets held for sale related to the planned sale of our medicated feed additive product portfolio, certain water soluble products and related assets, as well as foreign currency translation. For additional information, see Note 5. Acquisitions and Divestitures: B. Divestitures.
The gross goodwill balance was $3,280 million and $3,295 million as of September 30, 2024 and December 31, 2023, respectively. Accumulated goodwill impairment losses were $536 million as of September 30, 2024 and December 31, 2023.

16 |

B. Other Intangible Assets
The components of identifiable intangible assets are as follows:
As of September 30, 2024As of December 31, 2023
IdentifiableIdentifiable
GrossIntangible AssetsGrossIntangible Assets
CarryingAccumulatedLess AccumulatedCarryingAccumulatedLess Accumulated
(MILLIONS OF DOLLARS)AmountAmortizationAmortizationAmountAmortizationAmortization
Finite-lived intangible assets:
Developed technology rights$1,931 $(1,164)$767 $1,986 $(1,101)$885 
Brands and tradenames370 (245)125 383 (246)137 
Other276 (196)80 270 (190)80 
Total finite-lived intangible assets2,577 (1,605)972 2,639 (1,537)1,102 
Indefinite-lived intangible assets:
Brands and tradenames66 — 66 88 — 88 
In-process research and development141 — 141 141 — 141 
Product rights7 — 7 7 — 7 
Total indefinite-lived intangible assets214 — 214 236 — 236 
Identifiable intangible assets$2,791 $(1,605)$1,186 $2,875 $(1,537)$1,338 
C. Amortization
Amortization expense related to finite-lived acquired intangible assets that contribute to our ability to sell, manufacture, research, market and distribute products, compounds and intellectual property is included in Amortization of intangible assets as it benefits multiple business functions. Amortization expense related to finite-lived acquired intangible assets that are associated with a single function is included in Cost of sales, Selling, general and administrative expenses or Research and development expenses, as appropriate. Total amortization expense for finite-lived intangible assets was $42 million and $128 million for the three and nine months ended September 30, 2024, respectively, and $46 million and $141 million for the three and nine months ended September 30, 2023, respectively.
12. Share-based Payments
The Zoetis 2013 Equity and Incentive Plan, Amended and Restated as of May 19, 2022 (Equity Plan), provides long-term incentives to our employees and non-employee directors. The principal types of share-based awards available under the Equity Plan may include, but are not limited to, stock options, restricted stock and restricted stock units (RSUs), deferred stock units (DSUs), performance-vesting restricted stock units (PSUs) and other equity-based or cash-based awards.
The components of share-based compensation expense are as follows:
Three Months EndedNine Months Ended
September 30,September 30,
(MILLIONS OF DOLLARS)2024202320242023
Stock options / stock appreciation rights$2 $3 $8 $6 
RSUs / DSUs10 10 31 27 
PSUs6 4 16 10 
Share-based compensation expense—total(a)
$18 $17 $55 $43 
(a) For the three and nine months ended September 30, 2024 and 2023, we capitalized less than $1 million of share-based compensation expense to inventory.
During the nine months ended September 30, 2024, the company granted 270,450 stock options with a weighted-average exercise price of $195.84 per stock option and a weighted-average fair value of $50.90 per stock option. The fair-value based method for valuing each Zoetis stock option grant on the grant date uses the Black-Scholes-Merton option-pricing model, which incorporates a number of valuation assumptions. The weighted-average fair value was estimated based on the following assumptions: risk-free interest rate of 4.06%; expected dividend yield of 0.88%; expected stock price volatility of 27.02%; and expected term of 4.1 years. Stock options granted prior to 2023 generally vest after three years of continuous service from the date of grant and have a contractual term of 10 years. Beginning in 2023, stock options granted are subject to graded vesting over three years from the date of grant and have a contractual term of 10 years. The values determined through this fair-value based method generally are amortized on a straight-line basis over the vesting term into Cost of sales, Selling, general and administrative expenses, or Research and development expenses, as appropriate.
During the nine months ended September 30, 2024, the company granted 246,112 RSUs, with a weighted-average grant date fair value of $195.10 per RSU. RSUs are accounted for using a fair-value-based method that utilizes the closing price of Zoetis common stock on the date of grant. RSUs granted prior to 2023 generally vest after three years of continuous service from the date of grant. Beginning in 2023, RSUs granted are subject to graded vesting over three years from the date of grant. The values generally are amortized on a straight-line basis over the vesting term into Cost of sales, Selling, general and administrative expenses, or Research and development expenses, as appropriate.
During the nine months ended September 30, 2024, the company granted 101,099 PSUs with a weighted-average grant date fair value of $268.71 per PSU. PSUs are accounted for using a Monte Carlo simulation model. The units underlying the PSUs will be earned and vested over a three-year performance period, based upon the total shareholder return of the company in comparison to the total shareholder return of the companies

17 |
comprising the S&P 500 stock market index at the start of the performance period, excluding companies that during the performance period are acquired or no longer publicly traded (Relative TSR). The weighted-average fair value was estimated based on volatility assumptions of Zoetis common stock and an average of the S&P 500 companies, which were 26.2% and 30.6%, respectively. Depending on the company’s Relative TSR performance at the end of the performance period, the recipient may earn from 0% to 200% of the target number of units. Vested units are settled in shares of the company’s common stock. PSU values are amortized on a straight-line basis over the vesting term into Cost of sales, Selling, general and administrative expenses, or Research and development expenses, as appropriate.
13. Stockholders’ Equity
Zoetis is authorized to issue 6 billion shares of common stock and 1 billion shares of preferred stock.
In December 2021, our Board of Directors authorized a $3.5 billion multi-year share repurchase program. As of September 30, 2024, there was $200 million remaining under this authorization. In August 2024, our Board of Directors authorized a new multi-year share repurchase program of up to $6 billion of our outstanding common stock. Purchases of Zoetis shares may be made at the discretion of management, depending on market conditions, business needs and available liquidity.
Accumulated other comprehensive loss
Changes, net of tax, in accumulated other comprehensive loss, were as follows:
Currency Translation Adjustments
Other CurrencyBenefit PlansAccumulated Other
Cash FlowNet InvestmentTranslationActuarialComprehensive
(MILLIONS OF DOLLARS)HedgesHedgesAdjustmentsGains/(Losses)Loss
Balance, December 31, 2023$85 $18 $(944)$2 $(839)
Other comprehensive loss, net of tax(5)(5)(2)— 

(12)
Balance, September 30, 2024$80 $13 $(946)$2 $(851)
Balance, December 31, 2022$90 $41 $(944)$(4)$(817)
Other comprehensive income/(loss), net of tax— 5 (6)4 3 
Balance, September 30, 2023$90 $46 $(950)$— $(814)
14. Earnings per Share
The following table presents the calculation of basic and diluted earnings per share:
Three Months EndedNine Months Ended
(MILLIONS OF DOLLARS AND SHARES, EXCEPT PER SHARE DATA)September 30,September 30,
2024202320242023
Numerator
Net income before allocation to noncontrolling interests$692 $596 $1,915 $1,817 
Less: Net income/(loss) attributable to noncontrolling interests10 — 10 (2)
Net income attributable to Zoetis Inc.$682 $596 $1,905 $1,819 
Denominator
Weighted-average common shares outstanding452.9 460.3 455.4 461.9 
Common stock equivalents: stock options, RSUs, PSUs and DSUs0.6 1.1 0.7 1.1 
Weighted-average common and potential dilutive shares outstanding453.5 461.4 456.1 463.0 
Earnings per share attributable to Zoetis Inc. stockholders—basic$1.51 $1.29 $4.18 $3.94 
Earnings per share attributable to Zoetis Inc. stockholders—diluted$1.50 $1.29 $4.18 $3.93 
The number of stock options outstanding under the company’s Equity Plan that were excluded from the computation of diluted earnings per share, as the effect would have been antidilutive, were not material for the three and nine months ended September 30, 2024 and 2023.
15. Commitments and Contingencies
We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business. For a discussion of our tax contingencies, see Note 8. Income Taxes.
A. Legal Proceedings
Our non-tax contingencies include, among others, the following:
•    Product liability and other product-related litigation, which can include injury, consumer, off-label promotion, antitrust and breach of contract claims.
•    Commercial and other matters, which can include product-pricing claims and environmental claims and proceedings.
•    Patent litigation, which typically involves challenges to the coverage and/or validity of our patents or those of third parties on various products or processes.

18 |
•    Government investigations, which can involve regulation by national, state and local government agencies in the U.S. and in other countries.
Certain of these contingencies could result in losses, including damages, fines and/or civil penalties, and/or criminal charges, which could be substantial.
We believe that we have strong defenses in these types of matters, but litigation is inherently unpredictable and excessive verdicts do occur. We do not believe that any of these matters will have a material adverse effect on our financial position. However, we could incur judgments, enter into settlements or revise our expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on our results of operations or cash flows in the period in which the amounts are paid.
We have accrued for losses that are both probable and reasonably estimable. Substantially all of these contingencies are subject to significant uncertainties and, therefore, determining the likelihood of a loss and/or the measurement of any loss can be complex. Consequently, we are unable to estimate the range of reasonably possible loss in excess of amounts accrued. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but the assessment process relies on estimates and assumptions that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions.
Amounts recorded for legal and environmental contingencies can result from a complex series of judgments about future events and uncertainties and can rely on estimates and assumptions.
The principal matters to which we are a party are discussed below. In determining whether a pending matter is significant for financial reporting and disclosure purposes, we consider both quantitative and qualitative factors in order to assess materiality, such as, among other things, the amount of damages and the nature of any other relief sought in the proceeding, if such damages and other relief are specified; our view of the merits of the claims and of the strength of our defenses; whether the action purports to be a class action and our view of the likelihood that a class will be certified by the court; the jurisdiction in which the proceeding is pending; any experience that we or, to our knowledge, other companies have had in similar proceedings; whether disclosure of the action would be important to a reader of our financial statements, including whether disclosure might change a reader’s judgment about our financial statements in light of all of the information about the company that is available to the reader; the potential impact of the proceeding on our reputation; and the extent of public interest in the matter. In addition, with respect to patent matters, we consider, among other things, the financial significance of the product protected by the patent.
Ulianopolis, Brazil
In February 2012, the Municipality of Ulianopolis (State of Para, Brazil) filed a complaint against Fort Dodge Saúde Animal Ltda. (FDSAL), a Zoetis entity, and five other large companies alleging that waste sent to a local waste incineration facility for destruction, but that was not ultimately destroyed as the facility lost its operating permit, caused environmental impacts requiring cleanup.
The Municipality is seeking recovery of cleanup costs purportedly related to FDSAL’s share of all waste accumulated at the incineration facility awaiting destruction, and compensatory damages to be allocated among the six defendants. We believe we have strong arguments against the claim, including defense strategies against any claim of joint and several liability.
At the request of the Municipal prosecutor, in April 2012, the lawsuit was suspended for one year. Since that time, the prosecutor has initiated investigations into the Municipality's actions in the matter as well as the efforts undertaken by the six defendants to remove and dispose of their individual waste from the incineration facility. On October 3, 2014, the Municipal prosecutor announced that the investigation remained ongoing and outlined the terms of a proposed Term of Reference (a document that establishes the minimum elements to be addressed in the preparation of an Environmental Impact Assessment), under which the companies would be liable to withdraw the waste and remediate the area.
On March 5, 2015, we presented our response to the prosecutor’s proposed Term of Reference, arguing that the proposed terms were overly general in nature and expressing our interest in discussing alternatives to address the matter. The prosecutor agreed to consider our request to engage a technical consultant to conduct an environmental diagnostic of the contaminated area. On May 29, 2015, we, in conjunction with the other defendant companies, submitted a draft cooperation agreement to the prosecutor, which outlined the proposed terms and conditions for the engagement of a technical consultant to conduct the environmental diagnostic. On August 19, 2016, the parties and the prosecutor agreed to engage the services of a third-party consultant to conduct a limited environmental assessment of the site. The site assessment was conducted during June 2017, and a written report summarizing the results of the assessment was provided to the parties and the prosecutor in November 2017. The report noted that waste is still present on the site and that further (Phase II) environmental assessments are needed before a plan to manage that remaining waste can be prepared. On April 1, 2019, the defendants met with the Prosecutor to discuss the conclusions set forth in the written report. Following that discussion, on April 10, 2019, the Prosecutor issued a procedural order requesting that the defendants prepare and submit a technical proposal outlining the steps needed to conduct the additional Phase II environmental assessments. The defendants presented the technical proposal to the Prosecutor on October 21, 2019. On March 3, 2020, the Prosecutor notified the defendants that he submitted the proposal to the Ministry of the Environment for its review and consideration by the Prosecutor. On July 15, 2020, the Prosecutor recommended certain amendments to the proposal for the Phase II testing. On September 28, 2020, the parties and the Prosecutor agreed to the final terms and conditions concerning the cooperation agreement with respect to the Phase II testing. Phase II testing began the week of October 14, 2024. The consultant will provide a report upon completion of the testing.
B. Guarantees and Indemnifications
In the ordinary course of business and in connection with the sale of assets and businesses, we indemnify our counterparties against certain liabilities that may arise in connection with the transaction or related to activities prior to the transaction. These indemnifications typically pertain to environmental, tax, employee and/or product-related matters and patent-infringement claims. If the indemnified party were to make a successful claim pursuant to the terms of the indemnification, we would be required to reimburse the loss. These indemnifications are generally subject to threshold amounts, specified claim periods and other restrictions and limitations. Historically, we have not paid significant amounts under these provisions and, as of September 30, 2024, recorded amounts for the estimated fair value of these indemnifications were not material.

19 |
16. Segment Information
Operating Segments
We manage our operations through two geographic operating segments: the U.S. and International. Each operating segment has responsibility for its commercial activities. Within each of these operating segments, we offer a diversified product portfolio, including parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, animal health diagnostics and medicated feed additives, for both companion animal and livestock customers. Our chief operating decision maker uses the revenue and earnings of the two operating segments, among other factors, for performance evaluation and resource allocation.
Other Costs and Business Activities
Certain costs are not allocated to our operating segment results, such as costs associated with the following:
•    Other business activities, includes our Client Supply Services contract manufacturing results, our human health business, and expenses associated with our dedicated veterinary medicine research and development organization, research alliances, U.S. regulatory affairs and other operations focused on the development of our products. Other R&D-related costs associated with non-U.S. market and regulatory activities are generally included in the international commercial segment.
•    Corporate, includes enabling functions such as information technology, facilities, legal, finance, human resources, business development, certain diagnostic costs and communications, among others. These costs also include certain compensation costs, certain procurement costs and other miscellaneous operating expenses not charged to our operating segments, as well as interest income and expense.
•Certain transactions and events such as (i) Purchase accounting adjustments, where we incur expenses associated with the amortization of fair value adjustments to inventory, intangible assets and property, plant and equipment; (ii) Acquisition and divestiture-related costs, where we incur costs associated with acquiring and integrating newly acquired businesses, such as transaction costs and integration costs, as well as divestiture-related costs; and (iii) Certain significant items, which comprise substantive, unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis, such as restructuring charges and implementation costs associated with our cost-reduction/productivity initiatives that are not associated with an acquisition or divestiture, certain asset impairment charges, certain legal and commercial settlements and the impact of divestiture-related gains and losses.
•Other unallocated includes (i) certain overhead expenses associated with our global manufacturing operations not charged to our operating segments; (ii) certain costs associated with finance that specifically support our global manufacturing operations; (iii) certain supply chain and global logistics costs; and (iv) certain procurement costs.
Segment Assets
We manage our assets on a total company basis, not by operating segment. Therefore, our chief operating decision maker does not regularly review any asset information by operating segment and, accordingly, we do not report asset information by operating segment.

20 |
Selected Statement of Income Information
Earnings
Depreciation and Amortization(a)
Three Months EndedThree Months Ended
September 30,September 30,
(MILLIONS OF DOLLARS)2024202320242023
U.S.
Revenue$1,346 $1,174 
Cost of sales258 228 
Gross profit1,088 946 
    Gross margin80.8 %80.6 %
Operating expenses199 202 
Other (income)/deductions-net— — 
U.S. Earnings889 744 $20 $19 
International
Revenue(b)
1,021 956 
Cost of sales321 306 
Gross profit700 650 
    Gross margin68.6 %68.0 %
Operating expenses157 156 
Other (income)/deductions-net1 1 
International Earnings542 493 25 24 
Total operating segments1,431 1,237 45 43 
Other business activities
(137)(124)9 9 
Reconciling Items:
Corporate
(306)(258)31 33 
Purchase accounting adjustments
(35)(39)35 39 
Acquisition and divestiture-related costs
(7)(3)— — 
Certain significant items(c)
(1)(23)— — 
Other unallocated
(71)(73)1 — 
Total Earnings(d)
$874 $717 $121 $124 
(a)    Certain production facilities are shared. Depreciation and amortization is allocated to the reportable operating segments based on estimates of where the benefits of the related assets are realized.
(b)    Revenue denominated in euros was $234 million and $206 million for the three months ended September 30, 2024 and 2023, respectively.
(c)    For the three months ended September 30, 2023, primarily consisted of employee termination and exit costs related to organizational structure refinements and other cost-reduction and productivity initiatives, as well as certain asset impairment charges related to our diagnostics and precision animal health businesses.
(d)    Defined as income before provision for taxes on income.

21 |
Earnings
Depreciation and Amortization(a)
Nine Months EndedNine Months Ended
September 30,September 30,
(MILLIONS OF DOLLARS)2024202320242023
U.S.
Revenue$3,817 $3,344 
Cost of sales707 645 
Gross profit3,110 2,699 
    Gross margin81.5 %80.7 %
Operating expenses593 602 
Other (income)/deductions-net— — 
U.S. Earnings2,517 2,097 $65 $58 
International
Revenue(b)
3,063 2,929 
Cost of sales976 912 
Gross profit2,087 2,017 
    Gross margin68.1 %68.9 %
Operating expenses491 473 
Other (income)/deductions-net1 1 
International Earnings1,595 1,543 73 67 
Total operating segments4,112 3,640 138 125 
Other business activities
(411)(354)29 24 
Reconciling Items:
Corporate
(893)(722)96 95 
Purchase accounting adjustments
(107)(124)107 118 
Acquisition and divestiture-related costs
(12)(8)— — 
Certain significant items(c)
(77)45 — — 
Other unallocated
(211)(191)4 3 
Total Earnings(d)
$2,401 $2,286 $374 $365 
(a)    Certain production facilities are shared. Depreciation and amortization is allocated to the reportable operating segments based on estimates of where the benefits of the related assets are realized.
(b)    Revenue denominated in euros was $694 million and $627 million for the nine months ended September 30, 2024 and 2023, respectively.
(c)    For the nine months ended September 30, 2024, primarily consisted of employee termination costs related to organizational structure refinements, a loss on assets held for sale related to the planned sale of our medicated feed additive product portfolio, certain water soluble products and related assets, as well as asset impairment charges related to our aquaculture business, partially offset by a reversal of certain employee termination costs as a result of a change in strategy from our 2015 operational efficiency initiative.
For the nine months ended September 30, 2023, primarily consisted of a gain on the sale of a majority interest in our pet insurance business, partially offset by employee termination costs related to organizational structure refinements and certain asset impairment charges related to our precision animal health and diagnostics businesses.
(d)    Defined as income before provision for taxes on income.
17. Subsequent Event
On October 31, 2024, we completed the divestiture of our medicated feed additive product portfolio, certain water soluble products and related assets. We do not expect the closing of the divestiture to have a material impact to our consolidated financial statements. See Note 5. Acquisitions and Divestitures for additional information regarding the transaction.

22 |
Item 2.    Management’s Discussion and Analysis of Financial Condition and Results of Operations
Overview of our business
Zoetis is a global leader in the animal health industry, focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. For over 70 years, we have been innovating ways to predict, prevent, detect, and treat animal illness, and continue to stand by those raising and caring for animals worldwide - from veterinarians and pet owners to livestock farmers and ranchers.
We manage our operations through two geographic operating segments: the United States (U.S.) and International. Within each of these operating segments, we offer a diversified product portfolio for both companion animal and livestock customers in order to capitalize on local and regional trends and customer needs. See Notes to Condensed Consolidated Financial Statements — Note 16. Segment Information.
We directly market our products to veterinarians and livestock producers located in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America, and are a market leader in nearly all of the major regions in which we operate. Through our efforts to establish an early and direct presence in many emerging markets, such as Brazil, Chile, China and Mexico, we believe we are one of the largest animal health medicines and vaccines businesses as measured by revenue across emerging markets as a whole. In markets where we do not have a direct commercial presence, we generally contract with distributors that provide logistics and sales and marketing support for our products.
Our companion animal and livestock products are primarily available by prescription through a veterinarian. On a more limited basis, in certain markets, we sell certain products through retail and e-commerce outlets. We also market our products by advertising to veterinarians, livestock producers and pet owners.
We believe our investments in one of the industry’s largest sales organizations, including our extensive network of technical and veterinary operations specialists, our high-quality manufacturing and reliability of supply, and our long track record of developing products that meet customer needs, has led to enduring and valued relationships with our customers. Our research and development (R&D) efforts enable us to deliver innovative products to address unmet needs and evolve our product lines so that they remain relevant for our customers.
We have approximately 300 product lines that we sell in over 100 countries for the prediction, prevention, detection and treatment of diseases and conditions that affect various companion animal and livestock species. The diversity of our product portfolio and our global operations provides stability to our overall business. For instance, in livestock, impacts on our revenue that may result from disease outbreaks or weather conditions in a particular market or region are often offset by increased sales in other regions from exports and other species as consumers shift to other animal proteins.
A summary of our 2024 performance compared with the comparable 2023 periods follows:
% Change
Three Months EndedRelated to
September 30,Foreign
(MILLIONS OF DOLLARS)20242023TotalExchange
Operational(a)
Revenue$2,388 $2,151 11 (3)14 
Net income attributable to Zoetis682 596 14 (2)16 
Adjusted net income(a)
716 629 14 (1)15 
% Change
Nine Months EndedRelated to
September 30,Foreign
(MILLIONS OF DOLLARS)20242023TotalExchange
Operational(a)
Revenue$6,939 $6,331 10 (2)12 
Net income attributable to Zoetis1,905 1,819 5 (9)14 
Adjusted net income(a)
2,061 1,888 9 (7)16 
(a)    Operational results and adjusted net income are non-GAAP financial measures. See the Non-GAAP financial measures section of this Management’s Discussion and Analysis of Financial Condition and Results of Operations (MD&A) for more information.
Our operating environment
For a description of our operating environment, including factors which could materially affect our business, financial condition, or future results, see "Our Operating Environment" in the MD&A of our 2023 Annual Report on Form 10-K. Set forth below are updates to certain of the factors disclosed in our 2023 Annual Report on Form 10-K.
Quarterly Variability of Financial Results
Our quarterly financial results are subject to variability related to a number of factors including, but not limited to: the decline in global macroeconomic conditions, competitive dynamics, the regional conflict in the Middle East, geopolitical tensions with and economic uncertainty in China, inflation, global supply chain disruption, variability in distributor inventory stocking levels as a result of expected demand and promotional activities, weather patterns, herd management decisions, regulatory actions, disease outbreaks, product and geographic mix, timing of price increases and timing of investment decisions.

23 |
Disease Outbreaks
Sales of our livestock products have in the past, and may in the future be, adversely affected by the outbreak of disease carried by animals. Outbreaks of disease may reduce regional or global sales of particular animal-derived food products or result in reduced exports of such products, either due to heightened export restrictions or import prohibitions, which may reduce demand for our products. Also, the outbreak of any highly contagious disease near our main production sites could require us to immediately halt production of our products at such sites or force us to incur substantial expenses in procuring raw materials or products elsewhere. Alternatively, sales of products that treat specific disease outbreaks may increase.
Foreign Exchange Rates
Significant portions of our revenue and costs are exposed to changes in foreign exchange rates. Our products are sold in more than 100 countries and, as a result, our revenue is influenced by changes in foreign exchange rates. For the nine months ended September 30, 2024, approximately 41% of our revenue was denominated in foreign currencies. We seek to manage our foreign exchange risk, in part, through operational means, including managing same-currency revenue in relation to same-currency costs and same-currency assets in relation to same-currency liabilities. As we operate in multiple foreign currencies, including the Australian dollar, Brazilian real, British pound, Canadian dollar, Chinese renminbi, euro and other currencies, changes in those currencies relative to the U.S. dollar will impact our revenue, cost of goods and expenses, and consequently, net income. Exchange rate fluctuations may also have an impact beyond our reported financial results and directly impact operations. These fluctuations may affect the ability to buy and sell our goods and services between markets impacted by significant exchange rate variances. For the nine months ended September 30, 2024, approximately 59% of our total revenue was in U.S. dollars. Our year-over-year total revenue growth was unfavorably impacted by approximately 2% from changes in foreign currency values relative to the U.S. dollar. For operations in highly inflationary economies, we translate monetary items at rates in effect at the balance sheet date, with translation adjustments recorded in Other (income)/deductions––net, and we translate non-monetary items at historical rates.
Non-GAAP financial measures
We report information in accordance with U.S. generally accepted accounting principles (GAAP). Management also measures performance using non-GAAP financial measures that may exclude certain amounts from the most directly comparable GAAP measure. Despite the importance of these measures to management in goal setting and performance measurement, non-GAAP financial measures have no standardized meaning prescribed by U.S. GAAP and, therefore, have limits in their usefulness to investors and may not be comparable to the calculation of similar measures of other companies. We present certain identified non-GAAP measures solely to provide investors with useful information to more fully understand how management assesses performance.
Operational Results
We believe that it is important to not only understand overall revenue and earnings results, but also “operational" results. Operational results is a non-GAAP financial measure defined as revenue or earnings results excluding the impact of foreign exchange. This measure provides information on the change in revenue and earnings as if foreign currency exchange rates had not changed between the current and prior periods to facilitate a period-to-period comparison. We believe this non-GAAP measure provides a useful comparison to previous periods for the company and investors, but should not be viewed as a substitute for U.S. GAAP reported results.
Adjusted Net Income and Adjusted Earnings Per Share
Adjusted net income and the corresponding adjusted earnings per share (EPS) are non-GAAP financial measures of performance used by management. We believe these financial measures are useful supplemental information to investors when considered together with our U.S. GAAP financial measures. We report adjusted net income to portray the results of our major operations, and the discovery, development, manufacture and commercialization of our products, prior to considering certain income statement elements. We define adjusted net income and adjusted EPS as net income attributable to Zoetis and EPS before the impact of purchase accounting adjustments, acquisition and divestiture-related costs and certain significant items.
We recognize that, as an internal measure of performance, the adjusted net income and adjusted EPS measures have limitations, and we do not restrict our performance management process solely to these metrics. A limitation of the adjusted net income and adjusted EPS measures is that they provide a view of our operations without including all events during a period, such as the effects of an acquisition, divestiture or amortization of purchased intangibles, and do not provide a comparable view of our performance to other companies. The adjusted net income and adjusted EPS measures are not, and should not be viewed as, a substitute for U.S. GAAP reported net income attributable to Zoetis and reported EPS. See the Adjusted Net Income section below for more information.

24 |

Analysis of the condensed consolidated statements of income
The following discussion and analysis of our statements of income should be read along with our condensed consolidated financial statements and the notes thereto included elsewhere in Part I— Item 1 of this Quarterly Report on Form 10-Q.
Three Months EndedNine Months Ended
September 30,%September 30,%
(MILLIONS OF DOLLARS)20242023Change20242023Change
Revenue$2,388 $2,151 11 $6,939 $6,331 10 
Costs and expenses:
Cost of sales701 638 10 2,012 1,833 10 
% of revenue29.4 %29.7 %29.0 %29.0 %
Selling, general and administrative expenses565 525 8 1,693 1,586 7 
% of revenue24 %24 %24 %25 %
Research and development expenses167 152 10 500 440 14 
% of revenue7 %7 %7 %7 %
Amortization of intangible assets35 38 (8)107 112 (4)
Restructuring charges and certain acquisition and divestiture-related costs5 16 (69)51 45 13 
Interest expense, net of capitalized interest57 59 (3)174 180 (3)
Other (income)/deductions—net(16)6 *1 (151)*
Income before provision for taxes on income874 717 22 2,401 2,286 5 
% of revenue37 %33 %35 %36 %
Provision for taxes on income182 121 50 486 469 4 
Effective tax rate20.8 %16.9 %20.2 %20.5 %
Net income before allocation to noncontrolling interests692 596 16 1,915 1,817 5 
Less: Net income/(loss) attributable to noncontrolling interests10 — — 10 (2)*
Net income attributable to Zoetis Inc.$682 $596 14 $1,905 $1,819 5 
% of revenue29 %28 %27 %29 %
*Calculation not meaningful
Revenue
Three months ended September 30, 2024 vs. three months ended September 30, 2023
Total revenue increased by $237 million, or 11%, in the three months ended September 30, 2024, compared with the three months ended September 30, 2023, an increase of $297 million, or 14%, on an operational basis. Operational revenue growth was comprised primarily of the following:
•price growth of approximately 6%;
•volume growth from new products of approximately 3%;
•volume growth from other in-line products of approximately 3%; and
•volume growth from key dermatology products of approximately 2%.
Foreign exchange decreased reported revenue growth by approximately 3%.
Nine months ended September 30, 2024 vs. nine months ended September 30, 2023
Total revenue increased by $608 million, or 10%, in the nine months ended September 30, 2024, compared with the nine months ended September 30, 2023, an increase of $779 million, or 12%, on an operational basis. Operational revenue growth was comprised primarily of the following:
•price growth of approximately 7%;
•volume growth from new products of approximately 3%; and
•volume growth from key dermatology products of approximately 2%.
Foreign exchange decreased reported revenue growth by approximately 2%.

25 |
Costs and Expenses
Cost of sales
Three Months EndedNine Months Ended
September 30,% September 30,%
(MILLIONS OF DOLLARS)20242023Change20242023Change
Cost of sales$701 $638 10 $2,012 $1,833 10 
% of revenue29.4 %29.7 %29.0 %29.0 %
Three months ended September 30, 2024 vs. three months ended September 30, 2023
Cost of sales as a percentage of revenue was 29.4% in the three months ended September 30, 2024, compared with 29.7% in the three months ended September 30, 2023. The decrease was primarily as a result of:
•price increases;
•favorable product mix;
•lower inventory charges; and
•favorable foreign exchange,
partially offset by:
•unfavorable manufacturing and other costs; and
•higher freight costs.
Nine months ended September 30, 2024 vs. nine months ended September 30, 2023
Cost of sales as a percentage of revenue remained flat at 29.0% in the nine months ended September 30, 2024, compared with the nine months ended September 30, 2023 primarily as a result of:
•price increases;
•favorable product mix;
•lower freight costs; and
•lower inventory charges,
fully offset by:
•unfavorable manufacturing and other costs; and
•unfavorable foreign exchange.
Selling, general and administrative expenses
Three Months EndedNine Months Ended
September 30,%September 30,%
(MILLIONS OF DOLLARS)20242023Change20242023Change
Selling, general and administrative expenses$565 $525 8 $1,693 $1,586 7 
% of revenue24 %24 %24 %25 %
Three months ended September 30, 2024 vs. three months ended September 30, 2023
SG&A expenses increased by $40 million, or 8%, in the three months ended September 30, 2024, compared with the three months ended September 30, 2023, primarily as a result of:
•an increase in certain compensation-related costs;
•higher professional and consulting costs;
•higher selling and distribution costs; and
•increased technology project investments,
partially offset by:
•favorable foreign exchange;
•lower advertising and promotion costs due to timing of marketing activities; and
•lower contract labor costs.
Nine months ended September 30, 2024 vs. nine months ended September 30, 2023
SG&A expenses increased by $107 million, or 7%, in the nine months ended September 30, 2024, compared with the nine months ended September 30, 2023, primarily as a result of:
•an increase in certain compensation-related costs;
•higher selling and distribution costs;
•higher professional and consulting fees;
•higher logistics and freight costs; and

26 |
•an increase in technology project investments,
partially offset by:
•favorable foreign exchange;
•the reduced impact of purchase accounting adjustments; and
•lower advertising and promotion costs due to timing of marketing activities.
Research and development expenses
Three Months EndedNine Months Ended
September 30,%September 30,%
(MILLIONS OF DOLLARS)20242023Change20242023Change
Research and development expenses$167 $152 10 $500 $440 14 
% of revenue7 %7 %7 %7 %
Three months ended September 30, 2024 vs. three months ended September 30, 2023
R&D expenses increased by $15 million, or 10%, in the three months ended September 30, 2024, compared with the three months ended September 30, 2023, primarily as a result of:
•an increase in certain compensation-related costs to support innovation and portfolio progression;
•higher spend in project investments;
•increased costs due to recent acquisitions; and
•higher depreciation expense.
Nine months ended September 30, 2024 vs. nine months ended September 30, 2023
R&D expenses increased by $60 million, or 14%, in the nine months ended September 30, 2024, compared with the nine months ended September 30, 2023, primarily as a result of:
•an increase in certain compensation-related costs to support innovation and portfolio progression;
•higher spend in project investments;
•increased costs due to recent acquisitions;
•higher other operating costs; and
•higher depreciation expense.
Amortization of intangible assets
Three Months EndedNine Months Ended
September 30,%September 30,%
(MILLIONS OF DOLLARS)20242023Change20242023Change
Amortization of intangible assets$35 $38 (8)$107 $112 (4)
Amortization of intangible assets decreased in the three and nine months ended versus the comparable prior year periods primarily due to asset impairments taken in 2023 and assets that became fully amortized, partially offset by intangible assets placed in service in 2023.
Restructuring charges and certain acquisition and divestiture-related costs
Three Months EndedNine Months Ended
September 30,%September 30,%
(MILLIONS OF DOLLARS)20242023Change20242023Change
Restructuring charges and certain acquisition and divestiture-related costs$5 $16 (69)$51 $45 13 
Three months ended September 30, 2024 vs. three months ended September 30, 2023
Restructuring charges and certain acquisition and divestiture-related costs were $5 million and $16 million in the three months ended September 30, 2024 and 2023, respectively. Restructuring charges and certain acquisition and divestiture-related costs in the three months ended September 30, 2024 primarily consisted of costs related to the planned sale of our medicated feed additive product portfolio, certain water soluble products and related assets. Restructuring charges and certain acquisition and divestiture-related costs in the three months ended September 30, 2023 primarily consisted of employee termination and exit costs related to organizational structure refinements and other cost-reduction and productivity initiatives, as well as costs related to recent acquisitions.
Nine months ended September 30, 2024 vs. nine months ended September 30, 2023
Restructuring charges and certain acquisition and divestiture-related costs were $51 million and $45 million in the nine months ended September 30, 2024 and 2023, respectively. Restructuring charges and certain acquisition and divestiture-related costs for the nine months ended September 30, 2024 primarily consisted of employee termination costs related to organizational structure refinements, as well as costs related to the planned sale of our medicated feed additive product portfolio, certain water soluble products and related assets, partially offset by a reversal of certain employee

27 |
termination costs as a result of a change in strategy from our 2015 operational efficiency initiative. Restructuring charges and certain acquisition and divestiture-related costs in the nine months ended September 30, 2023 primarily consisted of employee termination and exit costs related to organizational structure refinements and other cost-reduction and productivity initiatives, as well as costs related to recent acquisitions.
Interest expense, net of capitalized interest
Three Months EndedNine Months Ended
September 30,%September 30,%
(MILLIONS OF DOLLARS)20242023Change20242023Change
Interest expense, net of capitalized interest$57 $59 (3)$174 $180 (3)
Three months ended September 30, 2024 vs. three months ended September 30, 2023
Interest expense, net of capitalized interest, decreased in the three months ended September 30, 2024 versus the comparable prior year period. The decrease was primarily as a result of higher capitalized interest in the current period associated with capital projects to support our future growth.
Nine months ended September 30, 2024 vs. nine months ended September 30, 2023
Interest expense, net of capitalized interest, decreased in the nine months ended September 30, 2024 versus the comparable prior year period. The decrease was primarily as a result of higher capitalized interest in the current period associated with capital projects to support our future growth and a higher debt balance during a portion of the prior year period.
Other (income)/deductions—net
Three Months EndedNine Months Ended
September 30,%September 30,%
(MILLIONS OF DOLLARS)20242023Change20242023Change
Other (income)/deductions—net$(16)$6 *$1 $(151)*
* Calculation not meaningful
Three months ended September 30, 2024 vs. three months ended September 30, 2023
The change in Other (income)/deductions—net in the three months ended September 30, 2024 versus the comparable prior year period was primarily as a result of lower foreign currency losses in the current period and certain asset impairment charges related to our diagnostics and precision animal health businesses in the prior year period.
Nine months ended September 30, 2024 vs. nine months ended September 30, 2023
The change in Other (income)/deductions—net in the nine months ended September 30, 2024 versus the comparable prior year period was primarily as a result of a gain on the sale of a majority interest in our pet insurance business in the prior year period, royalty-related income in the prior year period that was predominantly associated with a settlement received from a third-party for underpayment of royalties related to prior periods, a loss on assets held for sale related to the planned sale of our medicated feed additive product portfolio, certain water soluble products and related assets in the current period, as well as certain asset impairment charges related to our aquaculture business in the current period, partially offset by certain asset impairment charges related to our precision animal health and diagnostics businesses in the prior year period.
Provision for taxes on income
Three Months EndedNine Months Ended
September 30,%September 30,%
(MILLIONS OF DOLLARS)20242023Change20242023Change
Provision for taxes on income
$182 $121 50 $486 $469 4 
Effective tax rate
20.8 %16.9 %20.2 %20.5 %
The global minimum tax provisions (Pillar Two) resulting from the OECD Base Erosion and Profit Shifting project are effective beginning in 2024 and the impact of these provisions is included in our effective tax rate for the three and nine months ended September 30, 2024.
Three months ended September 30, 2024 vs. three months ended September 30, 2023
Our effective tax rate was 20.8% and 16.9% for the three months ended September 30, 2024 and 2023, respectively. The higher effective tax rate for the three months ended September 30, 2024, compared with the three months ended September 30, 2023, was primarily attributable to a benefit from the tax loss on the divestiture of Performance Livestock Analytics recorded in the third quarter of 2023, higher net discrete tax expenses and a less favorable jurisdictional mix of earnings (which includes the impact of the location of earnings and repatriation costs), partially offset by a higher benefit in the U.S. related to foreign-derived intangible income. Jurisdictional mix of earnings can vary depending on repatriation decisions, operating fluctuations in the normal course of business and the impact of non-deductible items and non-taxable items.

28 |
Nine months ended September 30, 2024 vs. nine months ended September 30, 2023
Our effective tax rate was 20.2% and 20.5% for the nine months ended September 30, 2024 and 2023, respectively. The lower effective tax rate for the nine months ended September 30, 2024, compared with the nine months ended September 30, 2023, was primarily attributable to a higher benefit in the U.S. related to foreign-derived intangible income, lower net discrete tax expenses and a more favorable jurisdictional mix of earnings (which includes the impact of the location of earnings and repatriation costs), partially offset by a benefit from the tax loss on the divestiture of Performance Livestock Analytics recorded in the third quarter of 2023. Jurisdictional mix of earnings can vary depending on repatriation decisions, operating fluctuations in the normal course of business and the impact of non-deductible items and non-taxable items.
Operating Segment Results
On a global basis, the mix of revenue between companion animal and livestock products was as follows:
% Change
Three Months EndedRelated to
September 30,Foreign
(MILLIONS OF DOLLARS)20242023TotalExchangeOperational
U.S.
Companion animal$1,068 $908 18 — 18 
Livestock278 266 5 — 5 
1,346 1,174 15 — 15 
International
Companion animal541 506 7 (4)11 
Livestock480 450 7 (8)15 
1,021 956 7 (6)13 
Total
Companion animal1,609 1,414 14 (1)15 
Livestock758 716 6 (5)11 
Contract manufacturing & human health21 21 — (2)2 
$2,388 $2,151 11 (3)14 
% Change
Nine Months EndedRelated to
September 30,Foreign
(MILLIONS OF DOLLARS)20242023TotalExchangeOperational
U.S.
Companion animal$3,046 $2,588 18 — 18 
Livestock771 756 2 — 2 
3,817 3,344 14 — 14 
International
Companion animal1,662 1,540 8 (4)12 
Livestock1,401 1,389 1 (7)8 
3,063 2,929 5 (5)10 
Total
Companion animal4,708 4,128 14 (2)16 
Livestock2,172 2,145 1 (5)6 
Contract manufacturing & human health 59 58 2 — 2 
$6,939 $6,331 10 (2)12 

29 |
Earnings by segment and the operational and foreign exchange changes versus the comparable prior year period were as follows:
% Change
Three Months EndedRelated to
September 30,Foreign
(MILLIONS OF DOLLARS)20242023TotalExchangeOperational
U.S.
Revenue$1,346 $1,174 15 — 15 
Cost of Sales258 228 13 — 13 
Gross Profit1,088 946 15 — 15 
Gross Margin80.8 %80.6 %
Operating Expenses199 202 (1)— (1)
Other (income)/deductions-net— — ***
U.S. Earnings889 744 19 — 19 
International
Revenue1,021 956 7 (6)13 
Cost of Sales321 306 5 (8)13 
Gross Profit700 650 8 (5)13 
Gross Margin68.6 %68.0 %
Operating Expenses157 156 1 (6)7 
Other (income)/deductions-net1 1 — 13 (13)
International Earnings542 493 10 (5)15 
Total operating segments1,431 1,237 16 (2)18 
Other business activities(137)(124)10 
Reconciling Items:
Corporate(306)(258)19 
Purchase accounting adjustments(35)(39)(10)
Acquisition and divestiture-related costs(7)(3)*
Certain significant items(1)(23)(96)
Other unallocated(71)(73)(3)
Total Earnings$874 $717 22 
* Calculation not meaningful

30 |
% Change
Nine Months EndedRelated to
September 30,Foreign
(MILLIONS OF DOLLARS)20242023TotalExchangeOperational
U.S.
Revenue$3,817 $3,344 14 — 14 
Cost of Sales707 645 10 — 10 
Gross Profit3,110 2,699 15 — 15 
Gross Margin81.5 %80.7 %
Operating Expenses593 602 (1)— (1)
Other (income)/deductions-net— — ***
U.S. Earnings2,517 2,097 20 — 20 
International
Revenue3,063 2,929 5 (5)10 
Cost of Sales976 912 7 (3)10 
Gross Profit2,087 2,017 3 (8)11 
Gross Margin68.1 %68.9 %
Operating Expenses491 473 4 (4)8 
Other (income)/deductions-net1 1 — (39)39 
International Earnings1,595 1,543 3 (9)12 
Total operating segments4,112 3,640 13 (3)16 
Other business activities(411)(354)16 
Reconciling Items:
Corporate(893)(722)24 
Purchase accounting adjustments(107)(124)(14)
Acquisition and divestiture-related costs(12)(8)50 
Certain significant items(77)45 *
Other unallocated(211)(191)10 
Total Earnings$2,401 $2,286 5 
* Calculation not meaningful
Three months ended September 30, 2024 vs. three months ended September 30, 2023
U.S. operating segment
U.S. segment revenue increased by $172 million, or 15%, in the three months ended September 30, 2024, compared with the three months ended September 30, 2023, reflecting an increase of $160 million in companion animal products and $12 million in livestock products.
•Companion animal revenue increased primarily due to growth in sales of our mAb products for osteoarthritis (OA) pain, Librela® and Solensia®, Simparica Trio® and key dermatology products.
•Livestock growth was primarily due to increased sales of cattle and swine products. Sales of cattle and swine products grew due to supply availability in the current year compared to the prior year period.
U.S. segment earnings increased by $145 million, or 19%, in the three months ended September 30, 2024, compared with the three months ended September 30, 2023, primarily due to higher revenue, partially offset by higher cost of sales.
International operating segment
International segment revenue increased by $65 million, or 7%, in the three months ended September 30, 2024, compared with the three months ended September 30, 2023. Operational revenue increased by $125 million, or 13%, driven by growth of $58 million in companion animal products and $67 million in livestock products.
•Companion animal operational revenue growth was driven primarily by the growth in sales of key dermatology products, our mAb products for OA pain, Librela and Solensia, small animal parasiticides and vaccine products.
•Livestock operational revenue growth was due to increased sales of cattle, poultry, fish and swine products, partially offset by declines in sheep products. Sales of cattle products grew primarily due to price, increased demand and improved supply, partially offset by market conditions in China. Sales of products in our poultry portfolio grew primarily due to price and key account penetration. Sales of products in our fish portfolio grew due to increased vaccine sales in Norway. Sales of products in our swine portfolio grew as a result of price, favorable market conditions and key market penetration. Sales of sheep products declined primarily due to poor market conditions.
•Additionally, International segment revenue was unfavorably impacted by foreign exchange which decreased revenue by $60 million, or 6%, primarily driven by the Argentinian peso, Brazilian real, Turkish lira, Mexican peso and Japanese yen.

31 |
International segment earnings increased by $49 million, or 10%, in the three months ended September 30, 2024, compared with the three months ended September 30, 2023. Operational earnings growth was $76 million, or 15%, primarily due to higher revenue, partially offset by higher cost of sales and operating expenses.
Nine months ended September 30, 2024 vs. nine months ended September 30, 2023
U.S. operating segment
U.S. segment revenue increased by $473 million, or 14%, in the nine months ended September 30, 2024, compared with the nine months ended September 30, 2023, reflecting an increase of $458 million in companion animal products and $15 million in livestock products.
•Companion animal revenue increased primarily due to growth in sales of Simparica Trio, our mAb products for OA pain, Librela and Solensia and key dermatology products, partially offset by lower sales of our small animal antiemetic product, Cerenia, and small animal diagnostics.
•Livestock growth was due to increased sales of cattle and swine products, partially offset by lower sales of poultry products. Sales of cattle products grew due to timing of supply partially offset by price. Sales of products in our poultry portfolio declined primarily as a result of the expanded use of lower cost alternatives and generic competition.
U.S. segment earnings increased by $420 million, or 20%, in the nine months ended September 30, 2024, compared with the nine months ended September 30, 2023, primarily due to higher revenue and lower operating expenses, partially offset by higher cost of sales.
International operating segment
International segment revenue increased by $134 million, or 5%, in the nine months ended September 30, 2024, compared with the nine months ended September 30, 2023. Operational revenue increased by $305 million, or 10%, driven by growth of $190 million in companion animal products and $115 million in livestock products.
•Companion animal operational revenue growth was driven primarily by the growth in sales of our mAb products for OA pain, Librela and Solensia, key dermatology products, vaccine products and small animal parasiticides.
•Livestock operational revenue growth was due to increased sales of cattle, poultry and fish products, partially offset by a decline in sheep products. Sales of cattle products grew due to price, partially offset by volume declines as compared to the prior year period due to prior year supply recoveries. Sales of products in our poultry portfolio grew due to price and demand generation efforts in key poultry markets. Sales of our fish portfolio grew due to increased vaccine sales in Norway, partially offset by lower sales of anti-infective products in Chile. Sales of sheep products declined primarily due to poor market conditions.
•Additionally, International segment revenue was unfavorably impacted by foreign exchange which decreased revenue by $171 million, or 5%, primarily driven by the Argentinian peso, Turkish lira, Japanese yen, Brazilian real, Chinese renminbi and Russian ruble.
International segment earnings increased by $52 million, or 3%, in the nine months ended September 30, 2024, compared with the nine months ended September 30, 2023. Operational earnings growth was $179 million, or 12%, primarily due to higher revenue, partially offset by higher cost of sales and operating expenses.
Other business activities
Other business activities includes our Client Supply Services contract manufacturing results, our human health business and expenses associated with our dedicated veterinary medicine research and development organization, research alliances, U.S. regulatory affairs and other operations focused on the development of our products. Other R&D-related costs associated with non-U.S. market and regulatory activities are generally included in the International segment.
Three months ended September 30, 2024 vs. three months ended September 30, 2023
Other business activities net loss increased by $13 million in the three months ended September 30, 2024, compared with the three months ended September 30, 2023, reflecting an increase in R&D costs due to an increase in higher project investments, certain compensation-related costs to support innovation, acquisitions and other operating costs.
Nine months ended September 30, 2024 vs. nine months ended September 30, 2023
Other business activities net loss increased by $57 million in the nine months ended September 30, 2024, compared with the nine months ended September 30, 2023, reflecting an increase in R&D costs due to an increase in higher project investments, certain compensation-related costs to support innovation, acquisitions and other operating costs.
Reconciling items
Reconciling items include certain costs that are not allocated to our operating segments results, such as costs associated with the following:
•Corporate, which includes certain costs associated with information technology, facilities, legal, finance, human resources, business development, certain diagnostic costs and communications, among others. These costs also include certain compensation costs, certain procurement costs, and other miscellaneous operating expenses that are not charged to our operating segments, as well as interest income and expense;
•Certain transactions and events such as Purchase accounting adjustments, Acquisition and divestiture-related costs and Certain significant items, which are defined below; and
•Other unallocated, which includes (i) certain overhead expenses associated with our global manufacturing operations not charged to our operating segments; (ii) certain costs associated with finance that specifically support our global manufacturing operations; (iii) certain supply chain and global logistics costs; and (iv) certain procurement costs.

32 |
Three months ended September 30, 2024 vs. three months ended September 30, 2023
Corporate expenses increased by $48 million, or 19%, in the three months ended September 30, 2024, compared with the three months ended September 30, 2023, primarily due to higher compensation-related costs and investments in information technology.
Other unallocated expenses decreased by $2 million, or 3%, in the three months ended September 30, 2024, compared with the three months ended September 30, 2023, primarily due to higher manufacturing costs and freight charges, partially offset by lower scrap charges and favorable foreign exchange.
Nine months ended September 30, 2024 vs. nine months ended September 30, 2023
Corporate expenses increased by $171 million, or 24%, in the nine months ended September 30, 2024, compared with the nine months ended September 30, 2023, primarily due to higher compensation-related costs, a settlement received from a third-party for underpayment of royalties in the prior year period, unfavorable foreign exchange and investments in information technology.
Other unallocated expenses increased by $20 million, or 10%, in the nine months ended September 30, 2024, compared with the nine months ended September 30, 2023, primarily due to unfavorable foreign exchange, higher manufacturing costs, higher inventory obsolescence, scrap and other charges, partially offset by lower freight charges.
See Notes to Condensed Consolidated Financial Statements—Note 16. Segment Information for further information.
Adjusted net income
General description of adjusted net income (a non-GAAP financial measure)
Adjusted net income is an alternative view of performance used by management, and we believe that investors’ understanding of our performance is enhanced by disclosing this performance measure. The adjusted net income measure is an important internal measurement for us. Additionally, we measure our overall performance on this basis in conjunction with other performance metrics. The following are examples of how the adjusted net income measure is utilized:
•senior management receives a monthly analysis of our operating results that is prepared on an adjusted net income basis;
•our annual budgets are prepared on an adjusted net income basis; and
•other goal setting and performance measurements.
Purchase accounting adjustments
Adjusted net income is calculated prior to considering certain significant purchase accounting impacts that result from business combinations and net asset acquisitions. These impacts, primarily associated with certain acquisitions, include amortization related to the increase in fair value of the acquired finite-lived intangible assets and depreciation related to the increase/decrease to fair value of the acquired fixed assets. Therefore, the adjusted net income measure includes the revenue earned upon the sale of the acquired products without considering the aforementioned significant charges.
While certain purchase accounting adjustments can occur through 20 or more years, this presentation provides an alternative view of our performance that is used by management to internally assess business performance. We believe the elimination of amortization attributable to acquired intangible assets provides management and investors an alternative view of our business results by providing a degree of parity to internally developed intangible assets for which R&D costs previously have been expensed.
A completely accurate comparison of internally developed intangible assets and acquired intangible assets cannot be achieved through adjusted net income. These components of adjusted net income are derived solely from the impact of the items listed above. We have not factored in the impact of any other differences in experience that might have occurred if we had discovered and developed those intangible assets on our own, and this approach does not intend to be representative of the results that would have occurred in those circumstances. For example, our R&D costs in total, and in the periods presented, may have been different; our speed to commercialization and resulting revenue, if any, may have been different; or our costs to manufacture may have been different. In addition, our marketing efforts may have been received differently by our customers. As such, in total, there can be no assurance that our adjusted net income amounts would have been the same as presented had we discovered and developed the acquired intangible assets.
Acquisition and divestiture-related costs
Adjusted net income is calculated prior to considering transaction, integration and disintegration costs associated with significant business combinations, net asset acquisitions and divestitures. These incremental costs are excluded as they are incurred to acquire and integrate, or dispose and disintegrate, certain businesses as a result of the acquisition or disposal decision and are unique to each transaction. We have made no adjustments for the resulting synergies from these transactions.
We believe that viewing income prior to considering these charges provides investors with a useful additional perspective because the significant costs incurred in a business combination, net asset acquisition or divestiture result primarily from the need to eliminate duplicate assets, activities or employees––a natural result of acquiring or disposing of a fully integrated set of activities. For this reason, we believe that the costs incurred to convert disparate systems, to close duplicative facilities or to eliminate duplicate positions (for example, in the context of a business combination) can be viewed differently from those costs incurred in the ordinary course of business.
The integration and disintegration costs associated with a business combination, asset acquisition or divestiture may occur over several years, with the more significant impacts generally ending within three years of the transaction. Because of the need for certain external approvals for some actions, the span of time needed to achieve certain restructuring, integration or disintegration activities can be lengthy. For example, due to the regulated nature of the animal health medicines, vaccines and diagnostic business, the closure of excess facilities can take several years, as all manufacturing changes are subject to extensive validation and testing and must be approved by the U.S. Food and Drug Administration and/or other regulatory authorities.

33 |
Certain significant items
Adjusted net income is calculated excluding certain significant items. Certain significant items represent substantive, unusual items that are evaluated on an individual basis. Such evaluation considers both the quantitative and the qualitative aspect of their unusual nature. Unusual, in this context, may represent items that are not part of our ongoing business; items that, either as a result of their nature or size, we would not expect to occur as part of our normal business on a regular basis; items that would be nonrecurring; or items that relate to products that we no longer sell. While not all-inclusive, examples of items that could be included as certain significant items would be costs related to a major non-acquisition or divestiture-related restructuring charge and associated implementation costs for a program that is specific in nature with a defined term, such as those related to our non-acquisition or divestiture-related cost-reduction and productivity initiatives; amounts related to disposals of products or facilities that do not qualify as discontinued operations as defined by U.S. GAAP; certain asset impairment charges; adjustments related to the resolution of certain tax positions; significant currency devaluation; the impact of adopting certain significant, event-driven tax legislation; or charges related to legal matters. See Notes to Condensed Consolidated Financial Statements—Note 15. Commitments and Contingencies. Our normal, ongoing defense costs or settlements of and accruals on legal matters made in the normal course of our business would not be considered certain significant items.
Reconciliation
A reconciliation of net income attributable to Zoetis, as reported under U.S. GAAP, to adjusted net income follows:
Three Months EndedNine Months Ended
September 30,%September 30,%
(MILLIONS OF DOLLARS)20242023Change20242023Change
GAAP reported net income attributable to Zoetis$682 $596 14 $1,905 $1,819 5 
Purchase accounting adjustments—net of tax27 30 (10)83 98 (15)
Acquisition and divestiture-related costs—net of tax5 3 67 9 7 29 
Certain significant items—net of tax2 — *64 (36)*
Non-GAAP adjusted net income(a)
$716 $629 14 $2,061 $1,888 9 
*Calculation not meaningful
(a)    The effective tax rate on adjusted pretax income was 20.8% and 19.6% for the three months ended September 30, 2024 and 2023, respectively.
The higher effective tax rate for the three months ended September 30, 2024, compared with the three months ended September 30, 2023, was primarily attributable to a less favorable jurisdictional mix of earnings (which includes the impact of the location of earnings and repatriation costs) and higher net discrete tax expenses, partially offset by a higher benefit in the U.S. related to foreign-derived intangible income. Jurisdictional mix of earnings can vary depending on repatriation decisions, operating fluctuations in the normal course of business and the impact of non-deductible and non-taxable items.
The effective tax rate on adjusted pretax income was 20.3% and 20.5% for the nine months ended September 30, 2024 and 2023, respectively.
The lower effective tax rate for the nine months ended September 30, 2024, compared with the nine months ended September 30, 2023, was primarily attributable to a higher benefit in the U.S. related to foreign-derived intangible income and a lower net discrete tax expenses, partially offset by a less favorable jurisdictional mix of earnings (which includes the impact of the location of earnings and repatriation costs). Jurisdictional mix of earnings can vary depending on repatriation decisions, operating fluctuations in the normal course of business and the impact of non-deductible and non-taxable items.
A reconciliation of reported diluted earnings per share (EPS), as reported under U.S. GAAP, to non-GAAP adjusted diluted EPS follows:
Three Months EndedNine Months Ended
September 30,%September 30,%
20242023Change20242023Change
Earnings per share—diluted(a):
GAAP reported EPS attributable to Zoetis —diluted$1.50 $1.29 16 $4.18 $3.93 6 
Purchase accounting adjustments—net of tax0.06 0.06 — 0.18 0.21 (14)
Acquisition and divestiture-related costs—net of tax0.01 0.01 — 0.02 0.02 — 
Certain significant items—net of tax0.01 — *0.14 (0.08)*
Non-GAAP adjusted EPS—diluted$1.58 $1.36 16 $4.52 $4.08 11 
* Calculation not meaningful
(a)    Diluted earnings per share was computed using the weighted-average common shares outstanding during the period plus the common stock equivalents related to stock options, restricted stock units, performance-vesting restricted stock units and deferred stock units.
Adjusted net income includes the following charges for each of the periods presented:
Three Months EndedNine Months Ended
September 30,September 30,
(MILLIONS OF DOLLARS)2024202320242023
Interest expense, net of capitalized interest$57 $59 $174 $180 
Interest income23 23 79 77 
Income taxes191 153 526 487 
Depreciation79 76 242 220 
Amortization7 9 25 27 

34 |
Adjusted net income, as shown above, excludes the following items:
Three Months EndedNine Months Ended
September 30,September 30,
(MILLIONS OF DOLLARS)2024202320242023
Purchase accounting adjustments:
Amortization and depreciation$35 $39 $107 $118 
Cost of sales— — — 6 
Total purchase accounting adjustments—pre-tax35 39 107 124 
Income taxes(a)
8 9 24 26 
Total purchase accounting adjustments—net of tax27 30 83 98 
Acquisition and divestiture-related costs:
Acquisition-related costs— 3 1 7 
Divestiture-related costs(b)
7 — 11 — 
Restructuring costs— — — 1 
Total acquisition and divestiture-related costs—pre-tax7 3 12 8 
Income taxes(a)
2 — 3 1 
Total acquisition and divestiture-related costs—net of tax5 3 9 7 
Certain significant items:
Other restructuring charges and cost-reduction/productivity initiatives(c)
(2)12 39 36 
Certain asset impairment charges(d)
— 11 11 21 
Loss on assets held for sale(e)
— — 22 — 
Net gain on sale of business(f)
— — — (101)
Other3 — 5 (1)
Total certain significant items—pre-tax1 23 77 (45)
Income taxes(a)
(1)23 13 (9)
Total certain significant items—net of tax2 — 64 (36)
Total purchase accounting adjustments, acquisition and divestiture-related costs, and certain significant items—net of tax$34 $33 $156 $69 
(a)    Income taxes include the tax effect of the associated pre-tax amounts, calculated by determining the jurisdictional location of the pre-tax amounts and applying that jurisdiction’s applicable tax rate. For the three and nine months ended September 30, 2023, income taxes in Certain significant items also includes a benefit from the tax loss on the divestiture of Performance Livestock Analytics, partially offset by a tax expense related to changes to prior years' tax positions with regard to the one-time mandatory deemed repatriation tax under the Tax Cuts and Jobs Act.
(b)    Represents costs related to the planned sale of our medicated feed additive product portfolio, certain water soluble products and related assets.     
(c)    For the nine months ended September 30, 2024, primarily consisted of employee termination costs related to organizational structure refinements, partially offset by a reversal of certain employee termination costs as a result of a change in strategy from our 2015 operational efficiency initiative.
For the three and nine months ended September 30, 2023, primarily consisted of employee termination and exit costs related to organizational structure refinements and other cost-reduction and productivity initiatives.
(d) For the nine months ended September 30, 2024, represents certain asset impairment charges related to our aquaculture business.
For the three and nine months ended September 30, 2023, represents certain asset impairment charges related to our precision animal health and diagnostics
businesses.
(e)    Represents a loss on assets held for sale related to the planned sale of our medicated feed additive product portfolio, certain water soluble products and related assets.
(f)    Primarily represents a net gain on the sale of a majority interest in our pet insurance business.


35 |
The classification of the above items excluded from adjusted net income are as follows:
Three Months EndedNine Months Ended
September 30,September 30,
(MILLIONS OF DOLLARS)2024202320242023
Cost of sales:
Purchase accounting adjustments$1 $1 $3 $10 
Inventory write-offs— 2 — 2 
Other1 — 1 — 
   Total Cost of sales2 3 4 12 
Selling, general & administrative expenses:
Purchase accounting adjustments3 4 9 18 
Other2 — 2 — 
   Total Selling, general & administrative expenses5 4 11 18 
Research & development expenses:
Purchase accounting adjustments1 1 2 1 
   Total Research & development expenses1 1 2 1 
Amortization of intangible assets:
Purchase accounting adjustments30 33 93 95 
   Total Amortization of intangible assets30 33 93 95 
Restructuring charges and certain acquisition and divestiture-related costs:
Acquisition-related costs— 3 1 7 
Divestiture-related costs7 — 11 — 
Employee termination costs(2)8 39 33 
Asset impairments— 1 — 1 
Exit costs— 4 — 4 
   Total Restructuring charges and certain acquisition and divestiture-related costs5 16 51 45 
Other (income)/deductions—net:
Net gain on sale of business— — — (101)
Asset impairment charges— 8 11 18 
Loss on assets held for sale— — 22 — 
Other— — 2 (1)
   Total Other (income)/deductions—net— 8 35 (84)
Provision for taxes on income9 32 40 18 
Total purchase accounting adjustments, acquisition and divestiture-related costs, and certain significant items—net of tax$34 $33 $156 $69 

Analysis of the condensed consolidated statements of comprehensive income
Changes in other comprehensive income for the periods presented are primarily related to foreign currency translation adjustments and unrealized gains/(losses) on derivative instruments. The foreign currency translation adjustment changes result from the strengthening or weakening of the U.S. dollar as compared to the currencies in the countries in which we do business. Unrealized gains/(losses) on the changes in the fair value of derivative instruments are recorded within Accumulated other comprehensive income/(loss) and reclassified into earnings depending on the nature and purpose of the financial instrument, as described in Note 9. Financial Instruments of the Notes to Condensed Consolidated Financial Statements.
Analysis of the condensed consolidated balance sheets
September 30, 2024 vs. December 31, 2023
For a discussion about the changes in Cash and cash equivalents, Short-term borrowings and Long-term debt, net of discount and issuance costs, see “Analysis of financial condition, liquidity and capital resources” below.
Accounts receivable, less allowance for doubtful accounts increased primarily as a result of higher net sales in the period.
Inventories decreased primarily due to a reclassification of certain assets to Assets held for sale and higher sales than anticipated for certain products, partially offset by the build-up of certain products for increased demand.

36 |
Assets held for sale and Liabilities associated with assets held for sale primarily reflects the reclassification of certain accounts related to the planned sale of our medicated feed additive product portfolio, certain water soluble products and related assets. See Note 5. Acquisitions and Divestitures of the Notes to Condensed Consolidated Financial Statements.
Property, plant and equipment increased primarily as a result of capital spending, partially offset by depreciation expense and a reclassification of certain assets to Assets held for sale.
Identifiable intangible assets, less accumulated amortization decreased primarily as a result of amortization expense and a reclassification of certain assets to Assets held for assets. See Note 11. Goodwill and Other Intangible Assets of the Notes to Condensed Consolidated Financial Statements.
The net changes in Noncurrent deferred tax assets, Noncurrent deferred tax liabilities, Income taxes payable and Other taxes payable primarily reflect adjustments to the accrual for the income tax provision, the timing of income tax payments and the tax impact of various acquisitions.
Accrued expenses increased primarily due to employee termination costs related to organizational structure refinements and the timing of payments for other expenses.
Accrued compensation and related items decreased primarily due to the payments of 2023 annual incentive bonuses, payments for sales incentive bonuses and savings plan contributions to eligible employees, as well as the timing of the bi-weekly payroll, partially offset by the accrual of 2024 annual incentive bonuses, sales incentive bonuses and savings plan contributions to eligible employees.
Other current liabilities increased primarily due to an increase in deferred revenue.
Other noncurrent liabilities decreased primarily due to the reversal of certain employee termination costs as a result of a change in strategy from our 2015 operational efficiency initiative, the mark-to-market adjustment of derivative instruments and the reclassification of certain liabilities to Liabilities associated with assets held for sale.
For an analysis of the changes in Total Equity, see the Condensed Consolidated Statements of Equity and Notes to Condensed Consolidated Financial Statements— Note 13. Stockholders’ Equity.
Analysis of the condensed consolidated statements of cash flows
Nine Months Ended
September 30,$
(MILLIONS OF DOLLARS)20242023Change
Net cash provided by (used in):
Operating activities
$2,048 $1,456 $592 
Investing activities
(441)(567)126 
Financing activities
(1,915)(2,712)797 
Effect of exchange-rate changes on cash and cash equivalents(19)(4)(15)
Net decrease in cash and cash equivalents$(327)$(1,827)$1,500 
Operating activities
Nine months ended September 30, 2024 vs. nine months ended September 30, 2023
Net cash provided by operating activities was $2,048 million for the nine months ended September 30, 2024, compared with $1,456 million for the nine months ended September 30, 2023. The increase in operating cash flows was primarily attributable to higher inventory build-up of certain products in the prior period for increased demand and to mitigate potential supply constraints, as well as higher net income adjusted by non-cash items.
Investing activities
Nine months ended September 30, 2024 vs. nine months ended September 30, 2023
Our net cash used in investing activities was $441 million for the nine months ended September 30, 2024, compared with net cash used in investing activities of $567 million for the nine months ended September 30, 2023. The net cash used in investing activities for the nine months ended September 30, 2024 was primarily due to capital expenditures. The net cash used in investing activities for the nine months ended September 30, 2023 was primarily due to capital expenditures and acquisitions, partially offset by net proceeds on the sale of a majority interest in our pet insurance business and net proceeds from derivative instrument activity.
Financing activities
Nine months ended September 30, 2024 vs. nine months ended September 30, 2023
Our net cash used in financing activities was $1,915 million for the nine months ended September 30, 2024, compared with net cash used in financing activities of $2,712 million for the nine months ended September 30, 2023. The net cash used in financing activities for the nine months ended September 30, 2024 was primarily attributable to the purchase of treasury shares and related payment of excise taxes, the payment of dividends and taxes paid on withholding shares, partially offset by proceeds in connection with the issuance of common stock under our equity incentive plan. The net cash used in financing activities for the nine months ended September 30, 2023 was primarily attributable to the repayment of the $1.35 billion aggregate principal amount of our 2013 senior notes due 2023 in February 2023, the purchase of treasury shares, the payment of dividends and taxes paid on withholding shares, partially offset by proceeds in connection with the issuance of common stock under our equity incentive plan.

37 |
Analysis of financial condition, liquidity and capital resources
While we believe our cash and cash equivalents on hand, our operating cash flows and our existing financing arrangements will be sufficient to support our cash needs for the next twelve months and beyond, this may be subject to the environment in which we operate. Risks to our meeting future funding requirements are described in Global economic conditions below.
Selected measures of liquidity and capital resources
Certain relevant measures of our liquidity and capital resources follow:
September 30,December 31,
(MILLIONS OF DOLLARS)20242023
Cash and cash equivalents$1,714 $2,041 
Accounts receivable, net(a)
1,411 1,304 
Short-term borrowings— 3 
Long-term debt6,574 6,564 
Working capital4,580 4,454 
Ratio of current assets to current liabilities
3.69:1
3.36:1
(a)    Accounts receivable are usually collected over a period of 45 to 75 days. For the nine months ended September 30, 2024 compared with December 31, 2023, the number of days that accounts receivables were outstanding remained within this range. We regularly monitor our accounts receivable for collectability, particularly in markets where economic conditions remain uncertain. We believe that our allowance for doubtful accounts is appropriate. Our assessment is based on such factors as past due aging, historical and expected collection patterns, the financial condition of our customers, the robust nature of our credit and collection practices and the economic environment.
For additional information about the sources and uses of our funds, see the Analysis of the condensed consolidated balance sheets and Analysis of the condensed consolidated statements of cash flows sections of this MD&A.
Credit facility and other lines of credit
In December 2022, we entered into an amended and restated revolving credit agreement with a syndicate of banks providing for a multi-year $1.0 billion senior unsecured revolving credit facility (the credit facility), which expires in December 2027. Subject to certain conditions, we have the right to increase the credit facility to up to $1.5 billion. The credit facility contains a financial covenant requiring us to not exceed a maximum total leverage ratio (the ratio of consolidated net debt as of the end of the period to consolidated Earnings Before Interest, Income Taxes, Depreciation and Amortization (EBITDA) for such period) of 3.50:1. Upon entering into a material acquisition, the maximum total leverage ratio increases to 4.00:1, and extends until the fourth full consecutive fiscal quarter ended immediately following the consummation of a material acquisition. In addition, the credit facility contains other customary covenants.
We were in compliance with all financial covenants as of September 30, 2024 and December 31, 2023. There were no amounts drawn under the credit facility as of September 30, 2024 or December 31, 2023.
We have additional lines of credit and other credit arrangements with a group of banks and other financial intermediaries for general corporate purposes. We maintain cash and cash equivalent balances in excess of our outstanding short-term borrowings. As of September 30, 2024, we had access to $56 million of lines of credit which expire at various times and are generally renewed annually. There were no borrowings outstanding related to these facilities as of September 30, 2024 and $3 million of borrowings outstanding related to these facilities as of December 31, 2023.
Domestic and international short-term funds
Many of our operations are conducted outside the U.S. The amount of funds held in the U.S. will fluctuate due to the timing of receipts and payments in the ordinary course of business and due to other reasons, such as business development activities. As part of our ongoing liquidity assessments, we regularly monitor the mix of U.S. and international cash flows (both inflows and outflows). Actual repatriation of overseas funds can result in additional U.S. and local income taxes, such as U.S. state income taxes, local withholding taxes, and taxes on currency gains and losses.
Global economic conditions
Global financial markets may be impacted by macroeconomic, business and financial volatility. Challenging economic conditions in recent years have not had, nor do we anticipate that it will have, a significant impact on our liquidity. Due to our operating cash flows, financial assets, access to capital markets and available lines of credit and revolving credit agreements, we continue to believe that we have the ability to meet our liquidity needs for the foreseeable future. As markets change, we continue to monitor our liquidity position. There can be no assurance that a challenging economic environment or an economic downturn will not impact our liquidity or our ability to obtain financing in the future.
Debt securities
On November 8, 2022, we issued $1.35 billion aggregate principal amount of our senior notes (2022 senior notes), with an original issue discount of $2 million. These notes are comprised of $600 million aggregate principal amount of 5.400% senior notes due 2025 and $750 million aggregate principal amount of 5.600% senior notes due 2032. On February 1, 2023, the net proceeds were used to redeem in full, upon maturity, the $1.35 billion aggregate principal amount of our 3.250% 2013 senior notes due 2023.
Our senior notes are governed by an indenture and supplemental indentures (collectively, the indenture) between us and Deutsche Bank Trust Company Americas, as trustee. The indenture contains certain covenants, including limitations on our and certain of our subsidiaries’ ability to incur liens or engage in sale lease-back transactions. The indenture also contains restrictions on our ability to consolidate, merge or sell substantially all of our assets. In addition, the indenture contains other customary terms, including certain events of default, upon the occurrence of which, the senior notes may be declared immediately due and payable.
Pursuant to the indenture, we are able to redeem the senior notes of any series, in whole or in part, at any time by paying a “make whole” premium, plus accrued and unpaid interest to, but excluding, the date of redemption. Upon the occurrence of a change of control of us and a downgrade of the

38 |
senior notes below an investment grade rating by each of Moody’s Investors Service, Inc. and Standard & Poor’s Ratings Services, we are, in certain circumstances, required to make an offer to repurchase all of the outstanding senior notes at a price equal to 101% of the aggregate principal amount of the senior notes together with accrued and unpaid interest to, but excluding, the date of repurchase.
Our outstanding debt securities are as follows:
DescriptionPrincipal AmountInterest RateTerms
2015 Senior Notes due 2025$750 million4.500%Interest due semi annually, not subject to amortization, aggregate principal due on November 13, 2025
2022 Senior Notes due 2025$600 million5.400%Interest due semi annually, not subject to amortization, aggregate principal due on November 14, 2025
2017 Senior Notes due 2027$750 million3.000%Interest due semi annually, not subject to amortization, aggregate principal due on September 12, 2027
2018 Senior Notes due 2028$500 million3.900%Interest due semi annually, not subject to amortization, aggregate principal due on August 20, 2028
2020 Senior Notes due 2030$750 million2.000%Interest due semi annually, not subject to amortization, aggregate principal due on May 15, 2030
2022 Senior Notes due 2032$750 million5.600%Interest due semi annually, not subject to amortization, aggregate principal due on November 16, 2032
2013 Senior Notes due 2043$1,150 million4.700%Interest due semi annually, not subject to amortization, aggregate principal due on February 1, 2043
2017 Senior Notes due 2047$500 million3.950%Interest due semi annually, not subject to amortization, aggregate principal due on September 12, 2047
2018 Senior Notes due 2048$400 million4.450%Interest due semi annually, not subject to amortization, aggregate principal due on August 20, 2048
2020 Senior Notes due 2050$500 million3.000%Interest due semi annually, not subject to amortization, aggregate principal due on May 15, 2050
Credit ratings
Two major corporate debt-rating organizations, Moody’s and S&P, assign ratings to our short-term and long-term debt. A security rating is not a recommendation to buy, sell or hold securities and the rating is subject to revision or withdrawal at any time by the rating organization. Each rating should be evaluated independently of any other rating.
The following table provides the current ratings assigned by these rating agencies to our commercial paper and senior unsecured non-credit-enhanced long-term debt:
Commercial PaperLong-term DebtDate of Last Action
Name of Rating AgencyRatingRatingOutlook
Moody’sP-2Baa1PositiveMarch 2024
S&PA-2BBBStableDecember 2016
Share repurchase program
In December 2021, our Board of Directors authorized a $3.5 billion multi-year share repurchase program. As of September 30, 2024, there was $200 million remaining under this authorization. In August 2024, our Board of Directors authorized a new multi-year share repurchase program of up to $6 billion of our outstanding common stock. Purchases of Zoetis shares may be made at the discretion of management, depending on market conditions, business needs and available liquidity. Share repurchases may be executed through various means, including open market or privately negotiated transactions. During the first nine months of 2024, 7.3 million shares were repurchased for $1,295 million, which excludes a $12 million accrual for excise tax on net share repurchases.
Off-balance sheet arrangements
In the ordinary course of business and in connection with the sale of assets and businesses, we may indemnify our counterparties against certain liabilities that may arise in connection with a transaction or that are related to activities prior to a transaction. These indemnifications typically pertain to environmental, tax, employee and/or product-related matters, and patent-infringement claims. If the indemnified party were to make a successful claim pursuant to the terms of the indemnification, we would be required to reimburse the loss. These indemnifications are generally subject to threshold amounts, specified claim periods and other restrictions and limitations. Historically, we have not paid significant amounts under these provisions and, as of September 30, 2024 and December 31, 2023, recorded amounts for the estimated fair value of these indemnifications are not material.
New accounting standards
There were no accounting standards that were recently issued but not adopted as of September 30, 2024 that the Company expects to have a material impact on its condensed consolidated financial statements.
Forward-looking statements and factors that may affect future results
This report contains “forward-looking” statements. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. We generally identify forward-looking statements by using words such as “anticipate,” “estimate,” “could,” “expect,” “intend,” “project,” “plan,” “predict,” “believe,” “seek,” “continue,” “outlook,” “objective,” “target,” “may,” “might,” “will,” “should,” “can have,” “likely” or the negative version of these words or comparable words or by using future dates in connection with any discussion of future performance, actions or events.
In particular, forward-looking statements include statements relating to our future actions, business plans or prospects, prospective products, product approvals or products under development, R&D costs, timing and likelihood of success, competing products, future operating or financial performance, future results of current and anticipated products and services, product and supply chain disruptions, strategies, sales efforts, expenses, production efficiencies, production margins, anticipated timing of generic market entries, anticipated timing of divestitures, integration of acquired businesses, interest rates, tax rates, changes in tax regimes and laws, foreign exchange rates, growth in emerging markets, the outcome of

39 |
contingencies, such as legal proceedings or investigations, plans related to share repurchases and dividends, government regulation and financial results. These statements are not guarantees of future performance, actions or events. Forward-looking statements are subject to risks and uncertainties, many of which are beyond our control, and are based on assumptions that could prove to be inaccurate. Among the factors that could cause actual results to differ materially from past results and future plans and projected future results are the following:
•the possible impact and timing of competing products, including generic alternatives, on our products and our ability to compete against such products;
•unanticipated safety, quality or efficacy concerns or issues about our products;
•the decline in global economic conditions, including the regional conflict in the Middle East, economic weakness in China and inflation;
•the economic, political, legal and business environment of the foreign jurisdictions in which we do business;
•consolidation of our customers and distributors;
•changes in the distribution channel for companion animal products;
•disruptive innovations and advances in medical practices and technologies;
•an outbreak of infectious disease carried by animals;
•failure to successfully acquire businesses, license rights or products, integrate businesses, form and manage alliances or divest businesses;
•restrictions and bans on the use of and consumer preferences regarding antibacterials in food-producing animals;
•perceived adverse effects linked to the consumption of food derived from animals that utilize our products or animals generally;
•increased regulation or decreased governmental support relating to the raising, processing or consumption of food-producing animals;
•adverse weather conditions and the availability of natural resources;
•the impact of climate change on our activities and the activities of our customers and suppliers, including, for example, altered distribution and intensity of rainfall, prolonged droughts or flooding, increased frequency of wildfires and other natural disasters, rising sea levels, and rising heat index;
•product launch delays, inventory shortages, recalls or unanticipated costs caused by manufacturing problems and capacity imbalances;
•failure of our R&D, acquisition and licensing efforts to generate new products and product lifecycle innovations;
•difficulties or delays in the development or commercialization of new products;
•illegal distribution and/or sale of our products or the misuse or off-label use of our products;
•legal factors, including product liability claims, antitrust litigation and governmental investigations, including tax disputes, environmental concerns, laws and regulations regarding data privacy, commercial disputes and patent disputes with branded and generic competitors, any of which could preclude commercialization of products or negatively affect the profitability of existing products;
•fluctuations in foreign exchange rates and potential currency controls;
•governmental laws and regulations affecting domestic and foreign operations, including without limitation, tax obligations and changes affecting the tax treatment by the U.S. of income earned outside the U.S. that may result from pending or possible future proposals;
•failure to protect our intellectual property rights or to operate our business without infringing the intellectual property rights of others;
•a cyberattack, information security breach or other misappropriation of our data;
•failure to generate sufficient cash to service our substantial indebtedness; and
•the other factors set forth under “Risk Factors” in Item 1A. of Part I of our 2023 Annual Report on Form 10-K.
However, there may also be other risks that we are unable to predict at this time. These risks or uncertainties may cause actual results to differ materially from those contemplated by a forward-looking statement. You should not put undue reliance on forward-looking statements. Forward-looking statements speak only as of the date on which they are made. We undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law or by the rules and regulations of the SEC. You are advised, however, to consult any further disclosures we make on related subjects in our Form 10-Q and 8-K reports and our other filings with the SEC. You should understand that it is not possible to predict or identify all such factors. Consequently, you should not consider the above to be a complete discussion of all potential risks or uncertainties.

40 |
Item 3.    Quantitative and Qualitative Disclosures About Market Risk
A significant portion of our revenue and costs are exposed to changes in foreign exchange rates. In addition, our outstanding borrowings may be subject to risk from changes in interest rates and foreign exchange rates. The overall objective of our financial risk management program is to seek to manage the impact of foreign exchange rate movements and interest rate movements on our earnings. We manage these financial exposures through operational means and by using certain financial instruments. These practices may change as economic conditions change.
For a complete discussion of our exposure to interest rate and foreign exchange risk, refer to Item 7A. Quantitative and Qualitative Disclosures About Market Risk in our Annual Report on Form 10-K for the year ended December 31, 2023. There have been no material changes from the information discussed therein.
Item 4.    Controls and Procedures
Disclosure Controls and Procedures
An evaluation was carried out under the supervision and with the participation of the company’s management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934). Based upon that evaluation as of September 30, 2024, the company’s Chief Executive Officer and Chief Financial Officer concluded that the company’s disclosure controls and procedures are effective at a reasonable level of assurance in alerting them in a timely manner to material information required to be disclosed in our periodic reports filed with the SEC.
Changes in Internal Control over Financial Reporting
During our most recent fiscal quarter, there has not been any change in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934) that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

41 |
PART II — OTHER INFORMATION
Item 1.    Legal Proceedings
The information required by this Item is incorporated herein by reference to Notes to Condensed Consolidated Financial Statements—Note 15. Commitments and Contingencies in Part I— Item 1, of this Quarterly Report on Form 10-Q.
Item 1A.     Risk Factors
In addition to the other information set forth in this Form 10-Q, you should carefully consider the factors discussed in the “Our Operating Environment” and “Forward-Looking Statements and Factors That May Affect Future Results” sections of the MD&A and in Part I, Item 1A. “Risk Factors,” of our 2023 Annual Report on Form 10-K, which could materially affect our business, financial condition, or future results and which are incorporated by reference herein. There have been no material changes from the risk factors disclosed in our 2023 Annual Report on Form 10-K.
Item 2.    Unregistered Sales of Equity Securities and Use of Proceeds
In December 2021, our Board of Directors authorized a $3.5 billion multi-year share repurchase program. As of September 30, 2024, there was $200 million remaining under this program. In August 2024, our Board of Directors authorized a new multi-year share repurchase program of up to $6 billion of our outstanding common stock.
The following table provides information with respect to the shares of the company’s common stock repurchased during the three months ended
September 30, 2024:
Issuer Purchases of Equity Securities(a)
Total Number of Shares Purchased(b)
Average Price Paid Per ShareTotal Number of Shares Purchased as Part of Publicly Announced ProgramsApproximate Dollar Value of Shares that May Yet Be Purchased Under Plans or Programs
July 1 - July 31, 2024691,089 $177.89676,214 $502,595,908
August 1 - August 31, 2024937,732 $182.41937,047 $6,331,664,747
September 1 - September 30, 2024691,557 $190.56690,968 $6,199,536,894
2,320,378 $183.492,304,229 $6,199,536,894
(a)    Amounts exclude the impact of excise tax on net share repurchases.
(b)     The company repurchased 16,149 shares during the three-month period ended September 30, 2024 that were not part of the publicly announced multi-year share repurchase authorization. These shares were reacquired from employees to satisfy tax withholding requirements on the vesting of restricted shares from equity-based awards.

Item 3.    Defaults Upon Senior Securities
None
Item 4.    Mine Safety Disclosures
None
Item 5.    Other Information
Rule 10b5-1 Trading Arrangements
Kristin Peck, Chief Executive Officer, adopted a pre-arranged trading plan on September 12, 2024, that is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. Ms. Peck's plan provides for (i) the sale of up to 52,000 shares of Zoetis common stock between December 13, 2024 and December 31, 2025 and (ii) the gifting of up to $300,000 worth of Zoetis common stock to a charitable fund between December 13, 2024 and December 31, 2025.
Roxanne Lagano, Executive Vice President, General Counsel and Corporate Secretary, adopted a pre-arranged trading plan on September 13, 2024, that is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. Ms. Lagano’s plan provides for the sale of (i) between December 16, 2024 and December 16, 2025, up to 4,339 shares of Zoetis common stock and (ii) between February 11, 2025 and December 16, 2025, 100% of the net shares (net of tax withholding) resulting from the vesting of 4,858 gross shares of Zoetis common stock relating to equity awards, subject to certain conditions.

42 |
Item 6.    Exhibits
Chief Executive Officer–Certification pursuant to Sarbanes-Oxley Act of 2002 Section 302
Chief Financial Officer–Certification pursuant to Sarbanes-Oxley Act of 2002 Section 302
Chief Executive Officer–Certification pursuant to Sarbanes-Oxley Act of 2002 Section 906
Chief Financial Officer–Certification pursuant to Sarbanes-Oxley Act of 2002 Section 906
EX-101.INSInline XBRL INSTANCE DOCUMENT
Inline XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
Inline XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
Inline XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
Inline XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
Inline XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
EX-104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

43 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Zoetis Inc.
November 4, 2024
By:
/S/ KRISTIN C. PECK
Kristin C. Peck
Chief Executive Officer and Director
November 4, 2024
By:
/S/ WETTENY JOSEPH
Wetteny Joseph
Executive Vice President and
Chief Financial Officer

44 |
 EX-31.1 2 a10qex311q32024.htm EX-31.1 Document

Exhibit 31.1

CERTIFICATION PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Kristin C. Peck, certify that:
1.    I have reviewed this Quarterly Report of Zoetis Inc. on Form 10-Q for the period ending September 30, 2024 as filed with the Securities and Exchange Commission on the date hereof;
2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.    The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)    designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)    designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)    evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)    disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.    The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a)    all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b)    any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
November 4, 2024
By:/s/ KRISTIN C. PECK
Kristin C. Peck
Chief Executive Officer

 EX-31.2 3 a10qex312q32024.htm EX-31.2 Document

Exhibit 31.2

CERTIFICATION PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Wetteny Joseph, certify that:
1.    I have reviewed this Quarterly Report of Zoetis Inc. on Form 10-Q for the period ending September 30, 2024 as filed with the Securities and Exchange Commission on the date hereof;
2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.    The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)    designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)    designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)    evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)    disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.    The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a)    all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b)    any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
November 4, 2024
By:
/s/ WETTENY JOSEPH
Wetteny Joseph
Executive Vice President and Chief Financial Officer


 EX-32.1 4 a10qex321q32024.htm EX-32.1 Document

Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to 18 U.S.C. §1350, I, Kristin C. Peck, Chief Executive Officer, hereby certify that, to the best of my knowledge, the Quarterly Report on Form 10-Q of Zoetis Inc. for the period ended September 30, 2024 (the "Report") (1) fully complies with Section 13(a) or 15(d) of the Securities and Exchange Act of 1934; and (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Zoetis Inc.
November 4, 2024
By:
/s/ KRISTIN C. PECK
Kristin C. Peck
Chief Executive Officer


 EX-32.2 5 a10qex322q32024.htm EX-32.2 Document

Exhibit 32.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
Pursuant to 18 U.S.C. §1350, I, Wetteny Joseph, Executive Vice President and Chief Financial Officer, hereby certify that, to the best of my knowledge, the Quarterly Report on Form 10-Q of Zoetis Inc. for the period ended September 30, 2024 (the “Report”) (1) fully complies with Section 13(a) or 15(d) of the Securities and Exchange Act of 1934; and (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Zoetis Inc.
November 4, 2024
By:
/s/ WETTENY JOSEPH
Wetteny Joseph
Executive Vice President and Chief Financial Officer


 EX-101.SCH 6 zts-20240930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 9952151 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 9952152 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 9952153 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 9952154 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 9952155 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (PARENTHETICAL) link:presentationLink link:calculationLink link:definitionLink 9952156 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 9952157 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 9952158 - Disclosure - Organization link:presentationLink link:calculationLink link:definitionLink 9952159 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 9952160 - Disclosure - Accounting Standards link:presentationLink link:calculationLink link:definitionLink 9952161 - Disclosure - Revenue link:presentationLink link:calculationLink link:definitionLink 9952162 - Disclosure - Acquisitions and Divestitures link:presentationLink link:calculationLink link:definitionLink 9952163 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Divestitures link:presentationLink link:calculationLink link:definitionLink 9952164 - Disclosure - Other (Income)/Deductions - Net link:presentationLink link:calculationLink link:definitionLink 9952165 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 9952166 - Disclosure - Financial Instruments link:presentationLink link:calculationLink link:definitionLink 9952167 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 9952168 - Disclosure - Goodwill and Other Intangible Assets link:presentationLink link:calculationLink link:definitionLink 9952169 - Disclosure - Share-Based Payments link:presentationLink link:calculationLink link:definitionLink 9952170 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 9952171 - Disclosure - Earnings per Share link:presentationLink link:calculationLink link:definitionLink 9952172 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 9952173 - Disclosure - Segment Information link:presentationLink link:calculationLink link:definitionLink 9952174 - Disclosure - Subsequent Event link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - Accounting Standards (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - Revenue Revenue Recognition and Deferred Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - Acquisitions and Divestitures (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Divestitures (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - Other (Income)/Deductions - Net (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - Goodwill and Other Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - Share-Based Payments (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - Earnings per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - Organization (Details) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - Revenue - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Revenue - Revenue by Geographic Area (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Revenue - Revenue by Major Species (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - Revenue - Revenue by Species (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Revenue - Revenue by Product (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Acquisitions and Divestitures - Consideration Transferred (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Acquisitions and Divestitures - Divestures (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Acquisitions and Divestitures - Schedule of Assets Held for Sale (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Divestitures (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Other (Income)/Deductions - Net (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Income Taxes - Taxes on Income (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Income Taxes - Deferred Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - Income Taxes - Tax Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - Financial Instruments - Credit Facilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - Financial Instruments - Commercial Paper Program (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - Financial Instruments - Senior Notes Offering and Other Long-Term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - Financial Instruments - Schedule of Long-term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - Financial Instruments - Fair Value of Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - Financial Instruments - Long-term Debt Maturity (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - Financial Instruments - Foreign Exchange Risk (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - Financial Instruments - Interest Rate Risk (Details) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - Financial Instruments Derivative Notional Amounts (Details) link:presentationLink link:calculationLink link:definitionLink 9954506 - Disclosure - Financial Instruments - Fair Value of Derivative Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 9954507 - Disclosure - Financial Instruments Cross-currency forward-exchange contracts (Details) link:presentationLink link:calculationLink link:definitionLink 9954508 - Disclosure - Financial Instruments Cross-currency interest rate swap contracts (Details) link:presentationLink link:calculationLink link:definitionLink 9954509 - Disclosure - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 9954510 - Disclosure - Goodwill and Other Intangible Assets - Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 9954511 - Disclosure - Goodwill and Other Intangible Assets - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954512 - Disclosure - Goodwill and Other Intangible Assets - Other Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954513 - Disclosure - Share-Based Payments - Components of Share-Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954514 - Disclosure - Share-Based Payments - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954515 - Disclosure - Stockholders' Equity - Changes in Common Shares and Treasury Stock (Details) link:presentationLink link:calculationLink link:definitionLink 9954516 - Disclosure - Stockholders' Equity - Changes in Accumulated Other Comprehensive Loss (Details) link:presentationLink link:calculationLink link:definitionLink 9954517 - Disclosure - Earnings per Share (Details) link:presentationLink link:calculationLink link:definitionLink 9954518 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 9954519 - Disclosure - Segment Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954520 - Disclosure - Segment Information Selected Statement of Income (Details) link:presentationLink link:calculationLink link:definitionLink 9954521 - Disclosure - Segment Information Selected Statement of Income Narrative (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 zts-20240930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 zts-20240930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 zts-20240930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Accrued expenses Restructuring Reserve, Current Supplemental cash flow information Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract] Adjustments to reconcile net income before noncontrolling interests to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Statistical Measurement [Domain] Statistical Measurement [Domain] Principal payments on long-term debt Repayments of long-term debt Repayments of Long-Term Debt Derivatives, Fair Value [Line Items] Derivatives, Fair Value [Line Items] Pain and sedation Pain & Sedation [Member] Pain & Sedation Cover page. Cover [Abstract] Net decrease in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect In-process research and development In Process Research and Development [Member] Other current liabilities Other Liabilities, Current Voting interest acquired, percent Business Acquisition, Percentage of Voting Interests Acquired Trading Symbol Trading Symbol Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Comprehensive income before allocation to noncontrolling interests Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest All Trading Arrangements All Trading Arrangements [Member] Restructuring Charges and Other Costs Associated with Acquisitions and Divestitures Cost Reduction And Productivity Initiatives And Acquisition Related Costs Disclosure [Text Block] Description of cost-reduction and productivity initiatives associated with a comprehensive plan to integrate acquired operations, generate cost savings and capture synergies across the company; as well as costs incurred in connection with an acquisition. These costs include (i) restructuring activities, including exit and disposal activities, the major types of costs associated with the plan activities and the accrual balance at the end of the period; (ii) integration costs, which represent external, incremental costs directly related to integrating acquired businesses; (iii) implementation costs, which represent external, incremental costs directly related to implementing cost-reduction initiatives prior to acquisition and primarily include expenditures related to system and process standardization and the expansion of shared services; (iv) additional depreciation-asset restructuring, which represents the impact of changes in the estimated useful lives of assets involved in restructuring actions; and (v) transaction costs, representing external costs incurred in connection with an acquisition. Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Derivative assets Derivative Asset, Subject to Master Netting Arrangement, before Offset Non-NEOs Non-NEOs [Member] Basic and Diluted Earnings Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Share-based compensation, award vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] International International [Member] International [Member] Dividends paid per common share (in dollars per share) Common Stock, Dividends, Per Share, Declared Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Derivative [Line Items] Derivative [Line Items] Income taxes Income Taxes Paid, Net Allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss, Current Components of Share-based Compensation Expense Share-Based Payment Arrangement, Cost by Plan [Table Text Block] Maximum total leverage ratio Line of Credit Facility, Covenant Compliance, Maximum Leverage Ratio Line of Credit Facility, Covenant Compliance, Maximum Leverage Ratio Disposal Group Name [Domain] Disposal Group Name [Domain] Pay vs Performance Disclosure [Line Items] Line of Credit Facility [Table] Line of Credit Facility [Table] Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax net of cash sold amount Cash Divested from Deconsolidation Accounts receivable Increase (Decrease) in Accounts Receivable Derivative [Table] Derivative [Table] Income Tax Contingency [Table] Income Tax Contingency [Table] Foreign Currency Fair Value Hedge Derivative [Line Items] Foreign Currency Fair Value Hedge Derivative [Line Items] Basis of Presentation Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Schedule of Derivative Instruments in Statement of Financial Position, Fair Value Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] Restructuring and Related Activities [Abstract] Restructuring and Related Activities [Abstract] Award Timing Disclosures [Line Items] Net Investment Hedging Net Investment Hedging [Member] Medicated feed additives Medicated Feed Additives [Member] Medicated Feed Additives [Member] Other Performance Measure, Amount Other Performance Measure, Amount Goodwill [Line Items] Goodwill [Line Items] Common stock, shares outstanding Common Stock, Shares, Outstanding Dogs and Cats Dogs and Cats [Member] Dogs and Cats [Member] Operating lease liabilities Operating Lease, Liability, Noncurrent Number of claims seeking damages Loss Contingency, Pending Claims, Number Remeasurement of retained noncontrolling investment to fair value Gain (Loss) On Disposition Of Business, Remeasurement Of Retained Noncontrolling Investment Gain (Loss) On Disposition Of Business, Remeasurement Of Retained Noncontrolling Investment Cash Flow Hedging Cash Flow Hedging [Member] Segment Information Segment Reporting, Policy [Policy Text Block] United States United States (U.S.) UNITED STATES Common stock equivalents: stock options, RSUs, PSUs and DSUs Weighted Average Number of Shares Outstanding, Diluted, Adjustment Other noncurrent assets Other Assets, Noncurrent Entity Tax Identification Number Entity Tax Identification Number Finite-lived intangible assets, gross carrying amount Finite-Lived Intangible Assets, Gross Schedule of Long-term Debt Instruments Schedule of Long-Term Debt Instruments [Table Text Block] Treasury stock acquired, shares Treasury Stock, Shares, Acquired Animal health diagnostics Animal Health Diagnostics [Member] Animal Health Diagnostics [Member] Livestock Livestock [Member] Livestock [Member] Operating Segments Operating Segments Operating Segments [Member] Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Operational Efficiency Operational Efficiency [Member] Operational Efficiency [Member] Operating Activities Net Cash Provided by (Used in) Operating Activities [Abstract] Treasury Stock Treasury Stock, Common [Member] Schedule of Derivative Instruments Schedule of Derivative Instruments [Table Text Block] Income taxes payable Taxes Payable, Current Noncurrent deferred tax assets Disposal Group, Including Discontinued Operation, Deferred Tax Assets Parasiticides Parasiticides [Member] Parasiticides [Member] Changes, Net of Tax, in Accumulated Other Comprehensive Loss Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Share-based compensation-related proceeds, net of taxes paid on withholding shares Share-based compensation-related proceeds, net of taxes paid on withholding shares Share-based compensation-related proceeds, net of taxes paid on withholding shares Other noncurrent assets Disposal Group, Including Discontinued Operation, Other Assets, Noncurrent Certain significant items, Depreciation and Amortization Certain Significant Reconciling Items Included in Depreciation, Depletion and Amortization Certain Significant Reconciling Items Included in Depreciation, Depletion and Amortization December 2021 Share Repurchase Program December 2021 Share Repurchase Program [Member] December 2021 Share Repurchase Program Equity Components [Axis] Equity Components [Axis] Other current assets Other Assets, Current Award Timing Method Award Timing Method [Text Block] Facility Closing Facility Closing [Member] Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Restructuring Type [Axis] Restructuring Type [Axis] Roxanne Lagano Trading Arrangement, Common Stock [Member] Roxanne Lagano Trading Arrangement, Common Stock Revenue Recognition and Deferred Revenue [Abstract] Revenue Recognition and Deferred Revenue [Abstract] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Insider Trading Policies and Procedures [Line Items] Sale proceeds Proceeds from Divestiture of Businesses Share-based compensation expense capitalized to inventory, less than Share-Based Payment Arrangement, Amount Capitalized Excise tax accrued on net share repurchases, not paid Excise Tax Accrued on Net Share Repurchased, Not Paid Excise Tax Accrued on Net Share Repurchased, Not Paid Proceeds from sale of businesses, net of cash sold Proceeds from Divestiture of Businesses, Net of Cash Divested Capacity of commercial paper program Short-term Debt, Maximum Borrowing Capacity Short-term Debt, Maximum Borrowing Capacity Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Adjustment to Compensation, Amount Adjustment to Compensation Amount PetMedix Ltd. PetMedix Ltd. [Member] PetMedix Ltd. Compensation Amount Outstanding Recovery Compensation Amount Denominator Earnings Per Share, Diluted [Abstract] Anti-infectives Anti-infective Products [Member] Anti-infective Products [Member] Disposal Group Classification [Axis] Disposal Group Classification [Axis] Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Number of regional segments Number of Regional Segments Number of Regional Segments Entity Small Business Entity Small Business Developed technology rights Developed Technology Rights [Member] Company Selected Measure Amount Company Selected Measure Amount Geographical [Axis] Geographical [Axis] Restructuring and Related Costs Restructuring and Related Costs [Table Text Block] Tabular List, Table Tabular List [Table Text Block] Net gain on sale of business Net gain on sale of business Gain (Loss) on Disposition of Business Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Reserve adjustment Restructuring Reserve, Accrual Adjustment Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Horses Horses [Member] Horses [Member] Other taxes payable Accrued Income Taxes, Noncurrent Acquisition and divestiture-related costs Business Combination, Acquisition And Divesture Related Costs Business Combination, Acquisition And Divesture Related Costs Credit Facility [Domain] Credit Facility [Domain] Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Vaccines Vaccines [Member] Vaccines [Member] Derivative, cash received on hedge Derivative, Cash Received on Hedge Goodwill Beginning Balance Ending Balance Goodwill Consolidation Items [Axis] Consolidation Items [Axis] Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Other comprehensive (loss)/income, net of tax(a): Other Comprehensive Income (Loss), Net of Tax [Abstract] Stock repurchase program, authorized amount Share Repurchase Program, Authorized, Amount Inventories Inventory Disclosure [Text Block] Treasury stock, shares Treasury stock, beginning balance (in shares) Treasury stock, ending balance (in shares) Treasury Stock, Common, Shares Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount 3.000% 2017 senior notes due 2027 Senior Notes 3.000% Due 2027 [Member] Senior Notes 3.000% Due 2027 Product and Service [Domain] Product and Service [Domain] Stock options / stock appreciation rights Stock options Share-Based Payment Arrangement, Option [Member] Foreign currency forward-exchange contracts Foreign currency forward-exchange contracts Foreign Exchange Forward [Member] Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block] Goodwill [Roll Forward] Goodwill [Roll Forward] Total derivatives Derivative, Fair Value, Net Comprehensive income attributable to Zoetis Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent Raw materials and supplies Inventory, Raw Materials and Supplies, Net of Reserves Security Exchange Name Security Exchange Name Award Type [Axis] Award Type [Axis] Noncurrent deferred tax liabilities Deferred Tax Liabilities, Net Earnings per share attributable to Zoetis Inc. stockholders: Numerator Earnings Per Share, Basic [Abstract] Swine Swine [Member] Swine [Member] PeerCompanies Peer Companies [Member] Peer Companies [Member] Work-in-process Inventory, Work in Process, Net of Reserves Property, plant and equipment, less accumulated depreciation of $2,657 in 2024 and $2,594 in 2023 Property, Plant and Equipment, Net Total liabilities Liabilities Equity attributable to noncontrolling interests Equity, Attributable to Noncontrolling Interest Short-term borrowings Short-Term Debt Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Utilization and other Restructuring Reserve, Utilization And Other Adjustment to restructuring reserve resulting from utilization and foreign currency translation. Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Revolving Credit Facility Revolving Credit Facility [Member] Expiration Date Trading Arrangement Expiration Date Investing Activities Net Cash Provided by (Used in) Investing Activities [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Revenue from External Customers by Major Species Revenue from External Customers by Major Species [Table Text Block] Revenue from External Customers by Major Species Debt, purchase price percent due to downgrade of investment grade Debt Instrument, Purchase Price Percent Due to Downgrade of Investment Grade Debt Instrument, Purchase Price Percent Due to Downgrade of Investment Grade Total Shareholder Return Amount Total Shareholder Return Amount After 2025 Long-Term Debt Maturity, After Year Four Long-Term Debt Maturity, After Year Four Common stock issued, shares Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Issued Schedule of Indefinite-lived and Finite-lived Intangible Assets [Table] Schedule Of Indefinitelived And Finitelived Intangible Assets [Table] Schedule of Indefinite-lived and Finite-lived Intangible Assets [Table] Other Goodwill, Other Increase (Decrease) Entity [Domain] Entity [Domain] Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Line of credit facility, maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Assets held for sale Total Assets Held for Sale Disposal Group, Including Discontinued Operation, Assets August 2024 Share Repurchase Program August 2024 Share Repurchase Program [Member] August 2024 Share Repurchase Program Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Inventories Disposal Group, Including Discontinued Operation, Inventory, Current Accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Debt Instrument [Line Items] Debt Instrument [Line Items] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Common stock, shares authorized Common Stock, Shares Authorized Acquisition of a noncontrolling interest, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Diluted (in shares) Weighted-average common and potential dilutive shares outstanding Weighted Average Number of Shares Outstanding, Diluted Share Repurchase Program Share Repurchase Program [Member] Share Repurchase Program Other developed markets Other Developed Markets [Member] Other Developed Markets [Member] MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Accumulated Other Comprehensive Income (Loss) [Roll Forward] AOCI Attributable to Parent, Net of Tax [Roll Forward] Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Total Zoetis Inc. equity Equity, Attributable to Parent Treasury stock, at cost, 50,341,454 and 43,523,885 shares of common stock at September 30, 2024 and December 31, 2023, respectively Treasury Stock, Value Financial Instruments Financial Instruments Disclosure [Text Block] Other noncurrent liabilities Restructuring Reserve, Noncurrent Litigation Case [Axis] Litigation Case [Axis] Hedging Designation [Domain] Hedging Designation [Domain] Balance Sheet Location [Axis] Statement of Financial Position Location, Balance [Axis] Deferred taxes Deferred Income Tax Expense (Benefit) Property, plant and equipment, less accumulated depreciation Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Noncurrent Changes in the Carrying Amount of Goodwill Schedule of Goodwill [Table Text Block] Payment of consideration related to previous acquisitions Payment for Contingent Consideration Liability, Financing Activities Dermatology Dermatology [Member] Dermatology Tax Contingencies Income Tax Uncertainties, Policy [Policy Text Block] Selling, general and administrative expenses Selling, General and Administrative Expense Fixed-to-floating interest rate swap contracts zts_FixedtoFloatInterestRateSwap [Member] zts_FixedtoFloatInterestRateSwap Income Tax Contingency [Line Items] Income Tax Contingency [Line Items] Accounts receivable, less allowance for doubtful accounts of $19 in 2024 and $18 in 2023 Accounts Receivable, after Allowance for Credit Loss, Current Share-based compensation, options granted, shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Product Product [Member] Other liabilities Increase (Decrease) in Other Operating Liabilities Asset write-offs and asset impairments Asset Impairment Charges Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Contract manufacturing & human health Contract Manufacturing and Human Health Diagnostics [Member] Contract Manufacturing and Human Health Diagnostics [Member] Document Fiscal Period Focus Document Fiscal Period Focus 2028 Long-Term Debt, Maturity, Year Four Acquisition and divestiture-related costs Business Combination, Acquisition Related Costs All Executive Categories All Executive Categories [Member] Balance Sheet Location [Domain] Statement of Financial Position Location, Balance [Domain] Number of major product categories Number of Major Product Categories Number of Major Product Categories Net Investment Hedges AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Assets Assets [Abstract] Other comprehensive loss, net of tax Other comprehensive loss, net of tax Other Comprehensive Income (Loss), Net of Tax Share-based compensation, expected dividend rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Restricted cash Restricted Cash, Current Document Type Document Type Derivative Contract [Domain] Derivative Contract [Domain] Commercial Paper Commercial Paper [Member] Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Total products and services Total Products and Services [Member] Total Products and Services [Member] Schedule of Selected Income Statement Information by Segment Schedule of Segment Reporting Information, by Segment [Table Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Other Income and Expenses [Abstract] Other Income and Expenses [Abstract] Share-based compensation, risk free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Total indefinite-lived intangible assets Indefinite-Lived Intangible Assets (Excluding Goodwill) Maximum Maximum [Member] Amortization of intangible assets Amortization of Intangible Assets Contract liabilities Contract with Customer, Liability Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Accumulated goodwill impairment losses Goodwill, Impaired, Accumulated Impairment Loss Finite-lived intangible assets, identifiable intangible assets, less accumulated amortization Finite-Lived Intangible Assets, Net Accounts payable Accounts Payable, Current Accounting Policies [Abstract] Accounting Policies [Abstract] Debt, unamortized discount Debt Instrument, Unamortized Discount Royalty-related income Royalty Income, Nonoperating Poultry Poultry [Member] Poultry [Member] Legal Proceedings Commitments and Contingencies, Policy [Policy Text Block] Guarantees and Indemnifications Guarantees, Indemnifications and Warranties Policies [Policy Text Block] Number of core animal species Number of Core Animal Species Marketed Number of Core Animal Species Marketed Acquisitions and Divestitures Business Combination Disclosure [Text Block] Current Fiscal Year End Date Current Fiscal Year End Date Statistical Measurement [Axis] Statistical Measurement [Axis] PEO Name PEO Name Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Income before provision for taxes on income Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Award Type [Domain] Award Type [Domain] Accounts receivable, less allowance for doubtful accounts Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net Name Outstanding Recovery, Individual Name Purchase accounting adjustments, Depreciation and Amortization Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles Disposal Groups, Including Discontinued Operations Disposal Groups, Including Discontinued Operations [Table Text Block] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Noncurrent deferred tax assets Deferred Income Tax Assets, Net Non-PEO NEO Non-PEO NEO [Member] Senior Notes Due 2023 Senior Notes Due 2023 [Member] Senior Notes Due 2023 [Member] Additional Paid-in Capital Additional Paid-in Capital [Member] Award Timing Predetermined Award Timing Predetermined [Flag] Identifiable intangible assets, less accumulated amortization Disposal Group, Including Discontinued Operation, Intangible Assets, Noncurrent Class of Stock [Line Items] Class of Stock [Line Items] Brazil BRAZIL Short-term Debt [Line Items] Short-Term Debt [Line Items] Recently Issued Accounting Standards New Accounting Pronouncements, Policy [Policy Text Block] Acquisition and divestiture-related costs, Depreciation and Amortization Acquisition And Divestiture Depreciation, Depletion and Amortization Acquisition And Divestiture Depreciation, Depletion and Amortization Revenue from External Customers by Species Revenue from External Customers by Species [Table Text Block] Revenue from External Customers by Species Class of Stock [Axis] Class of Stock [Axis] Diluted (in dollars per share) Earnings per share attributable to Zoetis stockholders—diluted (in dollars per share) Earnings Per Share, Diluted Roxanne Lagano [Member] Roxanne Lagano Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-lived intangible assets, accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Name Measure Name Entity Interactive Data Current Entity Interactive Data Current Type of Restructuring [Domain] Type of Restructuring [Domain] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] U.S. United States Segment [Member] United States Segment [Member] Canada CANADA Number of operating segments Number of Operating Segments Foreign currency loss Gain (Loss), Foreign Currency Transaction, before Tax Stock repurchase program, remaining number of shares authorized to be repurchased Share Repurchase Program, Remaining Authorized, Number of Shares Employee Termination Costs Employee Severance [Member] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] China CHINA Chile CHILE Share-based compensation expense Share-Based Payment Arrangement, Noncash Expense Other unallocated, Depreciation and Amortization Other Unallocated Items Included in Depreciation, Depletion and Amortization Other Unallocated Items Included in Depreciation, Depletion and Amortization Noncurrent deferred tax assets Deferred Tax Assets, Net of Valuation Allowance Australia AUSTRALIA Net income before allocation to noncontrolling interests Net income before allocation to noncontrolling interests Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Benefit Plans Actuarial Gains/(Losses) Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Net proceeds from sale of assets Proceeds from Sale of Property, Plant, and Equipment 3.950% 2017 senior notes due 2047 Senior Notes 3.950% Due 2047 [Member] Senior Notes 3.950% Due 2047 [Member] Collateral received Securities Received as Collateral Provision for taxes on income Income Tax Expense (Benefit) Interest rate percentage Debt Instrument, Interest Rate, Stated Percentage Derivative notional amount Derivative, Notional Amount Corporate Segment Reporting, Reconciling Item, Corporate Nonsegment [Member] Other noncurrent liabilities Disposal Group, Including Discontinued Operation, Other Liabilities, Noncurrent Cash paid during the period for: Supplemental Cash Flow Information [Abstract] Additional Collateral, Aggregate Fair Value Additional Collateral, Aggregate Fair Value Product Information [Line Items] Product Information [Line Items] Other (income)/deductions—net Other (income)/deductions—net Nonoperating Income (Expense) Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Capitalized interest Interest Costs Capitalized Provision for losses on inventory Inventory Write-down Effective tax rate for income from continuing operations Effective Income Tax Rate Reconciliation, Percent Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Interest expense, net of capitalized interest Interest Expense, Operating and Nonoperating Business Acquisition [Line Items] Business Acquisition [Line Items] Research and development expenses Research and Development Expense (Excluding Acquired in Process Cost) Total liabilities and equity Liabilities and Equity Subsequent Event Subsequent Events [Text Block] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] All Adjustments to Compensation All Adjustments to Compensation [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Accrued compensation and related items Employee-related Liabilities, Current Additional paid-in capital Additional Paid in Capital Short-term Debt, Type [Domain] Short-Term Debt, Type [Domain] Hedging Designation [Axis] Hedging Designation [Axis] Provision Restructuring Charges Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Legal Entity [Axis] Legal Entity [Axis] Interest income Interest Income (Expense), Nonoperating Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Operating lease right-of-use assets Disposal Group, Including Discontinued Operation, Operating Lease, Right-Of-Use Asset, Noncurrent Disposal Group, Including Discontinued Operation, Operating Lease, Right-Of-Use Asset, Noncurrent Schedule of Maturities of Long-term Debt Schedule of Maturities of Long-Term Debt [Table Text Block] Lease obligations obtained in exchange for right-of-use assets - operating Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Underlying Security Market Price Change Underlying Security Market Price Change, Percent Individual: Individual [Axis] Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Share-based compensation, expected term Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Inventories Inventories Inventory, Net Liabilities associated with assets held for sale Total Liabilities Associated with Assets Held for Sale Disposal Group, Including Discontinued Operation, Liabilities Proceeds from derivative instrument activity, net Payments for (Proceeds from) Hedge, Investing Activities Share-based compensation, target number of units percentage Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Target Number of Units, Percentage Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Target Number of Units, Percentage Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Product and Service [Axis] Product and Service [Axis] Entity Address, State or Province Entity Address, State or Province Statement [Line Items] Statement [Line Items] Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Line Of Credit For General Corporate Purpose Line Of Credit For General Corporate Purpose [Member] Line Of Credit For General Corporate Purpose Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Products and assets to sell agreement amount Disposal Group, Including Discontinued Operation, Consideration Roxanne Lagano Trading Arrangement, Equity Awards [Member] Roxanne Lagano Trading Arrangement, Equity Awards Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Payment to acquire business Business Combination, Consideration Transferred Liabilities and Equity Liabilities and Equity [Abstract] Maturity period (in years) Derivative, Term of Contract Estimated additional tax liability Income Tax Examination, Estimate of Possible Loss Loss on assets held for sale, selling costs allocation Gain (Loss) On Disposition Of Asset, Selling Costs Allocation Gain (Loss) On Disposition Of Asset, Selling Costs Allocation Minimum Minimum [Member] Restatement Determination Date Restatement Determination Date 2.000% 2020 senior notes due 2030 Senior notes 2.000% due 2030 [Member] Senior notes 2.000% due 2030 Adoption Date Trading Arrangement Adoption Date Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] United Kingdom UNITED KINGDOM Other non-pharmaceutical Other Non Pharmaceuticals [Member] Other Non Pharmaceuticals [Member] Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Accrued expenses Disposal Group, Including Discontinued Operation, Accrued Liabilities, Current Purchase accounting adjustments Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Consideration Transferred Currency [Axis] Currency [Axis] Short-term Debt, Type [Axis] Short-Term Debt, Type [Axis] Segments [Axis] Segments [Axis] Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Loss on assets held for sale, goodwill allocation Gain (Loss) On Disposition Of Asset, Goodwill Allocation Gain (Loss) On Disposition Of Asset, Goodwill Allocation Derivative Instrument [Axis] Derivative Instrument [Axis] Debt, principal amount Total long-term debt Long-Term Debt, Gross Exercise Price Award Exercise Price Dividends payable Dividends Payable, Current Schedule of Net Investment Hedges, Statements of Financial Performance and Financial Position, Location Schedule of Net Investment Hedges, Statements of Financial Performance and Financial Position, Location [Table Text Block] Earnings per Share Earnings Per Share [Text Block] Spain SPAIN Financial Instruments [Abstract] Financial Instruments [Abstract] Financial Instruments [Abstract] Arrangement Duration Trading Arrangement Duration Costs and expenses: Costs and Expenses [Abstract] Companion animal Companion Animal [Member] Companion Animal [Member] Goodwill and Other Intangible Assets Goodwill and Intangible Assets Disclosure [Text Block] Share-based compensation, weighted average grant date fair value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Duration of suspension of lawsuit Lawsuit Temporarily Suspended The number of years lawsuit was temporarily suspended. Accrued compensation and related items Disposal Group, Including Discontinued Operation,Employee Related, Current Disposal Group, Including Discontinued Operation,Employee Related, Current Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Other unallocated Other Unallocated Items Included in Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Other Unallocated Items Included in Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Restructuring Plan [Axis] Restructuring Plan [Axis] Segments [Domain] Segments [Domain] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Fish Fish [Member] Fish [Member] All Individuals All Individuals [Member] Other pharmaceutical Other Pharmaceuticals [Member] Other Pharmaceuticals [Member] Brands and tradenames Trademarks and Trade Names [Member] France FRANCE PEO PEO [Member] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Fair value, debt instrument Debt Instrument, Fair Value Disclosure Name Trading Arrangement, Individual Name Other, net Other Nonoperating Income (Expense) Gross goodwill Goodwill, Gross Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Identifiable intangible assets, less accumulated amortization Identifiable intangible assets, less accumulated amortization Intangible Assets, Net (Excluding Goodwill) Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Derivatives Net Unrealized Gains/ (Losses) Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent [Member] 2022 Senior Notes 2022 Senior Notes [Member] 2022 Senior Notes Disposal Group Name [Axis] Disposal Group Name [Axis] 2024 Long-Term Debt, Maturity, Remainder of Fiscal Year 3.900% 2018 senior notes due 2028 Senior Notes 3.900% Due 2028 [Member] Senior Notes 3.900% Due 2028 [Member] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Cumulative fair value adjustment for interest rate swap contracts Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease) Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract] Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Other business activities Other Operating Segment [Member] Cash dividends paid Payments of Ordinary Dividends Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Foreign currency forward-exchange contracts Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments Local Phone Number Local Phone Number Intangible Assets, gross carrying amount Intangible Assets, Gross (Excluding Goodwill) Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Germany GERMANY Operating expenses Operating Expenses Noncurrent deferred tax liabilities Deferred Income Tax Liabilities, Net Share-based compensation, expected volatility rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Other assets Increase (Decrease) in Other Operating Assets Other changes in assets and liabilities, net of acquisitions and divestitures: Increase (Decrease) in Operating Capital [Abstract] PEO Total Compensation Amount PEO Total Compensation Amount Reclassification of goodwill to assets held for sale Goodwill, Transfers Exit costs Business Exit Costs Derivative liabilities Derivative Liability, Subject to Master Netting Arrangement, before Offset Non-cash transactions: Other Noncash Investing and Financing Items [Abstract] Benefit plans: Actuarial gains, net of tax of $0 and $0 for the three months ended September 30, 2024 and 2023, respectively, and $0 and $1 for the nine months ended September 30, 2024 and 2023, respectively Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax International International Segment [Member] International Segment [Member] Share Repurchase Program [Domain] Share Repurchase Program [Domain] Forward-starting interest rate swap contracts zts_ForwardStartingInterestRateSwap [Member] zts_ForwardStartingInterestRateSwap Cash withheld for post-closing adustments Business Combination, Consideration Transferred, Cash Withheld For Post-Closing Adjustments Business Combination, Consideration Transferred, Cash Withheld For Post-Closing Adjustments Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Common Stock Common Stock [Member] Measure: Measure [Axis] Preferred stock, shares authorized Preferred Stock, Shares Authorized Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Total geographical area Total Geographical Area [Member] Total by Geographical Area [Member] Entity Emerging Growth Company Entity Emerging Growth Company Indefinite-lived Intangible Assets [Axis] Indefinite-Lived Intangible Assets [Axis] Share-based compensation, award graded vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Graded Vesting Period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Graded Vesting Period Segment Reporting [Abstract] Segment Reporting [Abstract] 5.400% 2022 senior notes due 2025 5.400% Senior Notes Due 2025 [Member] 5.400% Senior Notes Due 2025 Entity Central Index Key Entity Central Index Key 5.600% 2022 senior notes due 2032 5.600% Senior Notes Due 2032 [Member] 5.600% Senior Notes Due 2032 Components of Inventory Schedule of Inventory, Current [Table Text Block] Unrecognized tax benefits, income tax penalties and interest accrued Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Currency Translation Adjustment Net Unrealized Gain/(Losses) Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Acquisition-related costs Acquisition-related Costs [Member] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Stockholders' Equity Equity [Text Block] Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Equity Component [Domain] Equity Component [Domain] Other current assets Disposal Group, Including Discontinued Operation, Other Assets, Current Segment Information Segment Reporting Disclosure [Text Block] Net gain on sale of businesses, excluding transaction costs Gain on sale of business, excluding transaction costs Gain on sale of business, excluding transaction costs Sheep and other Manufactured Product, Other [Member] Japan JAPAN Restructuring charges and certain acquisition and divestiture-related costs Total Restructuring charges and certain acquisition and divestiture-related costs Restructuring Charges And Acquisition And Divestiture Related Costs This element represents (i) restructuring charges, which are amounts charged against earnings in the period for incurred and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a program that is planned and controlled by management, and materially changes either the scope of a business undertaken by an entity, or the manner in which that business is conducted; and (ii) acquisition-related costs, which are costs incurred to effect a business combination which costs have been expensed during the period. Such costs can include transaction costs such as banking, legal, accounting and other costs directly related to effect a business combination as well as external, incremental costs of integration planning that are directly related to a business combination, including costs associated with preparing for systems and other integration activities. Product rights Product Rights [Member] Product Rights [Member] 3.000% 2020 senior notes due 2050 Senior Notes 3.000% due 2050 [Member] Senior Notes 3.000% due 2050 Amortization of intangible assets Amortization Of Intangible Assets Not Associated With Single Function The amount of amortization that is not associated with a single function. Amounts associated in a single function are included in Cost of sales, Selling, information and administrative expenses and Research and development expenses. Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Share-based compensation awards APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Entity Shell Company Entity Shell Company Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Title Trading Arrangement, Individual Title Statement [Table] Statement [Table] Accounting Standards Significant Accounting Policies [Text Block] Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, Tax Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, Tax Gain (Loss) on Components Excluded from Assessment of Interest Rate Fair Value Hedge Effectiveness Gain (Loss) on Components Excluded from Assessment of Interest Rate Fair Value Hedge Effectiveness Liabilities associated with uncertain tax positions Unrecognized Tax Benefits Less: Comprehensive income/(loss) attributable to noncontrolling interests Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Consolidation Items [Domain] Consolidation Items [Domain] Internal Revenue Service (IRS) Internal Revenue Service (IRS) [Member] City Area Code City Area Code Schedule of Other Derivatives Not Designated as Hedging Instruments, Statements of Financial Performance and Financial Position, Location Derivatives Not Designated as Hedging Instruments [Table Text Block] Number of countries in which entity markets products Number of Countries in which Entity Operates Interest, net of capitalized interest Interest Paid, Excluding Capitalized Interest, Operating Activities Italy ITALY Disposal Group Classification [Domain] Disposal Group Classification [Domain] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Loss on assets held for sale Loss on assets held for sale Gain (Loss) on Disposition of Assets Total current assets Assets, Current Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Senior Notes Senior Notes [Member] Revenue Deferred Revenue Disclosure [Text Block] Other tax accounts, net Increase (Decrease) in Accrued Taxes Payable Purchases of treasury stock, including excise taxes paid Payments for Repurchase of Common Stock 2027 Long-Term Debt, Maturity, Year Three Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Long-term debt, net of discount and issuance costs Long-Term Debt, Excluding Current Maturities Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Share-based compensation, Options, weighted average grant date fair value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Restructuring Reserve [Roll Forward] Restructuring Reserve [Roll Forward] Other Other Intangible Assets [Member] Euro Member Countries, Euro Euro Member Countries, Euro Income Taxes Income Tax Disclosure [Text Block] Earnings Per Share [Abstract] Earnings Per Share [Abstract] Schedule of Significant Product Revenues Revenue from External Customers by Products and Services [Table Text Block] Equity [Abstract] Equity [Abstract] Retained earnings Retained Earnings (Accumulated Deficit) Class of Stock [Domain] Class of Stock [Domain] Inventories Increase (Decrease) in Inventories 2026 Long-Term Debt, Maturity, Year Two Other noncurrent liabilities Other Noncurrent Liabilities [Member] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Equity Awards Adjustments Equity Awards Adjustments [Member] Decrease in short-term borrowings, net Proceeds from (Repayments of) Short-Term Debt Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Underlying Securities Award Underlying Securities Amount PSUs Performance Shares Performance Shares [Member] 4.500% 2015 senior notes due 2025 Senior Notes 4.500% Due 2025 [Member] Senior Notes Due 2025 [Member] Credit Facility [Axis] Credit Facility [Axis] Amendment Flag Amendment Flag Maximum total leverage ratio, next 12 months Line of Credit Facility, Covenant Compliance, Maximum Leverage Ratio, Next Twelve Months Line of Credit Facility, Covenant Compliance, Maximum Leverage Ratio, Next Twelve Months Commercial Paper Commercial Paper Entity Registrant Name Entity Registrant Name Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Other asset impairment charges Other Asset Impairment Charges Depreciation and amortization expense Depreciation and amortization Depreciation, Depletion and Amortization Gross profit Gross Profit Certain significant items, Earnings Certain Significant Reconciling Items Included in Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Certain Significant Reconciling Items Included in Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Finite Lived and Indefinite Lived Intangible Assets [Line Items] Finite Lived And Indefinite Lived Intangible Assets [Line Items] Finite Lived and Indefinite Lived Intangible Assets [Line Items] Fair Value as of Grant Date Award Grant Date Fair Value Subsequent Events [Abstract] Subsequent Events [Abstract] Other (Income)/Deductions - Net Other Income and Other Expense Disclosure [Text Block] Fair Value, Inputs, Level 2 Fair Value, Inputs, Level 2 [Member] Other emerging markets Other Emerging Markets [Member] Other Emerging Markets [Member] Acquisitions, net of cash acquired Payments to Acquire Business Two, Net of Cash Acquired Ulianopolis, Brazil Ulianopolis, Brazil [Member] Ulianopolis, Brazil [Member] Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value Hierarchy and NAV [Domain] Stockholders’ equity: Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Geographical [Domain] Geographical [Domain] Geographical [Domain] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Forward-starting interest rate swaps Interest Rate Swap [Member] Schedule of Restructuring and Related Costs [Table] Restructuring Cost [Table] Restatement Determination Date: Restatement Determination Date [Axis] Title of 12(b) Security Title of 12(b) Security Common stock, $0.01 par value: 6,000,000,000 authorized; 501,891,243 and 501,891,243 shares issued; 451,549,789 and 458,367,358 shares outstanding at September 30, 2024, and December 31, 2023, respectively Common Stock, Value, Issued Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Income Tax Authority, Name [Domain] Income Tax Authority, Name [Domain] Number of major product lines Number of Major Product Lines Number of Major Product Lines Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Other investing activities Payments for (Proceeds from) Other Investing Activities Other noncurrent assets Other Noncurrent Assets [Member] Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] All Currencies [Domain] All Currencies [Domain] Derivative Instruments and Hedging Activities Disclosures [Line Items] Derivative Instruments and Hedging Activities Disclosures [Line Items] Other current liabilities Other Current Liabilities [Member] Identifiable intangible asset impairment charges(b) Impairment of Intangible Assets (Excluding Goodwill) Financing Activities Net Cash Provided by (Used in) Financing Activities [Abstract] Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Components of Other (Income)/Deductions—Net Schedule of Other Operating Cost and Expense, by Component [Table Text Block] Basic (in dollars per share) Earnings per share attributable to Zoetis stockholders—basic (in dollars per share) Earnings Per Share, Basic Schedule of Short-term Debt [Table] Short-Term Debt [Table] Accounts payable Increase (Decrease) in Accounts Payable Cash Acquired from Acquisition Cash Acquired from Acquisition Mexico MEXICO Amounts included in the measurement of lease liabilities: Operating Lease, Payments Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Share-based compensation, award expiration period Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Schedule of Product Information [Table] Nature of Operation, Product Information, Concentration of Risk [Table] Financing cash flows - finance leases Finance Lease, Principal Payments Capital expenditures Capital Expenditures Incurred but Not yet Paid Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Schedule of Goodwill [Table] Goodwill [Table] Derivatives Designated as Hedging Instruments: Designated as Hedging Instrument [Member] Disposal Group, Held-for-Sale, Not Discontinued Operations Disposal Group, Held-for-Sale, Not Discontinued Operations [Member] Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Schedule of Stock by Class [Table] Stock, Class of Stock [Table] Total current liabilities Liabilities, Current Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Share Repurchase Program [Axis] Share Repurchase Program [Axis] Total assets Assets Cost of sales Cost of sales Cost of Goods and Services Sold Line of credit facility Long-Term Line of Credit Share-based compensation, granted, shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Components of Identifiable Intangible Assets Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block] Gross margin, percentage Gross Margin Gross Margin Capital expenditures Payments to Acquire Property, Plant, and Equipment Other noncurrent liabilities Other Liabilities, Noncurrent Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Derivative Instruments and Hedging Activities Disclosures [Table] Derivative Instruments and Hedging Activities Disclosures [Table] Commitments and contingencies (Note 15) Commitments and Contingencies Loss on assets held for sale Disposal Group, Including Discontinued Operation, Asset Adjustment, Gain (Loss) On Assets Held For Sale Disposal Group, Including Discontinued Operation, Asset Adjustment, Gain (Loss) On Assets Held For Sale Termination Date Trading Arrangement Termination Date Organization Nature of Operations [Text Block] Revenue Revenues Cattle Cattle [Member] Cattle [Member] Deconsolidation of noncontrolling interests Noncontrolling Interest, Decrease from Deconsolidation 2025 Long-Term Debt, Maturity, Year One Share-Based Payments Share-Based Payment Arrangement [Text Block] Derivatives Not Designated as Hedging Instruments Derivatives Not Designated as Hedging Instruments: Not Designated as Hedging Instrument [Member] Revenue from External Customers by Geographic Areas Revenue from External Customers by Geographic Areas [Table Text Block] Entity Address, City or Town Entity Address, City or Town Debt Instrument [Axis] Debt Instrument [Axis] Share-based compensation expense—direct Share-Based Payment Arrangement, Expense Pumpkin Insurance Services Pumpkin Insurance Services [Member] Pumpkin Insurance Services Net income attributable to Zoetis Inc. Net Income (Loss) Attributable to Parent Net Income (Loss) Attributable to Parent Trading Arrangement: Trading Arrangement [Axis] Share-based compensation, weighted average exercise price (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Loss Contingencies [Table] Loss Contingencies [Table] Business Acquisition [Axis] Business Acquisition [Axis] Revolving credit facility, current borrowing capacity Line of Credit Facility, Current Borrowing Capacity Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Entity File Number Entity File Number Unrealized gains (losses) on derivatives for cash flow hedges, net and net investment hedges Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax Document Fiscal Year Focus Document Fiscal Year Focus Revenue from External Customers by Products and Services [Table] Segment Reporting, Revenue from External Customer, Product and Service [Table] Equity Attributable to Noncontrolling Interests Noncontrolling Interest [Member] Income Statement [Abstract] Income Statement [Abstract] Entity Address, Address Line One Entity Address, Address Line One Treasury stock acquired Treasury Stock, Value, Acquired, Cost Method Weighted-average common shares outstanding: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Revenue from External Customer [Line Items] Revenue from External Customer [Line Items] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Effect of exchange-rate changes on cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Employee termination costs, net Severance Costs Dividends, Common Stock Dividends, Common Stock Restructuring Plan [Domain] Restructuring Plan [Domain] Accrued expenses Other Accrued Liabilities, Current Name Forgone Recovery, Individual Name Unamortized debt discount / debt issuance costs Debt Instrument, Unamortized Discount (Premium), Net Document Period End Date Document Period End Date Finished goods Inventory, Finished Goods, Net of Reserves Other non-cash adjustments Other Noncash Income (Expense) Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Foreign exchange derivative instruments Cross Currency Interest Rate Contract [Member] Goodwill Disposal Group, Including Discontinued Operation, Goodwill, Noncurrent Insider Trading Arrangements [Line Items] Line of Credit Facility [Line Items] Line of Credit Facility [Line Items] Reconciling Items Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment [Member] Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Unrecognized net (losses)/gains on interest swap contracts, net of tax Gain (Loss) on Derivative Used in Net Investment Hedge, after Tax Other current assets Other Current Assets [Member] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount 4.450% 2018 senior notes due 2048 Senior Notes 4.450% Due 2048 [Member] Senior Notes 4.450% Due 2048 [Member] Contract liabilities, revenue recognized Contract with Customer, Liability, Revenue Recognized Adjustment to Compensation: Adjustment to Compensation [Axis] Less: Net income/(loss) attributable to noncontrolling interests Less: Net income/(loss) attributable to noncontrolling interests Net Income (Loss) Attributable to Noncontrolling Interest Number of additional defendants Loss Contingency, Additional Number of Defendants Loss Contingency, Additional Number of Defendants Document Transition Report Document Transition Report Document Quarterly Report Document Quarterly Report Foreign Currency Fair Value Hedge Derivative [Table] Foreign Currency Fair Value Hedge Derivative [Table] Litigation Case [Domain] Litigation Case [Domain] Kristin Peck [Member] Kristin Peck Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Current Reporting Status Entity Current Reporting Status Retained Earnings Retained Earnings [Member] Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Income Tax Authority, Name [Axis] Income Tax Authority, Name [Axis] Basic (in shares) Weighted-average common shares outstanding Weighted Average Number of Shares Outstanding, Basic Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Divestiture-related costs Restructuring And Related Activities, Divestiture Related Cost Restructuring And Related Activities, Divestiture Related Cost Total equity Beginning balance Ending balance Equity, Including Portion Attributable to Noncontrolling Interest RSUs / DSUs Restricted Stock Units (RSUs) Restricted Stock Units (RSUs) [Member] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Executive Category: Executive Category [Axis] Purchase of investments Payments to Acquire Investments Name Awards Close in Time to MNPI Disclosures, Individual Name Accounts payable Disposal Group, Including Discontinued Operation, Accounts Payable, Current 4.700% 2013 senior notes due 2043 Senior Notes Due 2043 [Member] Senior Notes Due 2043 [Member] Entity Filer Category Entity Filer Category Restructuring accrual balance Restructuring accrual balance Restructuring Reserve Collateral posted Collateral Already Posted, Aggregate Fair Value Loss Contingencies [Line Items] Loss Contingencies [Line Items] Company Selected Measure Name Company Selected Measure Name EX-101.PRE 10 zts-20240930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 12 R1.htm IDEA: XBRL DOCUMENT v3.24.3
Document and Entity Information - shares
 9 Months Ended
Sep. 30, 2024
Oct. 31, 2024
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2024  
Document Transition Report false  
Entity File Number 001-35797  
Entity Registrant Name Zoetis Inc.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 46-0696167  
Entity Address, Address Line One 10 Sylvan Way,  
Entity Address, City or Town Parsippany,  
Entity Address, State or Province NJ  
Entity Address, Postal Zip Code 07054  
City Area Code 973  
Local Phone Number 822-7000  
Title of 12(b) Security Common Stock, par value $0.01 per share  
Trading Symbol ZTS  
Security Exchange Name NYSE  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   451,165,011
Amendment Flag false  
Document Fiscal Year Focus 2024  
Document Fiscal Period Focus Q3  
Entity Central Index Key 0001555280  
Current Fiscal Year End Date --12-31  
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.24.3
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) - USD ($)
shares in Millions, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Income Statement [Abstract]        
Revenue $ 2,388 $ 2,151 $ 6,939 $ 6,331
Costs and expenses:        
Cost of sales 701 638 2,012 1,833
Selling, general and administrative expenses 565 525 1,693 1,586
Research and development expenses 167 152 500 440
Amortization of intangible assets 35 38 107 112
Restructuring charges and certain acquisition and divestiture-related costs 5 16 51 45
Interest expense, net of capitalized interest 57 59 174 180
Other (income)/deductions—net (16) 6 1 (151)
Income before provision for taxes on income 874 717 2,401 [1] 2,286 [1]
Provision for taxes on income 182 121 486 469
Net income before allocation to noncontrolling interests 692 596 1,915 1,817
Less: Net income/(loss) attributable to noncontrolling interests 10 0 10 (2)
Net income attributable to Zoetis Inc. $ 682 $ 596 $ 1,905 $ 1,819
Earnings per share attributable to Zoetis Inc. stockholders:        
Basic (in dollars per share) $ 1.51 $ 1.29 $ 4.18 $ 3.94
Diluted (in dollars per share) $ 1.50 $ 1.29 $ 4.18 $ 3.93
Weighted-average common shares outstanding:        
Basic (in shares) 452.9 460.3 455.4 461.9
Diluted (in shares) 453.5 461.4 456.1 463.0
Dividends paid per common share (in dollars per share) $ 0 $ 0 $ 0.864 $ 0.750
[1] Defined as income before provision for taxes on income.
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.24.3
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Net income before allocation to noncontrolling interests $ 692 $ 596 $ 1,915 $ 1,817
Other comprehensive (loss)/income, net of tax(a):        
Foreign currency translation adjustments [1] 21 60 (2) (6)
Benefit plans: Actuarial gains, net of tax of $0 and $0 for the three months ended September 30, 2024 and 2023, respectively, and $0 and $1 for the nine months ended September 30, 2024 and 2023, respectively [1] 0 0 0 4
Other comprehensive loss, net of tax (6) 81 (12) 3
Comprehensive income before allocation to noncontrolling interests 686 677 1,903 1,820
Less: Comprehensive income/(loss) attributable to noncontrolling interests 10 0 10 (2)
Comprehensive income attributable to Zoetis Inc. 676 677 1,893 1,822
Cash Flow Hedging        
Other comprehensive (loss)/income, net of tax(a):        
Unrealized gains (losses) on derivatives for cash flow hedges, net and net investment hedges [1] (4) 3 (5) 0
Net Investment Hedging        
Other comprehensive (loss)/income, net of tax(a):        
Unrealized gains (losses) on derivatives for cash flow hedges, net and net investment hedges [1] $ (23) $ 18 $ (5) $ 5
[1] Presented net of reclassification adjustments, which are not material in any period presented.
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.24.3
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) (UNAUDITED) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, Tax $ 0 $ 0 $ 0 $ 1,000
Cash Flow Hedging        
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax (1,000) 1,000 (1,000) 0
Net Investment Hedging        
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax $ (7,000) $ 5,000 $ (2,000) $ 1,000
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.24.3
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($)
$ in Millions
Sep. 30, 2024
Dec. 31, 2023
Assets    
Cash and cash equivalents [1] $ 1,714 $ 2,041
Accounts receivable, less allowance for doubtful accounts of $19 in 2024 and $18 in 2023 1,411 1,304
Inventories 2,416 2,564
Assets held for sale 314 0
Other current assets 427 434
Total current assets 6,282 6,343
Property, plant and equipment, less accumulated depreciation of $2,657 in 2024 and $2,594 in 2023 3,298 3,204
Operating lease right-of-use assets 223 230
Goodwill 2,744 2,759
Identifiable intangible assets, less accumulated amortization 1,186 1,338
Noncurrent deferred tax assets 409 206
Other noncurrent assets 215 206
Total assets 14,357 14,286
Liabilities and Equity    
Short-term borrowings 0 3
Accounts payable 404 411
Dividends payable 0 198
Accrued expenses 725 683
Accrued compensation and related items 335 382
Income taxes payable 97 110
Liabilities associated with assets held for sale 26 0
Other current liabilities 115 102
Total current liabilities 1,702 1,889
Long-term debt, net of discount and issuance costs 6,574 6,564
Noncurrent deferred tax liabilities 172 146
Operating lease liabilities 181 188
Other taxes payable 274 271
Other noncurrent liabilities 220 237
Total liabilities 9,123 9,295
Commitments and contingencies (Note 15)
Stockholders’ equity:    
Common stock, $0.01 par value: 6,000,000,000 authorized; 501,891,243 and 501,891,243 shares issued; 451,549,789 and 458,367,358 shares outstanding at September 30, 2024, and December 31, 2023, respectively 5 5
Treasury stock, at cost, 50,341,454 and 43,523,885 shares of common stock at September 30, 2024 and December 31, 2023, respectively (6,889) (5,597)
Additional paid-in capital 1,163 1,133
Retained earnings 11,806 10,295
Accumulated other comprehensive loss (851) (839)
Total Zoetis Inc. equity 5,234 4,997
Equity attributable to noncontrolling interests 0 (6)
Total equity 5,234 4,991
Total liabilities and equity $ 14,357 $ 14,286
[1] As of September 30, 2024 and December 31, 2023, includes $4 million and $2 million of restricted cash, respectively.
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.24.3
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (PARENTHETICAL) - USD ($)
$ in Millions
Sep. 30, 2024
Dec. 31, 2023
Statement of Financial Position [Abstract]    
Allowance for doubtful accounts $ 19 $ 18
Accumulated depreciation $ 2,657 $ 2,594
Common stock, par value (in dollars per share) $ 0.01  
Common stock, shares authorized 6,000,000,000  
Common stock issued, shares 501,891,243 501,891,243
Common stock, shares outstanding 451,549,789 458,367,358
Treasury stock, shares 50,341,454 43,523,885
Restricted cash $ 4 $ 2
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.24.3
CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (UNAUDITED) - USD ($)
$ in Millions
Total
Common Stock
Treasury Stock
Treasury Stock
Share Repurchase Program
Additional Paid-in Capital
Retained Earnings
Accumulated Other Comprehensive Loss
Equity Attributable to Noncontrolling Interests
Beginning balance (in shares) at Dec. 31, 2022   501,900,000            
Beginning balance at Dec. 31, 2022 $ 4,403 $ 5 $ (4,539)   $ 1,088 $ 8,668 $ (817) $ (2)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 1,817         1,819   (2)
Other comprehensive loss, net of tax 3           3  
Treasury stock, beginning balance (in shares) at Dec. 31, 2022     38,100,000          
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Treasury stock acquired, shares     5,000,000.0 [1] 700,000 [2]        
Share-based compensation awards [2] 61   $ 34   28 (1)    
Treasury stock acquired [1] (864)   (864)          
Dividends, Common Stock (346)         (346)    
Ending balance (in shares) at Sep. 30, 2023   501,900,000            
Ending balance at Sep. 30, 2023 5,074 $ 5 $ (5,369)   1,116 10,140 (814) (4)
Treasury stock, ending balance (in shares) at Sep. 30, 2023     42,400,000          
Beginning balance (in shares) at Jun. 30, 2023   501,900,000            
Beginning balance at Jun. 30, 2023 4,621 $ 5 $ (5,126)   1,098 9,543 (895) (4)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 596         596   0
Other comprehensive loss, net of tax 81           81  
Treasury stock, beginning balance (in shares) at Jun. 30, 2023     41,200,000          
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Treasury stock acquired, shares     1,400,000 [3] 200,000 [4]        
Share-based compensation awards [4] 28   $ 9   18 1    
Treasury stock acquired [3] (252)   (252)          
Ending balance (in shares) at Sep. 30, 2023   501,900,000            
Ending balance at Sep. 30, 2023 $ 5,074 $ 5 $ (5,369)   1,116 10,140 (814) (4)
Treasury stock, ending balance (in shares) at Sep. 30, 2023     42,400,000          
Beginning balance (in shares) at Dec. 31, 2023 501,891,243 501,900,000            
Beginning balance at Dec. 31, 2023 $ 4,991 $ 5 $ (5,597)   1,133 10,295 (839) (6)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 1,915         1,905   10
Other comprehensive loss, net of tax (12)           (12)  
Deconsolidation of noncontrolling interests $ (4)             (4)
Treasury stock, beginning balance (in shares) at Dec. 31, 2023 43,523,885   43,500,000          
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Treasury stock acquired, shares     7,300,000 [1] 500,000 [2]        
Share-based compensation awards [2] $ 45   $ 15   30 0    
Treasury stock acquired [1] (1,307)   (1,307)          
Dividends, Common Stock $ (394)         (394)    
Ending balance (in shares) at Sep. 30, 2024 501,891,243 501,900,000            
Ending balance at Sep. 30, 2024 $ 5,234 $ 5 $ (6,889)   1,163 11,806 (851) 0
Treasury stock, ending balance (in shares) at Sep. 30, 2024 50,341,454   50,300,000          
Beginning balance (in shares) at Jun. 30, 2024   501,900,000            
Beginning balance at Jun. 30, 2024 $ 4,960 $ 5 $ (6,464)   1,146 11,124 (845) (6)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 692         682   10
Other comprehensive loss, net of tax (6)           (6)  
Deconsolidation of noncontrolling interests (4)             (4)
Treasury stock, beginning balance (in shares) at Jun. 30, 2024     48,000,000.0          
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Treasury stock acquired, shares     2,300,000 [3] 0 [4]        
Share-based compensation awards [4] 19   $ 2   17 0    
Treasury stock acquired [3] $ (427)   (427)          
Ending balance (in shares) at Sep. 30, 2024 501,891,243 501,900,000            
Ending balance at Sep. 30, 2024 $ 5,234 $ 5 $ (6,889)   $ 1,163 $ 11,806 $ (851) $ 0
Treasury stock, ending balance (in shares) at Sep. 30, 2024 50,341,454   50,300,000          
[1] Reflects the acquisition of treasury shares in connection with the share repurchase program and includes excise tax accrued on net share repurchases. For additional information, see Note 13. Stockholders’ Equity.
[2] Includes the issuance of shares of Zoetis Inc. common stock and the reacquisition of shares of treasury stock associated with exercises of employee share-based awards. Also includes the reacquisition of shares of treasury stock associated with the vesting of employee share-based awards to satisfy tax withholding requirements. For additional information, see Note 12. Share-based Payments and Note 13. Stockholders’ Equity.
[3] Reflects the acquisition of treasury shares in connection with the share repurchase program and includes excise tax accrued on net share repurchases. For additional information, see Note 13. Stockholders’ Equity.
[4] Includes the issuance of shares of Zoetis Inc. common stock and the reacquisition of shares of treasury stock associated with exercises of employee share-based awards. Also includes the reacquisition of shares of treasury stock associated with the vesting of employee share-based awards to satisfy tax withholding requirements. For additional information, see Note 12. Share-based Payments and Note 13. Stockholders’ Equity.
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.24.3
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)
$ in Millions
 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Operating Activities    
Net income before allocation to noncontrolling interests $ 1,915 $ 1,817
Adjustments to reconcile net income before noncontrolling interests to net cash provided by operating activities:    
Depreciation and amortization expense [1],[2] 374 365
Share-based compensation expense 55 43
Asset write-offs and asset impairments 16 27
Net gain on sale of businesses, excluding transaction costs 0 (118)
Provision for losses on inventory 71 82
Deferred taxes (186) (40)
Other non-cash adjustments 11 (6)
Other changes in assets and liabilities, net of acquisitions and divestitures:    
Accounts receivable (134) (54)
Inventories (113) (497)
Other assets (14) (119)
Accounts payable 5 (9)
Other liabilities 36 (27)
Other tax accounts, net (10) (8)
Net cash provided by operating activities 2,048 1,456
Investing Activities    
Capital expenditures (439) (534)
Acquisitions, net of cash acquired (8) (155)
Purchase of investments (4) (3)
Proceeds from derivative instrument activity, net 11 23
Proceeds from sale of businesses, net of cash sold 0 96
Net proceeds from sale of assets 1 4
Other investing activities (2) 2
Net cash used in investing activities (441) (567)
Financing Activities    
Decrease in short-term borrowings, net (3) 0
Principal payments on long-term debt 0 (1,350)
Payment of consideration related to previous acquisitions (5) (3)
Share-based compensation-related proceeds, net of taxes paid on withholding shares (10) 18
Purchases of treasury stock, including excise taxes paid (1,305) (857)
Cash dividends paid (592) (520)
Net cash used in financing activities (1,915) (2,712)
Effect of exchange-rate changes on cash and cash equivalents (19) (4)
Net decrease in cash and cash equivalents (327) (1,827)
Cash and cash equivalents at beginning of period 2,041 3,581
Cash and cash equivalents at end of period 1,714 1,754
Cash paid during the period for:    
Income taxes 657 586
Interest, net of capitalized interest 205 225
Amounts included in the measurement of lease liabilities: 46 42
Financing cash flows - finance leases 1 0
Non-cash transactions:    
Capital expenditures 4 4
Excise tax accrued on net share repurchases, not paid 12 7
Lease obligations obtained in exchange for right-of-use assets - operating 39 74
Disposal Group, Held-for-Sale, Not Discontinued Operations    
Adjustments to reconcile net income before noncontrolling interests to net cash provided by operating activities:    
Loss on assets held for sale $ 22 $ 0
[1] Certain production facilities are shared. Depreciation and amortization is allocated to the reportable operating segments based on estimates of where the benefits of the related assets are realized.
[2] Defined as income before provision for taxes on income.
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.24.3
Organization
 9 Months Ended
Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization
1. Organization
Zoetis Inc. (including its subsidiaries, collectively, Zoetis, the company, we, us or our) is a global leader in the animal health industry, focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. We organize and operate our business in two geographic regions: the United States (U.S.) and International.
We directly market our products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. Our products are sold in more than 100 countries, including developed and emerging markets. We have a diversified business, commercializing products across eight core species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock); and within eight major product categories: parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, animal health diagnostics and medicated feed additives.
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.24.3
Basis of Presentation
 9 Months Ended
Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation
2. Basis of Presentation
The accompanying unaudited condensed consolidated financial statements were prepared following the requirements of the Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by accounting principles generally accepted in the United States of America (U.S. GAAP) can be condensed or omitted. Balance sheet amounts and operating results for subsidiaries operating outside the U.S. are as of and for the three and nine months ended August 31, 2024 and August 31, 2023.
Revenue, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.
Certain reclassifications of prior year information have been made to conform to the current year's presentation.
We are responsible for the unaudited condensed consolidated financial statements included in this Form 10-Q. The condensed consolidated financial statements include all normal and recurring adjustments that are considered necessary for the fair presentation of our financial position and operating results. The information included in this interim report should be read in conjunction with the financial statements and accompanying notes included in our 2023 Annual Report on Form 10-K.
In the third quarter of 2024, we concluded that we were no longer the primary beneficiary of a variable interest entity (VIE) that was previously consolidated. The effects of the deconsolidation were not material to the condensed consolidated financial statements.
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.24.3
Accounting Standards
 9 Months Ended
Sep. 30, 2024
Accounting Policies [Abstract]  
Accounting Standards
3. Accounting Standards
Recently Issued Accounting Standards
In December 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The new guidance requires expanded annual and interim disclosures for significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss. This update is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. The update is to be applied retrospectively to all periods presented in the financial statements. Early adoption is permitted. The adoption of this guidance will impact our disclosures only and we do not expect it to have an impact on our consolidated financial statements.
In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax disclosures. The new guidance requires standardized categories for the effective tax rate reconciliation, disaggregation of income taxes paid and other income tax-related disclosures. This update is effective for fiscal years beginning after December 15, 2024. We are currently evaluating the impact that the new guidance will have on our notes to the consolidated financial statements.
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.24.3
Revenue
 9 Months Ended
Sep. 30, 2024
Revenue Recognition and Deferred Revenue [Abstract]  
Revenue
4. Revenue
A. Revenue from Product Sales
We offer a diversified portfolio of products which allows us to capitalize on local and regional customer needs. Generally, our products are promoted to veterinarians and livestock producers by our sales organization which includes sales representatives and technical and veterinary operations specialists, and then sold directly by us or through distributors, retailers or e-commerce outlets. The depth of our product portfolio enables us to address the varying needs of customers in different species and geographies. Many of our top-selling product lines are distributed across both of our operating segments, leveraging our research and development (R&D) operations and manufacturing and supply chain network.
Over the course of our history, we have focused on developing a diverse portfolio of animal health products, including medicines, vaccines and diagnostics, complemented by biodevices, genetic tests and a range of services. We refer to all different brands of a particular product, or its dosage forms for all species, as a product line. We have approximately 300 comprehensive product lines, including products for both companion animals and livestock, within our major product categories.
In the first quarter of 2024, we modified the list of major product categories to include a category for pain and sedation products, which were previously included within other pharmaceutical products. The prior period presentation has been revised to reflect the new product category.
Our major product categories are:
•parasiticides: products that prevent or eliminate external and internal parasites such as fleas, ticks and worms;
•vaccines: biological preparations that help prevent diseases of the respiratory, gastrointestinal and reproductive tracts or induce a specific immune response;
•dermatology: products that relieve itch associated with allergic conditions and atopic dermatitis;
•anti-infectives: products that prevent, kill or slow the growth of bacteria, fungi or protozoa;
•pain and sedation: products that alleviate pain, primarily associated with osteoarthritis and postoperative pain;
•other pharmaceutical: antiemetic, reproductive and oncology products;
•animal health diagnostics: testing and analysis of blood, urine and other animal samples and related products and services, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services and blood glucose monitors; and
•medicated feed additives: products added to animal feed that provide medicines to livestock.
Our remaining revenue is derived from other non-pharmaceutical product categories, such as nutritionals, as well as products and services in biodevices, genetic tests and precision animal health.
Our companion animal products help extend and improve the quality of life for pets; increase convenience and compliance for pet owners; and help veterinarians improve the quality of their care and the efficiency of their businesses. Growth in the companion animal medicines, vaccines and diagnostics sector is driven by economic development, related increases in disposable income and increases in pet ownership and spending on pet care. Companion animals are also living longer, deepening the human-animal bond, receiving increased medical treatment and benefiting from advances in animal health medicine, vaccines and diagnostics.
Our livestock products primarily help prevent or treat diseases and conditions to allow veterinarians and producers to care for their animals and to enable the cost-effective production of safe, high-quality animal protein. Human population growth and increasing standards of living are important long-term growth drivers for our livestock products in three major ways. First, population growth and increasing standards of living drive demand for improved nutrition, particularly through increased consumption of animal protein. Second, population growth leads to greater natural resource constraints driving a need for enhanced productivity. Finally, as standards of living improve and the global food chain faces increased scrutiny, there is more focus on food quality, safety and reliability of supply.
The following tables present our revenue disaggregated by geographic area, species and major product category:
Revenue by geographic area
Three Months EndedNine Months Ended
September 30,September 30,
(MILLIONS OF DOLLARS)2024202320242023
United States$1,346 $1,174 $3,817 $3,344 
Australia83 84 239 248 
Brazil101 101 301 276 
Canada66 63 202 183 
Chile31 31 93 109 
China61 69 205 255 
France36 34 111 102 
Germany57 50 166 148 
Italy31 26 95 87 
Japan33 34 109 120 
Mexico39 42 129 119 
Spain35 30 100 94 
United Kingdom80 78 230 209 
Other developed markets148 127 413 374 
Other emerging markets220 187 670 605 
2,367 2,130 6,880 6,273 
Contract manufacturing & human health21 21 59 58 
Total Revenue$2,388 $2,151 $6,939 $6,331 
Revenue by major species
Three Months EndedNine Months Ended
September 30,September 30,
(MILLIONS OF DOLLARS)2024202320242023
U.S.
Companion animal$1,068 $908 $3,046 $2,588 
Livestock278 266 771 756 
1,346 1,174 3,817 3,344 
International
Companion animal541 506 1,662 1,540 
Livestock480 450 1,401 1,389 
1,021 956 3,063 2,929 
Total
Companion animal1,609 1,414 4,708 4,128 
Livestock758 716 2,172 2,145 
Contract manufacturing & human health21 21 59 58 
Total Revenue$2,388 $2,151 $6,939 $6,331 
Revenue by species
Three Months EndedNine Months Ended
September 30,September 30,
(MILLIONS OF DOLLARS)2024202320242023
Companion Animal:
Dogs and Cats$1,551 $1,354 $4,516 $3,931 
Horses58 60 192 197 
1,609 1,414 4,708 4,128 
Livestock:
Cattle391 374 1,132 1,102 
Poultry139 127 410 397 
Swine131 129 388 404 
Fish70 57 177 158 
Sheep and other27 29 65 84 
758 716 2,172 2,145 
Contract manufacturing & human health21 21 59 58 
Total Revenue$2,388 $2,151 $6,939 $6,331 
Revenue by major product category
Three Months EndedNine Months Ended
September 30,September 30,
(MILLIONS OF DOLLARS)2024202320242023
Parasiticides$530 $465 $1,634 $1,465 
Vaccines468 449 1,365 1,308 
Dermatology453 397 1,234 1,048 
Anti-infectives274 264 819 796 
Pain and sedation219 147 634 408 
Other pharmaceutical169 166 478 514 
Animal health diagnostics101 95 286 284 
Medicated feed additives91 86 242 257 
Other non-pharmaceutical62 61 188 193 
2,367 2,130 6,880 6,273 
Contract manufacturing & human health21 21 59 58 
Total Revenue$2,388 $2,151 $6,939 $6,331 
B. Revenue from Contracts with Customers
Contract liabilities reflected within Other current liabilities as of December 31, 2023 and 2022, and subsequently recognized as revenue during each of the first nine months of 2024 and 2023 were $4 million. Contract liabilities as of September 30, 2024 and December 31, 2023 were $21 million and $11 million, respectively.
Estimated future revenue expected to be generated from long-term contracts with unsatisfied performance obligations as of September 30, 2024 is not material.
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.24.3
Acquisitions and Divestitures
 9 Months Ended
Sep. 30, 2024
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]  
Acquisitions and Divestitures
5. Acquisitions and Divestitures
A. Acquisitions
During the third quarter of 2023, we acquired 100% of the issued share capital of PetMedix Ltd. (PetMedix), a privately held research and development stage animal health biopharmaceutical company based in the United Kingdom, which develops antibody-based therapeutics for companion animals. The purchase price included upfront cash consideration of $111 million, excluding $19 million of cash acquired, $5 million in cash withheld for customary post-closing adjustments, and contingent consideration up to $100 million based on the achievement of certain milestones. There are additional contingent payments to be made to the seller upon receipt of payments from a third party related to a preexisting collaboration arrangement between PetMedix and the third party. The initial fair value assessment of the contingent consideration and additional contingent payments is not material and the transaction did not have a material impact on our condensed consolidated financial statements.
During the third quarter of 2023, we also completed the acquisition of adivo GmbH (adivo), a privately held research and development stage animal health biopharmaceutical company based in Germany. The transaction did not have a material impact on our condensed consolidated financial statements.
B. Divestitures
During the second quarter of 2024, we entered into a definitive agreement where Phibro Animal Health will acquire Zoetis’ medicated feed additive product portfolio, certain water soluble products and related assets for $350 million, subject to customary closing adjustments. Net assets and liabilities related to the sale met all the criteria to be classified as held for sale during the second quarter of 2024. We have determined that this future divestiture does not qualify for reporting as a discontinued operation, as it does not represent a strategic shift that has or will have a major effect on our operations and/or financial results. Proceeds upon the closing of this transaction were received in the fourth quarter of 2024. See Note 17. Subsequent Event for additional information.
As of September 30, 2024, major classes of assets held for sale and liabilities associated with assets held for sale are summarized below:
September 30,
(MILLIONS OF DOLLARS)2024
Assets held for sale
Accounts receivable, less allowance for doubtful accounts$1 
Inventories162 
Other current assets2 
Property, plant and equipment, less accumulated depreciation108 
Operating lease right-of-use assets2 
Goodwill(a)
12 
Identifiable intangible assets, less accumulated amortization26 
Noncurrent deferred tax assets2 
Other noncurrent assets9 
Loss on assets held for sale(a)
(10)
  Total Assets Held for Sale$314 
Liabilities associated with assets held for sale
Accounts payable$11 
Accrued expenses8 
Accrued compensation and related items1 
Other noncurrent liabilities6 
  Total Liabilities Associated with Assets Held for Sale$26 
(a) We recorded a loss on assets held for sale of $22 million in the Condensed Consolidated Statements of Income during the nine months ended September 30, 2024. Of the loss on assets held for sale, $12 million is allocated to goodwill and the remaining $10 million relates to selling costs to be recognized upon closing and foreign currency translation losses to be reclassified out of accumulated other comprehensive income into earnings upon closing of the transaction.
During the second quarter of 2023, we received net cash proceeds of $93 million ($99 million sales proceeds, net of cash sold of $6 million) for the sale of a majority interest in our pet insurance business, Pumpkin Insurance Services. We recorded a net pre-tax gain of $101 million within Other (income)/deductions—net, which includes $24 million related to the remeasurement of our retained noncontrolling investment to fair value. We also completed the divestiture of Performance Livestock Analytics, part of our precision animal health business in the third quarter of 2023. The transaction did not have a material impact on our condensed consolidated financial statements.
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.24.3
Restructuring Charges and Other Costs Associated with Acquisitions and Divestitures
 9 Months Ended
Sep. 30, 2024
Restructuring and Related Activities [Abstract]  
Restructuring Charges and Other Costs Associated with Acquisitions and Divestitures
6. Restructuring Charges and Other Costs Associated with Acquisitions and Divestitures
In connection with our cost-reduction/productivity initiatives, we typically incur restructuring charges associated with workforce reductions and site closings. In connection with our acquisition and divestiture activities, we typically incur costs associated with executing the transactions. Acquisition activity may also include integrating the acquired operations, which may include expenditures for consulting and the integration of systems and processes, product transfers and restructuring the company, which may include charges related to employees, assets and activities that will not continue in the company. Divestiture activity may also include costs to separate the divested operations, which may include expenditures for consulting and the disintegration of systems and processes, transfer costs, and restructuring charges which may include charges related to employees, assets and activities that will not continue in the company's ongoing operations. All operating functions can be impacted by these actions, including sales and marketing, manufacturing and R&D, as well as functions such as business technology, shared services and corporate operations.
The components of costs incurred in connection with restructuring initiatives, acquisitions and divestitures are as follows:
Three Months EndedNine Months Ended
September 30,September 30,
(MILLIONS OF DOLLARS)2024202320242023
Restructuring charges and certain acquisition and divestiture-related costs:
Acquisition-related costs$— $3 $1 $7 
Divestiture-related costs(a)
7 — 11 — 
Restructuring charges, net(b):
Employee termination costs, net(2)8 39 33 
Asset impairment charges— 1 — 1 
Exit costs— 4 — 4 
Total Restructuring charges and certain acquisition and divestiture-related costs
$5 $16 $51 $45 
(a)    Divestiture-related costs consisted of costs related to the planned sale of our medicated feed additive product portfolio, certain water soluble products and related assets.
(b) The restructuring charges for the nine months ended September 30, 2024 primarily consisted of employee termination costs related to organizational structure refinements, partially offset by a reversal of certain employee termination costs as a result of a change in strategy from our 2015 operational efficiency initiative.
The restructuring charges for the three and nine months ended September 30, 2023 primarily consisted of employee termination and exit costs related to organizational structure refinements and other cost-reduction and productivity initiatives.
The change in our restructuring accrual is as follows:
(MILLIONS OF DOLLARS)
Accrual
Balance, December 31, 2023(a)
$35 
Provision46 
Reserve adjustment(7)
Utilization and other(b)
(28)
Balance, September 30, 2024(a)
$46 
(a)     At September 30, 2024 and December 31, 2023, included in Accrued expenses ($44 million and $26 million, respectively) and Other noncurrent liabilities ($2 million and $9 million, respectively).
(b)     Includes adjustments for foreign currency translation.
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.24.3
Other (Income)/Deductions - Net
 9 Months Ended
Sep. 30, 2024
Other Income and Expenses [Abstract]  
Other (Income)/Deductions - Net
7. Other (Income)/Deductions—Net
The components of Other (income)/deductions—net are as follows:
Three Months EndedNine Months Ended
September 30,September 30,
(MILLIONS OF DOLLARS)2024202320242023
Royalty-related income(a)
$(2)$(1)$(5)$(36)
Interest income(23)(23)(79)(79)
Identifiable intangible asset impairment charges(b)
— 6 11 17 
Loss on assets held for sale(c)
— — 22 — 
Other asset impairment charges— 1 — 1 
Net gain on sale of business(d)
— — — (101)
Foreign currency loss(e)
5 19 42 41 
Other, net4 4 10 6 
Other (income)/deductions—net$(16)$6 $1 $(151)
(a)     For the nine months ended September 30, 2023, predominantly associated with a settlement for underpayment of royalties in prior periods.
(b)    For the nine months ended September 30, 2024, represents asset impairment charges related to our aquaculture business.
For the three months ended September 30, 2023, primarily represents asset impairment charges related to our diagnostics business.
For the nine months ended September 30, 2023, primarily represents asset impairment charges related to our precision animal health and diagnostics businesses.
(c)    Represents a loss on assets held for sale related to the planned sale of our medicated feed additive product portfolio, certain water soluble products and related assets. For additional information, see Note 5. Acquisitions and Divestitures.
(d)    Relates to the gain on sale of a majority interest in our pet insurance business. For additional information, see Note 5. Acquisitions and Divestitures.
(e)    Primarily driven by costs related to hedging and exposures to certain emerging and developed market currencies.
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.24.3
Income Taxes
 9 Months Ended
Sep. 30, 2024
Income Tax Disclosure [Abstract]  
Income Taxes
8. Income Taxes
A. Taxes on Income
Our effective tax rate was 20.8% and 16.9% for the three months ended September 30, 2024 and 2023, respectively. The higher effective tax rate for the three months ended September 30, 2024, compared with the three months ended September 30, 2023, was primarily attributable to a benefit from the tax loss on the divestiture of Performance Livestock Analytics recorded in the third quarter of 2023, higher net discrete tax expenses and a less favorable jurisdictional mix of earnings (which includes the impact of the location of earnings and repatriation costs), partially offset by a higher benefit in the U.S. related to foreign-derived intangible income. Jurisdictional mix of earnings can vary depending on repatriation decisions, operating fluctuations in the normal course of business and the impact of non-deductible items and non-taxable items.
Our effective tax rate was 20.2% and 20.5% for the nine months ended September 30, 2024 and 2023, respectively. The lower effective tax rate for the nine months ended September 30, 2024, compared with the nine months ended September 30, 2023, was primarily attributable to a higher benefit in the U.S. related to foreign-derived intangible income, lower net discrete tax expenses and a more favorable jurisdictional mix of earnings (which includes the impact of the location of earnings and repatriation costs), partially offset by a benefit from the tax loss on the divestiture of Performance Livestock Analytics recorded in the third quarter of 2023. Jurisdictional mix of earnings can vary depending on repatriation decisions, operating fluctuations in the normal course of business and the impact of non-deductible items and non-taxable items.
In 2022, the company implemented an initiative to maximize its cash position in the U.S. This initiative resulted in a tax benefit in the U.S. in connection with a prepayment from a related foreign entity in Belgium which qualifies as foreign-derived intangible income; however, this income tax benefit was deferred to 2023 and 2024. A portion of this benefit was recognized during the three and nine months ended September 30, 2024 and 2023.
The global minimum tax provisions (Pillar Two) resulting from the Organisation for Economic Co-operation and Development (OECD) Base Erosion and Profit Shifting project are effective beginning in 2024 and the impact of these provisions is included in our effective tax rate for the three and nine months ended September 30, 2024.
B. Deferred Taxes
As of September 30, 2024, the total net deferred income tax asset of $237 million is included in Noncurrent deferred tax assets ($409 million) and Noncurrent deferred tax liabilities ($172 million).
As of December 31, 2023, the total net deferred income tax asset of $60 million is included in Noncurrent deferred tax assets ($206 million) and Noncurrent deferred tax liabilities ($146 million).
C. Tax Contingencies
Uncertain Tax Positions
As of September 30, 2024, the net tax liabilities associated with uncertain tax positions of $217 million (exclusive of interest and penalties related to uncertain tax positions of $36 million) are included in Other taxes payable.
As of December 31, 2023, the net tax liabilities associated with uncertain tax positions of $209 million (exclusive of interest and penalties related to uncertain tax positions of $27 million) are included in Other taxes payable.
Our tax liabilities for uncertain tax positions relate primarily to issues common among multinational corporations. Any settlements or statute of limitations expirations could result in a significant decrease in our uncertain tax positions. Substantially all of these unrecognized tax benefits, if recognized, would impact our effective income tax rate. We do not expect that within the next twelve months any of our uncertain tax positions could significantly decrease as a result of settlements with taxing authorities or the expiration of the statutes of limitations. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but our estimates of uncertain tax positions and potential tax benefits may not be representative of actual outcomes, and any variation from such estimates could materially affect our financial statements in the period of settlement or when the statutes of limitations expire, as we treat these events as discrete items in the period of resolution. Finalizing audits with the relevant taxing authorities can include formal administrative and legal proceedings, and, as a result, it is difficult to estimate the timing and range of possible changes related to our uncertain tax positions, and such changes could be significant.
Status of Tax Audits and Potential Impact on Accrual for Uncertain Tax Positions
We are currently under income tax audit by the U.S. Internal Revenue Service (IRS) for tax years 2017 and 2018. In July 2024, the IRS issued Notices of Proposed Adjustment (NOPA) related to the one-time mandatory deemed repatriation tax incurred on the 2018 U.S. Federal Income Tax return. In September 2024, the IRS issued a Revenue Agent Report for the adjustments identified in the NOPA. As of September 30, 2024, the additional tax liability, based on the income adjustment proposed by the IRS under the NOPA, is approximately $450 million, excluding interest and penalties.
Based on current facts and circumstances, we disagree with the IRS’ position and will defend our position taken on the 2018 U.S. Federal Income Tax return. We believe the amount previously accrued related to this uncertain tax position remains appropriate, but we will continue to evaluate the adequacy of our tax reserve as the audit progresses. However, the outcome of tax audits cannot be predicted with certainty. If any issues addressed in our tax audits are not consistent with management’s expectations, we could be required to adjust our provision for income taxes and this amount could be material to our financial statements.
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.24.3
Financial Instruments
 9 Months Ended
Sep. 30, 2024
Financial Instruments [Abstract]  
Financial Instruments
9. Financial Instruments
A. Debt
Credit Facilities
In December 2022, we entered into an amended and restated revolving credit agreement with a syndicate of banks providing for a multi-year $1.0 billion senior unsecured revolving credit facility (the credit facility), which expires in December 2027. Subject to certain conditions, we have the right to increase the credit facility to up to $1.5 billion. The credit facility contains a financial covenant requiring us to not exceed a maximum total leverage ratio (the ratio of consolidated net debt as of the end of the period to consolidated Earnings Before Interest, Income Taxes, Depreciation and Amortization (EBITDA) for such period) of 3.50:1. Upon entering into a material acquisition, the maximum total leverage ratio increases to 4.00:1, and extends until the fourth full consecutive fiscal quarter ended immediately following the consummation of a material acquisition. In addition, the credit facility contains other customary covenants.
We were in compliance with all financial covenants as of September 30, 2024 and December 31, 2023. There were no amounts drawn under the credit facility as of September 30, 2024 or December 31, 2023.
We have additional lines of credit and other credit arrangements with a group of banks and other financial intermediaries for general corporate purposes. We maintain cash and cash equivalent balances in excess of our outstanding short-term borrowings. As of September 30, 2024, we had access to $56 million of lines of credit which expire at various times and are generally renewed annually. There were no borrowings outstanding related to these facilities as of September 30, 2024 and $3 million of borrowings outstanding related to these facilities as of December 31, 2023.
Commercial Paper Program
In February 2013, we entered into a commercial paper program with a capacity of up to $1.0 billion. As of September 30, 2024 and December 31, 2023, there was no commercial paper outstanding under this program.
Senior Notes and Other Long-Term Debt
On November 8, 2022, we issued $1.35 billion aggregate principal amount of our senior notes (2022 senior notes), with an original issue discount of $2 million. These notes are comprised of $600 million aggregate principal amount of 5.400% senior notes due 2025 and $750 million aggregate principal amount of 5.600% senior notes due 2032. On February 1, 2023, the net proceeds were used to redeem in full, upon maturity, the $1.35 billion aggregate principal amount of our 3.250% 2013 senior notes due 2023.
Our senior notes are governed by an indenture and supplemental indentures (collectively, the indenture) between us and Deutsche Bank Trust Company Americas, as trustee. The indenture contains certain covenants, including limitations on our and certain of our subsidiaries’ ability to incur liens or engage in sale-leaseback transactions. The indenture also contains restrictions on our ability to consolidate, merge or sell substantially all of our assets. In addition, the indenture contains other customary terms, including certain events of default, upon the occurrence of which the senior notes may be declared immediately due and payable.
Pursuant to the indenture, we are able to redeem the senior notes of any series, in whole or in part, at any time by paying a “make whole” premium, plus accrued and unpaid interest to, but excluding, the date of redemption. Upon the occurrence of a change of control of us and a downgrade of the senior notes below an investment grade rating by each of Moody’s Investors Service, Inc. and Standard & Poor’s Ratings Services, we are, in certain circumstances, required to make an offer to repurchase all of the outstanding senior notes at a price equal to 101% of the aggregate principal amount of the senior notes together with accrued and unpaid interest to, but excluding, the date of repurchase.
The components of our long-term debt are as follows:
September 30,December 31,
(MILLIONS OF DOLLARS)20242023
4.500% 2015 senior notes due 2025
$750 $750 
5.400% 2022 senior notes due 2025
600 600 
3.000% 2017 senior notes due 2027
750 750 
3.900% 2018 senior notes due 2028
500 500 
2.000% 2020 senior notes due 2030
750 750 
5.600% 2022 senior notes due 2032
750 750 
4.700% 2013 senior notes due 2043
1,150 1,150 
3.950% 2017 senior notes due 2047
500 500 
4.450% 2018 senior notes due 2048
400 400 
3.000% 2020 senior notes due 2050
500 500 
6,650 6,650 
Unamortized debt discount / debt issuance costs(56)(60)
Cumulative fair value adjustment for interest rate swap contracts(20)(26)
Long-term debt, net of discount and issuance costs$6,574 $6,564 
The fair value of our long-term debt was $6,334 million and $6,319 million as of September 30, 2024 and December 31, 2023, respectively, and has been determined using a third-party model that uses significant inputs derived from, or corroborated by, observable market data, including benchmark security prices and Zoetis’ credit spreads (Level 2 inputs).
The following table provides the principal amount of debt outstanding, as of September 30, 2024, by scheduled maturity date:
After
(MILLIONS OF DOLLARS)202420252026202720282028Total
Maturities$— $1,350 $— $750 $500 $4,050 $6,650 
Interest Expense
Interest expense, net of capitalized interest, was $57 million and $174 million for the three and nine months ended September 30, 2024, respectively, and $59 million and $180 million for the three and nine months ended September 30, 2023, respectively. Capitalized interest expense was $9 million and $26 million for the three and nine months ended September 30, 2024, respectively, and $7 million and $19 million for the three and nine months ended September 30, 2023, respectively.
B. Derivative Financial Instruments
Foreign Exchange Risk
A significant portion of our revenue, earnings and net investment in foreign affiliates is exposed to changes in foreign exchange rates. We seek to manage our foreign exchange risk, in part, through operational means, including managing same-currency revenue in relation to same-currency costs and same-currency assets in relation to same-currency liabilities. Depending on market conditions, foreign exchange risk is also managed through the use of various derivative financial instruments. These derivative financial instruments serve to manage the exposure of our net investment in certain foreign operations to changes in foreign exchange rates and protect net income against the impact of translation into U.S. dollars of certain foreign exchange-denominated transactions.
All derivative financial instruments used to manage foreign currency risk are measured at fair value and are reported as assets or liabilities on the Condensed Consolidated Balance Sheets. The derivative financial instruments primarily offset exposures in the Australian dollar, British pound, Canadian dollar, Chinese renminbi, euro and Norwegian krone. Changes in fair value are reported in earnings or in Accumulated other comprehensive loss, depending on the nature and purpose of the financial instrument, as follows:
•For foreign currency forward-exchange contracts not designated as hedging instruments, we recognize the gains and losses that are used to offset the same foreign currency assets or liabilities immediately into earnings along with the earnings impact of the items they generally offset. These contracts essentially take the opposite currency position of that reflected in the month-end balance sheet to counterbalance the effect of any currency movement. The vast majority of the foreign currency forward-exchange contracts mature within 60 days and all mature within four years.
•For foreign exchange derivative instruments that are designated as hedging instruments against our net investment in foreign operations, changes in the fair value are recorded as a component of cumulative translation adjustment within Accumulated other comprehensive loss and reclassified into earnings when the foreign investment is sold or substantially liquidated. These instruments include cross-currency interest rate swaps and foreign currency forward-exchange contracts. Gains and losses excluded from the assessment of hedge effectiveness are recognized in earnings (Interest expense, net of capitalized interest). The cash flows from these contracts are reflected within the investing section of our Condensed Consolidated Statements of Cash Flows. These contracts have varying maturities and all mature within one year.
Interest Rate Risk
The company may use interest rate swap contracts on certain investing and borrowing transactions to manage its net exposure to interest rates and to reduce its overall cost of borrowing.
•In anticipation of issuing fixed-rate debt, we may use forward-starting interest rate swaps that are designated as cash flow hedges to hedge against changes in interest rates that could impact expected future issuances of debt. Unrealized gains or losses on the forward-starting interest rate swaps are reported in Accumulated other comprehensive loss and are recognized in earnings over the life of the future fixed rate notes. When the company discontinues hedge accounting because it is no longer probable that an anticipated transaction will occur within the originally expected period of execution, or within an additional two-month period thereafter, changes to fair value accumulated in other comprehensive income are recognized immediately in earnings.
•During the period from 2019 to 2022, we entered into forward-starting interest rate swaps with an aggregate notional value of $650 million. We designated these swaps as cash flow hedges against interest rate exposure related principally to the issuance of fixed-rate debt to refinance our 3.250% 2013 senior notes due 2023. Upon issuance of our 2022 senior notes, we terminated these contracts and received $114 million in cash from the counterparties for settlement. The settlement amount, which represented the fair value of the contracts at the time of termination, was recorded in Accumulated other comprehensive loss, and will be amortized into income (offset to Interest expense, net of capitalized interest) over the life of the 5.600% 2022 senior notes due 2032.
•As of September 30, 2024, we had outstanding forward-starting interest rate swaps, having an effective date and mandatory termination date in March 2026, to hedge against interest rate exposure related principally to the anticipated future issuance of fixed-rate debt to be used primarily to refinance our 4.500% 2015 senior notes due 2025.
•We may use fixed-to-floating interest rate swaps that are designated as fair value hedges to hedge against changes in the fair value of certain fixed-rate debt attributable to changes in the benchmark of the Secured Overnight Financing Rate (SOFR). These derivative instruments effectively convert a portion of the company’s long-term debt from fixed-rate to floating-rate debt based on the daily SOFR rate plus a spread. Gains or losses on the fixed-to-floating interest rate swaps due to changes in SOFR are recorded in Interest expense, net of capitalized interest. Changes in the fair value of the fixed-to-floating interest rate swaps are offset by changes in the fair value of the underlying fixed-rate debt. As of September 30, 2024, we had outstanding fixed-to-floating interest rate swaps that correspond to a portion of the 3.900% 2018 senior notes due 2028 and the 2.000% 2020 senior notes due 2030. The amounts recorded during the three and nine
months ended September 30, 2024 for changes in the fair value of these hedges are not material to our condensed consolidated financial statements.
During the first quarter of 2023, we executed amendments to certain of our interest rate swap contracts, which changed the floating rate index from LIBOR to SOFR. These amendments did not have a material impact on our condensed consolidated financial statements.
Outstanding Positions
The aggregate notional amount of derivative instruments are as follows:
Notional
September 30,December 31,
(MILLIONS)20242023
Derivatives not Designated as Hedging Instruments:
     Foreign currency forward-exchange contracts $1,965 $1,948 
Derivatives Designated as Hedging Instruments:
     Foreign exchange derivative instruments (in foreign currency):
          Euro 750 650 
          Danish krone475 600 
          Swiss franc25 25 
     Forward-starting interest rate swaps $200 $100 
     Fixed-to-floating interest rate swap contracts$250 $250 
Fair Value of Derivative Instruments
The classification and fair values of derivative instruments are as follows:
Fair Value of Derivatives
September 30,December 31,
(MILLIONS OF DOLLARS)Balance Sheet Location20242023
Derivatives Not Designated as Hedging Instruments:
   Foreign currency forward-exchange contractsOther current assets$17 $11 
   Foreign currency forward-exchange contracts
Other current liabilities
(14)(11)
Total derivatives not designated as hedging instruments$3 $— 
Derivatives Designated as Hedging Instruments:
   Forward-starting interest rate swap contractsOther noncurrent assets$12 $12 
   Foreign exchange derivative instruments Other current assets17 5 
   Foreign exchange derivative instruments Other noncurrent assets— 11 
   Foreign exchange derivative instruments Other current liabilities(17)(20)
   Foreign exchange derivative instruments Other noncurrent liabilities— (1)
   Fixed-to-floating interest rate swap contractsOther noncurrent liabilities(20)(26)
Total derivatives designated as hedging instruments(8)(19)
Total derivatives$(5)$(19)
The company’s derivative transactions are subject to master netting agreements that mitigate credit risk by permitting net settlement of transactions with the same counterparty. The company also has collateral security agreements with certain of its counterparties. Under these collateral security agreements each party is required to post cash collateral when the net fair value of derivative instruments covered by the collateral agreement exceeds contractually established thresholds. At September 30, 2024, there was $12 million of collateral received and $22 million of collateral posted related to derivative instruments recorded in Other current liabilities and Other current assets, respectively. At December 31, 2023, there was $13 million of collateral received and $33 million of collateral posted related to derivative instruments recorded in Other current liabilities and Other current assets, respectively.
We use a market approach in valuing financial instruments on a recurring basis. Our derivative financial instruments are measured at fair value on a recurring basis using Level 2 inputs in the calculation of fair value.
The amounts of net gains/(losses) on derivative instruments not designated as hedging instruments, recorded in Other (income)/deductions—net, are as follows:
Three Months EndedNine Months Ended
September 30,September 30,
(MILLIONS OF DOLLARS)2024202320242023
Foreign currency forward-exchange contracts$11 $16 $12 $(20)
These amounts were substantially offset in Other (income)/deductions—net by the effect of changing exchange rates on the underlying foreign currency exposures.
The amounts of unrecognized net (losses)/gains on interest rate swap contracts, recorded, net of tax, in Accumulated other comprehensive loss, are as follows:
Three Months EndedNine Months Ended
September 30,September 30,
(MILLIONS OF DOLLARS)2024202320242023
Forward-starting interest rate swap contracts$(3)$5 $— $5 
Foreign exchange derivative instruments$(23)$18 $(5)$5 
Gains on interest rate swap contracts, recognized within Interest expense, net of capitalized interest, are as follows:
Three Months EndedNine Months Ended
September 30,September 30,
(MILLIONS OF DOLLARS)2024202320242023
Foreign exchange derivative instruments$4 $4 $12 $14 
The net amount of deferred gains related to derivative instruments designated as cash flow hedges that is expected to be reclassified from Accumulated other comprehensive loss into earnings over the next 12 months is not material.
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.24.3
Inventories
 9 Months Ended
Sep. 30, 2024
Inventory Disclosure [Abstract]  
Inventories
10. Inventories
The components of inventory are as follows:
September 30,December 31,
(MILLIONS OF DOLLARS)20242023
Finished goods$1,049 $1,147 
Work-in-process951 966 
Raw materials and supplies416 451 
Inventories$2,416 $2,564 
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.24.3
Goodwill and Other Intangible Assets
 9 Months Ended
Sep. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Other Intangible Assets
11. Goodwill and Other Intangible Assets
A. Goodwill
The components of, and changes in, the carrying amount of goodwill are as follows:
(MILLIONS OF DOLLARS)U.S.InternationalTotal
Balance, December 31, 2023$1,532 $1,227 $2,759 
Other(a)
(17)2 (15)
Balance, September 30, 2024$1,515 $1,229 $2,744 
(a)     Includes adjustments for the reclassification of goodwill of $24 million to Assets held for sale related to the planned sale of our medicated feed additive product portfolio, certain water soluble products and related assets, as well as foreign currency translation. For additional information, see Note 5. Acquisitions and Divestitures: B. Divestitures.
The gross goodwill balance was $3,280 million and $3,295 million as of September 30, 2024 and December 31, 2023, respectively. Accumulated goodwill impairment losses were $536 million as of September 30, 2024 and December 31, 2023.
B. Other Intangible Assets
The components of identifiable intangible assets are as follows:
As of September 30, 2024As of December 31, 2023
IdentifiableIdentifiable
GrossIntangible AssetsGrossIntangible Assets
CarryingAccumulatedLess AccumulatedCarryingAccumulatedLess Accumulated
(MILLIONS OF DOLLARS)AmountAmortizationAmortizationAmountAmortizationAmortization
Finite-lived intangible assets:
Developed technology rights$1,931 $(1,164)$767 $1,986 $(1,101)$885 
Brands and tradenames370 (245)125 383 (246)137 
Other276 (196)80 270 (190)80 
Total finite-lived intangible assets2,577 (1,605)972 2,639 (1,537)1,102 
Indefinite-lived intangible assets:
Brands and tradenames66 — 66 88 — 88 
In-process research and development141 — 141 141 — 141 
Product rights7 — 7 7 — 7 
Total indefinite-lived intangible assets214 — 214 236 — 236 
Identifiable intangible assets$2,791 $(1,605)$1,186 $2,875 $(1,537)$1,338 
C. Amortization
Amortization expense related to finite-lived acquired intangible assets that contribute to our ability to sell, manufacture, research, market and distribute products, compounds and intellectual property is included in Amortization of intangible assets as it benefits multiple business functions. Amortization expense related to finite-lived acquired intangible assets that are associated with a single function is included in Cost of sales, Selling, general and administrative expenses or Research and development expenses, as appropriate. Total amortization expense for finite-lived intangible assets was $42 million and $128 million for the three and nine months ended September 30, 2024, respectively, and $46 million and $141 million for the three and nine months ended September 30, 2023, respectively.
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.24.3
Share-Based Payments
 9 Months Ended
Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]  
Share-Based Payments
12. Share-based Payments
The Zoetis 2013 Equity and Incentive Plan, Amended and Restated as of May 19, 2022 (Equity Plan), provides long-term incentives to our employees and non-employee directors. The principal types of share-based awards available under the Equity Plan may include, but are not limited to, stock options, restricted stock and restricted stock units (RSUs), deferred stock units (DSUs), performance-vesting restricted stock units (PSUs) and other equity-based or cash-based awards.
The components of share-based compensation expense are as follows:
Three Months EndedNine Months Ended
September 30,September 30,
(MILLIONS OF DOLLARS)2024202320242023
Stock options / stock appreciation rights$2 $3 $8 $6 
RSUs / DSUs10 10 31 27 
PSUs6 4 16 10 
Share-based compensation expense—total(a)
$18 $17 $55 $43 
(a) For the three and nine months ended September 30, 2024 and 2023, we capitalized less than $1 million of share-based compensation expense to inventory.
During the nine months ended September 30, 2024, the company granted 270,450 stock options with a weighted-average exercise price of $195.84 per stock option and a weighted-average fair value of $50.90 per stock option. The fair-value based method for valuing each Zoetis stock option grant on the grant date uses the Black-Scholes-Merton option-pricing model, which incorporates a number of valuation assumptions. The weighted-average fair value was estimated based on the following assumptions: risk-free interest rate of 4.06%; expected dividend yield of 0.88%; expected stock price volatility of 27.02%; and expected term of 4.1 years. Stock options granted prior to 2023 generally vest after three years of continuous service from the date of grant and have a contractual term of 10 years. Beginning in 2023, stock options granted are subject to graded vesting over three years from the date of grant and have a contractual term of 10 years. The values determined through this fair-value based method generally are amortized on a straight-line basis over the vesting term into Cost of sales, Selling, general and administrative expenses, or Research and development expenses, as appropriate.
During the nine months ended September 30, 2024, the company granted 246,112 RSUs, with a weighted-average grant date fair value of $195.10 per RSU. RSUs are accounted for using a fair-value-based method that utilizes the closing price of Zoetis common stock on the date of grant. RSUs granted prior to 2023 generally vest after three years of continuous service from the date of grant. Beginning in 2023, RSUs granted are subject to graded vesting over three years from the date of grant. The values generally are amortized on a straight-line basis over the vesting term into Cost of sales, Selling, general and administrative expenses, or Research and development expenses, as appropriate.
During the nine months ended September 30, 2024, the company granted 101,099 PSUs with a weighted-average grant date fair value of $268.71 per PSU. PSUs are accounted for using a Monte Carlo simulation model. The units underlying the PSUs will be earned and vested over a three-year performance period, based upon the total shareholder return of the company in comparison to the total shareholder return of the companies
comprising the S&P 500 stock market index at the start of the performance period, excluding companies that during the performance period are acquired or no longer publicly traded (Relative TSR). The weighted-average fair value was estimated based on volatility assumptions of Zoetis common stock and an average of the S&P 500 companies, which were 26.2% and 30.6%, respectively. Depending on the company’s Relative TSR performance at the end of the performance period, the recipient may earn from 0% to 200% of the target number of units. Vested units are settled in shares of the company’s common stock. PSU values are amortized on a straight-line basis over the vesting term into Cost of sales, Selling, general and administrative expenses, or Research and development expenses, as appropriate.
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.24.3
Stockholders' Equity
 9 Months Ended
Sep. 30, 2024
Equity [Abstract]  
Stockholders' Equity
13. Stockholders’ Equity
Zoetis is authorized to issue 6 billion shares of common stock and 1 billion shares of preferred stock.
In December 2021, our Board of Directors authorized a $3.5 billion multi-year share repurchase program. As of September 30, 2024, there was $200 million remaining under this authorization. In August 2024, our Board of Directors authorized a new multi-year share repurchase program of up to $6 billion of our outstanding common stock. Purchases of Zoetis shares may be made at the discretion of management, depending on market conditions, business needs and available liquidity.
Accumulated other comprehensive loss
Changes, net of tax, in accumulated other comprehensive loss, were as follows:
Currency Translation Adjustments
Other CurrencyBenefit PlansAccumulated Other
Cash FlowNet InvestmentTranslationActuarialComprehensive
(MILLIONS OF DOLLARS)HedgesHedgesAdjustmentsGains/(Losses)Loss
Balance, December 31, 2023$85 $18 $(944)$2 $(839)
Other comprehensive loss, net of tax(5)(5)(2)— 

(12)
Balance, September 30, 2024$80 $13 $(946)$2 $(851)
Balance, December 31, 2022$90 $41 $(944)$(4)$(817)
Other comprehensive income/(loss), net of tax— 5 (6)4 3 
Balance, September 30, 2023$90 $46 $(950)$— $(814)
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.24.3
Earnings per Share
 9 Months Ended
Sep. 30, 2024
Earnings Per Share [Abstract]  
Earnings per Share
14. Earnings per Share
The following table presents the calculation of basic and diluted earnings per share:
Three Months EndedNine Months Ended
(MILLIONS OF DOLLARS AND SHARES, EXCEPT PER SHARE DATA)September 30,September 30,
2024202320242023
Numerator
Net income before allocation to noncontrolling interests$692 $596 $1,915 $1,817 
Less: Net income/(loss) attributable to noncontrolling interests10 — 10 (2)
Net income attributable to Zoetis Inc.$682 $596 $1,905 $1,819 
Denominator
Weighted-average common shares outstanding452.9 460.3 455.4 461.9 
Common stock equivalents: stock options, RSUs, PSUs and DSUs0.6 1.1 0.7 1.1 
Weighted-average common and potential dilutive shares outstanding453.5 461.4 456.1 463.0 
Earnings per share attributable to Zoetis Inc. stockholders—basic$1.51 $1.29 $4.18 $3.94 
Earnings per share attributable to Zoetis Inc. stockholders—diluted$1.50 $1.29 $4.18 $3.93 
The number of stock options outstanding under the company’s Equity Plan that were excluded from the computation of diluted earnings per share, as the effect would have been antidilutive, were not material for the three and nine months ended September 30, 2024 and 2023.
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.24.3
Commitments and Contingencies
 9 Months Ended
Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies
15. Commitments and Contingencies
We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business. For a discussion of our tax contingencies, see Note 8. Income Taxes.
A. Legal Proceedings
Our non-tax contingencies include, among others, the following:
•    Product liability and other product-related litigation, which can include injury, consumer, off-label promotion, antitrust and breach of contract claims.
•    Commercial and other matters, which can include product-pricing claims and environmental claims and proceedings.
•    Patent litigation, which typically involves challenges to the coverage and/or validity of our patents or those of third parties on various products or processes.
•    Government investigations, which can involve regulation by national, state and local government agencies in the U.S. and in other countries.
Certain of these contingencies could result in losses, including damages, fines and/or civil penalties, and/or criminal charges, which could be substantial.
We believe that we have strong defenses in these types of matters, but litigation is inherently unpredictable and excessive verdicts do occur. We do not believe that any of these matters will have a material adverse effect on our financial position. However, we could incur judgments, enter into settlements or revise our expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on our results of operations or cash flows in the period in which the amounts are paid.
We have accrued for losses that are both probable and reasonably estimable. Substantially all of these contingencies are subject to significant uncertainties and, therefore, determining the likelihood of a loss and/or the measurement of any loss can be complex. Consequently, we are unable to estimate the range of reasonably possible loss in excess of amounts accrued. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but the assessment process relies on estimates and assumptions that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions.
Amounts recorded for legal and environmental contingencies can result from a complex series of judgments about future events and uncertainties and can rely on estimates and assumptions.
The principal matters to which we are a party are discussed below. In determining whether a pending matter is significant for financial reporting and disclosure purposes, we consider both quantitative and qualitative factors in order to assess materiality, such as, among other things, the amount of damages and the nature of any other relief sought in the proceeding, if such damages and other relief are specified; our view of the merits of the claims and of the strength of our defenses; whether the action purports to be a class action and our view of the likelihood that a class will be certified by the court; the jurisdiction in which the proceeding is pending; any experience that we or, to our knowledge, other companies have had in similar proceedings; whether disclosure of the action would be important to a reader of our financial statements, including whether disclosure might change a reader’s judgment about our financial statements in light of all of the information about the company that is available to the reader; the potential impact of the proceeding on our reputation; and the extent of public interest in the matter. In addition, with respect to patent matters, we consider, among other things, the financial significance of the product protected by the patent.
Ulianopolis, Brazil
In February 2012, the Municipality of Ulianopolis (State of Para, Brazil) filed a complaint against Fort Dodge Saúde Animal Ltda. (FDSAL), a Zoetis entity, and five other large companies alleging that waste sent to a local waste incineration facility for destruction, but that was not ultimately destroyed as the facility lost its operating permit, caused environmental impacts requiring cleanup.
The Municipality is seeking recovery of cleanup costs purportedly related to FDSAL’s share of all waste accumulated at the incineration facility awaiting destruction, and compensatory damages to be allocated among the six defendants. We believe we have strong arguments against the claim, including defense strategies against any claim of joint and several liability.
At the request of the Municipal prosecutor, in April 2012, the lawsuit was suspended for one year. Since that time, the prosecutor has initiated investigations into the Municipality's actions in the matter as well as the efforts undertaken by the six defendants to remove and dispose of their individual waste from the incineration facility. On October 3, 2014, the Municipal prosecutor announced that the investigation remained ongoing and outlined the terms of a proposed Term of Reference (a document that establishes the minimum elements to be addressed in the preparation of an Environmental Impact Assessment), under which the companies would be liable to withdraw the waste and remediate the area.
On March 5, 2015, we presented our response to the prosecutor’s proposed Term of Reference, arguing that the proposed terms were overly general in nature and expressing our interest in discussing alternatives to address the matter. The prosecutor agreed to consider our request to engage a technical consultant to conduct an environmental diagnostic of the contaminated area. On May 29, 2015, we, in conjunction with the other defendant companies, submitted a draft cooperation agreement to the prosecutor, which outlined the proposed terms and conditions for the engagement of a technical consultant to conduct the environmental diagnostic. On August 19, 2016, the parties and the prosecutor agreed to engage the services of a third-party consultant to conduct a limited environmental assessment of the site. The site assessment was conducted during June 2017, and a written report summarizing the results of the assessment was provided to the parties and the prosecutor in November 2017. The report noted that waste is still present on the site and that further (Phase II) environmental assessments are needed before a plan to manage that remaining waste can be prepared. On April 1, 2019, the defendants met with the Prosecutor to discuss the conclusions set forth in the written report. Following that discussion, on April 10, 2019, the Prosecutor issued a procedural order requesting that the defendants prepare and submit a technical proposal outlining the steps needed to conduct the additional Phase II environmental assessments. The defendants presented the technical proposal to the Prosecutor on October 21, 2019. On March 3, 2020, the Prosecutor notified the defendants that he submitted the proposal to the Ministry of the Environment for its review and consideration by the Prosecutor. On July 15, 2020, the Prosecutor recommended certain amendments to the proposal for the Phase II testing. On September 28, 2020, the parties and the Prosecutor agreed to the final terms and conditions concerning the cooperation agreement with respect to the Phase II testing. Phase II testing began the week of October 14, 2024. The consultant will provide a report upon completion of the testing.
B. Guarantees and Indemnifications
In the ordinary course of business and in connection with the sale of assets and businesses, we indemnify our counterparties against certain liabilities that may arise in connection with the transaction or related to activities prior to the transaction. These indemnifications typically pertain to environmental, tax, employee and/or product-related matters and patent-infringement claims. If the indemnified party were to make a successful claim pursuant to the terms of the indemnification, we would be required to reimburse the loss. These indemnifications are generally subject to threshold amounts, specified claim periods and other restrictions and limitations. Historically, we have not paid significant amounts under these provisions and, as of September 30, 2024, recorded amounts for the estimated fair value of these indemnifications were not material.
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.24.3
Segment Information
 9 Months Ended
Sep. 30, 2024
Segment Reporting [Abstract]  
Segment Information
16. Segment Information
Operating Segments
We manage our operations through two geographic operating segments: the U.S. and International. Each operating segment has responsibility for its commercial activities. Within each of these operating segments, we offer a diversified product portfolio, including parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, animal health diagnostics and medicated feed additives, for both companion animal and livestock customers. Our chief operating decision maker uses the revenue and earnings of the two operating segments, among other factors, for performance evaluation and resource allocation.
Other Costs and Business Activities
Certain costs are not allocated to our operating segment results, such as costs associated with the following:
•    Other business activities, includes our Client Supply Services contract manufacturing results, our human health business, and expenses associated with our dedicated veterinary medicine research and development organization, research alliances, U.S. regulatory affairs and other operations focused on the development of our products. Other R&D-related costs associated with non-U.S. market and regulatory activities are generally included in the international commercial segment.
•    Corporate, includes enabling functions such as information technology, facilities, legal, finance, human resources, business development, certain diagnostic costs and communications, among others. These costs also include certain compensation costs, certain procurement costs and other miscellaneous operating expenses not charged to our operating segments, as well as interest income and expense.
•Certain transactions and events such as (i) Purchase accounting adjustments, where we incur expenses associated with the amortization of fair value adjustments to inventory, intangible assets and property, plant and equipment; (ii) Acquisition and divestiture-related costs, where we incur costs associated with acquiring and integrating newly acquired businesses, such as transaction costs and integration costs, as well as divestiture-related costs; and (iii) Certain significant items, which comprise substantive, unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis, such as restructuring charges and implementation costs associated with our cost-reduction/productivity initiatives that are not associated with an acquisition or divestiture, certain asset impairment charges, certain legal and commercial settlements and the impact of divestiture-related gains and losses.
•Other unallocated includes (i) certain overhead expenses associated with our global manufacturing operations not charged to our operating segments; (ii) certain costs associated with finance that specifically support our global manufacturing operations; (iii) certain supply chain and global logistics costs; and (iv) certain procurement costs.
Segment Assets
We manage our assets on a total company basis, not by operating segment. Therefore, our chief operating decision maker does not regularly review any asset information by operating segment and, accordingly, we do not report asset information by operating segment.
Selected Statement of Income Information
Earnings
Depreciation and Amortization(a)
Three Months EndedThree Months Ended
September 30,September 30,
(MILLIONS OF DOLLARS)2024202320242023
U.S.
Revenue$1,346 $1,174 
Cost of sales258 228 
Gross profit1,088 946 
    Gross margin80.8 %80.6 %
Operating expenses199 202 
Other (income)/deductions-net— — 
U.S. Earnings889 744 $20 $19 
International
Revenue(b)
1,021 956 
Cost of sales321 306 
Gross profit700 650 
    Gross margin68.6 %68.0 %
Operating expenses157 156 
Other (income)/deductions-net1 1 
International Earnings542 493 25 24 
Total operating segments1,431 1,237 45 43 
Other business activities
(137)(124)9 9 
Reconciling Items:
Corporate
(306)(258)31 33 
Purchase accounting adjustments
(35)(39)35 39 
Acquisition and divestiture-related costs
(7)(3)— — 
Certain significant items(c)
(1)(23)— — 
Other unallocated
(71)(73)1 — 
Total Earnings(d)
$874 $717 $121 $124 
(a)    Certain production facilities are shared. Depreciation and amortization is allocated to the reportable operating segments based on estimates of where the benefits of the related assets are realized.
(b)    Revenue denominated in euros was $234 million and $206 million for the three months ended September 30, 2024 and 2023, respectively.
(c)    For the three months ended September 30, 2023, primarily consisted of employee termination and exit costs related to organizational structure refinements and other cost-reduction and productivity initiatives, as well as certain asset impairment charges related to our diagnostics and precision animal health businesses.
(d)    Defined as income before provision for taxes on income.
Earnings
Depreciation and Amortization(a)
Nine Months EndedNine Months Ended
September 30,September 30,
(MILLIONS OF DOLLARS)2024202320242023
U.S.
Revenue$3,817 $3,344 
Cost of sales707 645 
Gross profit3,110 2,699 
    Gross margin81.5 %80.7 %
Operating expenses593 602 
Other (income)/deductions-net— — 
U.S. Earnings2,517 2,097 $65 $58 
International
Revenue(b)
3,063 2,929 
Cost of sales976 912 
Gross profit2,087 2,017 
    Gross margin68.1 %68.9 %
Operating expenses491 473 
Other (income)/deductions-net1 1 
International Earnings1,595 1,543 73 67 
Total operating segments4,112 3,640 138 125 
Other business activities
(411)(354)29 24 
Reconciling Items:
Corporate
(893)(722)96 95 
Purchase accounting adjustments
(107)(124)107 118 
Acquisition and divestiture-related costs
(12)(8)— — 
Certain significant items(c)
(77)45 — — 
Other unallocated
(211)(191)4 3 
Total Earnings(d)
$2,401 $2,286 $374 $365 
(a)    Certain production facilities are shared. Depreciation and amortization is allocated to the reportable operating segments based on estimates of where the benefits of the related assets are realized.
(b)    Revenue denominated in euros was $694 million and $627 million for the nine months ended September 30, 2024 and 2023, respectively.
(c)    For the nine months ended September 30, 2024, primarily consisted of employee termination costs related to organizational structure refinements, a loss on assets held for sale related to the planned sale of our medicated feed additive product portfolio, certain water soluble products and related assets, as well as asset impairment charges related to our aquaculture business, partially offset by a reversal of certain employee termination costs as a result of a change in strategy from our 2015 operational efficiency initiative.
For the nine months ended September 30, 2023, primarily consisted of a gain on the sale of a majority interest in our pet insurance business, partially offset by employee termination costs related to organizational structure refinements and certain asset impairment charges related to our precision animal health and diagnostics businesses.
(d)    Defined as income before provision for taxes on income.
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.24.3
Subsequent Event
 9 Months Ended
Sep. 30, 2024
Subsequent Events [Abstract]  
Subsequent Event
17. Subsequent Event
On October 31, 2024, we completed the divestiture of our medicated feed additive product portfolio, certain water soluble products and related assets. We do not expect the closing of the divestiture to have a material impact to our consolidated financial statements. See Note 5. Acquisitions and Divestitures for additional information regarding the transaction.
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.24.3
Pay vs Performance Disclosure - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Pay vs Performance Disclosure        
Net Income (Loss) Attributable to Parent $ 682 $ 596 $ 1,905 $ 1,819
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.24.3
Insider Trading Arrangements
 3 Months Ended 9 Months Ended
Sep. 30, 2024
shares
Sep. 30, 2024
shares
Trading Arrangements, by Individual    
Non-Rule 10b5-1 Arrangement Adopted false  
Rule 10b5-1 Arrangement Terminated false  
Non-Rule 10b5-1 Arrangement Terminated false  
Kristin Peck [Member]    
Trading Arrangements, by Individual    
Material Terms of Trading Arrangement   Kristin Peck, Chief Executive Officer, adopted a pre-arranged trading plan on September 12, 2024, that is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. Ms. Peck's plan provides for (i) the sale of up to 52,000 shares of Zoetis common stock between December 13, 2024 and December 31, 2025 and (ii) the gifting of up to $300,000 worth of Zoetis common stock to a charitable fund between December 13, 2024 and December 31, 2025.
Name Kristin Peck  
Title Chief Executive Officer  
Rule 10b5-1 Arrangement Adopted true  
Adoption Date September 12, 2024  
Expiration Date December 31, 2025  
Arrangement Duration 383 days  
Aggregate Available 52,000 52,000
Roxanne Lagano [Member]    
Trading Arrangements, by Individual    
Material Terms of Trading Arrangement  
Roxanne Lagano, Executive Vice President, General Counsel and Corporate Secretary, adopted a pre-arranged trading plan on September 13, 2024, that is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. Ms. Lagano’s plan provides for the sale of (i) between December 16, 2024 and December 16, 2025, up to 4,339 shares of Zoetis common stock and (ii) between February 11, 2025 and December 16, 2025, 100% of the net shares (net of tax withholding) resulting from the vesting of 4,858 gross shares of Zoetis common stock relating to equity awards, subject to certain conditions.
Name Roxanne Lagano  
Title Executive Vice President, General Counsel and Corporate Secretary  
Rule 10b5-1 Arrangement Adopted true  
Adoption Date September 13, 2024  
Roxanne Lagano Trading Arrangement, Common Stock [Member] | Roxanne Lagano [Member]    
Trading Arrangements, by Individual    
Expiration Date December 16, 2025  
Arrangement Duration 365 days  
Aggregate Available 4,339 4,339
Roxanne Lagano Trading Arrangement, Equity Awards [Member] | Roxanne Lagano [Member]    
Trading Arrangements, by Individual    
Expiration Date December 16, 2025  
Arrangement Duration 308 days  
Aggregate Available 4,858 4,858
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.24.3
Accounting Standards (Policies)
 9 Months Ended
Sep. 30, 2024
Accounting Policies [Abstract]  
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements were prepared following the requirements of the Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by accounting principles generally accepted in the United States of America (U.S. GAAP) can be condensed or omitted. Balance sheet amounts and operating results for subsidiaries operating outside the U.S. are as of and for the three and nine months ended August 31, 2024 and August 31, 2023.
Revenue, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.
Certain reclassifications of prior year information have been made to conform to the current year's presentation.
We are responsible for the unaudited condensed consolidated financial statements included in this Form 10-Q. The condensed consolidated financial statements include all normal and recurring adjustments that are considered necessary for the fair presentation of our financial position and operating results. The information included in this interim report should be read in conjunction with the financial statements and accompanying notes included in our 2023 Annual Report on Form 10-K.
Recently Issued Accounting Standards
Recently Issued Accounting Standards
In December 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The new guidance requires expanded annual and interim disclosures for significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss. This update is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. The update is to be applied retrospectively to all periods presented in the financial statements. Early adoption is permitted. The adoption of this guidance will impact our disclosures only and we do not expect it to have an impact on our consolidated financial statements.
In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax disclosures. The new guidance requires standardized categories for the effective tax rate reconciliation, disaggregation of income taxes paid and other income tax-related disclosures. This update is effective for fiscal years beginning after December 15, 2024. We are currently evaluating the impact that the new guidance will have on our notes to the consolidated financial statements.
Tax Contingencies
Our tax liabilities for uncertain tax positions relate primarily to issues common among multinational corporations. Any settlements or statute of limitations expirations could result in a significant decrease in our uncertain tax positions. Substantially all of these unrecognized tax benefits, if recognized, would impact our effective income tax rate. We do not expect that within the next twelve months any of our uncertain tax positions could significantly decrease as a result of settlements with taxing authorities or the expiration of the statutes of limitations. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but our estimates of uncertain tax positions and potential tax benefits may not be representative of actual outcomes, and any variation from such estimates could materially affect our financial statements in the period of settlement or when the statutes of limitations expire, as we treat these events as discrete items in the period of resolution. Finalizing audits with the relevant taxing authorities can include formal administrative and legal proceedings, and, as a result, it is difficult to estimate the timing and range of possible changes related to our uncertain tax positions, and such changes could be significant.
Status of Tax Audits and Potential Impact on Accrual for Uncertain Tax Positions
We are currently under income tax audit by the U.S. Internal Revenue Service (IRS) for tax years 2017 and 2018. In July 2024, the IRS issued Notices of Proposed Adjustment (NOPA) related to the one-time mandatory deemed repatriation tax incurred on the 2018 U.S. Federal Income Tax return. In September 2024, the IRS issued a Revenue Agent Report for the adjustments identified in the NOPA. As of September 30, 2024, the additional tax liability, based on the income adjustment proposed by the IRS under the NOPA, is approximately $450 million, excluding interest and penalties.
Based on current facts and circumstances, we disagree with the IRS’ position and will defend our position taken on the 2018 U.S. Federal Income Tax return. We believe the amount previously accrued related to this uncertain tax position remains appropriate, but we will continue to evaluate the adequacy of our tax reserve as the audit progresses. However, the outcome of tax audits cannot be predicted with certainty. If any issues addressed in our tax audits are not consistent with management’s expectations, we could be required to adjust our provision for income taxes and this amount could be material to our financial statements.
Legal Proceedings
A. Legal Proceedings
Our non-tax contingencies include, among others, the following:
•    Product liability and other product-related litigation, which can include injury, consumer, off-label promotion, antitrust and breach of contract claims.
•    Commercial and other matters, which can include product-pricing claims and environmental claims and proceedings.
•    Patent litigation, which typically involves challenges to the coverage and/or validity of our patents or those of third parties on various products or processes.
•    Government investigations, which can involve regulation by national, state and local government agencies in the U.S. and in other countries.
Certain of these contingencies could result in losses, including damages, fines and/or civil penalties, and/or criminal charges, which could be substantial.
We believe that we have strong defenses in these types of matters, but litigation is inherently unpredictable and excessive verdicts do occur. We do not believe that any of these matters will have a material adverse effect on our financial position. However, we could incur judgments, enter into settlements or revise our expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on our results of operations or cash flows in the period in which the amounts are paid.
We have accrued for losses that are both probable and reasonably estimable. Substantially all of these contingencies are subject to significant uncertainties and, therefore, determining the likelihood of a loss and/or the measurement of any loss can be complex. Consequently, we are unable to estimate the range of reasonably possible loss in excess of amounts accrued. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but the assessment process relies on estimates and assumptions that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions.
Amounts recorded for legal and environmental contingencies can result from a complex series of judgments about future events and uncertainties and can rely on estimates and assumptions.
The principal matters to which we are a party are discussed below. In determining whether a pending matter is significant for financial reporting and disclosure purposes, we consider both quantitative and qualitative factors in order to assess materiality, such as, among other things, the amount of damages and the nature of any other relief sought in the proceeding, if such damages and other relief are specified; our view of the merits of the claims and of the strength of our defenses; whether the action purports to be a class action and our view of the likelihood that a class will be certified by the court; the jurisdiction in which the proceeding is pending; any experience that we or, to our knowledge, other companies have had in similar proceedings; whether disclosure of the action would be important to a reader of our financial statements, including whether disclosure might change a reader’s judgment about our financial statements in light of all of the information about the company that is available to the reader; the potential impact of the proceeding on our reputation; and the extent of public interest in the matter. In addition, with respect to patent matters, we consider, among other things, the financial significance of the product protected by the patent.
Guarantees and Indemnifications
B. Guarantees and Indemnifications
In the ordinary course of business and in connection with the sale of assets and businesses, we indemnify our counterparties against certain liabilities that may arise in connection with the transaction or related to activities prior to the transaction. These indemnifications typically pertain to environmental, tax, employee and/or product-related matters and patent-infringement claims. If the indemnified party were to make a successful claim pursuant to the terms of the indemnification, we would be required to reimburse the loss. These indemnifications are generally subject to threshold amounts, specified claim periods and other restrictions and limitations. Historically, we have not paid significant amounts under these provisions and, as of September 30, 2024, recorded amounts for the estimated fair value of these indemnifications were not material.
Segment Information
Operating Segments
We manage our operations through two geographic operating segments: the U.S. and International. Each operating segment has responsibility for its commercial activities. Within each of these operating segments, we offer a diversified product portfolio, including parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, animal health diagnostics and medicated feed additives, for both companion animal and livestock customers. Our chief operating decision maker uses the revenue and earnings of the two operating segments, among other factors, for performance evaluation and resource allocation.
Other Costs and Business Activities
Certain costs are not allocated to our operating segment results, such as costs associated with the following:
•    Other business activities, includes our Client Supply Services contract manufacturing results, our human health business, and expenses associated with our dedicated veterinary medicine research and development organization, research alliances, U.S. regulatory affairs and other operations focused on the development of our products. Other R&D-related costs associated with non-U.S. market and regulatory activities are generally included in the international commercial segment.
•    Corporate, includes enabling functions such as information technology, facilities, legal, finance, human resources, business development, certain diagnostic costs and communications, among others. These costs also include certain compensation costs, certain procurement costs and other miscellaneous operating expenses not charged to our operating segments, as well as interest income and expense.
•Certain transactions and events such as (i) Purchase accounting adjustments, where we incur expenses associated with the amortization of fair value adjustments to inventory, intangible assets and property, plant and equipment; (ii) Acquisition and divestiture-related costs, where we incur costs associated with acquiring and integrating newly acquired businesses, such as transaction costs and integration costs, as well as divestiture-related costs; and (iii) Certain significant items, which comprise substantive, unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis, such as restructuring charges and implementation costs associated with our cost-reduction/productivity initiatives that are not associated with an acquisition or divestiture, certain asset impairment charges, certain legal and commercial settlements and the impact of divestiture-related gains and losses.
•Other unallocated includes (i) certain overhead expenses associated with our global manufacturing operations not charged to our operating segments; (ii) certain costs associated with finance that specifically support our global manufacturing operations; (iii) certain supply chain and global logistics costs; and (iv) certain procurement costs.
Segment Assets
We manage our assets on a total company basis, not by operating segment. Therefore, our chief operating decision maker does not regularly review any asset information by operating segment and, accordingly, we do not report asset information by operating segment.
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.24.3
Revenue Revenue Recognition and Deferred Revenue (Tables)
 9 Months Ended
Sep. 30, 2024
Revenue Recognition and Deferred Revenue [Abstract]  
Revenue from External Customers by Geographic Areas
The following tables present our revenue disaggregated by geographic area, species and major product category:
Revenue by geographic area
Three Months EndedNine Months Ended
September 30,September 30,
(MILLIONS OF DOLLARS)2024202320242023
United States$1,346 $1,174 $3,817 $3,344 
Australia83 84 239 248 
Brazil101 101 301 276 
Canada66 63 202 183 
Chile31 31 93 109 
China61 69 205 255 
France36 34 111 102 
Germany57 50 166 148 
Italy31 26 95 87 
Japan33 34 109 120 
Mexico39 42 129 119 
Spain35 30 100 94 
United Kingdom80 78 230 209 
Other developed markets148 127 413 374 
Other emerging markets220 187 670 605 
2,367 2,130 6,880 6,273 
Contract manufacturing & human health21 21 59 58 
Total Revenue$2,388 $2,151 $6,939 $6,331 
Revenue from External Customers by Major Species
Revenue by major species
Three Months EndedNine Months Ended
September 30,September 30,
(MILLIONS OF DOLLARS)2024202320242023
U.S.
Companion animal$1,068 $908 $3,046 $2,588 
Livestock278 266 771 756 
1,346 1,174 3,817 3,344 
International
Companion animal541 506 1,662 1,540 
Livestock480 450 1,401 1,389 
1,021 956 3,063 2,929 
Total
Companion animal1,609 1,414 4,708 4,128 
Livestock758 716 2,172 2,145 
Contract manufacturing & human health21 21 59 58 
Total Revenue$2,388 $2,151 $6,939 $6,331 
Revenue from External Customers by Species
Revenue by species
Three Months EndedNine Months Ended
September 30,September 30,
(MILLIONS OF DOLLARS)2024202320242023
Companion Animal:
Dogs and Cats$1,551 $1,354 $4,516 $3,931 
Horses58 60 192 197 
1,609 1,414 4,708 4,128 
Livestock:
Cattle391 374 1,132 1,102 
Poultry139 127 410 397 
Swine131 129 388 404 
Fish70 57 177 158 
Sheep and other27 29 65 84 
758 716 2,172 2,145 
Contract manufacturing & human health21 21 59 58 
Total Revenue$2,388 $2,151 $6,939 $6,331 
Schedule of Significant Product Revenues
Revenue by major product category
Three Months EndedNine Months Ended
September 30,September 30,
(MILLIONS OF DOLLARS)2024202320242023
Parasiticides$530 $465 $1,634 $1,465 
Vaccines468 449 1,365 1,308 
Dermatology453 397 1,234 1,048 
Anti-infectives274 264 819 796 
Pain and sedation219 147 634 408 
Other pharmaceutical169 166 478 514 
Animal health diagnostics101 95 286 284 
Medicated feed additives91 86 242 257 
Other non-pharmaceutical62 61 188 193 
2,367 2,130 6,880 6,273 
Contract manufacturing & human health21 21 59 58 
Total Revenue$2,388 $2,151 $6,939 $6,331 
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.24.3
Acquisitions and Divestitures (Tables)
 9 Months Ended
Sep. 30, 2024
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]  
Disposal Groups, Including Discontinued Operations
As of September 30, 2024, major classes of assets held for sale and liabilities associated with assets held for sale are summarized below:
September 30,
(MILLIONS OF DOLLARS)2024
Assets held for sale
Accounts receivable, less allowance for doubtful accounts$1 
Inventories162 
Other current assets2 
Property, plant and equipment, less accumulated depreciation108 
Operating lease right-of-use assets2 
Goodwill(a)
12 
Identifiable intangible assets, less accumulated amortization26 
Noncurrent deferred tax assets2 
Other noncurrent assets9 
Loss on assets held for sale(a)
(10)
  Total Assets Held for Sale$314 
Liabilities associated with assets held for sale
Accounts payable$11 
Accrued expenses8 
Accrued compensation and related items1 
Other noncurrent liabilities6 
  Total Liabilities Associated with Assets Held for Sale$26 
(a) We recorded a loss on assets held for sale of $22 million in the Condensed Consolidated Statements of Income during the nine months ended September 30, 2024. Of the loss on assets held for sale, $12 million is allocated to goodwill and the remaining $10 million relates to selling costs to be recognized upon closing and foreign currency translation losses to be reclassified out of accumulated other comprehensive income into earnings upon closing of the transaction.
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.24.3
Restructuring Charges and Other Costs Associated with Acquisitions and Divestitures (Tables)
 9 Months Ended
Sep. 30, 2024
Restructuring and Related Activities [Abstract]  
Restructuring and Related Costs
The components of costs incurred in connection with restructuring initiatives, acquisitions and divestitures are as follows:
Three Months EndedNine Months Ended
September 30,September 30,
(MILLIONS OF DOLLARS)2024202320242023
Restructuring charges and certain acquisition and divestiture-related costs:
Acquisition-related costs$— $3 $1 $7 
Divestiture-related costs(a)
7 — 11 — 
Restructuring charges, net(b):
Employee termination costs, net(2)8 39 33 
Asset impairment charges— 1 — 1 
Exit costs— 4 — 4 
Total Restructuring charges and certain acquisition and divestiture-related costs
$5 $16 $51 $45 
(a)    Divestiture-related costs consisted of costs related to the planned sale of our medicated feed additive product portfolio, certain water soluble products and related assets.
(b) The restructuring charges for the nine months ended September 30, 2024 primarily consisted of employee termination costs related to organizational structure refinements, partially offset by a reversal of certain employee termination costs as a result of a change in strategy from our 2015 operational efficiency initiative.
The restructuring charges for the three and nine months ended September 30, 2023 primarily consisted of employee termination and exit costs related to organizational structure refinements and other cost-reduction and productivity initiatives.
The change in our restructuring accrual is as follows:
(MILLIONS OF DOLLARS)
Accrual
Balance, December 31, 2023(a)
$35 
Provision46 
Reserve adjustment(7)
Utilization and other(b)
(28)
Balance, September 30, 2024(a)
$46 
(a)     At September 30, 2024 and December 31, 2023, included in Accrued expenses ($44 million and $26 million, respectively) and Other noncurrent liabilities ($2 million and $9 million, respectively).
(b)     Includes adjustments for foreign currency translation.
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.24.3
Other (Income)/Deductions - Net (Tables)
 9 Months Ended
Sep. 30, 2024
Other Income and Expenses [Abstract]  
Components of Other (Income)/Deductions—Net
The components of Other (income)/deductions—net are as follows:
Three Months EndedNine Months Ended
September 30,September 30,
(MILLIONS OF DOLLARS)2024202320242023
Royalty-related income(a)
$(2)$(1)$(5)$(36)
Interest income(23)(23)(79)(79)
Identifiable intangible asset impairment charges(b)
— 6 11 17 
Loss on assets held for sale(c)
— — 22 — 
Other asset impairment charges— 1 — 1 
Net gain on sale of business(d)
— — — (101)
Foreign currency loss(e)
5 19 42 41 
Other, net4 4 10 6 
Other (income)/deductions—net$(16)$6 $1 $(151)
(a)     For the nine months ended September 30, 2023, predominantly associated with a settlement for underpayment of royalties in prior periods.
(b)    For the nine months ended September 30, 2024, represents asset impairment charges related to our aquaculture business.
For the three months ended September 30, 2023, primarily represents asset impairment charges related to our diagnostics business.
For the nine months ended September 30, 2023, primarily represents asset impairment charges related to our precision animal health and diagnostics businesses.
(c)    Represents a loss on assets held for sale related to the planned sale of our medicated feed additive product portfolio, certain water soluble products and related assets. For additional information, see Note 5. Acquisitions and Divestitures.
(d)    Relates to the gain on sale of a majority interest in our pet insurance business. For additional information, see Note 5. Acquisitions and Divestitures.
(e)    Primarily driven by costs related to hedging and exposures to certain emerging and developed market currencies.
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.24.3
Financial Instruments (Tables)
 9 Months Ended
Sep. 30, 2024
Financial Instruments [Abstract]  
Schedule of Long-term Debt Instruments
The components of our long-term debt are as follows:
September 30,December 31,
(MILLIONS OF DOLLARS)20242023
4.500% 2015 senior notes due 2025
$750 $750 
5.400% 2022 senior notes due 2025
600 600 
3.000% 2017 senior notes due 2027
750 750 
3.900% 2018 senior notes due 2028
500 500 
2.000% 2020 senior notes due 2030
750 750 
5.600% 2022 senior notes due 2032
750 750 
4.700% 2013 senior notes due 2043
1,150 1,150 
3.950% 2017 senior notes due 2047
500 500 
4.450% 2018 senior notes due 2048
400 400 
3.000% 2020 senior notes due 2050
500 500 
6,650 6,650 
Unamortized debt discount / debt issuance costs(56)(60)
Cumulative fair value adjustment for interest rate swap contracts(20)(26)
Long-term debt, net of discount and issuance costs$6,574 $6,564 
Schedule of Maturities of Long-term Debt
The following table provides the principal amount of debt outstanding, as of September 30, 2024, by scheduled maturity date:
After
(MILLIONS OF DOLLARS)202420252026202720282028Total
Maturities$— $1,350 $— $750 $500 $4,050 $6,650 
Schedule of Derivative Instruments
The aggregate notional amount of derivative instruments are as follows:
Notional
September 30,December 31,
(MILLIONS)20242023
Derivatives not Designated as Hedging Instruments:
     Foreign currency forward-exchange contracts $1,965 $1,948 
Derivatives Designated as Hedging Instruments:
     Foreign exchange derivative instruments (in foreign currency):
          Euro 750 650 
          Danish krone475 600 
          Swiss franc25 25 
     Forward-starting interest rate swaps $200 $100 
     Fixed-to-floating interest rate swap contracts$250 $250 
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value
The classification and fair values of derivative instruments are as follows:
Fair Value of Derivatives
September 30,December 31,
(MILLIONS OF DOLLARS)Balance Sheet Location20242023
Derivatives Not Designated as Hedging Instruments:
   Foreign currency forward-exchange contractsOther current assets$17 $11 
   Foreign currency forward-exchange contracts
Other current liabilities
(14)(11)
Total derivatives not designated as hedging instruments$3 $— 
Derivatives Designated as Hedging Instruments:
   Forward-starting interest rate swap contractsOther noncurrent assets$12 $12 
   Foreign exchange derivative instruments Other current assets17 5 
   Foreign exchange derivative instruments Other noncurrent assets— 11 
   Foreign exchange derivative instruments Other current liabilities(17)(20)
   Foreign exchange derivative instruments Other noncurrent liabilities— (1)
   Fixed-to-floating interest rate swap contractsOther noncurrent liabilities(20)(26)
Total derivatives designated as hedging instruments(8)(19)
Total derivatives$(5)$(19)
Schedule of Other Derivatives Not Designated as Hedging Instruments, Statements of Financial Performance and Financial Position, Location
The amounts of net gains/(losses) on derivative instruments not designated as hedging instruments, recorded in Other (income)/deductions—net, are as follows:
Three Months EndedNine Months Ended
September 30,September 30,
(MILLIONS OF DOLLARS)2024202320242023
Foreign currency forward-exchange contracts$11 $16 $12 $(20)
Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss)
The amounts of unrecognized net (losses)/gains on interest rate swap contracts, recorded, net of tax, in Accumulated other comprehensive loss, are as follows:
Three Months EndedNine Months Ended
September 30,September 30,
(MILLIONS OF DOLLARS)2024202320242023
Forward-starting interest rate swap contracts$(3)$5 $— $5 
Foreign exchange derivative instruments$(23)$18 $(5)$5 
Schedule of Net Investment Hedges, Statements of Financial Performance and Financial Position, Location
Gains on interest rate swap contracts, recognized within Interest expense, net of capitalized interest, are as follows:
Three Months EndedNine Months Ended
September 30,September 30,
(MILLIONS OF DOLLARS)2024202320242023
Foreign exchange derivative instruments$4 $4 $12 $14 
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.24.3
Inventories (Tables)
 9 Months Ended
Sep. 30, 2024
Inventory Disclosure [Abstract]  
Components of Inventory
The components of inventory are as follows:
September 30,December 31,
(MILLIONS OF DOLLARS)20242023
Finished goods$1,049 $1,147 
Work-in-process951 966 
Raw materials and supplies416 451 
Inventories$2,416 $2,564 
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.24.3
Goodwill and Other Intangible Assets (Tables)
 9 Months Ended
Sep. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Changes in the Carrying Amount of Goodwill
The components of, and changes in, the carrying amount of goodwill are as follows:
(MILLIONS OF DOLLARS)U.S.InternationalTotal
Balance, December 31, 2023$1,532 $1,227 $2,759 
Other(a)
(17)2 (15)
Balance, September 30, 2024$1,515 $1,229 $2,744 
(a)     Includes adjustments for the reclassification of goodwill of $24 million to Assets held for sale related to the planned sale of our medicated feed additive product portfolio, certain water soluble products and related assets, as well as foreign currency translation. For additional information, see Note 5. Acquisitions and Divestitures: B. Divestitures.
Components of Identifiable Intangible Assets
The components of identifiable intangible assets are as follows:
As of September 30, 2024As of December 31, 2023
IdentifiableIdentifiable
GrossIntangible AssetsGrossIntangible Assets
CarryingAccumulatedLess AccumulatedCarryingAccumulatedLess Accumulated
(MILLIONS OF DOLLARS)AmountAmortizationAmortizationAmountAmortizationAmortization
Finite-lived intangible assets:
Developed technology rights$1,931 $(1,164)$767 $1,986 $(1,101)$885 
Brands and tradenames370 (245)125 383 (246)137 
Other276 (196)80 270 (190)80 
Total finite-lived intangible assets2,577 (1,605)972 2,639 (1,537)1,102 
Indefinite-lived intangible assets:
Brands and tradenames66 — 66 88 — 88 
In-process research and development141 — 141 141 — 141 
Product rights7 — 7 7 — 7 
Total indefinite-lived intangible assets214 — 214 236 — 236 
Identifiable intangible assets$2,791 $(1,605)$1,186 $2,875 $(1,537)$1,338 
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.24.3
Share-Based Payments (Tables)
 9 Months Ended
Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]  
Components of Share-based Compensation Expense
The components of share-based compensation expense are as follows:
Three Months EndedNine Months Ended
September 30,September 30,
(MILLIONS OF DOLLARS)2024202320242023
Stock options / stock appreciation rights$2 $3 $8 $6 
RSUs / DSUs10 10 31 27 
PSUs6 4 16 10 
Share-based compensation expense—total(a)
$18 $17 $55 $43 
(a) For the three and nine months ended September 30, 2024 and 2023, we capitalized less than $1 million of share-based compensation expense to inventory.
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.24.3
Stockholders' Equity (Tables)
 9 Months Ended
Sep. 30, 2024
Equity [Abstract]  
Changes, Net of Tax, in Accumulated Other Comprehensive Loss
Changes, net of tax, in accumulated other comprehensive loss, were as follows:
Currency Translation Adjustments
Other CurrencyBenefit PlansAccumulated Other
Cash FlowNet InvestmentTranslationActuarialComprehensive
(MILLIONS OF DOLLARS)HedgesHedgesAdjustmentsGains/(Losses)Loss
Balance, December 31, 2023$85 $18 $(944)$2 $(839)
Other comprehensive loss, net of tax(5)(5)(2)— 

(12)
Balance, September 30, 2024$80 $13 $(946)$2 $(851)
Balance, December 31, 2022$90 $41 $(944)$(4)$(817)
Other comprehensive income/(loss), net of tax— 5 (6)4 3 
Balance, September 30, 2023$90 $46 $(950)$— $(814)
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.24.3
Earnings per Share (Tables)
 9 Months Ended
Sep. 30, 2024
Earnings Per Share [Abstract]  
Basic and Diluted Earnings Per Share
The following table presents the calculation of basic and diluted earnings per share:
Three Months EndedNine Months Ended
(MILLIONS OF DOLLARS AND SHARES, EXCEPT PER SHARE DATA)September 30,September 30,
2024202320242023
Numerator
Net income before allocation to noncontrolling interests$692 $596 $1,915 $1,817 
Less: Net income/(loss) attributable to noncontrolling interests10 — 10 (2)
Net income attributable to Zoetis Inc.$682 $596 $1,905 $1,819 
Denominator
Weighted-average common shares outstanding452.9 460.3 455.4 461.9 
Common stock equivalents: stock options, RSUs, PSUs and DSUs0.6 1.1 0.7 1.1 
Weighted-average common and potential dilutive shares outstanding453.5 461.4 456.1 463.0 
Earnings per share attributable to Zoetis Inc. stockholders—basic$1.51 $1.29 $4.18 $3.94 
Earnings per share attributable to Zoetis Inc. stockholders—diluted$1.50 $1.29 $4.18 $3.93 
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.24.3
Segment Information (Tables)
 9 Months Ended
Sep. 30, 2024
Segment Reporting [Abstract]  
Schedule of Selected Income Statement Information by Segment
Earnings
Depreciation and Amortization(a)
Three Months EndedThree Months Ended
September 30,September 30,
(MILLIONS OF DOLLARS)2024202320242023
U.S.
Revenue$1,346 $1,174 
Cost of sales258 228 
Gross profit1,088 946 
    Gross margin80.8 %80.6 %
Operating expenses199 202 
Other (income)/deductions-net— — 
U.S. Earnings889 744 $20 $19 
International
Revenue(b)
1,021 956 
Cost of sales321 306 
Gross profit700 650 
    Gross margin68.6 %68.0 %
Operating expenses157 156 
Other (income)/deductions-net1 1 
International Earnings542 493 25 24 
Total operating segments1,431 1,237 45 43 
Other business activities
(137)(124)9 9 
Reconciling Items:
Corporate
(306)(258)31 33 
Purchase accounting adjustments
(35)(39)35 39 
Acquisition and divestiture-related costs
(7)(3)— — 
Certain significant items(c)
(1)(23)— — 
Other unallocated
(71)(73)1 — 
Total Earnings(d)
$874 $717 $121 $124 
(a)    Certain production facilities are shared. Depreciation and amortization is allocated to the reportable operating segments based on estimates of where the benefits of the related assets are realized.
(b)    Revenue denominated in euros was $234 million and $206 million for the three months ended September 30, 2024 and 2023, respectively.
(c)    For the three months ended September 30, 2023, primarily consisted of employee termination and exit costs related to organizational structure refinements and other cost-reduction and productivity initiatives, as well as certain asset impairment charges related to our diagnostics and precision animal health businesses.
(d)    Defined as income before provision for taxes on income.
Earnings
Depreciation and Amortization(a)
Nine Months EndedNine Months Ended
September 30,September 30,
(MILLIONS OF DOLLARS)2024202320242023
U.S.
Revenue$3,817 $3,344 
Cost of sales707 645 
Gross profit3,110 2,699 
    Gross margin81.5 %80.7 %
Operating expenses593 602 
Other (income)/deductions-net— — 
U.S. Earnings2,517 2,097 $65 $58 
International
Revenue(b)
3,063 2,929 
Cost of sales976 912 
Gross profit2,087 2,017 
    Gross margin68.1 %68.9 %
Operating expenses491 473 
Other (income)/deductions-net1 1 
International Earnings1,595 1,543 73 67 
Total operating segments4,112 3,640 138 125 
Other business activities
(411)(354)29 24 
Reconciling Items:
Corporate
(893)(722)96 95 
Purchase accounting adjustments
(107)(124)107 118 
Acquisition and divestiture-related costs
(12)(8)— — 
Certain significant items(c)
(77)45 — — 
Other unallocated
(211)(191)4 3 
Total Earnings(d)
$2,401 $2,286 $374 $365 
(a)    Certain production facilities are shared. Depreciation and amortization is allocated to the reportable operating segments based on estimates of where the benefits of the related assets are realized.
(b)    Revenue denominated in euros was $694 million and $627 million for the nine months ended September 30, 2024 and 2023, respectively.
(c)    For the nine months ended September 30, 2024, primarily consisted of employee termination costs related to organizational structure refinements, a loss on assets held for sale related to the planned sale of our medicated feed additive product portfolio, certain water soluble products and related assets, as well as asset impairment charges related to our aquaculture business, partially offset by a reversal of certain employee termination costs as a result of a change in strategy from our 2015 operational efficiency initiative.
For the nine months ended September 30, 2023, primarily consisted of a gain on the sale of a majority interest in our pet insurance business, partially offset by employee termination costs related to organizational structure refinements and certain asset impairment charges related to our precision animal health and diagnostics businesses.
(d)    Defined as income before provision for taxes on income.
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.24.3
Organization (Details)
Sep. 30, 2024
country
specie
geographicRegion
productCategory
Product Information [Line Items]  
Number of regional segments | geographicRegion 2
Number of countries in which entity markets products 45
Number of core animal species | specie 8
Number of major product categories | productCategory 8
Product  
Product Information [Line Items]  
Number of countries in which entity markets products 100
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.24.3
Revenue - Narrative (Details)
$ in Millions
 9 Months Ended
Sep. 30, 2024
USD ($)
product_category
Sep. 30, 2023
USD ($)
Dec. 31, 2023
USD ($)
Revenue Recognition and Deferred Revenue [Abstract]      
Number of major product lines | product_category 300    
Contract liabilities, revenue recognized $ 4 $ 4  
Contract liabilities $ 21   $ 11
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.24.3
Revenue - Revenue by Geographic Area (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Revenue from External Customer [Line Items]        
Revenue $ 2,388 $ 2,151 $ 6,939 $ 6,331
United States        
Revenue from External Customer [Line Items]        
Revenue 1,346 1,174 3,817 3,344
Australia        
Revenue from External Customer [Line Items]        
Revenue 83 84 239 248
Brazil        
Revenue from External Customer [Line Items]        
Revenue 101 101 301 276
Canada        
Revenue from External Customer [Line Items]        
Revenue 66 63 202 183
Chile        
Revenue from External Customer [Line Items]        
Revenue 31 31 93 109
China        
Revenue from External Customer [Line Items]        
Revenue 61 69 205 255
France        
Revenue from External Customer [Line Items]        
Revenue 36 34 111 102
Germany        
Revenue from External Customer [Line Items]        
Revenue 57 50 166 148
Italy        
Revenue from External Customer [Line Items]        
Revenue 31 26 95 87
Japan        
Revenue from External Customer [Line Items]        
Revenue 33 34 109 120
Mexico        
Revenue from External Customer [Line Items]        
Revenue 39 42 129 119
Spain        
Revenue from External Customer [Line Items]        
Revenue 35 30 100 94
United Kingdom        
Revenue from External Customer [Line Items]        
Revenue 80 78 230 209
Other developed markets        
Revenue from External Customer [Line Items]        
Revenue 148 127 413 374
Other emerging markets        
Revenue from External Customer [Line Items]        
Revenue 220 187 670 605
Total geographical area        
Revenue from External Customer [Line Items]        
Revenue 2,367 2,130 6,880 6,273
Contract manufacturing & human health        
Revenue from External Customer [Line Items]        
Revenue $ 21 $ 21 $ 59 $ 58
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.24.3
Revenue - Revenue by Major Species (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Revenue from External Customer [Line Items]        
Revenue $ 2,388 $ 2,151 $ 6,939 $ 6,331
Contract manufacturing & human health        
Revenue from External Customer [Line Items]        
Revenue 21 21 59 58
Companion animal        
Revenue from External Customer [Line Items]        
Revenue 1,609 1,414 4,708 4,128
Companion animal | U.S.        
Revenue from External Customer [Line Items]        
Revenue 1,068 908 3,046 2,588
Companion animal | International        
Revenue from External Customer [Line Items]        
Revenue 541 506 1,662 1,540
Livestock        
Revenue from External Customer [Line Items]        
Revenue 758 716 2,172 2,145
Livestock | U.S.        
Revenue from External Customer [Line Items]        
Revenue 278 266 771 756
Livestock | International        
Revenue from External Customer [Line Items]        
Revenue 480 450 1,401 1,389
Operating Segments | U.S.        
Revenue from External Customer [Line Items]        
Revenue 1,346 1,174 3,817 3,344
Operating Segments | International        
Revenue from External Customer [Line Items]        
Revenue $ 1,021 $ 956 $ 3,063 [1] $ 2,929 [1]
[1] Revenue denominated in euros was $694 million and $627 million for the nine months ended September 30, 2024 and 2023, respectively.
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.24.3
Revenue - Revenue by Species (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Revenue from External Customer [Line Items]        
Revenue $ 2,388 $ 2,151 $ 6,939 $ 6,331
Contract manufacturing & human health        
Revenue from External Customer [Line Items]        
Revenue 21 21 59 58
Dogs and Cats        
Revenue from External Customer [Line Items]        
Revenue 1,551 1,354 4,516 3,931
Horses        
Revenue from External Customer [Line Items]        
Revenue 58 60 192 197
Cattle        
Revenue from External Customer [Line Items]        
Revenue 391 374 1,132 1,102
Swine        
Revenue from External Customer [Line Items]        
Revenue 131 129 388 404
Poultry        
Revenue from External Customer [Line Items]        
Revenue 139 127 410 397
Fish        
Revenue from External Customer [Line Items]        
Revenue 70 57 177 158
Sheep and other        
Revenue from External Customer [Line Items]        
Revenue 27 29 65 84
Livestock        
Revenue from External Customer [Line Items]        
Revenue 758 716 2,172 2,145
Companion animal        
Revenue from External Customer [Line Items]        
Revenue 1,609 1,414 4,708 4,128
Other pharmaceutical        
Revenue from External Customer [Line Items]        
Revenue $ 169 $ 166 $ 478 $ 514
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.24.3
Revenue - Revenue by Product (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Revenue from External Customer [Line Items]        
Revenue $ 2,388 $ 2,151 $ 6,939 $ 6,331
Contract manufacturing & human health        
Revenue from External Customer [Line Items]        
Revenue 21 21 59 58
Total products and services        
Revenue from External Customer [Line Items]        
Revenue 2,367 2,130 6,880 6,273
Parasiticides        
Revenue from External Customer [Line Items]        
Revenue 530 465 1,634 1,465
Vaccines        
Revenue from External Customer [Line Items]        
Revenue 468 449 1,365 1,308
Dermatology        
Revenue from External Customer [Line Items]        
Revenue 453 397 1,234 1,048
Anti-infectives        
Revenue from External Customer [Line Items]        
Revenue 274 264 819 796
Pain and sedation        
Revenue from External Customer [Line Items]        
Revenue 219 147 634 408
Other pharmaceutical        
Revenue from External Customer [Line Items]        
Revenue 169 166 478 514
Animal health diagnostics        
Revenue from External Customer [Line Items]        
Revenue 101 95 286 284
Medicated feed additives        
Revenue from External Customer [Line Items]        
Revenue 91 86 242 257
Other non-pharmaceutical        
Revenue from External Customer [Line Items]        
Revenue $ 62 $ 61 $ 188 $ 193
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.24.3
Acquisitions and Divestitures - Consideration Transferred (Details) - PetMedix Ltd. - USD ($)
$ in Millions
Aug. 03, 2023
Sep. 30, 2024
Business Acquisition [Line Items]    
Voting interest acquired, percent   100.00%
Payment to acquire business $ 100  
Acquisition of a noncontrolling interest, net of cash acquired 111  
Cash withheld for post-closing adustments $ 5  
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.24.3
Acquisitions and Divestitures - Divestures (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended 9 Months Ended
Aug. 03, 2023
Sep. 30, 2024
Jun. 30, 2024
Sep. 30, 2023
Jun. 30, 2024
Sep. 30, 2024
Sep. 30, 2023
Apr. 28, 2024
Dec. 31, 2023
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                  
Products and assets to sell agreement amount               $ 350  
Proceeds from sale of businesses, net of cash sold           $ 0 $ 96    
Net gain on sale of business   $ 0   $ 0   $ 0 $ 101    
Remeasurement of retained noncontrolling investment to fair value                 $ 24
PetMedix Ltd.                  
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                  
Cash Acquired from Acquisition $ 19                
Pumpkin Insurance Services                  
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                  
Proceeds from sale of businesses, net of cash sold         $ 93        
Sale proceeds     $ 99            
net of cash sold amount     $ 6            
Net gain on sale of business         $ 101        
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.24.3
Acquisitions and Divestitures - Schedule of Assets Held for Sale (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Total Assets Held for Sale $ 314   $ 314   $ 0
Total Liabilities Associated with Assets Held for Sale 26   26   $ 0
Loss on assets held for sale, goodwill allocation 12   12    
Loss on assets held for sale, selling costs allocation 10   10    
Disposal Group, Held-for-Sale, Not Discontinued Operations          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Accounts receivable, less allowance for doubtful accounts 1   1    
Inventories 162   162    
Other current assets 2   2    
Property, plant and equipment, less accumulated depreciation 108   108    
Operating lease right-of-use assets 2   2    
Goodwill 12   12    
Identifiable intangible assets, less accumulated amortization 26   26    
Noncurrent deferred tax assets 2   2    
Other noncurrent assets 9   9    
Loss on assets held for sale (10)   (10)    
Total Assets Held for Sale 314   314    
Accounts payable 11   11    
Accrued expenses 8   8    
Accrued compensation and related items 1   1    
Other noncurrent liabilities 6   6    
Total Liabilities Associated with Assets Held for Sale 26   26    
Loss on assets held for sale $ 0 $ 0 $ (22) $ 0  
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.24.3
Restructuring Charges and Other Costs Associated with Acquisitions and Divestitures (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Restructuring Cost and Reserve [Line Items]          
Divestiture-related costs $ 7 $ 0 $ 11 $ 0  
Asset write-offs and asset impairments     16 27  
Exit costs 0 4 0 4  
Total Restructuring charges and certain acquisition and divestiture-related costs 5 16 51 45  
Restructuring Reserve [Roll Forward]          
Restructuring accrual balance [1],[2]     35    
Provision     46    
Reserve adjustment     (7)    
Utilization and other [1],[3]     (28)    
Restructuring accrual balance [1],[2] 46   46    
Other current liabilities          
Restructuring Reserve [Roll Forward]          
Accrued expenses 44   44   $ 26
Other noncurrent liabilities          
Restructuring Reserve [Roll Forward]          
Other noncurrent liabilities 2   2   $ 9
Acquisition-related costs          
Restructuring Cost and Reserve [Line Items]          
Acquisition and divestiture-related costs 0 3 1 7  
Employee Termination Costs          
Restructuring Cost and Reserve [Line Items]          
Employee termination costs, net (2) 8 39 33  
Facility Closing          
Restructuring Cost and Reserve [Line Items]          
Asset write-offs and asset impairments $ 0 $ 1 $ 0 $ 1  
[1] (3)
[2] At September 30, 2024 and December 31, 2023, included in Accrued expenses ($44 million and $26 million, respectively) and Other noncurrent liabilities ($2 million and $9 million, respectively).
[3] Includes adjustments for foreign currency translation.
XML 61 R50.htm IDEA: XBRL DOCUMENT v3.24.3
Other (Income)/Deductions - Net (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Royalty-related income $ (2) $ (1) $ (5) $ (36)
Interest income (23) (23) (79) (79)
Identifiable intangible asset impairment charges(b) 0 6 11 17
Other asset impairment charges 0 1 0 1
Net gain on sale of business 0 0 0 (101)
Foreign currency loss 5 19 42 41
Other, net 4 4 10 6
Other (income)/deductions—net (16) 6 1 (151)
Disposal Group, Held-for-Sale, Not Discontinued Operations        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Loss on assets held for sale $ 0 $ 0 $ 22 $ 0
XML 62 R51.htm IDEA: XBRL DOCUMENT v3.24.3
Income Taxes - Taxes on Income (Details)
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Income Tax Disclosure [Abstract]        
Effective tax rate for income from continuing operations 20.80% 16.90% 20.20% 20.50%
XML 63 R52.htm IDEA: XBRL DOCUMENT v3.24.3
Income Taxes - Deferred Taxes (Details) - USD ($)
$ in Millions
Sep. 30, 2024
Dec. 31, 2023
Income Tax Disclosure [Abstract]    
Noncurrent deferred tax liabilities $ 237 $ 60
Noncurrent deferred tax assets 409 206
Noncurrent deferred tax liabilities $ 172 $ 146
XML 64 R53.htm IDEA: XBRL DOCUMENT v3.24.3
Income Taxes - Tax Contingencies (Details) - USD ($)
$ in Millions
 1 Months Ended
Jul. 31, 2024
Sep. 30, 2024
Dec. 31, 2023
Income Tax Contingency [Line Items]      
Liabilities associated with uncertain tax positions   $ 217 $ 209
Unrecognized tax benefits, income tax penalties and interest accrued   $ 36 $ 27
Internal Revenue Service (IRS)      
Income Tax Contingency [Line Items]      
Estimated additional tax liability $ 450    
XML 65 R54.htm IDEA: XBRL DOCUMENT v3.24.3
Financial Instruments - Credit Facilities (Details)
Sep. 30, 2024
USD ($)
Dec. 31, 2023
USD ($)
Line of Credit Facility [Line Items]    
Line of credit facility, maximum borrowing capacity $ 56,000,000  
Foreign exchange derivative instruments | Derivatives Designated as Hedging Instruments:    
Line of Credit Facility [Line Items]    
Collateral posted $ 22,000,000 $ 33,000,000
Operational Efficiency    
Line of Credit Facility [Line Items]    
Maximum total leverage ratio 3.50  
Maximum total leverage ratio, next 12 months 4.00  
Revolving Credit Facility    
Line of Credit Facility [Line Items]    
Revolving credit facility, current borrowing capacity $ 1,000,000,000.0  
Line of credit facility, maximum borrowing capacity 1,500,000,000  
Line of credit facility $ 0 $ 0
XML 66 R55.htm IDEA: XBRL DOCUMENT v3.24.3
Financial Instruments - Commercial Paper Program (Details) - USD ($)
Sep. 30, 2024
Dec. 31, 2023
Feb. 28, 2013
Short-term Debt [Line Items]      
Commercial Paper $ 0 $ 0  
Commercial Paper      
Short-term Debt [Line Items]      
Capacity of commercial paper program     $ 1,000,000,000.0
XML 67 R56.htm IDEA: XBRL DOCUMENT v3.24.3
Financial Instruments - Senior Notes Offering and Other Long-Term Debt (Details) - USD ($)
$ in Millions
 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Feb. 01, 2023
Nov. 08, 2022
Jan. 28, 2013
Debt Instrument [Line Items]            
Repayments of long-term debt $ 0 $ 1,350        
Debt, principal amount 6,650   $ 6,650      
Senior Notes            
Debt Instrument [Line Items]            
Debt, purchase price percent due to downgrade of investment grade           101.00%
Senior Notes | 2.000% 2020 senior notes due 2030            
Debt Instrument [Line Items]            
Debt, principal amount $ 750   750      
Interest rate percentage 2.00%          
Senior Notes | 3.000% 2020 senior notes due 2050            
Debt Instrument [Line Items]            
Debt, principal amount $ 500   500      
Interest rate percentage 3.00%          
Senior Notes | 2022 Senior Notes            
Debt Instrument [Line Items]            
Debt, principal amount         $ 1,350  
Debt, unamortized discount         $ 2  
Senior Notes | 5.400% 2022 senior notes due 2025            
Debt Instrument [Line Items]            
Debt, principal amount $ 600   600      
Interest rate percentage         5.40%  
Senior Notes | 5.600% 2022 senior notes due 2032            
Debt Instrument [Line Items]            
Debt, principal amount $ 750   $ 750      
Interest rate percentage         5.60%  
Senior Notes | Senior Notes Due 2023            
Debt Instrument [Line Items]            
Debt, principal amount       $ 1,350    
Interest rate percentage 3.25%          
XML 68 R57.htm IDEA: XBRL DOCUMENT v3.24.3
Financial Instruments - Schedule of Long-term Debt (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Feb. 01, 2023
Nov. 08, 2022
Debt Instrument [Line Items]              
Debt, principal amount $ 6,650   $ 6,650   $ 6,650    
Unamortized debt discount / debt issuance costs (56)   (56)   (60)    
Cumulative fair value adjustment for interest rate swap contracts (20)   (20)   (26)    
Long-term debt, net of discount and issuance costs 6,574   6,574   6,564    
Capitalized interest $ 9 $ 7 $ 26 $ 19      
Senior Notes | Senior Notes Due 2023              
Debt Instrument [Line Items]              
Interest rate percentage 3.25%   3.25%        
Debt, principal amount           $ 1,350  
Senior Notes | 4.500% 2015 senior notes due 2025              
Debt Instrument [Line Items]              
Interest rate percentage 4.50%   4.50%        
Debt, principal amount $ 750   $ 750   750    
Senior Notes | 5.400% 2022 senior notes due 2025              
Debt Instrument [Line Items]              
Interest rate percentage             5.40%
Debt, principal amount $ 600   $ 600   600    
Senior Notes | 3.000% 2017 senior notes due 2027              
Debt Instrument [Line Items]              
Interest rate percentage 3.00%   3.00%        
Debt, principal amount $ 750   $ 750   750    
Senior Notes | 3.900% 2018 senior notes due 2028              
Debt Instrument [Line Items]              
Interest rate percentage 3.90%   3.90%        
Debt, principal amount $ 500   $ 500   500    
Senior Notes | 2.000% 2020 senior notes due 2030              
Debt Instrument [Line Items]              
Interest rate percentage 2.00%   2.00%        
Debt, principal amount $ 750   $ 750   750    
Senior Notes | 5.600% 2022 senior notes due 2032              
Debt Instrument [Line Items]              
Interest rate percentage             5.60%
Debt, principal amount $ 750   $ 750   750    
Senior Notes | 4.700% 2013 senior notes due 2043              
Debt Instrument [Line Items]              
Interest rate percentage 4.70%   4.70%        
Debt, principal amount $ 1,150   $ 1,150   1,150    
Senior Notes | 3.950% 2017 senior notes due 2047              
Debt Instrument [Line Items]              
Interest rate percentage 3.95%   3.95%        
Debt, principal amount $ 500   $ 500   500    
Senior Notes | 4.450% 2018 senior notes due 2048              
Debt Instrument [Line Items]              
Interest rate percentage 4.45%   4.45%        
Debt, principal amount $ 400   $ 400   400    
Senior Notes | 3.000% 2020 senior notes due 2050              
Debt Instrument [Line Items]              
Interest rate percentage 3.00%   3.00%        
Debt, principal amount $ 500   $ 500   $ 500    
XML 69 R58.htm IDEA: XBRL DOCUMENT v3.24.3
Financial Instruments - Fair Value of Debt (Details) - USD ($)
$ in Millions
Sep. 30, 2024
Dec. 31, 2023
Senior Notes | Fair Value, Inputs, Level 2    
Debt Instrument [Line Items]    
Fair value, debt instrument $ 6,334 $ 6,319
XML 70 R59.htm IDEA: XBRL DOCUMENT v3.24.3
Financial Instruments - Long-term Debt Maturity (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Financial Instruments [Abstract]          
2024 $ 0   $ 0    
2025 1,350,000,000   1,350,000,000    
2026 0   0    
2027 750,000,000   750,000,000    
2028 500,000,000   500,000,000    
After 2025 4,050,000,000   4,050,000,000    
Total long-term debt 6,650,000,000   6,650,000,000   $ 6,650,000,000
Interest expense, net of capitalized interest 57,000,000 $ 59,000,000 174,000,000 $ 180,000,000  
Capitalized interest 9,000,000 $ 7,000,000 26,000,000 $ 19,000,000  
Line Of Credit For General Corporate Purpose          
Line of Credit Facility [Line Items]          
Line of credit facility $ 0   $ 0   $ 3,000,000
XML 71 R60.htm IDEA: XBRL DOCUMENT v3.24.3
Financial Instruments - Foreign Exchange Risk (Details)
 9 Months Ended
Sep. 30, 2024
Derivatives Not Designated as Hedging Instruments | Foreign currency forward-exchange contracts  
Derivative [Line Items]  
Maturity period (in years) 60 days
Derivatives Not Designated as Hedging Instruments | Maximum | Foreign currency forward-exchange contracts  
Derivative [Line Items]  
Maturity period (in years) 4 years
Derivatives Designated as Hedging Instruments: | Maximum | Foreign exchange derivative instruments  
Derivative [Line Items]  
Maturity period (in years) 1 year
XML 72 R61.htm IDEA: XBRL DOCUMENT v3.24.3
Financial Instruments - Interest Rate Risk (Details) - USD ($)
$ in Millions
 9 Months Ended
Sep. 30, 2024
Dec. 31, 2023
Nov. 08, 2022
Derivative Instruments and Hedging Activities Disclosures [Line Items]      
Derivative, cash received on hedge $ 114    
Forward-starting interest rate swaps | Derivatives Designated as Hedging Instruments:      
Derivative Instruments and Hedging Activities Disclosures [Line Items]      
Derivative notional amount $ 200 $ 100  
Senior Notes | Forward-starting interest rate swaps | Derivatives Designated as Hedging Instruments:      
Derivative Instruments and Hedging Activities Disclosures [Line Items]      
Derivative notional amount   $ 650  
Senior Notes | Senior Notes Due 2023      
Derivative Instruments and Hedging Activities Disclosures [Line Items]      
Interest rate percentage 3.25%    
Senior Notes | 4.500% 2015 senior notes due 2025      
Derivative Instruments and Hedging Activities Disclosures [Line Items]      
Interest rate percentage 4.50%    
Senior Notes | 5.600% 2022 senior notes due 2032      
Derivative Instruments and Hedging Activities Disclosures [Line Items]      
Interest rate percentage     5.60%
Senior Notes | 3.900% 2018 senior notes due 2028      
Derivative Instruments and Hedging Activities Disclosures [Line Items]      
Interest rate percentage 3.90%    
Senior Notes | 2.000% 2020 senior notes due 2030      
Derivative Instruments and Hedging Activities Disclosures [Line Items]      
Interest rate percentage 2.00%    
XML 73 R62.htm IDEA: XBRL DOCUMENT v3.24.3
Financial Instruments Derivative Notional Amounts (Details)
€ in Millions, kr in Millions, SFr in Millions, $ in Millions
Sep. 30, 2024
USD ($)
Sep. 30, 2024
EUR (€)
Sep. 30, 2024
DKK (kr)
Sep. 30, 2024
CHF (SFr)
Dec. 31, 2023
USD ($)
Dec. 31, 2023
EUR (€)
Dec. 31, 2023
DKK (kr)
Dec. 31, 2023
CHF (SFr)
Foreign exchange derivative instruments                
Derivative [Line Items]                
Derivative notional amount $ 250 € 750 kr 475 SFr 25 $ 250 € 650 kr 600 SFr 25
Derivatives Not Designated as Hedging Instruments: | Foreign currency forward-exchange contracts                
Derivative [Line Items]                
Derivative notional amount 1,965       1,948      
Derivatives Designated as Hedging Instruments: | Forward-starting interest rate swaps                
Derivative [Line Items]                
Derivative notional amount $ 200       $ 100      
XML 74 R63.htm IDEA: XBRL DOCUMENT v3.24.3
Financial Instruments - Fair Value of Derivative Instruments (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Derivatives, Fair Value [Line Items]          
Total derivatives $ (5)   $ (5)   $ (19)
Derivatives Designated as Hedging Instruments:          
Derivatives, Fair Value [Line Items]          
Total derivatives (8)   (8)   (19)
Foreign currency forward-exchange contracts | Derivatives Not Designated as Hedging Instruments:          
Derivatives, Fair Value [Line Items]          
Total derivatives 3   3   0
Foreign currency forward-exchange contracts 11 $ 16 12 $ (20)  
Foreign currency forward-exchange contracts | Derivatives Not Designated as Hedging Instruments: | Other current assets          
Derivatives, Fair Value [Line Items]          
Derivative assets 17   17   11
Foreign currency forward-exchange contracts | Derivatives Not Designated as Hedging Instruments: | Other current liabilities          
Derivatives, Fair Value [Line Items]          
Derivative liabilities (14)   (14)   (11)
Forward-starting interest rate swap contracts | Derivatives Designated as Hedging Instruments: | Other noncurrent assets          
Derivatives, Fair Value [Line Items]          
Derivative assets 12   12   12
Foreign exchange derivative instruments | Derivatives Designated as Hedging Instruments:          
Derivatives, Fair Value [Line Items]          
Collateral received 12   12    
Collateral posted 22   22   33
Additional Collateral, Aggregate Fair Value         13
Foreign exchange derivative instruments | Derivatives Designated as Hedging Instruments: | Other current assets          
Derivatives, Fair Value [Line Items]          
Derivative assets 17   17   5
Foreign exchange derivative instruments | Derivatives Designated as Hedging Instruments: | Other current liabilities          
Derivatives, Fair Value [Line Items]          
Derivative liabilities (17)   (17)   (20)
Foreign exchange derivative instruments | Derivatives Designated as Hedging Instruments: | Other noncurrent assets          
Derivatives, Fair Value [Line Items]          
Derivative assets 0   0   11
Foreign exchange derivative instruments | Derivatives Designated as Hedging Instruments: | Other noncurrent liabilities          
Derivatives, Fair Value [Line Items]          
Derivative liabilities 0   0   (1)
Fixed-to-floating interest rate swap contracts | Derivatives Designated as Hedging Instruments: | Other noncurrent liabilities          
Derivatives, Fair Value [Line Items]          
Derivative liabilities $ (20)   $ (20)   $ (26)
XML 75 R64.htm IDEA: XBRL DOCUMENT v3.24.3
Financial Instruments Cross-currency forward-exchange contracts (Details) - Derivatives Designated as Hedging Instruments: - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Forward-starting interest rate swap contracts        
Foreign Currency Fair Value Hedge Derivative [Line Items]        
Unrecognized net (losses)/gains on interest swap contracts, net of tax $ (3) $ 5 $ 0 $ 5
Foreign exchange derivative instruments        
Foreign Currency Fair Value Hedge Derivative [Line Items]        
Unrecognized net (losses)/gains on interest swap contracts, net of tax $ (23) $ 18 $ (5) $ 5
XML 76 R65.htm IDEA: XBRL DOCUMENT v3.24.3
Financial Instruments Cross-currency interest rate swap contracts (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Foreign exchange derivative instruments | Derivatives Designated as Hedging Instruments:        
Foreign Currency Fair Value Hedge Derivative [Line Items]        
Gain (Loss) on Components Excluded from Assessment of Interest Rate Fair Value Hedge Effectiveness $ 4 $ 4 $ 12 $ 14
XML 77 R66.htm IDEA: XBRL DOCUMENT v3.24.3
Inventories (Details) - USD ($)
$ in Millions
Sep. 30, 2024
Dec. 31, 2023
Inventory Disclosure [Abstract]    
Finished goods $ 1,049 $ 1,147
Work-in-process 951 966
Raw materials and supplies 416 451
Inventories $ 2,416 $ 2,564
XML 78 R67.htm IDEA: XBRL DOCUMENT v3.24.3
Goodwill and Other Intangible Assets - Goodwill (Details)
$ in Millions
 9 Months Ended
Sep. 30, 2024
USD ($)
Goodwill [Roll Forward]  
Beginning Balance $ 2,759
Other (15) [1]
Ending Balance 2,744
Reclassification of goodwill to assets held for sale 24
United States (U.S.)  
Goodwill [Roll Forward]  
Beginning Balance 1,532
Other (17) [1]
Ending Balance 1,515
International  
Goodwill [Roll Forward]  
Beginning Balance 1,227
Other 2 [1]
Ending Balance $ 1,229
[1] $24 million to Assets held for sale related to the planned sale of our medicated feed additive product portfolio, certain water soluble products and related assets, as well as foreign currency translation. For additional information, see Note 5. Acquisitions and Divestitures: B. Divestitures.
XML 79 R68.htm IDEA: XBRL DOCUMENT v3.24.3
Goodwill and Other Intangible Assets - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]          
Gross goodwill $ 3,280   $ 3,280   $ 3,295
Accumulated goodwill impairment losses 536   536   $ 536
Amortization of intangible assets $ 42 $ 46 $ 128 $ 141  
XML 80 R69.htm IDEA: XBRL DOCUMENT v3.24.3
Goodwill and Other Intangible Assets - Other Intangible Assets (Details) - USD ($)
$ in Millions
Sep. 30, 2024
Dec. 31, 2023
Finite Lived and Indefinite Lived Intangible Assets [Line Items]    
Finite-lived intangible assets, gross carrying amount $ 2,577 $ 2,639
Finite-lived intangible assets, accumulated amortization (1,605) (1,537)
Finite-lived intangible assets, identifiable intangible assets, less accumulated amortization 972 1,102
Total indefinite-lived intangible assets 214 236
Intangible Assets, gross carrying amount 2,791 2,875
Identifiable intangible assets, less accumulated amortization 1,186 1,338
Brands and tradenames    
Finite Lived and Indefinite Lived Intangible Assets [Line Items]    
Total indefinite-lived intangible assets 66 88
In-process research and development    
Finite Lived and Indefinite Lived Intangible Assets [Line Items]    
Total indefinite-lived intangible assets 141 141
Product rights    
Finite Lived and Indefinite Lived Intangible Assets [Line Items]    
Total indefinite-lived intangible assets 7 7
Developed technology rights    
Finite Lived and Indefinite Lived Intangible Assets [Line Items]    
Finite-lived intangible assets, gross carrying amount 1,931 1,986
Finite-lived intangible assets, accumulated amortization (1,164) (1,101)
Finite-lived intangible assets, identifiable intangible assets, less accumulated amortization 767 885
Brands and tradenames    
Finite Lived and Indefinite Lived Intangible Assets [Line Items]    
Finite-lived intangible assets, gross carrying amount 370 383
Finite-lived intangible assets, accumulated amortization (245) (246)
Finite-lived intangible assets, identifiable intangible assets, less accumulated amortization 125 137
Other    
Finite Lived and Indefinite Lived Intangible Assets [Line Items]    
Finite-lived intangible assets, gross carrying amount 276 270
Finite-lived intangible assets, accumulated amortization (196) (190)
Finite-lived intangible assets, identifiable intangible assets, less accumulated amortization $ 80 $ 80
XML 81 R70.htm IDEA: XBRL DOCUMENT v3.24.3
Share-Based Payments - Components of Share-Based Compensation Expense (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Share-based compensation expense—direct [1] $ 18 $ 17 $ 55 $ 43
Share-based compensation expense capitalized to inventory, less than 1 1 1 1
Stock options / stock appreciation rights        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Share-based compensation expense—direct 2 3 8 6
RSUs / DSUs        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Share-based compensation expense—direct 10 10 31 27
PSUs        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Share-based compensation expense—direct $ 6 $ 4 $ 16 $ 10
[1] For the three and nine months ended September 30, 2024 and 2023, we capitalized less than $1 million of share-based compensation expense to inventory
XML 82 R71.htm IDEA: XBRL DOCUMENT v3.24.3
Share-Based Payments - Narrative (Details) - $ / shares
 9 Months Ended 12 Months Ended
Sep. 30, 2024
Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Share-based compensation, options granted, shares 270,450  
Share-based compensation, weighted average exercise price (in dollars per share) $ 195.84  
Share-based compensation, Options, weighted average grant date fair value (in dollars per share) $ 50.90  
Share-based compensation, risk free interest rate 4.06%  
Share-based compensation, expected dividend rate 0.88%  
Share-based compensation, expected volatility rate 27.02%  
Share-based compensation, expected term 4 years 1 month 6 days  
Stock options    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Share-based compensation, award vesting period 3 years  
Share-based compensation, award expiration period 10 years  
Restricted Stock Units (RSUs)    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Share-based compensation, award vesting period   3 years
Share-based compensation, award graded vesting period 3 years  
Share-based compensation, granted, shares 246,112  
Share-based compensation, weighted average grant date fair value (in dollars per share) $ 195.10  
Performance Shares    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Share-based compensation, expected volatility rate 26.20%  
Share-based compensation, award vesting period 3 years  
Share-based compensation, granted, shares 101,099  
Share-based compensation, weighted average grant date fair value (in dollars per share) $ 268.71  
Performance Shares | PeerCompanies    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Share-based compensation, expected volatility rate 30.60%  
Performance Shares | Minimum    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Share-based compensation, target number of units percentage 0.00%  
Performance Shares | Maximum    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Share-based compensation, target number of units percentage 200.00%  
XML 83 R72.htm IDEA: XBRL DOCUMENT v3.24.3
Stockholders' Equity - Changes in Common Shares and Treasury Stock (Details) - USD ($)
Sep. 30, 2024
Dec. 31, 2022
Class of Stock [Line Items]    
Common stock, shares authorized 6,000,000,000  
Preferred stock, shares authorized 1,000,000,000  
December 2021 Share Repurchase Program    
Class of Stock [Line Items]    
Stock repurchase program, authorized amount   $ 3,500,000,000
Stock repurchase program, remaining number of shares authorized to be repurchased 200,000,000  
August 2024 Share Repurchase Program    
Class of Stock [Line Items]    
Stock repurchase program, authorized amount $ 6,000,000,000  
XML 84 R73.htm IDEA: XBRL DOCUMENT v3.24.3
Stockholders' Equity - Changes in Accumulated Other Comprehensive Loss (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Accumulated Other Comprehensive Income (Loss) [Roll Forward]        
Beginning balance $ 4,960 $ 4,621 $ 4,991 $ 4,403
Other comprehensive loss, net of tax (6) 81 (12) 3
Ending balance 5,234 5,074 5,234 5,074
Accumulated Other Comprehensive Loss        
Accumulated Other Comprehensive Income (Loss) [Roll Forward]        
Beginning balance (845) (895) (839) (817)
Other comprehensive loss, net of tax (6) 81 (12) 3
Ending balance (851) (814) (851) (814)
Derivatives Net Unrealized Gains/ (Losses)        
Accumulated Other Comprehensive Income (Loss) [Roll Forward]        
Beginning balance     85 90
Other comprehensive loss, net of tax     (5) 0
Ending balance 80 90 80 90
Net Investment Hedges        
Accumulated Other Comprehensive Income (Loss) [Roll Forward]        
Beginning balance     18 41
Other comprehensive loss, net of tax     (5) 5
Ending balance 13 46 13 46
Currency Translation Adjustment Net Unrealized Gain/(Losses)        
Accumulated Other Comprehensive Income (Loss) [Roll Forward]        
Beginning balance     (944) (944)
Other comprehensive loss, net of tax     (2) (6)
Ending balance (946) (950) (946) (950)
Benefit Plans Actuarial Gains/(Losses)        
Accumulated Other Comprehensive Income (Loss) [Roll Forward]        
Beginning balance     2 (4)
Other comprehensive loss, net of tax     0 4
Ending balance $ 2 $ 0 $ 2 $ 0
XML 85 R74.htm IDEA: XBRL DOCUMENT v3.24.3
Earnings per Share (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Numerator        
Net income before allocation to noncontrolling interests $ 692 $ 596 $ 1,915 $ 1,817
Less: Net income/(loss) attributable to noncontrolling interests 10 0 10 (2)
Net income attributable to Zoetis Inc. $ 682 $ 596 $ 1,905 $ 1,819
Denominator        
Weighted-average common shares outstanding 452.9 460.3 455.4 461.9
Common stock equivalents: stock options, RSUs, PSUs and DSUs 0.6 1.1 0.7 1.1
Weighted-average common and potential dilutive shares outstanding 453.5 461.4 456.1 463.0
Earnings per share attributable to Zoetis stockholders—basic (in dollars per share) $ 1.51 $ 1.29 $ 4.18 $ 3.94
Earnings per share attributable to Zoetis stockholders—diluted (in dollars per share) $ 1.50 $ 1.29 $ 4.18 $ 3.93
XML 86 R75.htm IDEA: XBRL DOCUMENT v3.24.3
Commitments and Contingencies (Details) - Ulianopolis, Brazil - defendant
 1 Months Ended
Apr. 30, 2012
Feb. 29, 2012
Loss Contingencies [Line Items]    
Number of additional defendants   5
Number of claims seeking damages   6
Duration of suspension of lawsuit 1 year  
XML 87 R76.htm IDEA: XBRL DOCUMENT v3.24.3
Segment Information (Details)
 9 Months Ended
Sep. 30, 2024
segment
Segment Reporting [Abstract]  
Number of operating segments 2
XML 88 R77.htm IDEA: XBRL DOCUMENT v3.24.3
Segment Information Selected Statement of Income (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Segment Reporting Information [Line Items]        
Revenue $ 2,388 $ 2,151 $ 6,939 $ 6,331
Cost of sales 701 638 2,012 1,833
Other (income)/deductions—net (16) 6 1 (151)
Income before provision for taxes on income 874 717 2,401 [1] 2,286 [1]
Depreciation and amortization 121 124 374 [1],[2] 365 [1],[2]
Other business activities        
Segment Reporting Information [Line Items]        
Income before provision for taxes on income (137) (124) (411) (354)
Depreciation and amortization 9 9 29 [2] 24 [2]
Operating Segments        
Segment Reporting Information [Line Items]        
Income before provision for taxes on income 1,431 1,237 4,112 3,640
Depreciation and amortization 45 43 138 [2] 125 [2]
Operating Segments | U.S.        
Segment Reporting Information [Line Items]        
Revenue 1,346 1,174 3,817 3,344
Cost of sales 258 228 707 645
Gross profit $ 1,088 $ 946 $ 3,110 $ 2,699
Gross margin, percentage 80.80% 80.60% 81.50% 80.70%
Operating expenses $ 199 $ 202 $ 593 $ 602
Other (income)/deductions—net 0 0 0 0
Income before provision for taxes on income 889 744 2,517 2,097
Depreciation and amortization 20 19 65 [2] 58 [2]
Operating Segments | International        
Segment Reporting Information [Line Items]        
Revenue 1,021 956 3,063 [3] 2,929 [3]
Cost of sales 321 306 976 912
Gross profit $ 700 $ 650 $ 2,087 $ 2,017
Gross margin, percentage 68.60% 68.00% 68.10% 68.90%
Operating expenses $ 157 $ 156 $ 491 $ 473
Other (income)/deductions—net 1 1 1 1
Income before provision for taxes on income 542 493 1,595 1,543
Depreciation and amortization 25 24 73 [2] 67 [2]
Corporate        
Segment Reporting Information [Line Items]        
Income before provision for taxes on income (306) (258) (893) (722)
Depreciation and amortization 31 33 96 [2] 95 [2]
Reconciling Items        
Segment Reporting Information [Line Items]        
Purchase accounting adjustments (35) (39) (107) (124)
Purchase accounting adjustments, Depreciation and Amortization 35 39 107 [2] 118 [2]
Acquisition and divestiture-related costs (7) (3) (12) (8)
Acquisition and divestiture-related costs, Depreciation and Amortization 0 0 0 [2] 0 [2]
Certain significant items, Earnings (1) (23) (77) [4] 45 [4]
Certain significant items, Depreciation and Amortization 0 0 0 [2],[4] 0 [2],[4]
Other unallocated (71) (73) (211) (191)
Other unallocated, Depreciation and Amortization $ 1 $ 0 $ 4 [2] $ 3 [2]
[1] Defined as income before provision for taxes on income.
[2] Certain production facilities are shared. Depreciation and amortization is allocated to the reportable operating segments based on estimates of where the benefits of the related assets are realized.
[3] Revenue denominated in euros was $694 million and $627 million for the nine months ended September 30, 2024 and 2023, respectively.
[4]
For the nine months ended September 30, 2023, primarily consisted of a gain on the sale of a majority interest in our pet insurance business, partially offset by employee termination costs related to organizational structure refinements and certain asset impairment charges related to our precision animal health and diagnostics businesses.
XML 89 R78.htm IDEA: XBRL DOCUMENT v3.24.3
Segment Information Selected Statement of Income Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Segment Reporting Information [Line Items]        
Revenue $ 2,388 $ 2,151 $ 6,939 $ 6,331
International | Operating Segments        
Segment Reporting Information [Line Items]        
Revenue 1,021 956 3,063 [1] 2,929 [1]
International | Operating Segments | Euro Member Countries, Euro        
Segment Reporting Information [Line Items]        
Revenue $ 234 $ 206 $ 694 $ 627
[1] Revenue denominated in euros was $694 million and $627 million for the nine months ended September 30, 2024 and 2023, respectively.
EXCEL 90 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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Ă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

-8?20$3;8T.P M6BP^0"X99K>]9!:G"D6B;&XET22II^NL[DF*42I3!7F9]DD4I\A,9\@V']*=';>[OM+YG/ZM2 MV;/1SKG]Q\G$YCM1CTQ&S._WXCS;REU:.EUEN=%F>C:;=A6_".)F_*LX:R%M^9]L2Q^^^<@ Y M&R6G\,"---:U=[3/Y\#X(.#F[JQV^D*63I@%=^+2Z'HOU;9Y#+S%Q'N-MAX. MQZX2/YK_4HUZLY&Y6.B\KH1R73T:43: RN[DWHZ8XI4X&QUN85P5;*D<5!); MJ>Y1<&_SIO#5JZ)[:P>X7AV:CQ(NF%71@M-!SF^N%\OK;+E@\"F[N5HM9K=P MDMW"XOEH/@!(?I 2_296VF9 MWK"U$19N?35>GV(#]BDMW"S/=0TV45N6.5 +-X7UV5"9$-ODJW@0JA8^#J:- M*;$W9OF/&KZT+6\MO(!(P8*(:VA7'Q+3QI38&U^!R-0Y,#5-.M]QLQ4=[8W; M">-C8N*8$INCA6$G*Y7K2KS[OA!%G7<5.V;7POF8F#JFQ.[H^-@M_]EO8%?T];-[3TXS!!38D6L%'19!_%YO[XP'TR)A7"I=?$HR_)/ M)X"*@Z%NVW"PF8^)26)*;(D,NJH8@RM$P=;\Z66K!I@D F))9$[G]SM=%L+8 MO]@2AD'WY+-AD@B();'D1L%09]D>&K:M1)\,G690SS-T54G7-F3[OS?7K6<% M=-Y>[P@P7P3$OLC$MIU5#D\E \P1 ;$CLOK.BA]U0[=L1A6?"Y-"0"P%Z)WL MP;*U,.V?JUQ )&#S4MNZ_\^'62(@M@2X04)W9;>&%TTD,#,&ACSQ:EC!9!$0 MRV(H]F0G:UW*IH>\\S$Q@03$ GD.0]F?8ZZWJHT#FW[M8V(""8@%@H:G[,1/ M:V N"8E=@@:H_>P+II606"MH@-K'Q!P3$CMF,!AD)[<<,'H]*$1S6<22\:+" M03;,,B&Q9=#PL-_0F'1"8ND,A8>#=8E))R26SE"<. B)62(&)^28B]@T>38Y]3,PX$;%Q4,R>O2/,.1'Y3 ?# M[*WF8=Z)R&P\34$U&K!XW-?0QDW1%D^5SN8V(6BHDM M] )S(3;"&(@RNP)_WAAC%HJ)+?2Z-GL)-1\3LU!,;*'A"=F8S:%*I>LU.F:A MF-A";V+JJA+&=WJ,+MT36^@MS$PH">&'CXE9*#[&DDR#"<\NZM+'Q"P4$UOH M+PKS2:CMVO9Z.62@FMM";M:F-D%L_BYY@%DJ(+?06 MYDHYT5^W3C +)<06&L9<"",?FMF;CXE9*#E*ONVY"_4W$V$62HYBH;G1UH[S MVM\%D& 62HYBH6?,?FUB%DK(=P%XZO_2#X01S3T+L'AS3 MW^"68.Y)CKE9H+?%+<'VU$KY[4LP]*?6^@6',0TK.Q\3@F+W1,L7P\FH+05 MT*2]V9Y_*L1&*E%Q[VAVY8?)R.YV%=[<>Q M^U'7PV9?3LWPT';E?+FR;?M3,UZ6_:[NFLU[LRNU+)=1]_G^YF+U\^N M_,_$=KL];,K/=O/[5,[C/P;7?]K^?=B7,E:+UZ;?E7%=U1_'V^FAOA[2PV5R MM7AY6U?]RUNJZKF#!()D_B"%()T_R"#(Y@]R"/+Y@P*"8OZ@#$%Y_J 5!*WF M#WJ$H,?Y@](295P2)$VP)M Z(=>)P.N$8"<"L1.2G0C,3HAV(E [(=N)P.V$ M<"<"N1/2G0CL3HAW(M!;4&\AT%M0;R'06R8OVP1Z"^HM!'H+ZBT$>@OJ+01Z M"^HM!'H+ZBT$>@OJ+01Z"^HM!'HKZJT$>BOJK01Z*^JM!'KK9+.$0&]%O95 M;T6]E4!O1;V50&]%O95 ;T6]E4!O1;V50&]#O8U ;T.]C4!O0[V-0&]#O8U M;YML=A/H;:BW$>AMJ+<1Z&VHMQ'H;:BW$>AMJ+<1Z.VHMQ/H[:BW$^CMJ+<3 MZ.VHMQ/H[:BW$^CMDX^5!'H[ZNT$>COJ[01Z.^KM!'H[ZNT$>@?J'01Z!^H= M!'H'ZAT$>@?J'01Z!^H=!'H'ZAT$>L?D9Q,"O0/U#@*] _4. KT#]0X"O3/J MG0GTSJAW)M [H]Z90.^,>F<"O3/JG0GTSJAW)M [H]Z90.\\^5F00.^,>N?O MU'L8/X]EN/5\K?'YWTGU>+FWW!Y_77Z=1 E75YSK^XKA^2]02P,$% @ M@VYD62XH"M@5 @ _"P !, !;0V]N=&5N=%]4>7!E&ULS=K?3MLP M% ;P5ZERBQK7_S=$N0%N-R[V EYRVD9-8LLVK+S]G!20-K$*5*1]-XU:V^<[ M\9%^5[WZ\10H+0Y#/Z9UMO<:E375[>T<0]]7MP=RL^I\^.ZBM2G:G%SW#AEK2L70M\U+I=U M]CBV?Z4LGQ/JDW9=2!=E0\7>3)A6_AWP?.[[(\78M;2X=S%_>CK8]&+T\FYW# =/_G9^7.9 M4X%EYWWT(96)1?IXW,M(IM/+4 I1S-WI5WQ-+*7/?C^:IMU2^\[L,+2!]?0?K@*Y1&4$3E M**1R%%,Y"JH<156.PBI'<96CP,I19!4HL@H4606*K )%5H$BJT"15:#(*E!D M%2BR"A19)8JL$D56B2*K1)%5HL@J4625*+)*%%DEBJP215:%(JM"D56AR*I0 M9%4HLBH4616*K I%5H4BJT*15:/(JE%DU2BR:A19-8JL&D56C2*K1I%5H\BJ M460U*+(:%%D-BJP&15:#(JM!D=6@R&I09#4HLAH462V*K!9%5HLBJT61U:+( M:E%DM2BR6A19[?^4]:?W^T^.GY_UX+KQ)9_-?WJ^_@U02P$"% ,4 " "# M;F19!T%-8H$ "Q $ @ $ 9&]C4')O<',O87!P M+GAM;%!+ 0(4 Q0 ( (-N9%DG%.'0[P "L" 1 " M :\ !D;V-0&UL4$L! M A0#% @ @VYD6&PO=V]R:W-H965T&UL4$L! A0#% @ @VYD69_P M"01@ P ,0P !@ ("! 1L 'AL+W=O02/8P@ TC 8 M " @9<> !X;"]W;W)K&PO=V]R:W-H965T M&UL4$L! A0#% @ @VYD604EKE_P#@ 1)L !@ M ("!VRH 'AL+W=O&PO=V]R:W-H965T&UL4$L! M A0#% @ @VYD6=Q,TEO3! 6@L !D ("!;$< 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ @VYD M66.KBZ!Q" !!4 !D ("!GET 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ @VYD61+L=K#(" E1D M !D ("!:G$ 'AL+W=O@ M>&PO=V]R:W-H965T&UL4$L! A0#% @ @VYD68&$^RG\!0 : \ !D M ("!*)( 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ @VYD63U](9<.! 40D !D ("!?*0 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ @VYD6?!B M@1"_ @ "P8 !D ("!#<( 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ @VYD62T"G1B8$ DBT !D M ("!D\X 'AL+W=O&PO M=V]R:W-H965T@0 M !,* 9 " @9CE !X;"]W;W)K&UL4$L! A0#% @ @VYD60\,S^3$! .PP !D ("! M2>H 'AL+W=O/VEJ$$ !K"P &0 @(%$[P >&PO=V]R:W-H965TCG>PLP8 ,T7 9 M " @1ST !X;"]W;W)K&UL4$L! A0#% M @ @VYD68G$J6J4 @ B@4 !D ("!!OL 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ @VYD632\UD U M P 0P< !D ("!!P8! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ @VYD68C>HZ*C @ Y@< !D M ("!CA0! 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ @VYD6=M?]B5-!@ V2X !D ("!T"(! M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ M@VYD6:5U]7O5 @ !@@ !D ("!@38! 'AL+W=O&UL4$L! A0#% @ @VYD63)*F *U!@ M"3, !D ("!;D8! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ @VYD62B><*%E @ ;08 !D M ("!TE0! 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ @VYD6?XN_X"8 @ MPD !D ("!MEX! 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ @VYD M643%&NU? @ (08 !D ("!R'(! 'AL+W=O=0$ >&PO=V]R:W-H965T7, 4T0( !<* 9 " @?QY 0!X;"]W;W)K M&UL4$L! A0#% @ @VYD69H) B_T! Q2( M !D ("!!'T! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ @VYD697 6!5Y P 9 X !D M ("!-(X! 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ @VYD64Q&M;&PO=V]R:W-H965T&UL4$L! A0#% @ @VYD6>(&O.W?!0 (RL !D M ("!W+(! 'AL+W=O&PO M=V]R:W-H965TCRJ0( M (H' 9 " @8:] 0!X;"]W;W)K&UL4$L! A0#% @ @VYD61U&N>8; @ FP0 !D ("! M9L ! 'AL+W=OT/H* #=10 &0 @(&XP@$ >&PO=V]R:W-H965TG- 0!X;"]W;W)K&UL4$L! A0#% M @ @VYD63%V]*1M P Q!8 T ( !(=(! 'AL+W-T>6QE M&PO=V]R:V)O;VLN>&UL4$L! A0#% @ M@VYD67H$ UU< @ (2X !H ( !O=P! 'AL+U]R96QS+W=O M XML 91 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 92 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 94 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html 441 337 1 true 113 0 false 14 false false R1.htm 0000001 - Document - Document and Entity Information Sheet http://www.zoetis.com/role/DocumentandEntityInformation Document and Entity Information Cover 1 false false R2.htm 9952151 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) Sheet http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) Statements 2 false false R3.htm 9952152 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) Sheet http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) Statements 3 false false R4.htm 9952153 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) (UNAUDITED) Sheet http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEParentheticalUNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) (UNAUDITED) Statements 4 false false R5.htm 9952154 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) Sheet http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) Statements 5 false false R6.htm 9952155 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (PARENTHETICAL) Sheet http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDPARENTHETICAL CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (PARENTHETICAL) Statements 6 false false R7.htm 9952156 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (UNAUDITED) Sheet http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (UNAUDITED) Statements 7 false false R8.htm 9952157 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Sheet http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Statements 8 false false R9.htm 9952158 - Disclosure - Organization Sheet http://www.zoetis.com/role/Organization Organization Notes 9 false false R10.htm 9952159 - Disclosure - Basis of Presentation Sheet http://www.zoetis.com/role/BasisofPresentation Basis of Presentation Notes 10 false false R11.htm 9952160 - Disclosure - Accounting Standards Sheet http://www.zoetis.com/role/AccountingStandards Accounting Standards Notes 11 false false R12.htm 9952161 - Disclosure - Revenue Sheet http://www.zoetis.com/role/Revenue Revenue Notes 12 false false R13.htm 9952162 - Disclosure - Acquisitions and Divestitures Sheet http://www.zoetis.com/role/AcquisitionsandDivestitures Acquisitions and Divestitures Notes 13 false false R14.htm 9952163 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Divestitures Sheet http://www.zoetis.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandDivestitures Restructuring Charges and Other Costs Associated with Acquisitions and Divestitures Notes 14 false false R15.htm 9952164 - Disclosure - Other (Income)/Deductions - Net Sheet http://www.zoetis.com/role/OtherIncomeDeductionsNet Other (Income)/Deductions - Net Notes 15 false false R16.htm 9952165 - Disclosure - Income Taxes Sheet http://www.zoetis.com/role/IncomeTaxes Income Taxes Notes 16 false false R17.htm 9952166 - Disclosure - Financial Instruments Sheet http://www.zoetis.com/role/FinancialInstruments Financial Instruments Notes 17 false false R18.htm 9952167 - Disclosure - Inventories Sheet http://www.zoetis.com/role/Inventories Inventories Notes 18 false false R19.htm 9952168 - Disclosure - Goodwill and Other Intangible Assets Sheet http://www.zoetis.com/role/GoodwillandOtherIntangibleAssets Goodwill and Other Intangible Assets Notes 19 false false R20.htm 9952169 - Disclosure - Share-Based Payments Sheet http://www.zoetis.com/role/ShareBasedPayments Share-Based Payments Notes 20 false false R21.htm 9952170 - Disclosure - Stockholders' Equity Sheet http://www.zoetis.com/role/StockholdersEquity Stockholders' Equity Notes 21 false false R22.htm 9952171 - Disclosure - Earnings per Share Sheet http://www.zoetis.com/role/EarningsperShare Earnings per Share Notes 22 false false R23.htm 9952172 - Disclosure - Commitments and Contingencies Sheet http://www.zoetis.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 23 false false R24.htm 9952173 - Disclosure - Segment Information Sheet http://www.zoetis.com/role/SegmentInformation Segment Information Notes 24 false false R25.htm 9952174 - Disclosure - Subsequent Event Sheet http://www.zoetis.com/role/SubsequentEvent Subsequent Event Notes 25 false false R26.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 26 false false R27.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 27 false false R28.htm 9954471 - Disclosure - Accounting Standards (Policies) Sheet http://www.zoetis.com/role/AccountingStandardsPolicies Accounting Standards (Policies) Policies http://www.zoetis.com/role/AccountingStandards 28 false false R29.htm 9954472 - Disclosure - Revenue Revenue Recognition and Deferred Revenue (Tables) Sheet http://www.zoetis.com/role/RevenueRevenueRecognitionandDeferredRevenueTables Revenue Revenue Recognition and Deferred Revenue (Tables) Tables 29 false false R30.htm 9954473 - Disclosure - Acquisitions and Divestitures (Tables) Sheet http://www.zoetis.com/role/AcquisitionsandDivestituresTables Acquisitions and Divestitures (Tables) Tables http://www.zoetis.com/role/AcquisitionsandDivestitures 30 false false R31.htm 9954474 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Divestitures (Tables) Sheet http://www.zoetis.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandDivestituresTables Restructuring Charges and Other Costs Associated with Acquisitions and Divestitures (Tables) Tables http://www.zoetis.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandDivestitures 31 false false R32.htm 9954475 - Disclosure - Other (Income)/Deductions - Net (Tables) Sheet http://www.zoetis.com/role/OtherIncomeDeductionsNetTables Other (Income)/Deductions - Net (Tables) Tables http://www.zoetis.com/role/OtherIncomeDeductionsNet 32 false false R33.htm 9954476 - Disclosure - Financial Instruments (Tables) Sheet http://www.zoetis.com/role/FinancialInstrumentsTables Financial Instruments (Tables) Tables http://www.zoetis.com/role/FinancialInstruments 33 false false R34.htm 9954477 - Disclosure - Inventories (Tables) Sheet http://www.zoetis.com/role/InventoriesTables Inventories (Tables) Tables http://www.zoetis.com/role/Inventories 34 false false R35.htm 9954478 - Disclosure - Goodwill and Other Intangible Assets (Tables) Sheet http://www.zoetis.com/role/GoodwillandOtherIntangibleAssetsTables Goodwill and Other Intangible Assets (Tables) Tables http://www.zoetis.com/role/GoodwillandOtherIntangibleAssets 35 false false R36.htm 9954479 - Disclosure - Share-Based Payments (Tables) Sheet http://www.zoetis.com/role/ShareBasedPaymentsTables Share-Based Payments (Tables) Tables http://www.zoetis.com/role/ShareBasedPayments 36 false false R37.htm 9954480 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.zoetis.com/role/StockholdersEquityTables Stockholders' Equity (Tables) Tables http://www.zoetis.com/role/StockholdersEquity 37 false false R38.htm 9954481 - Disclosure - Earnings per Share (Tables) Sheet http://www.zoetis.com/role/EarningsperShareTables Earnings per Share (Tables) Tables http://www.zoetis.com/role/EarningsperShare 38 false false R39.htm 9954482 - Disclosure - Segment Information (Tables) Sheet http://www.zoetis.com/role/SegmentInformationTables Segment Information (Tables) Tables http://www.zoetis.com/role/SegmentInformation 39 false false R40.htm 9954483 - Disclosure - Organization (Details) Sheet http://www.zoetis.com/role/OrganizationDetails Organization (Details) Details http://www.zoetis.com/role/Organization 40 false false R41.htm 9954484 - Disclosure - Revenue - Narrative (Details) Sheet http://www.zoetis.com/role/RevenueNarrativeDetails Revenue - Narrative (Details) Details 41 false false R42.htm 9954485 - Disclosure - Revenue - Revenue by Geographic Area (Details) Sheet http://www.zoetis.com/role/RevenueRevenuebyGeographicAreaDetails Revenue - Revenue by Geographic Area (Details) Details 42 false false R43.htm 9954486 - Disclosure - Revenue - Revenue by Major Species (Details) Sheet http://www.zoetis.com/role/RevenueRevenuebyMajorSpeciesDetails Revenue - Revenue by Major Species (Details) Details 43 false false R44.htm 9954487 - Disclosure - Revenue - Revenue by Species (Details) Sheet http://www.zoetis.com/role/RevenueRevenuebySpeciesDetails Revenue - Revenue by Species (Details) Details 44 false false R45.htm 9954488 - Disclosure - Revenue - Revenue by Product (Details) Sheet http://www.zoetis.com/role/RevenueRevenuebyProductDetails Revenue - Revenue by Product (Details) Details 45 false false R46.htm 9954489 - Disclosure - Acquisitions and Divestitures - Consideration Transferred (Details) Sheet http://www.zoetis.com/role/AcquisitionsandDivestituresConsiderationTransferredDetails Acquisitions and Divestitures - Consideration Transferred (Details) Details 46 false false R47.htm 9954490 - Disclosure - Acquisitions and Divestitures - Divestures (Details) Sheet http://www.zoetis.com/role/AcquisitionsandDivestituresDivesturesDetails Acquisitions and Divestitures - Divestures (Details) Details 47 false false R48.htm 9954491 - Disclosure - Acquisitions and Divestitures - Schedule of Assets Held for Sale (Details) Sheet http://www.zoetis.com/role/AcquisitionsandDivestituresScheduleofAssetsHeldforSaleDetails Acquisitions and Divestitures - Schedule of Assets Held for Sale (Details) Details 48 false false R49.htm 9954492 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Divestitures (Details) Sheet http://www.zoetis.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandDivestituresDetails Restructuring Charges and Other Costs Associated with Acquisitions and Divestitures (Details) Details http://www.zoetis.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandDivestituresTables 49 false false R50.htm 9954493 - Disclosure - Other (Income)/Deductions - Net (Details) Sheet http://www.zoetis.com/role/OtherIncomeDeductionsNetDetails Other (Income)/Deductions - Net (Details) Details http://www.zoetis.com/role/OtherIncomeDeductionsNetTables 50 false false R51.htm 9954494 - Disclosure - Income Taxes - Taxes on Income (Details) Sheet http://www.zoetis.com/role/IncomeTaxesTaxesonIncomeDetails Income Taxes - Taxes on Income (Details) Details 51 false false R52.htm 9954495 - Disclosure - Income Taxes - Deferred Taxes (Details) Sheet http://www.zoetis.com/role/IncomeTaxesDeferredTaxesDetails Income Taxes - Deferred Taxes (Details) Details 52 false false R53.htm 9954496 - Disclosure - Income Taxes - Tax Contingencies (Details) Sheet http://www.zoetis.com/role/IncomeTaxesTaxContingenciesDetails Income Taxes - Tax Contingencies (Details) Details 53 false false R54.htm 9954497 - Disclosure - Financial Instruments - Credit Facilities (Details) Sheet http://www.zoetis.com/role/FinancialInstrumentsCreditFacilitiesDetails Financial Instruments - Credit Facilities (Details) Details 54 false false R55.htm 9954498 - Disclosure - Financial Instruments - Commercial Paper Program (Details) Sheet http://www.zoetis.com/role/FinancialInstrumentsCommercialPaperProgramDetails Financial Instruments - Commercial Paper Program (Details) Details 55 false false R56.htm 9954499 - Disclosure - Financial Instruments - Senior Notes Offering and Other Long-Term Debt (Details) Notes http://www.zoetis.com/role/FinancialInstrumentsSeniorNotesOfferingandOtherLongTermDebtDetails Financial Instruments - Senior Notes Offering and Other Long-Term Debt (Details) Details 56 false false R57.htm 9954500 - Disclosure - Financial Instruments - Schedule of Long-term Debt (Details) Sheet http://www.zoetis.com/role/FinancialInstrumentsScheduleofLongtermDebtDetails Financial Instruments - Schedule of Long-term Debt (Details) Details 57 false false R58.htm 9954501 - Disclosure - Financial Instruments - Fair Value of Debt (Details) Sheet http://www.zoetis.com/role/FinancialInstrumentsFairValueofDebtDetails Financial Instruments - Fair Value of Debt (Details) Details 58 false false R59.htm 9954502 - Disclosure - Financial Instruments - Long-term Debt Maturity (Details) Sheet http://www.zoetis.com/role/FinancialInstrumentsLongtermDebtMaturityDetails Financial Instruments - Long-term Debt Maturity (Details) Details 59 false false R60.htm 9954503 - Disclosure - Financial Instruments - Foreign Exchange Risk (Details) Sheet http://www.zoetis.com/role/FinancialInstrumentsForeignExchangeRiskDetails Financial Instruments - Foreign Exchange Risk (Details) Details 60 false false R61.htm 9954504 - Disclosure - Financial Instruments - Interest Rate Risk (Details) Sheet http://www.zoetis.com/role/FinancialInstrumentsInterestRateRiskDetails Financial Instruments - Interest Rate Risk (Details) Details 61 false false R62.htm 9954505 - Disclosure - Financial Instruments Derivative Notional Amounts (Details) Sheet http://www.zoetis.com/role/FinancialInstrumentsDerivativeNotionalAmountsDetails Financial Instruments Derivative Notional Amounts (Details) Details 62 false false R63.htm 9954506 - Disclosure - Financial Instruments - Fair Value of Derivative Instruments (Details) Sheet http://www.zoetis.com/role/FinancialInstrumentsFairValueofDerivativeInstrumentsDetails Financial Instruments - Fair Value of Derivative Instruments (Details) Details 63 false false R64.htm 9954507 - Disclosure - Financial Instruments Cross-currency forward-exchange contracts (Details) Sheet http://www.zoetis.com/role/FinancialInstrumentsCrosscurrencyforwardexchangecontractsDetails Financial Instruments Cross-currency forward-exchange contracts (Details) Details 64 false false R65.htm 9954508 - Disclosure - Financial Instruments Cross-currency interest rate swap contracts (Details) Sheet http://www.zoetis.com/role/FinancialInstrumentsCrosscurrencyinterestrateswapcontractsDetails Financial Instruments Cross-currency interest rate swap contracts (Details) Details 65 false false R66.htm 9954509 - Disclosure - Inventories (Details) Sheet http://www.zoetis.com/role/InventoriesDetails Inventories (Details) Details http://www.zoetis.com/role/InventoriesTables 66 false false R67.htm 9954510 - Disclosure - Goodwill and Other Intangible Assets - Goodwill (Details) Sheet http://www.zoetis.com/role/GoodwillandOtherIntangibleAssetsGoodwillDetails Goodwill and Other Intangible Assets - Goodwill (Details) Details 67 false false R68.htm 9954511 - Disclosure - Goodwill and Other Intangible Assets - Narrative (Details) Sheet http://www.zoetis.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails Goodwill and Other Intangible Assets - Narrative (Details) Details 68 false false R69.htm 9954512 - Disclosure - Goodwill and Other Intangible Assets - Other Intangible Assets (Details) Sheet http://www.zoetis.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails Goodwill and Other Intangible Assets - Other Intangible Assets (Details) Details 69 false false R70.htm 9954513 - Disclosure - Share-Based Payments - Components of Share-Based Compensation Expense (Details) Sheet http://www.zoetis.com/role/ShareBasedPaymentsComponentsofShareBasedCompensationExpenseDetails Share-Based Payments - Components of Share-Based Compensation Expense (Details) Details 70 false false R71.htm 9954514 - Disclosure - Share-Based Payments - Narrative (Details) Sheet http://www.zoetis.com/role/ShareBasedPaymentsNarrativeDetails Share-Based Payments - Narrative (Details) Details 71 false false R72.htm 9954515 - Disclosure - Stockholders' Equity - Changes in Common Shares and Treasury Stock (Details) Sheet http://www.zoetis.com/role/StockholdersEquityChangesinCommonSharesandTreasuryStockDetails Stockholders' Equity - Changes in Common Shares and Treasury Stock (Details) Details 72 false false R73.htm 9954516 - Disclosure - Stockholders' Equity - Changes in Accumulated Other Comprehensive Loss (Details) Sheet http://www.zoetis.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveLossDetails Stockholders' Equity - Changes in Accumulated Other Comprehensive Loss (Details) Details 73 false false R74.htm 9954517 - Disclosure - Earnings per Share (Details) Sheet http://www.zoetis.com/role/EarningsperShareDetails Earnings per Share (Details) Details http://www.zoetis.com/role/EarningsperShareTables 74 false false R75.htm 9954518 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.zoetis.com/role/CommitmentsandContingenciesDetails Commitments and Contingencies (Details) Details http://www.zoetis.com/role/CommitmentsandContingencies 75 false false R76.htm 9954519 - Disclosure - Segment Information (Details) Sheet http://www.zoetis.com/role/SegmentInformationDetails Segment Information (Details) Details http://www.zoetis.com/role/SegmentInformationTables 76 false false R77.htm 9954520 - Disclosure - Segment Information Selected Statement of Income (Details) Sheet http://www.zoetis.com/role/SegmentInformationSelectedStatementofIncomeDetails Segment Information Selected Statement of Income (Details) Details 77 false false R78.htm 9954521 - Disclosure - Segment Information Selected Statement of Income Narrative (Details) Sheet http://www.zoetis.com/role/SegmentInformationSelectedStatementofIncomeNarrativeDetails Segment Information Selected Statement of Income Narrative (Details) Details 78 false false All Reports Book All Reports zts-20240930.htm zts-20240930.xsd zts-20240930_cal.xml zts-20240930_def.xml zts-20240930_lab.xml zts-20240930_pre.xml http://fasb.org/srt/2024 http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 97 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "zts-20240930.htm": { "nsprefix": "zts", "nsuri": "http://www.zoetis.com/20240930", "dts": { "inline": { "local": [ "zts-20240930.htm" ] }, "schema": { "local": [ "zts-20240930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/currency/2024/currency-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "calculationLink": { "local": [ "zts-20240930_cal.xml" ] }, "definitionLink": { "local": [ "zts-20240930_def.xml" ] }, "labelLink": { "local": [ "zts-20240930_lab.xml" ] }, "presentationLink": { "local": [ "zts-20240930_pre.xml" ] } }, "keyStandard": 300, "keyCustom": 37, "axisStandard": 30, "axisCustom": 0, "memberStandard": 59, "memberCustom": 53, "hidden": { "total": 8, "http://xbrl.sec.gov/ecd/2024": 3, "http://xbrl.sec.gov/dei/2024": 5 }, "contextCount": 441, "entityCount": 1, "segmentCount": 113, "elementCount": 684, "unitCount": 14, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 1177, "http://xbrl.sec.gov/dei/2024": 29, "http://xbrl.sec.gov/ecd/2024": 22, "http://fasb.org/srt/2024": 2 }, "report": { "R1": { "role": "http://www.zoetis.com/role/DocumentandEntityInformation", "longName": "0000001 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED", "longName": "9952151 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "zts:RevenuefromExternalCustomersbySpeciesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:SellingGeneralAndAdministrativeExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "unique": true } }, "R3": { "role": "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED", "longName": "9952152 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "unique": true } }, "R4": { "role": "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEParentheticalUNAUDITED", "longName": "9952153 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) (UNAUDITED)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) (UNAUDITED)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED", "longName": "9952154 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDPARENTHETICAL", "longName": "9952155 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (PARENTHETICAL)", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (PARENTHETICAL)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED", "longName": "9952156 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (UNAUDITED)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (UNAUDITED)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-67", "name": "us-gaap:CommonStockSharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-67", "name": "us-gaap:CommonStockSharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED", "longName": "9952157 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "unique": true } }, "R9": { "role": "http://www.zoetis.com/role/Organization", "longName": "9952158 - Disclosure - Organization", "shortName": "Organization", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.zoetis.com/role/BasisofPresentation", "longName": "9952159 - Disclosure - Basis of Presentation", "shortName": "Basis of Presentation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.zoetis.com/role/AccountingStandards", "longName": "9952160 - Disclosure - Accounting Standards", "shortName": "Accounting Standards", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.zoetis.com/role/Revenue", "longName": "9952161 - Disclosure - Revenue", "shortName": "Revenue", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DeferredRevenueDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DeferredRevenueDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.zoetis.com/role/AcquisitionsandDivestitures", "longName": "9952162 - Disclosure - Acquisitions and Divestitures", "shortName": "Acquisitions and Divestitures", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.zoetis.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandDivestitures", "longName": "9952163 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Divestitures", "shortName": "Restructuring Charges and Other Costs Associated with Acquisitions and Divestitures", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "zts:CostReductionAndProductivityInitiativesAndAcquisitionRelatedCostsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "zts:CostReductionAndProductivityInitiativesAndAcquisitionRelatedCostsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.zoetis.com/role/OtherIncomeDeductionsNet", "longName": "9952164 - Disclosure - Other (Income)/Deductions - Net", "shortName": "Other (Income)/Deductions - Net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.zoetis.com/role/IncomeTaxes", "longName": "9952165 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.zoetis.com/role/FinancialInstruments", "longName": "9952166 - Disclosure - Financial Instruments", "shortName": "Financial Instruments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.zoetis.com/role/Inventories", "longName": "9952167 - Disclosure - Inventories", "shortName": "Inventories", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.zoetis.com/role/GoodwillandOtherIntangibleAssets", "longName": "9952168 - Disclosure - Goodwill and Other Intangible Assets", "shortName": "Goodwill and Other Intangible Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.zoetis.com/role/ShareBasedPayments", "longName": "9952169 - Disclosure - Share-Based Payments", "shortName": "Share-Based Payments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.zoetis.com/role/StockholdersEquity", "longName": "9952170 - Disclosure - Stockholders' Equity", "shortName": "Stockholders' Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.zoetis.com/role/EarningsperShare", "longName": "9952171 - Disclosure - Earnings per Share", "shortName": "Earnings per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.zoetis.com/role/CommitmentsandContingencies", "longName": "9952172 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.zoetis.com/role/SegmentInformation", "longName": "9952173 - Disclosure - Segment Information", "shortName": "Segment Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.zoetis.com/role/SubsequentEvent", "longName": "9952174 - Disclosure - Subsequent Event", "shortName": "Subsequent Event", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true } }, "R26": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true }, "uniqueAnchor": null }, "R27": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "27", "firstAnchor": { "contextRef": "c-3", "name": "ecd:NonRule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:NonRule10b51ArrTrmntdFlag", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "ecd:NonRule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:NonRule10b51ArrTrmntdFlag", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.zoetis.com/role/AccountingStandardsPolicies", "longName": "9954471 - Disclosure - Accounting Standards (Policies)", "shortName": "Accounting Standards (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.zoetis.com/role/RevenueRevenueRecognitionandDeferredRevenueTables", "longName": "9954472 - Disclosure - Revenue Revenue Recognition and Deferred Revenue (Tables)", "shortName": "Revenue Revenue Recognition and Deferred Revenue (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.zoetis.com/role/AcquisitionsandDivestituresTables", "longName": "9954473 - Disclosure - Acquisitions and Divestitures (Tables)", "shortName": "Acquisitions and Divestitures (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.zoetis.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandDivestituresTables", "longName": "9954474 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Divestitures (Tables)", "shortName": "Restructuring Charges and Other Costs Associated with Acquisitions and Divestitures (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.zoetis.com/role/OtherIncomeDeductionsNetTables", "longName": "9954475 - Disclosure - Other (Income)/Deductions - Net (Tables)", "shortName": "Other (Income)/Deductions - Net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.zoetis.com/role/FinancialInstrumentsTables", "longName": "9954476 - Disclosure - Financial Instruments (Tables)", "shortName": "Financial Instruments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:FinancialInstrumentsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:FinancialInstrumentsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.zoetis.com/role/InventoriesTables", "longName": "9954477 - Disclosure - Inventories (Tables)", "shortName": "Inventories (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.zoetis.com/role/GoodwillandOtherIntangibleAssetsTables", "longName": "9954478 - Disclosure - Goodwill and Other Intangible Assets (Tables)", "shortName": "Goodwill and Other Intangible Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.zoetis.com/role/ShareBasedPaymentsTables", "longName": "9954479 - Disclosure - Share-Based Payments (Tables)", "shortName": "Share-Based Payments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.zoetis.com/role/StockholdersEquityTables", "longName": "9954480 - Disclosure - Stockholders' Equity (Tables)", "shortName": "Stockholders' Equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.zoetis.com/role/EarningsperShareTables", "longName": "9954481 - Disclosure - Earnings per Share (Tables)", "shortName": "Earnings per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.zoetis.com/role/SegmentInformationTables", "longName": "9954482 - Disclosure - Segment Information (Tables)", "shortName": "Segment Information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.zoetis.com/role/OrganizationDetails", "longName": "9954483 - Disclosure - Organization (Details)", "shortName": "Organization (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-14", "name": "zts:NumberofRegionalSegments", "unitRef": "geographicregion", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:NatureOfOperations", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "zts:NumberofRegionalSegments", "unitRef": "geographicregion", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:NatureOfOperations", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.zoetis.com/role/RevenueNarrativeDetails", "longName": "9954484 - Disclosure - Revenue - Narrative (Details)", "shortName": "Revenue - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-14", "name": "zts:NumberOfMajorProductLines", "unitRef": "product_category", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:DeferredRevenueDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "zts:NumberOfMajorProductLines", "unitRef": "product_category", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:DeferredRevenueDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.zoetis.com/role/RevenueRevenuebyGeographicAreaDetails", "longName": "9954485 - Disclosure - Revenue - Revenue by Geographic Area (Details)", "shortName": "Revenue - Revenue by Geographic Area (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "zts:RevenuefromExternalCustomersbySpeciesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-83", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "unique": true } }, "R43": { "role": "http://www.zoetis.com/role/RevenueRevenuebyMajorSpeciesDetails", "longName": "9954486 - Disclosure - Revenue - Revenue by Major Species (Details)", "shortName": "Revenue - Revenue by Major Species (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "zts:RevenuefromExternalCustomersbySpeciesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-151", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "zts:RevenuefromExternalCustomersbyMajorSpeciesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "unique": true } }, "R44": { "role": "http://www.zoetis.com/role/RevenueRevenuebySpeciesDetails", "longName": "9954487 - Disclosure - Revenue - Revenue by Species (Details)", "shortName": "Revenue - Revenue by Species (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "zts:RevenuefromExternalCustomersbySpeciesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-183", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "zts:RevenuefromExternalCustomersbySpeciesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "unique": true } }, "R45": { "role": "http://www.zoetis.com/role/RevenueRevenuebyProductDetails", "longName": "9954488 - Disclosure - Revenue - Revenue by Product (Details)", "shortName": "Revenue - Revenue by Product (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "zts:RevenuefromExternalCustomersbySpeciesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-247", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "unique": true } }, "R46": { "role": "http://www.zoetis.com/role/AcquisitionsandDivestituresConsiderationTransferredDetails", "longName": "9954489 - Disclosure - Acquisitions and Divestitures - Consideration Transferred (Details)", "shortName": "Acquisitions and Divestitures - Consideration Transferred (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-251", "name": "us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-251", "name": "us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.zoetis.com/role/AcquisitionsandDivestituresDivesturesDetails", "longName": "9954490 - Disclosure - Acquisitions and Divestitures - Divestures (Details)", "shortName": "Acquisitions and Divestitures - Divestures (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-253", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-253", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.zoetis.com/role/AcquisitionsandDivestituresScheduleofAssetsHeldforSaleDetails", "longName": "9954491 - Disclosure - Acquisitions and Divestitures - Schedule of Assets Held for Sale (Details)", "shortName": "Acquisitions and Divestitures - Schedule of Assets Held for Sale (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "zts:GainLossOnDispositionOfAssetGoodwillAllocation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "unique": true } }, "R49": { "role": "http://www.zoetis.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandDivestituresDetails", "longName": "9954492 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Divestitures (Details)", "shortName": "Restructuring Charges and Other Costs Associated with Acquisitions and Divestitures (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-3", "name": "zts:RestructuringAndRelatedActivitiesDivestitureRelatedCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "zts:RestructuringAndRelatedActivitiesDivestitureRelatedCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.zoetis.com/role/OtherIncomeDeductionsNetDetails", "longName": "9954493 - Disclosure - Other (Income)/Deductions - Net (Details)", "shortName": "Other (Income)/Deductions - Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:RoyaltyIncomeNonoperating", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock", "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:RoyaltyIncomeNonoperating", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock", "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.zoetis.com/role/IncomeTaxesTaxesonIncomeDetails", "longName": "9954494 - Disclosure - Income Taxes - Taxes on Income (Details)", "shortName": "Income Taxes - Taxes on Income (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.zoetis.com/role/IncomeTaxesDeferredTaxesDetails", "longName": "9954495 - Disclosure - Income Taxes - Deferred Taxes (Details)", "shortName": "Income Taxes - Deferred Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:DeferredTaxLiabilities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:DeferredTaxLiabilities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.zoetis.com/role/IncomeTaxesTaxContingenciesDetails", "longName": "9954496 - Disclosure - Income Taxes - Tax Contingencies (Details)", "shortName": "Income Taxes - Tax Contingencies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:UnrecognizedTaxBenefits", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:UnrecognizedTaxBenefits", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.zoetis.com/role/FinancialInstrumentsCreditFacilitiesDetails", "longName": "9954497 - Disclosure - Financial Instruments - Credit Facilities (Details)", "shortName": "Financial Instruments - Credit Facilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:FinancialInstrumentsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:FinancialInstrumentsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.zoetis.com/role/FinancialInstrumentsCommercialPaperProgramDetails", "longName": "9954498 - Disclosure - Financial Instruments - Commercial Paper Program (Details)", "shortName": "Financial Instruments - Commercial Paper Program (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:CommercialPaper", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:CommercialPaper", "span", "div", "us-gaap:FinancialInstrumentsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:CommercialPaper", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:CommercialPaper", "span", "div", "us-gaap:FinancialInstrumentsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.zoetis.com/role/FinancialInstrumentsSeniorNotesOfferingandOtherLongTermDebtDetails", "longName": "9954499 - Disclosure - Financial Instruments - Senior Notes Offering and Other Long-Term Debt (Details)", "shortName": "Financial Instruments - Senior Notes Offering and Other Long-Term Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RepaymentsOfLongTermDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-289", "name": "zts:DebtInstrumentPurchasePricePercentDueToDowngradeOfInvestmentGrade", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:FinancialInstrumentsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "unique": true } }, "R57": { "role": "http://www.zoetis.com/role/FinancialInstrumentsScheduleofLongtermDebtDetails", "longName": "9954500 - Disclosure - Financial Instruments - Schedule of Long-term Debt (Details)", "shortName": "Financial Instruments - Schedule of Long-term Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "us-gaap:FinancialInstrumentsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-15", "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "us-gaap:FinancialInstrumentsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "unique": true } }, "R58": { "role": "http://www.zoetis.com/role/FinancialInstrumentsFairValueofDebtDetails", "longName": "9954501 - Disclosure - Financial Instruments - Fair Value of Debt (Details)", "shortName": "Financial Instruments - Fair Value of Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-308", "name": "us-gaap:DebtInstrumentFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "us-gaap:FinancialInstrumentsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-308", "name": "us-gaap:DebtInstrumentFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "us-gaap:FinancialInstrumentsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.zoetis.com/role/FinancialInstrumentsLongtermDebtMaturityDetails", "longName": "9954502 - Disclosure - Financial Instruments - Long-term Debt Maturity (Details)", "shortName": "Financial Instruments - Long-term Debt Maturity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-280", "name": "us-gaap:LineOfCredit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:FinancialInstrumentsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "unique": true } }, "R60": { "role": "http://www.zoetis.com/role/FinancialInstrumentsForeignExchangeRiskDetails", "longName": "9954503 - Disclosure - Financial Instruments - Foreign Exchange Risk (Details)", "shortName": "Financial Instruments - Foreign Exchange Risk (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-310", "name": "us-gaap:DerivativeTermOfContract", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-310", "name": "us-gaap:DerivativeTermOfContract", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true } }, "R61": { "role": "http://www.zoetis.com/role/FinancialInstrumentsInterestRateRiskDetails", "longName": "9954504 - Disclosure - Financial Instruments - Interest Rate Risk (Details)", "shortName": "Financial Instruments - Interest Rate Risk (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeCashReceivedOnHedge", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeCashReceivedOnHedge", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true } }, "R62": { "role": "http://www.zoetis.com/role/FinancialInstrumentsDerivativeNotionalAmountsDetails", "longName": "9954505 - Disclosure - Financial Instruments Derivative Notional Amounts (Details)", "shortName": "Financial Instruments Derivative Notional Amounts (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-316", "name": "us-gaap:DerivativeNotionalAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-316", "name": "us-gaap:DerivativeNotionalAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true } }, "R63": { "role": "http://www.zoetis.com/role/FinancialInstrumentsFairValueofDerivativeInstrumentsDetails", "longName": "9954506 - Disclosure - Financial Instruments - Fair Value of Derivative Instruments (Details)", "shortName": "Financial Instruments - Fair Value of Derivative Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:DerivativeFairValueOfDerivativeNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-15", "name": "us-gaap:DerivativeFairValueOfDerivativeNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "unique": true } }, "R64": { "role": "http://www.zoetis.com/role/FinancialInstrumentsCrosscurrencyforwardexchangecontractsDetails", "longName": "9954507 - Disclosure - Financial Instruments Cross-currency forward-exchange contracts (Details)", "shortName": "Financial Instruments Cross-currency forward-exchange contracts (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c-343", "name": "us-gaap:TranslationAdjustmentForNetInvestmentHedgeIncreaseDecreaseNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-343", "name": "us-gaap:TranslationAdjustmentForNetInvestmentHedgeIncreaseDecreaseNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true } }, "R65": { "role": "http://www.zoetis.com/role/FinancialInstrumentsCrosscurrencyinterestrateswapcontractsDetails", "longName": "9954508 - Disclosure - Financial Instruments Cross-currency interest rate swap contracts (Details)", "shortName": "Financial Instruments Cross-currency interest rate swap contracts (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "c-347", "name": "us-gaap:GainLossOnComponentsExcludedFromAssessmentOfInterestRateFairValueHedgeEffectiveness", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-347", "name": "us-gaap:GainLossOnComponentsExcludedFromAssessmentOfInterestRateFairValueHedgeEffectiveness", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true } }, "R66": { "role": "http://www.zoetis.com/role/InventoriesDetails", "longName": "9954509 - Disclosure - Inventories (Details)", "shortName": "Inventories (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:InventoryFinishedGoodsNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:InventoryFinishedGoodsNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true } }, "R67": { "role": "http://www.zoetis.com/role/GoodwillandOtherIntangibleAssetsGoodwillDetails", "longName": "9954510 - Disclosure - Goodwill and Other Intangible Assets - Goodwill (Details)", "shortName": "Goodwill and Other Intangible Assets - Goodwill (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "c-15", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillOtherIncreaseDecrease", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "unique": true } }, "R68": { "role": "http://www.zoetis.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "longName": "9954511 - Disclosure - Goodwill and Other Intangible Assets - Narrative (Details)", "shortName": "Goodwill and Other Intangible Assets - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:GoodwillGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-15", "name": "us-gaap:GoodwillGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "unique": true } }, "R69": { "role": "http://www.zoetis.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails", "longName": "9954512 - Disclosure - Goodwill and Other Intangible Assets - Other Intangible Assets (Details)", "shortName": "Goodwill and Other Intangible Assets - Other Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true } }, "R70": { "role": "http://www.zoetis.com/role/ShareBasedPaymentsComponentsofShareBasedCompensationExpenseDetails", "longName": "9954513 - Disclosure - Share-Based Payments - Components of Share-Based Compensation Expense (Details)", "shortName": "Share-Based Payments - Components of Share-Based Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true } }, "R71": { "role": "http://www.zoetis.com/role/ShareBasedPaymentsNarrativeDetails", "longName": "9954514 - Disclosure - Share-Based Payments - Narrative (Details)", "shortName": "Share-Based Payments - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true } }, "R72": { "role": "http://www.zoetis.com/role/StockholdersEquityChangesinCommonSharesandTreasuryStockDetails", "longName": "9954515 - Disclosure - Stockholders' Equity - Changes in Common Shares and Treasury Stock (Details)", "shortName": "Stockholders' Equity - Changes in Common Shares and Treasury Stock (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "unique": true } }, "R73": { "role": "http://www.zoetis.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveLossDetails", "longName": "9954516 - Disclosure - Stockholders' Equity - Changes in Accumulated Other Comprehensive Loss (Details)", "shortName": "Stockholders' Equity - Changes in Accumulated Other Comprehensive Loss (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "c-22", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-387", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "unique": true } }, "R74": { "role": "http://www.zoetis.com/role/EarningsperShareDetails", "longName": "9954517 - Disclosure - Earnings per Share (Details)", "shortName": "Earnings per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "unique": true } }, "R75": { "role": "http://www.zoetis.com/role/CommitmentsandContingenciesDetails", "longName": "9954518 - Disclosure - Commitments and Contingencies (Details)", "shortName": "Commitments and Contingencies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "c-411", "name": "zts:LossContingencyAdditionalNumberOfDefendants", "unitRef": "defendant", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-411", "name": "zts:LossContingencyAdditionalNumberOfDefendants", "unitRef": "defendant", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true } }, "R76": { "role": "http://www.zoetis.com/role/SegmentInformationDetails", "longName": "9954519 - Disclosure - Segment Information (Details)", "shortName": "Segment Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true, "unique": true } }, "R77": { "role": "http://www.zoetis.com/role/SegmentInformationSelectedStatementofIncomeDetails", "longName": "9954520 - Disclosure - Segment Information Selected Statement of Income (Details)", "shortName": "Segment Information Selected Statement of Income (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "zts:RevenuefromExternalCustomersbySpeciesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-415", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "unique": true } }, "R78": { "role": "http://www.zoetis.com/role/SegmentInformationSelectedStatementofIncomeNarrativeDetails", "longName": "9954521 - Disclosure - Segment Information Selected Statement of Income Narrative (Details)", "shortName": "Segment Information Selected Statement of Income Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "zts:RevenuefromExternalCustomersbySpeciesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-421", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "zts-20240930.htm", "unique": true } } }, "tag": { "zts_A2022SeniorNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "A2022SeniorNotesMember", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsSeniorNotesOfferingandOtherLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2022 Senior Notes", "label": "2022 Senior Notes [Member]", "documentation": "2022 Senior Notes" } } }, "auth_ref": [] }, "zts_A5400SeniorNotesDue2025Member": { "xbrltype": "domainItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "A5400SeniorNotesDue2025Member", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsScheduleofLongtermDebtDetails", "http://www.zoetis.com/role/FinancialInstrumentsSeniorNotesOfferingandOtherLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "5.400% 2022 senior notes due 2025", "label": "5.400% Senior Notes Due 2025 [Member]", "documentation": "5.400% Senior Notes Due 2025" } } }, "auth_ref": [] }, "zts_A5600SeniorNotesDue2032Member": { "xbrltype": "domainItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "A5600SeniorNotesDue2032Member", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsInterestRateRiskDetails", "http://www.zoetis.com/role/FinancialInstrumentsScheduleofLongtermDebtDetails", "http://www.zoetis.com/role/FinancialInstrumentsSeniorNotesOfferingandOtherLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "5.600% 2022 senior notes due 2032", "label": "5.600% Senior Notes Due 2032 [Member]", "documentation": "5.600% Senior Notes Due 2032" } } }, "auth_ref": [] }, "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AOCIAttributableToParentNetOfTaxRollForward", "presentation": [ "http://www.zoetis.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Roll Forward]", "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "country_AU": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "AU", "presentation": [ "http://www.zoetis.com/role/RevenueRevenuebyGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Australia", "label": "AUSTRALIA" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Abstract]", "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r108", "r878" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "verboseLabel": "Accounts receivable, less allowance for doubtful accounts of $19 in 2024 and $18 in 2023", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r1030" ] }, "us-gaap_AccruedIncomeTaxesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedIncomeTaxesNoncurrent", "crdr": "credit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Other taxes payable", "label": "Accrued Income Taxes, Noncurrent", "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent." } } }, "auth_ref": [ "r116", "r181" ] }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "presentation": [ "http://www.zoetis.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Benefit Plans Actuarial Gains/(Losses)", "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent." } } }, "auth_ref": [ "r7", "r8", "r23", "r34", "r132", "r1004", "r1005", "r1006" ] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDPARENTHETICAL" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated depreciation", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r48", "r246", "r667" ] }, "us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember", "presentation": [ "http://www.zoetis.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivatives Net Unrealized Gains/ (Losses)", "label": "Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) resulting from gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges, attributable to the parent." } } }, "auth_ref": [ "r6", "r34", "r557" ] }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "presentation": [ "http://www.zoetis.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net Investment Hedges", "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]", "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent." } } }, "auth_ref": [ "r262", "r263", "r264", "r267", "r274", "r275", "r1004" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "presentation": [ "http://www.zoetis.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r273", "r274", "r590", "r592", "r593", "r594", "r595", "r596" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive loss", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r33", "r34", "r133", "r255", "r663", "r703", "r704" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "presentation": [ "http://www.zoetis.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r273", "r274", "r590", "r592", "r593", "r594", "r595", "r596" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED", "http://www.zoetis.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Loss", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r4", "r23", "r34", "r565", "r568", "r609", "r699", "r700", "r1004", "r1005", "r1006", "r1017", "r1018", "r1019", "r1020" ] }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedTranslationAdjustmentMember", "presentation": [ "http://www.zoetis.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Currency Translation Adjustment Net Unrealized Gain/(Losses)", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent." } } }, "auth_ref": [ "r5", "r23", "r34", "r130", "r131", "r274", "r275", "r592", "r593", "r594", "r595", "r596", "r1004" ] }, "zts_AcquisitionAndDivestitureDepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "AcquisitionAndDivestitureDepreciationDepletionAndAmortization", "crdr": "debit", "presentation": [ "http://www.zoetis.com/role/SegmentInformationSelectedStatementofIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisition and divestiture-related costs, Depreciation and Amortization", "label": "Acquisition And Divestiture Depreciation, Depletion and Amortization", "documentation": "Acquisition And Divestiture Depreciation, Depletion and Amortization" } } }, "auth_ref": [] }, "us-gaap_AcquisitionRelatedCostsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AcquisitionRelatedCostsMember", "presentation": [ "http://www.zoetis.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandDivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisition-related costs", "label": "Acquisition-related Costs [Member]", "documentation": "Category of acquisition-related costs allocated to (included in) reported pro forma earnings (supplemental pro forma information)." } } }, "auth_ref": [] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r943" ] }, "us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract", "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental cash flow information", "label": "Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AdditionalCollateralAggregateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalCollateralAggregateFairValue", "crdr": "debit", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsFairValueofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Collateral, Aggregate Fair Value", "label": "Additional Collateral, Aggregate Fair Value", "documentation": "The aggregate fair value of additional assets that would be required to be posted as collateral for derivative instruments with credit-risk-related contingent features if the credit-risk-related contingent features were triggered at the end of the reporting period." } } }, "auth_ref": [ "r90" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r121", "r878", "r1153" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-in Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r717", "r1017", "r1018", "r1019", "r1020", "r1090", "r1154" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r956" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r956" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r956" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r956" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation awards", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r62", "r63", "r484" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net income before noncontrolling interests to net cash provided by operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table", "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]" } } }, "auth_ref": [ "r989" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r915", "r925", "r935", "r967" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r918", "r928", "r938", "r970" ] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Pension Adjustments Service Cost", "label": "Aggregate Pension Adjustments Service Cost [Member]" } } }, "auth_ref": [ "r990" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r956" ] }, "currency_AllCurrenciesDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2024", "localname": "AllCurrenciesDomain", "presentation": [ "http://www.zoetis.com/role/SegmentInformationSelectedStatementofIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "All Currencies [Domain]", "label": "All Currencies [Domain]" } } }, "auth_ref": [] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r963" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r919", "r929", "r939", "r963", "r971", "r975", "r983" ] }, "us-gaap_AllOtherSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllOtherSegmentsMember", "presentation": [ "http://www.zoetis.com/role/SegmentInformationSelectedStatementofIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other business activities", "label": "Other Operating Segment [Member]", "documentation": "Operating segments classified as other. Excludes intersegment elimination and reconciling items." } } }, "auth_ref": [ "r326", "r353", "r354", "r355", "r356", "r357", "r360", "r840", "r841" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r981" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.zoetis.com/role/ShareBasedPaymentsComponentsofShareBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation expense\u2014direct", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r513", "r518" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDPARENTHETICAL" ], "lang": { "en-us": { "role": { "terseLabel": "Allowance for doubtful accounts", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": [ "r256", "r369", "r373" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://www.zoetis.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": [ "http://www.zoetis.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of intangible assets", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r16", "r390", "r397", "r848" ] }, "zts_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction": { "xbrltype": "monetaryItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction", "crdr": "debit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of intangible assets", "label": "Amortization Of Intangible Assets Not Associated With Single Function", "documentation": "The amount of amortization that is not associated with a single function. Amounts associated in a single function are included in Cost of sales, Selling, information and administrative expenses and Research and development expenses." } } }, "auth_ref": [] }, "zts_AnimalHealthDiagnosticsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "AnimalHealthDiagnosticsMember", "presentation": [ "http://www.zoetis.com/role/RevenueRevenuebyProductDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Animal health diagnostics", "label": "Animal Health Diagnostics [Member]", "documentation": "Animal Health Diagnostics [Member]" } } }, "auth_ref": [] }, "zts_AntiInfectiveProductsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "AntiInfectiveProductsMember", "presentation": [ "http://www.zoetis.com/role/RevenueRevenuebyProductDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Anti-infectives", "label": "Anti-infective Products [Member]", "documentation": "Anti-infective Products [Member]" } } }, "auth_ref": [] }, "us-gaap_AssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetImpairmentCharges", "crdr": "debit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED", "http://www.zoetis.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandDivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset write-offs and asset impairments", "label": "Asset Impairment Charges", "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill." } } }, "auth_ref": [ "r16", "r47" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r178", "r191", "r250", "r291", "r321", "r329", "r355", "r359", "r370", "r424", "r425", "r427", "r428", "r429", "r430", "r431", "r433", "r434", "r553", "r559", "r584", "r659", "r755", "r840", "r841", "r878", "r906", "r1072", "r1073", "r1111" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r243", "r259", "r291", "r370", "r424", "r425", "r427", "r428", "r429", "r430", "r431", "r433", "r434", "r553", "r559", "r584", "r878", "r1072", "r1073", "r1111" ] }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation", "crdr": "debit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 }, "http://www.zoetis.com/role/AcquisitionsandDivestituresScheduleofAssetsHeldforSaleDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.zoetis.com/role/AcquisitionsandDivestituresScheduleofAssetsHeldforSaleDetails", "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Assets held for sale", "totalLabel": "Total Assets Held for Sale", "label": "Disposal Group, Including Discontinued Operation, Assets", "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r3", "r97", "r103", "r157", "r241", "r242" ] }, "zts_August2024ShareRepurchaseProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "August2024ShareRepurchaseProgramMember", "presentation": [ "http://www.zoetis.com/role/StockholdersEquityChangesinCommonSharesandTreasuryStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "August 2024 Share Repurchase Program", "label": "August 2024 Share Repurchase Program [Member]", "documentation": "August 2024 Share Repurchase Program" } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r978" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r979" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r974" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r974" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r974" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r974" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r974" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r974" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [ "http://www.zoetis.com/role/ShareBasedPaymentsComponentsofShareBasedCompensationExpenseDetails", "http://www.zoetis.com/role/ShareBasedPaymentsNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r977" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r976" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r975" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r975" ] }, "country_BR": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "BR", "presentation": [ "http://www.zoetis.com/role/RevenueRevenuebyGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Brazil", "label": "BRAZIL" } } }, "auth_ref": [] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationAxis", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsFairValueofDerivativeInstrumentsDetails", "http://www.zoetis.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandDivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Axis]", "label": "Statement of Financial Position Location, Balance [Axis]", "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": [ "r405", "r1122", "r1123" ] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationDomain", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsFairValueofDerivativeInstrumentsDetails", "http://www.zoetis.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandDivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Domain]", "label": "Statement of Financial Position Location, Balance [Domain]", "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": [ "r82", "r85", "r405", "r1122", "r1123" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.zoetis.com/role/AccountingStandardsPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://www.zoetis.com/role/AcquisitionsandDivestituresConsiderationTransferredDetails", "http://www.zoetis.com/role/AcquisitionsandDivestituresDivesturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Acquiree [Domain]", "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r391", "r392", "r393", "r394", "r395", "r548", "r861", "r862" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://www.zoetis.com/role/AcquisitionsandDivestituresConsiderationTransferredDetails", "http://www.zoetis.com/role/AcquisitionsandDivestituresDivesturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Axis]", "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r65", "r67", "r391", "r392", "r393", "r394", "r395", "r548", "r861", "r862" ] }, "us-gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionLineItems", "presentation": [ "http://www.zoetis.com/role/AcquisitionsandDivestituresConsiderationTransferredDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Line Items]", "label": "Business Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r548" ] }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "presentation": [ "http://www.zoetis.com/role/AcquisitionsandDivestituresConsiderationTransferredDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Voting interest acquired, percent", "label": "Business Acquisition, Percentage of Voting Interests Acquired", "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination." } } }, "auth_ref": [ "r66" ] }, "zts_BusinessCombinationAcquisitionAndDivestureRelatedCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "BusinessCombinationAcquisitionAndDivestureRelatedCosts", "crdr": "debit", "presentation": [ "http://www.zoetis.com/role/SegmentInformationSelectedStatementofIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisition and divestiture-related costs", "label": "Business Combination, Acquisition And Divesture Related Costs", "documentation": "Business Combination, Acquisition And Divesture Related Costs" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationAcquisitionRelatedCosts", "crdr": "debit", "presentation": [ "http://www.zoetis.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandDivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisition and divestiture-related costs", "label": "Business Combination, Acquisition Related Costs", "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities." } } }, "auth_ref": [ "r64" ] }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "lang": { "en-us": { "role": { "label": "Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationConsiderationTransferred1", "crdr": "credit", "presentation": [ "http://www.zoetis.com/role/AcquisitionsandDivestituresConsiderationTransferredDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payment to acquire business", "label": "Business Combination, Consideration Transferred", "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer." } } }, "auth_ref": [ "r0", "r1", "r20" ] }, "zts_BusinessCombinationConsiderationTransferredCashWithheldForPostClosingAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "BusinessCombinationConsiderationTransferredCashWithheldForPostClosingAdjustments", "crdr": "debit", "presentation": [ "http://www.zoetis.com/role/AcquisitionsandDivestituresConsiderationTransferredDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash withheld for post-closing adustments", "label": "Business Combination, Consideration Transferred, Cash Withheld For Post-Closing Adjustments", "documentation": "Business Combination, Consideration Transferred, Cash Withheld For Post-Closing Adjustments" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationDisclosureTextBlock", "presentation": [ "http://www.zoetis.com/role/AcquisitionsandDivestitures" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisitions and Divestitures", "label": "Business Combination Disclosure [Text Block]", "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)." } } }, "auth_ref": [ "r168", "r549" ] }, "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred", "crdr": "credit", "presentation": [ "http://www.zoetis.com/role/SegmentInformationSelectedStatementofIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase accounting adjustments", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Consideration Transferred", "documentation": "This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to items of consideration transferred in connection with a business combination for which the initial accounting was incomplete." } } }, "auth_ref": [ "r68" ] }, "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles", "crdr": "debit", "presentation": [ "http://www.zoetis.com/role/SegmentInformationSelectedStatementofIncomeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Purchase accounting adjustments, Depreciation and Amortization", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles", "documentation": "This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to intangibles acquired in connection with a business combination for which the initial accounting was incomplete." } } }, "auth_ref": [ "r68" ] }, "us-gaap_BusinessExitCosts1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessExitCosts1", "crdr": "debit", "presentation": [ "http://www.zoetis.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandDivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exit costs", "label": "Business Exit Costs", "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r16" ] }, "country_CA": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "CA", "presentation": [ "http://www.zoetis.com/role/RevenueRevenuebyGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Canada", "label": "CANADA" } } }, "auth_ref": [] }, "country_CL": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "CL", "presentation": [ "http://www.zoetis.com/role/RevenueRevenuebyGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Chile", "label": "CHILE" } } }, "auth_ref": [] }, "country_CN": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "CN", "presentation": [ "http://www.zoetis.com/role/RevenueRevenuebyGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "China", "label": "CHINA" } } }, "auth_ref": [] }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalExpendituresIncurredButNotYetPaid", "crdr": "credit", "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Capital expenditures", "label": "Capital Expenditures Incurred but Not yet Paid", "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred." } } }, "auth_ref": [ "r40", "r41", "r42" ] }, "us-gaap_CashAcquiredFromAcquisition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAcquiredFromAcquisition", "crdr": "debit", "presentation": [ "http://www.zoetis.com/role/AcquisitionsandDivestituresDivesturesDetails", "http://www.zoetis.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Acquired from Acquisition", "label": "Cash Acquired from Acquisition", "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business)." } } }, "auth_ref": [ "r36" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r38", "r245", "r827" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalents at beginning of period", "periodEndLabel": "Cash and cash equivalents at end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r38", "r149", "r288" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "totalLabel": "Net decrease in cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r2", "r149" ] }, "us-gaap_CashDivestedFromDeconsolidation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashDivestedFromDeconsolidation", "crdr": "credit", "presentation": [ "http://www.zoetis.com/role/AcquisitionsandDivestituresDivesturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "net of cash sold amount", "label": "Cash Divested from Deconsolidation", "documentation": "Reduction in cash due to no longer including the former subsidiary's cash in the consolidated entity's cash." } } }, "auth_ref": [ "r145" ] }, "us-gaap_CashFlowHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowHedgingMember", "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEParentheticalUNAUDITED", "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Flow Hedging", "label": "Cash Flow Hedging [Member]", "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk." } } }, "auth_ref": [ "r79" ] }, "zts_CattleMember": { "xbrltype": "domainItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "CattleMember", "presentation": [ "http://www.zoetis.com/role/RevenueRevenuebySpeciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cattle", "label": "Cattle [Member]", "documentation": "Cattle [Member]" } } }, "auth_ref": [] }, "zts_CertainSignificantReconcilingItemsIncludedinDepreciationDepletionandAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "CertainSignificantReconcilingItemsIncludedinDepreciationDepletionandAmortization", "crdr": "debit", "presentation": [ "http://www.zoetis.com/role/SegmentInformationSelectedStatementofIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Certain significant items, Depreciation and Amortization", "label": "Certain Significant Reconciling Items Included in Depreciation, Depletion and Amortization", "documentation": "Certain Significant Reconciling Items Included in Depreciation, Depletion and Amortization" } } }, "auth_ref": [] }, "zts_CertainSignificantReconcilingItemsIncludedinIncomeLossfromContinuingOperationsbeforeIncomeTaxesNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "CertainSignificantReconcilingItemsIncludedinIncomeLossfromContinuingOperationsbeforeIncomeTaxesNoncontrollingInterest", "crdr": "credit", "presentation": [ "http://www.zoetis.com/role/SegmentInformationSelectedStatementofIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Certain significant items, Earnings", "label": "Certain Significant Reconciling Items Included in Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Certain Significant Reconciling Items Included in Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r954" ] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year", "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]" } } }, "auth_ref": [ "r951" ] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested", "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]" } } }, "auth_ref": [ "r949" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://www.zoetis.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Domain]", "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r199", "r252", "r253", "r254", "r291", "r311", "r312", "r314", "r316", "r323", "r324", "r370", "r424", "r427", "r428", "r429", "r433", "r434", "r454", "r455", "r458", "r461", "r468", "r584", "r709", "r710", "r711", "r712", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r743", "r764", "r782", "r802", "r803", "r804", "r805", "r806", "r993", "r1012", "r1021" ] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems", "presentation": [ "http://www.zoetis.com/role/StockholdersEquityChangesinCommonSharesandTreasuryStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Line Items]", "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r252", "r253", "r254", "r323", "r454", "r455", "r456", "r458", "r461", "r466", "r468", "r709", "r710", "r711", "r712", "r855", "r993", "r1012" ] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r955" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r955" ] }, "us-gaap_CollateralAlreadyPostedAggregateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollateralAlreadyPostedAggregateFairValue", "crdr": "debit", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsCreditFacilitiesDetails", "http://www.zoetis.com/role/FinancialInstrumentsFairValueofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collateral posted", "label": "Collateral Already Posted, Aggregate Fair Value", "documentation": "The aggregate fair value of assets that are already posted, at the end of the reporting period, as collateral for derivative instruments with credit-risk-related contingent features." } } }, "auth_ref": [ "r89" ] }, "us-gaap_CommercialPaper": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommercialPaper", "crdr": "credit", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsCommercialPaperProgramDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commercial Paper", "label": "Commercial Paper", "documentation": "Carrying value as of the balance sheet date of short-term borrowings using unsecured obligations issued by banks, corporations and other borrowers to investors. The maturities of these money market securities generally do not exceed 270 days." } } }, "auth_ref": [ "r107", "r179", "r1119" ] }, "us-gaap_CommercialPaperMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommercialPaperMember", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsCommercialPaperProgramDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commercial Paper", "label": "Commercial Paper [Member]", "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds." } } }, "auth_ref": [ "r162", "r423", "r898", "r899", "r900", "r903" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies (Note 15)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r117", "r183", "r661", "r742" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.zoetis.com/role/CommitmentsandContingencies" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r161", "r414", "r415", "r810", "r1057", "r1065" ] }, "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesPolicyTextBlock", "presentation": [ "http://www.zoetis.com/role/AccountingStandardsPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Legal Proceedings", "label": "Commitments and Contingencies, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies." } } }, "auth_ref": [ "r50", "r811" ] }, "us-gaap_CommonStockDividendsPerShareDeclared": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockDividendsPerShareDeclared", "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends paid per common share (in dollars per share)", "label": "Common Stock, Dividends, Per Share, Declared", "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding." } } }, "auth_ref": [ "r167" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r894", "r895", "r896", "r898", "r899", "r900", "r903", "r1017", "r1018", "r1020", "r1090", "r1152", "r1154" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDPARENTHETICAL" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r120" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDPARENTHETICAL", "http://www.zoetis.com/role/StockholdersEquityChangesinCommonSharesandTreasuryStockDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Common stock, shares authorized", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r120", "r743" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDPARENTHETICAL", "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "verboseLabel": "Common stock issued, shares", "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r120" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDPARENTHETICAL" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares outstanding", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r24", "r120", "r743", "r761", "r1154", "r1155" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, $0.01 par value: 6,000,000,000 authorized; 501,891,243 and 501,891,243 shares issued; 451,549,789 and 458,367,358 shares outstanding at September\u00a030, 2024, and December\u00a031, 2023, respectively", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r120", "r662", "r878" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r960" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r959" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r961" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r958" ] }, "zts_CompanionAnimalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "CompanionAnimalMember", "presentation": [ "http://www.zoetis.com/role/RevenueRevenuebyMajorSpeciesDetails", "http://www.zoetis.com/role/RevenueRevenuebySpeciesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Companion animal", "label": "Companion Animal [Member]", "documentation": "Companion Animal [Member]" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive income attributable to Zoetis Inc.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r35", "r270", "r272", "r280", "r655", "r674", "r676" ] }, "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Less: Comprehensive income/(loss) attributable to noncontrolling interests", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r14", "r72", "r75", "r270", "r272", "r279", "r654", "r674", "r675" ] }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive income before allocation to noncontrolling interests", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r75", "r171", "r270", "r272", "r278", "r653", "r674" ] }, "srt_ConsolidationItemsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidationItemsAxis", "presentation": [ "http://www.zoetis.com/role/RevenueRevenuebyMajorSpeciesDetails", "http://www.zoetis.com/role/SegmentInformationSelectedStatementofIncomeDetails", "http://www.zoetis.com/role/SegmentInformationSelectedStatementofIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Axis]", "label": "Consolidation Items [Axis]", "documentation": "Information by components, eliminations, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments." } } }, "auth_ref": [ "r189", "r200", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r293", "r321", "r331", "r353", "r354", "r355", "r356", "r357", "r359", "r360", "r361", "r424", "r425", "r426", "r427", "r429", "r430", "r431", "r432", "r433", "r840", "r841", "r997", "r998", "r1072", "r1073" ] }, "srt_ConsolidationItemsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidationItemsDomain", "presentation": [ "http://www.zoetis.com/role/RevenueRevenuebyMajorSpeciesDetails", "http://www.zoetis.com/role/SegmentInformationSelectedStatementofIncomeDetails", "http://www.zoetis.com/role/SegmentInformationSelectedStatementofIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Domain]", "label": "Consolidation Items [Domain]", "documentation": "Components, elimination, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments." } } }, "auth_ref": [ "r189", "r200", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r293", "r321", "r331", "r353", "r354", "r355", "r356", "r357", "r359", "r360", "r361", "r424", "r425", "r426", "r427", "r429", "r430", "r431", "r432", "r433", "r840", "r841", "r997", "r998", "r1072", "r1073" ] }, "zts_ContractManufacturingandHumanHealthDiagnosticsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "ContractManufacturingandHumanHealthDiagnosticsMember", "presentation": [ "http://www.zoetis.com/role/RevenueRevenuebyGeographicAreaDetails", "http://www.zoetis.com/role/RevenueRevenuebyMajorSpeciesDetails", "http://www.zoetis.com/role/RevenueRevenuebyProductDetails", "http://www.zoetis.com/role/RevenueRevenuebySpeciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract manufacturing & human health", "label": "Contract Manufacturing and Human Health Diagnostics [Member]", "documentation": "Contract Manufacturing and Human Health Diagnostics [Member]" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiability", "crdr": "credit", "presentation": [ "http://www.zoetis.com/role/RevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract liabilities", "label": "Contract with Customer, Liability", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r470", "r471", "r472" ] }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityRevenueRecognized", "crdr": "credit", "presentation": [ "http://www.zoetis.com/role/RevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract liabilities, revenue recognized", "label": "Contract with Customer, Liability, Revenue Recognized", "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due." } } }, "auth_ref": [ "r473" ] }, "us-gaap_CorporateNonSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateNonSegmentMember", "presentation": [ "http://www.zoetis.com/role/SegmentInformationSelectedStatementofIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate", "label": "Segment Reporting, Reconciling Item, Corporate Nonsegment [Member]", "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment." } } }, "auth_ref": [ "r27", "r354", "r355", "r356", "r357", "r360", "r1026" ] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://www.zoetis.com/role/SegmentInformationSelectedStatementofIncomeDetails": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 2.0 }, "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED", "http://www.zoetis.com/role/SegmentInformationSelectedStatementofIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of sales", "verboseLabel": "Cost of sales", "label": "Cost of Goods and Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r136", "r137", "r618" ] }, "zts_CostReductionAndProductivityInitiativesAndAcquisitionRelatedCostsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "CostReductionAndProductivityInitiativesAndAcquisitionRelatedCostsDisclosureTextBlock", "presentation": [ "http://www.zoetis.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandDivestitures" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Charges and Other Costs Associated with Acquisitions and Divestitures", "label": "Cost Reduction And Productivity Initiatives And Acquisition Related Costs Disclosure [Text Block]", "documentation": "Description of cost-reduction and productivity initiatives associated with a comprehensive plan to integrate acquired operations, generate cost savings and capture synergies across the company; as well as costs incurred in connection with an acquisition. These costs include (i) restructuring activities, including exit and disposal activities, the major types of costs associated with the plan activities and the accrual balance at the end of the period; (ii) integration costs, which represent external, incremental costs directly related to integrating acquired businesses; (iii) implementation costs, which represent external, incremental costs directly related to implementing cost-reduction initiatives prior to acquisition and primarily include expenditures related to system and process standardization and the expansion of shared services; (iv) additional depreciation-asset restructuring, which represents the impact of changes in the estimated useful lives of assets involved in restructuring actions; and (v) transaction costs, representing external costs incurred in connection with an acquisition." } } }, "auth_ref": [] }, "us-gaap_CostsAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostsAndExpensesAbstract", "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Costs and expenses:", "label": "Costs and Expenses [Abstract]" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover page.", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityAxis", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsCreditFacilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Axis]", "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [ "r423", "r1070" ] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityDomain", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsCreditFacilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Domain]", "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [ "r423", "r1070", "r1071" ] }, "us-gaap_CrossCurrencyInterestRateContractMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CrossCurrencyInterestRateContractMember", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsCreditFacilitiesDetails", "http://www.zoetis.com/role/FinancialInstrumentsCrosscurrencyforwardexchangecontractsDetails", "http://www.zoetis.com/role/FinancialInstrumentsCrosscurrencyinterestrateswapcontractsDetails", "http://www.zoetis.com/role/FinancialInstrumentsDerivativeNotionalAmountsDetails", "http://www.zoetis.com/role/FinancialInstrumentsFairValueofDerivativeInstrumentsDetails", "http://www.zoetis.com/role/FinancialInstrumentsForeignExchangeRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign exchange derivative instruments", "label": "Cross Currency Interest Rate Contract [Member]", "documentation": "Derivative instrument whose primary underlying risk is tied to interest rates and foreign exchange rates." } } }, "auth_ref": [ "r1079", "r1089" ] }, "srt_CurrencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CurrencyAxis", "presentation": [ "http://www.zoetis.com/role/SegmentInformationSelectedStatementofIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Currency [Axis]", "label": "Currency [Axis]", "documentation": "Information by currency." } } }, "auth_ref": [ "r1107" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.zoetis.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "country_DE": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "DE", "presentation": [ "http://www.zoetis.com/role/RevenueRevenuebyGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Germany", "label": "GERMANY" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsInterestRateRiskDetails", "http://www.zoetis.com/role/FinancialInstrumentsLongtermDebtMaturityDetails", "http://www.zoetis.com/role/FinancialInstrumentsScheduleofLongtermDebtDetails", "http://www.zoetis.com/role/FinancialInstrumentsSeniorNotesOfferingandOtherLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r30", "r110", "r111", "r180", "r182", "r293", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r850", "r851", "r852", "r853", "r854", "r876", "r1013", "r1058", "r1059", "r1060", "r1109", "r1110" ] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "calculation": { "http://www.zoetis.com/role/FinancialInstrumentsLongtermDebtMaturityDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsLongtermDebtMaturityDetails", "http://www.zoetis.com/role/FinancialInstrumentsScheduleofLongtermDebtDetails", "http://www.zoetis.com/role/FinancialInstrumentsSeniorNotesOfferingandOtherLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt, principal amount", "totalLabel": "Total long-term debt", "label": "Long-Term Debt, Gross", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": [ "r30", "r182", "r452" ] }, "us-gaap_DebtInstrumentFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFairValue", "crdr": "credit", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsFairValueofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value, debt instrument", "label": "Debt Instrument, Fair Value Disclosure", "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable." } } }, "auth_ref": [ "r443", "r583", "r851", "r852", "r1091", "r1092", "r1093", "r1094", "r1101" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsInterestRateRiskDetails", "http://www.zoetis.com/role/FinancialInstrumentsScheduleofLongtermDebtDetails", "http://www.zoetis.com/role/FinancialInstrumentsSeniorNotesOfferingandOtherLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate percentage", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r113", "r436" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsFairValueofDebtDetails", "http://www.zoetis.com/role/FinancialInstrumentsScheduleofLongtermDebtDetails", "http://www.zoetis.com/role/FinancialInstrumentsSeniorNotesOfferingandOtherLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r293", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r850", "r851", "r852", "r853", "r854", "r876", "r1013", "r1109", "r1110" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsInterestRateRiskDetails", "http://www.zoetis.com/role/FinancialInstrumentsLongtermDebtMaturityDetails", "http://www.zoetis.com/role/FinancialInstrumentsScheduleofLongtermDebtDetails", "http://www.zoetis.com/role/FinancialInstrumentsSeniorNotesOfferingandOtherLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r30", "r293", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r850", "r851", "r852", "r853", "r854", "r876", "r1013", "r1058", "r1059", "r1060", "r1109", "r1110" ] }, "zts_DebtInstrumentPurchasePricePercentDueToDowngradeOfInvestmentGrade": { "xbrltype": "percentItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "DebtInstrumentPurchasePricePercentDueToDowngradeOfInvestmentGrade", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsSeniorNotesOfferingandOtherLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt, purchase price percent due to downgrade of investment grade", "label": "Debt Instrument, Purchase Price Percent Due to Downgrade of Investment Grade", "documentation": "Debt Instrument, Purchase Price Percent Due to Downgrade of Investment Grade" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTable", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsFairValueofDebtDetails", "http://www.zoetis.com/role/FinancialInstrumentsScheduleofLongtermDebtDetails", "http://www.zoetis.com/role/FinancialInstrumentsSeniorNotesOfferingandOtherLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth_ref": [ "r30", "r54", "r57", "r95", "r165", "r166", "r293", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r850", "r851", "r852", "r853", "r854", "r876", "r1013", "r1109", "r1110" ] }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentUnamortizedDiscount", "crdr": "debit", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsSeniorNotesOfferingandOtherLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt, unamortized discount", "label": "Debt Instrument, Unamortized Discount", "documentation": "Amount, after accumulated amortization, of debt discount." } } }, "auth_ref": [ "r1075", "r1108", "r1109", "r1110" ] }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentUnamortizedDiscountPremiumNet", "crdr": "debit", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unamortized debt discount / debt issuance costs", "label": "Debt Instrument, Unamortized Discount (Premium), Net", "documentation": "Amount, after accumulated amortization, of debt discount (premium)." } } }, "auth_ref": [ "r1075", "r1108", "r1109", "r1110" ] }, "zts_December2021ShareRepurchaseProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "December2021ShareRepurchaseProgramMember", "presentation": [ "http://www.zoetis.com/role/StockholdersEquityChangesinCommonSharesandTreasuryStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "December 2021 Share Repurchase Program", "label": "December 2021 Share Repurchase Program [Member]", "documentation": "December 2021 Share Repurchase Program" } } }, "auth_ref": [] }, "us-gaap_DeferredIncomeTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxAssetsNet", "crdr": "debit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Noncurrent deferred tax assets", "label": "Deferred Income Tax Assets, Net", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting." } } }, "auth_ref": [ "r522", "r523" ] }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred taxes", "label": "Deferred Income Tax Expense (Benefit)", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r16", "r196", "r1015" ] }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxLiabilitiesNet", "crdr": "credit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED", "http://www.zoetis.com/role/IncomeTaxesDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Noncurrent deferred tax liabilities", "label": "Deferred Income Tax Liabilities, Net", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting." } } }, "auth_ref": [ "r522", "r523", "r660" ] }, "us-gaap_DeferredRevenueDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredRevenueDisclosureTextBlock", "presentation": [ "http://www.zoetis.com/role/Revenue" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue", "label": "Deferred Revenue Disclosure [Text Block]", "documentation": "The entire disclosure for deferred revenues at the end of the reporting period, and description and amounts of significant changes that occurred during the reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP." } } }, "auth_ref": [ "r192" ] }, "us-gaap_DeferredTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsNet", "crdr": "debit", "presentation": [ "http://www.zoetis.com/role/IncomeTaxesDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Noncurrent deferred tax assets", "label": "Deferred Tax Assets, Net of Valuation Allowance", "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r1084" ] }, "us-gaap_DeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilities", "crdr": "credit", "presentation": [ "http://www.zoetis.com/role/IncomeTaxesDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Noncurrent deferred tax liabilities", "label": "Deferred Tax Liabilities, Net", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting." } } }, "auth_ref": [ "r1084" ] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED", "http://www.zoetis.com/role/SegmentInformationSelectedStatementofIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization expense", "verboseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r16", "r321", "r334", "r359", "r840", "r841" ] }, "us-gaap_DerivativeCashReceivedOnHedge": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeCashReceivedOnHedge", "crdr": "credit", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsInterestRateRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative, cash received on hedge", "label": "Derivative, Cash Received on Hedge", "documentation": "The amount of cash received during the period on settlement of a hedge." } } }, "auth_ref": [] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeContractTypeDomain", "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEParentheticalUNAUDITED", "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED", "http://www.zoetis.com/role/FinancialInstrumentsCreditFacilitiesDetails", "http://www.zoetis.com/role/FinancialInstrumentsCrosscurrencyforwardexchangecontractsDetails", "http://www.zoetis.com/role/FinancialInstrumentsCrosscurrencyinterestrateswapcontractsDetails", "http://www.zoetis.com/role/FinancialInstrumentsDerivativeNotionalAmountsDetails", "http://www.zoetis.com/role/FinancialInstrumentsFairValueofDerivativeInstrumentsDetails", "http://www.zoetis.com/role/FinancialInstrumentsForeignExchangeRiskDetails", "http://www.zoetis.com/role/FinancialInstrumentsInterestRateRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Contract [Domain]", "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r732", "r734", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r756", "r757", "r758", "r759", "r769", "r770", "r771", "r772", "r775", "r776", "r777", "r778", "r794", "r795", "r798", "r799", "r894", "r896", "r1095", "r1096", "r1097", "r1098", "r1099", "r1100", "r1102", "r1103" ] }, "us-gaap_DerivativeFairValueOfDerivativeAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeFairValueOfDerivativeAsset", "crdr": "debit", "calculation": { "http://www.zoetis.com/role/FinancialInstrumentsFairValueofDerivativeInstrumentsDetails": { "parentTag": "us-gaap_DerivativeFairValueOfDerivativeNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsFairValueofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative assets", "label": "Derivative Asset, Subject to Master Netting Arrangement, before Offset", "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement." } } }, "auth_ref": [ "r28", "r129", "r173", "r174", "r260", "r831" ] }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeFairValueOfDerivativeLiability", "crdr": "credit", "calculation": { "http://www.zoetis.com/role/FinancialInstrumentsFairValueofDerivativeInstrumentsDetails": { "parentTag": "us-gaap_DerivativeFairValueOfDerivativeNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsFairValueofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Derivative liabilities", "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset", "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement." } } }, "auth_ref": [ "r28", "r129", "r173", "r174", "r260", "r831" ] }, "us-gaap_DerivativeFairValueOfDerivativeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeFairValueOfDerivativeNet", "crdr": "debit", "calculation": { "http://www.zoetis.com/role/FinancialInstrumentsFairValueofDerivativeInstrumentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsFairValueofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total derivatives", "label": "Derivative, Fair Value, Net", "documentation": "Fair value of the assets less the liabilities of a derivative or group of derivatives." } } }, "auth_ref": [ "r583" ] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentRiskAxis", "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEParentheticalUNAUDITED", "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED", "http://www.zoetis.com/role/FinancialInstrumentsCreditFacilitiesDetails", "http://www.zoetis.com/role/FinancialInstrumentsCrosscurrencyforwardexchangecontractsDetails", "http://www.zoetis.com/role/FinancialInstrumentsCrosscurrencyinterestrateswapcontractsDetails", "http://www.zoetis.com/role/FinancialInstrumentsDerivativeNotionalAmountsDetails", "http://www.zoetis.com/role/FinancialInstrumentsFairValueofDerivativeInstrumentsDetails", "http://www.zoetis.com/role/FinancialInstrumentsForeignExchangeRiskDetails", "http://www.zoetis.com/role/FinancialInstrumentsInterestRateRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instrument [Axis]", "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": [ "r83", "r86", "r88", "r175", "r732", "r734", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r756", "r757", "r758", "r759", "r769", "r770", "r771", "r772", "r775", "r776", "r777", "r778", "r794", "r795", "r798", "r799", "r831", "r894", "r896", "r1095", "r1096", "r1097", "r1098", "r1099", "r1100", "r1102", "r1103" ] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsInterestRateRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Line Items]", "label": "Derivative Instruments and Hedging Activities Disclosures [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsInterestRateRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Table]", "label": "Derivative Instruments and Hedging Activities Disclosures [Table]", "documentation": "Disclosure of information about derivatives and hedging activities." } } }, "auth_ref": [] }, "us-gaap_DerivativeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLineItems", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsDerivativeNotionalAmountsDetails", "http://www.zoetis.com/role/FinancialInstrumentsForeignExchangeRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Line Items]", "label": "Derivative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r570" ] }, "us-gaap_DerivativeNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeNotionalAmount", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsDerivativeNotionalAmountsDetails", "http://www.zoetis.com/role/FinancialInstrumentsInterestRateRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative notional amount", "label": "Derivative, Notional Amount", "documentation": "Nominal or face amount used to calculate payment on derivative." } } }, "auth_ref": [ "r1086", "r1087" ] }, "us-gaap_DerivativeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeTable", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsDerivativeNotionalAmountsDetails", "http://www.zoetis.com/role/FinancialInstrumentsForeignExchangeRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Table]", "label": "Derivative [Table]", "documentation": "Disclosure of information about derivative instrument or group of derivative instruments, including, but not limited to, type of derivative instrument, risk being hedged, notional amount, hedge designation, related hedged item, inception date, and maturity date." } } }, "auth_ref": [ "r25", "r76", "r77", "r78", "r81", "r84", "r86", "r91", "r92", "r94", "r570" ] }, "us-gaap_DerivativeTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeTermOfContract", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsForeignExchangeRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maturity period (in years)", "label": "Derivative, Term of Contract", "documentation": "Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_DerivativesFairValueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativesFairValueLineItems", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsFairValueofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivatives, Fair Value [Line Items]", "label": "Derivatives, Fair Value [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "zts_DermatologyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "DermatologyMember", "presentation": [ "http://www.zoetis.com/role/RevenueRevenuebyProductDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dermatology", "label": "Dermatology [Member]", "documentation": "Dermatology" } } }, "auth_ref": [] }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DesignatedAsHedgingInstrumentMember", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsCreditFacilitiesDetails", "http://www.zoetis.com/role/FinancialInstrumentsCrosscurrencyforwardexchangecontractsDetails", "http://www.zoetis.com/role/FinancialInstrumentsCrosscurrencyinterestrateswapcontractsDetails", "http://www.zoetis.com/role/FinancialInstrumentsDerivativeNotionalAmountsDetails", "http://www.zoetis.com/role/FinancialInstrumentsFairValueofDerivativeInstrumentsDetails", "http://www.zoetis.com/role/FinancialInstrumentsForeignExchangeRiskDetails", "http://www.zoetis.com/role/FinancialInstrumentsInterestRateRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivatives Designated as Hedging Instruments:", "label": "Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": [ "r25" ] }, "us-gaap_DevelopedTechnologyRightsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DevelopedTechnologyRightsMember", "presentation": [ "http://www.zoetis.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Developed technology rights", "label": "Developed Technology Rights [Member]", "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property." } } }, "auth_ref": [ "r169", "r1045", "r1047", "r1048", "r1049", "r1051", "r1052", "r1054", "r1055" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.zoetis.com/role/ShareBasedPayments" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Payments", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r482", "r486", "r515", "r516", "r517", "r864" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement [Abstract]", "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupClassificationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupClassificationAxis", "presentation": [ "http://www.zoetis.com/role/AcquisitionsandDivestituresScheduleofAssetsHeldforSaleDetails", "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED", "http://www.zoetis.com/role/OtherIncomeDeductionsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Classification [Axis]", "label": "Disposal Group Classification [Axis]", "documentation": "Information by disposal group classification." } } }, "auth_ref": [ "r241" ] }, "us-gaap_DisposalGroupClassificationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupClassificationDomain", "presentation": [ "http://www.zoetis.com/role/AcquisitionsandDivestituresScheduleofAssetsHeldforSaleDetails", "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED", "http://www.zoetis.com/role/OtherIncomeDeductionsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Classification [Domain]", "label": "Disposal Group Classification [Domain]", "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupHeldforsaleNotDiscontinuedOperationsMember", "presentation": [ "http://www.zoetis.com/role/AcquisitionsandDivestituresScheduleofAssetsHeldforSaleDetails", "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED", "http://www.zoetis.com/role/OtherIncomeDeductionsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group, Held-for-Sale, Not Discontinued Operations", "label": "Disposal Group, Held-for-Sale, Not Discontinued Operations [Member]", "documentation": "Disposal group that is classified as held-for-sale. Excludes disposals classified as discontinued operations." } } }, "auth_ref": [ "r11", "r26", "r241" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet", "crdr": "debit", "calculation": { "http://www.zoetis.com/role/AcquisitionsandDivestituresScheduleofAssetsHeldforSaleDetails": { "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.zoetis.com/role/AcquisitionsandDivestituresScheduleofAssetsHeldforSaleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, less allowance for doubtful accounts", "label": "Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net", "documentation": "Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r3", "r97", "r103", "r157" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.zoetis.com/role/AcquisitionsandDivestituresScheduleofAssetsHeldforSaleDetails": { "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.zoetis.com/role/AcquisitionsandDivestituresScheduleofAssetsHeldforSaleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Disposal Group, Including Discontinued Operation, Accounts Payable, Current", "documentation": "Amount classified as accounts payable attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r3", "r97", "r103", "r156", "r157" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.zoetis.com/role/AcquisitionsandDivestituresScheduleofAssetsHeldforSaleDetails": { "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.zoetis.com/role/AcquisitionsandDivestituresScheduleofAssetsHeldforSaleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses", "label": "Disposal Group, Including Discontinued Operation, Accrued Liabilities, Current", "documentation": "Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r3", "r97", "r103", "r156", "r157" ] }, "zts_DisposalGroupIncludingDiscontinuedOperationAssetAdjustmentGainLossOnAssetsHeldForSale": { "xbrltype": "monetaryItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "DisposalGroupIncludingDiscontinuedOperationAssetAdjustmentGainLossOnAssetsHeldForSale", "crdr": "debit", "calculation": { "http://www.zoetis.com/role/AcquisitionsandDivestituresScheduleofAssetsHeldforSaleDetails": { "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.zoetis.com/role/AcquisitionsandDivestituresScheduleofAssetsHeldforSaleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss on assets held for sale", "label": "Disposal Group, Including Discontinued Operation, Asset Adjustment, Gain (Loss) On Assets Held For Sale", "documentation": "Disposal Group, Including Discontinued Operation, Asset Adjustment, Gain (Loss) On Assets Held For Sale" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration", "crdr": "debit", "presentation": [ "http://www.zoetis.com/role/AcquisitionsandDivestituresDivesturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Products and assets to sell agreement amount", "label": "Disposal Group, Including Discontinued Operation, Consideration", "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets", "crdr": "debit", "calculation": { "http://www.zoetis.com/role/AcquisitionsandDivestituresScheduleofAssetsHeldforSaleDetails": { "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.zoetis.com/role/AcquisitionsandDivestituresScheduleofAssetsHeldforSaleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Noncurrent deferred tax assets", "label": "Disposal Group, Including Discontinued Operation, Deferred Tax Assets", "documentation": "Amount classified as deferred tax assets attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r3", "r97", "r103", "r157" ] }, "zts_DisposalGroupIncludingDiscontinuedOperationEmployeeRelatedCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "DisposalGroupIncludingDiscontinuedOperationEmployeeRelatedCurrent", "crdr": "credit", "calculation": { "http://www.zoetis.com/role/AcquisitionsandDivestituresScheduleofAssetsHeldforSaleDetails": { "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.zoetis.com/role/AcquisitionsandDivestituresScheduleofAssetsHeldforSaleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued compensation and related items", "label": "Disposal Group, Including Discontinued Operation,Employee Related, Current", "documentation": "Disposal Group, Including Discontinued Operation,Employee Related, Current" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent", "crdr": "debit", "calculation": { "http://www.zoetis.com/role/AcquisitionsandDivestituresScheduleofAssetsHeldforSaleDetails": { "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.zoetis.com/role/AcquisitionsandDivestituresScheduleofAssetsHeldforSaleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "label": "Disposal Group, Including Discontinued Operation, Goodwill, Noncurrent", "documentation": "Amount classified as goodwill attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r3", "r9", "r97", "r103", "r157" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.zoetis.com/role/AcquisitionsandDivestituresScheduleofAssetsHeldforSaleDetails": { "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.zoetis.com/role/AcquisitionsandDivestituresScheduleofAssetsHeldforSaleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Identifiable intangible assets, less accumulated amortization", "label": "Disposal Group, Including Discontinued Operation, Intangible Assets, Noncurrent", "documentation": "Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r3", "r9", "r97", "r103", "r157" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationInventoryCurrent", "crdr": "debit", "calculation": { "http://www.zoetis.com/role/AcquisitionsandDivestituresScheduleofAssetsHeldforSaleDetails": { "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.zoetis.com/role/AcquisitionsandDivestituresScheduleofAssetsHeldforSaleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "label": "Disposal Group, Including Discontinued Operation, Inventory, Current", "documentation": "Amount classified as inventory attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r3", "r97", "r103", "r156", "r157" ] }, "zts_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssetNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssetNoncurrent", "crdr": "debit", "calculation": { "http://www.zoetis.com/role/AcquisitionsandDivestituresScheduleofAssetsHeldforSaleDetails": { "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.zoetis.com/role/AcquisitionsandDivestituresScheduleofAssetsHeldforSaleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of-use assets", "label": "Disposal Group, Including Discontinued Operation, Operating Lease, Right-Of-Use Asset, Noncurrent", "documentation": "Disposal Group, Including Discontinued Operation, Operating Lease, Right-Of-Use Asset, Noncurrent" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets", "crdr": "debit", "calculation": { "http://www.zoetis.com/role/AcquisitionsandDivestituresScheduleofAssetsHeldforSaleDetails": { "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.zoetis.com/role/AcquisitionsandDivestituresScheduleofAssetsHeldforSaleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other current assets", "label": "Disposal Group, Including Discontinued Operation, Other Assets, Current", "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r3", "r97", "r103", "r156", "r157" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets", "crdr": "debit", "calculation": { "http://www.zoetis.com/role/AcquisitionsandDivestituresScheduleofAssetsHeldforSaleDetails": { "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.zoetis.com/role/AcquisitionsandDivestituresScheduleofAssetsHeldforSaleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other noncurrent assets", "label": "Disposal Group, Including Discontinued Operation, Other Assets, Noncurrent", "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r3", "r9", "r97", "r103", "r157" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities", "crdr": "credit", "calculation": { "http://www.zoetis.com/role/AcquisitionsandDivestituresScheduleofAssetsHeldforSaleDetails": { "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.zoetis.com/role/AcquisitionsandDivestituresScheduleofAssetsHeldforSaleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other noncurrent liabilities", "label": "Disposal Group, Including Discontinued Operation, Other Liabilities, Noncurrent", "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r3", "r9", "r97", "r103", "r157" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent", "crdr": "debit", "calculation": { "http://www.zoetis.com/role/AcquisitionsandDivestituresScheduleofAssetsHeldforSaleDetails": { "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.zoetis.com/role/AcquisitionsandDivestituresScheduleofAssetsHeldforSaleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment, less accumulated depreciation", "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Noncurrent", "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r3", "r9", "r97", "r103", "r157" ] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "presentation": [ "http://www.zoetis.com/role/AcquisitionsandDivestituresDivesturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Name [Domain]", "label": "Disposal Group Name [Domain]", "documentation": "Name of disposal group." } } }, "auth_ref": [ "r861", "r862" ] }, "us-gaap_DividendsCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsCommonStock", "crdr": "debit", "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Dividends, Common Stock", "label": "Dividends, Common Stock", "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK)." } } }, "auth_ref": [ "r13", "r167" ] }, "us-gaap_DividendsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsPayableCurrent", "crdr": "credit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends payable", "label": "Dividends Payable, Current", "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r111" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.zoetis.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.zoetis.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.zoetis.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.zoetis.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r910" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://www.zoetis.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r942" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://www.zoetis.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "zts_DogsAndCatsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "DogsAndCatsMember", "presentation": [ "http://www.zoetis.com/role/RevenueRevenuebySpeciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dogs and Cats", "label": "Dogs and Cats [Member]", "documentation": "Dogs and Cats [Member]" } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year", "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]" } } }, "auth_ref": [ "r953" ] }, "country_ES": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "ES", "presentation": [ "http://www.zoetis.com/role/RevenueRevenuebyGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Spain", "label": "SPAIN" } } }, "auth_ref": [] }, "currency_EUR": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2024", "localname": "EUR", "presentation": [ "http://www.zoetis.com/role/SegmentInformationSelectedStatementofIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Euro Member Countries, Euro", "label": "Euro Member Countries, Euro" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share [Abstract]", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED", "http://www.zoetis.com/role/EarningsperShareDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Basic (in dollars per share)", "terseLabel": "Earnings per share attributable to Zoetis stockholders\u2014basic (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r281", "r299", "r300", "r301", "r302", "r303", "r304", "r309", "r311", "r314", "r315", "r316", "r320", "r546", "r551", "r573", "r574", "r656", "r677", "r832" ] }, "us-gaap_EarningsPerShareBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasicAbstract", "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED", "http://www.zoetis.com/role/EarningsperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings per share attributable to Zoetis Inc. stockholders:", "verboseLabel": "Numerator", "label": "Earnings Per Share, Basic [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED", "http://www.zoetis.com/role/EarningsperShareDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Diluted (in dollars per share)", "terseLabel": "Earnings per share attributable to Zoetis stockholders\u2014diluted (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r281", "r299", "r300", "r301", "r302", "r303", "r304", "r311", "r314", "r315", "r316", "r320", "r546", "r551", "r573", "r574", "r656", "r677", "r832" ] }, "us-gaap_EarningsPerShareDilutedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDilutedAbstract", "presentation": [ "http://www.zoetis.com/role/EarningsperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Denominator", "label": "Earnings Per Share, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.zoetis.com/role/EarningsperShare" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings per Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r308", "r317", "r318", "r319" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of exchange-rate changes on cash and cash equivalents", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r589" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": [ "http://www.zoetis.com/role/IncomeTaxesTaxesonIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective tax rate for income from continuing operations", "label": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r525", "r867" ] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued compensation and related items", "label": "Employee-related Liabilities, Current", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r111" ] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount", "crdr": "debit", "presentation": [ "http://www.zoetis.com/role/ShareBasedPaymentsComponentsofShareBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation expense capitalized to inventory, less than", "label": "Share-Based Payment Arrangement, Amount Capitalized", "documentation": "Amount of cost capitalized for award under share-based payment arrangement." } } }, "auth_ref": [ "r514" ] }, "us-gaap_EmployeeSeveranceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeSeveranceMember", "presentation": [ "http://www.zoetis.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandDivestituresDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Employee Termination Costs", "label": "Employee Severance [Member]", "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.zoetis.com/role/ShareBasedPaymentsComponentsofShareBasedCompensationExpenseDetails", "http://www.zoetis.com/role/ShareBasedPaymentsNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock options / stock appreciation rights", "verboseLabel": "Stock options", "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.zoetis.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.zoetis.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.zoetis.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.zoetis.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.zoetis.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r908" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.zoetis.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.zoetis.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": [ "http://www.zoetis.com/role/ShareBasedPaymentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Entity [Domain]", "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.zoetis.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r908" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://www.zoetis.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://www.zoetis.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r908" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.zoetis.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.zoetis.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r992" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://www.zoetis.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r908" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://www.zoetis.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r908" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://www.zoetis.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r908" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.zoetis.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r908" ] }, "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems", "presentation": [ "http://www.zoetis.com/role/RevenueRevenuebyGeographicAreaDetails", "http://www.zoetis.com/role/RevenueRevenuebyMajorSpeciesDetails", "http://www.zoetis.com/role/RevenueRevenuebyProductDetails", "http://www.zoetis.com/role/RevenueRevenuebySpeciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue from External Customer [Line Items]", "label": "Revenue from External Customer [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Footnote", "label": "Equity Awards Adjustments, Footnote [Text Block]" } } }, "auth_ref": [ "r947" ] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table", "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]" } } }, "auth_ref": [ "r988" ] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments", "label": "Equity Awards Adjustments [Member]" } } }, "auth_ref": [ "r988" ] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table", "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]" } } }, "auth_ref": [ "r988" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Equity [Abstract]", "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED", "http://www.zoetis.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r24", "r238", "r273", "r274", "r275", "r294", "r295", "r296", "r298", "r303", "r305", "r307", "r322", "r371", "r372", "r403", "r469", "r536", "r537", "r543", "r544", "r545", "r547", "r550", "r551", "r564", "r565", "r566", "r567", "r568", "r569", "r572", "r590", "r592", "r593", "r594", "r595", "r596", "r599", "r601", "r609", "r673", "r699", "r700", "r701", "r717", "r782" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r957" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r915", "r925", "r935", "r967" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r912", "r922", "r932", "r964" ] }, "zts_ExciseTaxAccruedOnNetShareRepurchasedNotPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "ExciseTaxAccruedOnNetShareRepurchasedNotPaid", "crdr": "credit", "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Excise tax accrued on net share repurchases, not paid", "label": "Excise Tax Accrued on Net Share Repurchased, Not Paid", "documentation": "Excise Tax Accrued on Net Share Repurchased, Not Paid" } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r963" ] }, "country_FR": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "FR", "presentation": [ "http://www.zoetis.com/role/RevenueRevenuebyGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "France", "label": "FRANCE" } } }, "auth_ref": [] }, "us-gaap_FacilityClosingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FacilityClosingMember", "presentation": [ "http://www.zoetis.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandDivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Facility Closing", "label": "Facility Closing [Member]", "documentation": "Closing of a facility associated with exit from or disposal of business activities or restructurings pursuant to a plan." } } }, "auth_ref": [] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsFairValueofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r443", "r475", "r476", "r477", "r478", "r479", "r480", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r612", "r613", "r614", "r851", "r852", "r858", "r859", "r860", "r870", "r872" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsFairValueofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Inputs, Level 2", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r443", "r475", "r480", "r576", "r577", "r581", "r613", "r851", "r852", "r858", "r859", "r860", "r870" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsFairValueofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r443", "r475", "r476", "r477", "r478", "r479", "r480", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r612", "r613", "r614", "r851", "r852", "r858", "r859", "r860", "r870", "r872" ] }, "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsFairValueofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]", "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]", "documentation": "Disclosure of information about location and fair value of derivative instrument and nonderivative instrument designated as hedging instrument." } } }, "auth_ref": [ "r82", "r84", "r93" ] }, "us-gaap_FinanceLeasePrincipalPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeasePrincipalPayments", "crdr": "credit", "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Financing cash flows - finance leases", "label": "Finance Lease, Principal Payments", "documentation": "Amount of cash outflow for principal payment on finance lease." } } }, "auth_ref": [ "r604", "r606" ] }, "zts_FinancialInstrumentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "FinancialInstrumentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments [Abstract]", "label": "Financial Instruments [Abstract]", "documentation": "Financial Instruments [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FinancialInstrumentsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentsDisclosureTextBlock", "presentation": [ "http://www.zoetis.com/role/FinancialInstruments" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments", "label": "Financial Instruments Disclosure [Text Block]", "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures." } } }, "auth_ref": [] }, "zts_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://www.zoetis.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Finite Lived and Indefinite Lived Intangible Assets [Line Items]", "label": "Finite Lived And Indefinite Lived Intangible Assets [Line Items]", "documentation": "Finite Lived and Indefinite Lived Intangible Assets [Line Items]" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "calculation": { "http://www.zoetis.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.zoetis.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Finite-lived intangible assets, accumulated amortization", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r248", "r376", "r396", "r848" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.zoetis.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r389", "r391", "r392", "r393", "r395", "r396", "r399", "r400", "r619", "r620", "r823" ] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "calculation": { "http://www.zoetis.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.zoetis.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-lived intangible assets, gross carrying amount", "label": "Finite-Lived Intangible Assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r376", "r396", "r620", "r848" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.zoetis.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r389", "r391", "r392", "r393", "r395", "r396", "r399", "r400", "r823" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.zoetis.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.zoetis.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Finite-lived intangible assets, identifiable intangible assets, less accumulated amortization", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r619", "r1052" ] }, "zts_FishMember": { "xbrltype": "domainItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "FishMember", "presentation": [ "http://www.zoetis.com/role/RevenueRevenuebySpeciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fish", "label": "Fish [Member]", "documentation": "Fish [Member]" } } }, "auth_ref": [] }, "us-gaap_ForeignCurrencyFairValueHedgeDerivativeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyFairValueHedgeDerivativeLineItems", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsCrosscurrencyforwardexchangecontractsDetails", "http://www.zoetis.com/role/FinancialInstrumentsCrosscurrencyinterestrateswapcontractsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Currency Fair Value Hedge Derivative [Line Items]", "label": "Foreign Currency Fair Value Hedge Derivative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ForeignCurrencyFairValueHedgeDerivativeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyFairValueHedgeDerivativeTable", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsCrosscurrencyforwardexchangecontractsDetails", "http://www.zoetis.com/role/FinancialInstrumentsCrosscurrencyinterestrateswapcontractsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Currency Fair Value Hedge Derivative [Table]", "label": "Foreign Currency Fair Value Hedge Derivative [Table]", "documentation": "Disclosure of information about derivative instruments designated as foreign currency fair value hedging instruments." } } }, "auth_ref": [] }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "crdr": "credit", "calculation": { "http://www.zoetis.com/role/OtherIncomeDeductionsNetDetails": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.zoetis.com/role/OtherIncomeDeductionsNetDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Foreign currency loss", "label": "Gain (Loss), Foreign Currency Transaction, before Tax", "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": [ "r585", "r586", "r587", "r588", "r779" ] }, "us-gaap_ForeignExchangeForwardMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignExchangeForwardMember", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsDerivativeNotionalAmountsDetails", "http://www.zoetis.com/role/FinancialInstrumentsFairValueofDerivativeInstrumentsDetails", "http://www.zoetis.com/role/FinancialInstrumentsForeignExchangeRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency forward-exchange contracts", "verboseLabel": "Foreign currency forward-exchange contracts", "label": "Foreign Exchange Forward [Member]", "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate." } } }, "auth_ref": [ "r749", "r753", "r758", "r771", "r777", "r796", "r797", "r798", "r896" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r919", "r929", "r939", "r971" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r919", "r929", "r939", "r971" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r919", "r929", "r939", "r971" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r919", "r929", "r939", "r971" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r919", "r929", "r939", "r971" ] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year", "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]" } } }, "auth_ref": [ "r952" ] }, "country_GB": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "GB", "presentation": [ "http://www.zoetis.com/role/RevenueRevenuebyGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "United Kingdom", "label": "UNITED KINGDOM" } } }, "auth_ref": [] }, "us-gaap_GainLossOnComponentsExcludedFromAssessmentOfInterestRateFairValueHedgeEffectiveness": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnComponentsExcludedFromAssessmentOfInterestRateFairValueHedgeEffectiveness", "crdr": "credit", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsCrosscurrencyinterestrateswapcontractsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain (Loss) on Components Excluded from Assessment of Interest Rate Fair Value Hedge Effectiveness", "label": "Gain (Loss) on Components Excluded from Assessment of Interest Rate Fair Value Hedge Effectiveness", "documentation": "The net gain (loss) included in earnings for the period relating to components of the gain (loss) on interest rate fair value hedging instruments excluded from the assessment of fair value hedge effectiveness." } } }, "auth_ref": [ "r177" ] }, "zts_GainLossOnDispositionOfAssetGoodwillAllocation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "GainLossOnDispositionOfAssetGoodwillAllocation", "crdr": "credit", "presentation": [ "http://www.zoetis.com/role/AcquisitionsandDivestituresScheduleofAssetsHeldforSaleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss on assets held for sale, goodwill allocation", "label": "Gain (Loss) On Disposition Of Asset, Goodwill Allocation", "documentation": "Gain (Loss) On Disposition Of Asset, Goodwill Allocation" } } }, "auth_ref": [] }, "zts_GainLossOnDispositionOfAssetSellingCostsAllocation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "GainLossOnDispositionOfAssetSellingCostsAllocation", "crdr": "credit", "presentation": [ "http://www.zoetis.com/role/AcquisitionsandDivestituresScheduleofAssetsHeldforSaleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss on assets held for sale, selling costs allocation", "label": "Gain (Loss) On Disposition Of Asset, Selling Costs Allocation", "documentation": "Gain (Loss) On Disposition Of Asset, Selling Costs Allocation" } } }, "auth_ref": [] }, "us-gaap_GainLossOnDispositionOfAssets1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnDispositionOfAssets1", "crdr": "credit", "calculation": { "http://www.zoetis.com/role/OtherIncomeDeductionsNetDetails": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 }, "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 15.0 } }, "presentation": [ "http://www.zoetis.com/role/AcquisitionsandDivestituresScheduleofAssetsHeldforSaleDetails", "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED", "http://www.zoetis.com/role/OtherIncomeDeductionsNetDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Loss on assets held for sale", "terseLabel": "Loss on assets held for sale", "label": "Gain (Loss) on Disposition of Assets", "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee." } } }, "auth_ref": [ "r1010" ] }, "zts_GainLossOnDispositionOfBusinessRemeasurementOfRetainedNoncontrollingInvestment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "GainLossOnDispositionOfBusinessRemeasurementOfRetainedNoncontrollingInvestment", "crdr": "debit", "presentation": [ "http://www.zoetis.com/role/AcquisitionsandDivestituresDivesturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remeasurement of retained noncontrolling investment to fair value", "label": "Gain (Loss) On Disposition Of Business, Remeasurement Of Retained Noncontrolling Investment", "documentation": "Gain (Loss) On Disposition Of Business, Remeasurement Of Retained Noncontrolling Investment" } } }, "auth_ref": [] }, "us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments", "crdr": "credit", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsFairValueofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency forward-exchange contracts", "label": "Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments", "documentation": "Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments." } } }, "auth_ref": [ "r83", "r87" ] }, "us-gaap_GainLossOnSaleOfBusiness": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnSaleOfBusiness", "crdr": "credit", "calculation": { "http://www.zoetis.com/role/OtherIncomeDeductionsNetDetails": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.zoetis.com/role/AcquisitionsandDivestituresDivesturesDetails", "http://www.zoetis.com/role/OtherIncomeDeductionsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net gain on sale of business", "negatedTerseLabel": "Net gain on sale of business", "label": "Gain (Loss) on Disposition of Business", "documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant." } } }, "auth_ref": [ "r558", "r1010" ] }, "zts_GainOnSaleOfBusinessExcludingTransactionCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "GainOnSaleOfBusinessExcludingTransactionCosts", "crdr": "credit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Net gain on sale of businesses, excluding transaction costs", "label": "Gain on sale of business, excluding transaction costs", "documentation": "Gain on sale of business, excluding transaction costs" } } }, "auth_ref": [] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED", "http://www.zoetis.com/role/GoodwillandOtherIntangibleAssetsGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "periodStartLabel": "Beginning Balance", "periodEndLabel": "Ending Balance", "label": "Goodwill", "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r247", "r377", "r651", "r841", "r847", "r871", "r878", "r1034", "r1041" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]", "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "presentation": [ "http://www.zoetis.com/role/GoodwillandOtherIntangibleAssets" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Other Intangible Assets", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for goodwill and intangible assets." } } }, "auth_ref": [ "r1032", "r1044" ] }, "us-gaap_GoodwillGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillGross", "crdr": "debit", "presentation": [ "http://www.zoetis.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Gross goodwill", "label": "Goodwill, Gross", "documentation": "Amount, before accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r379", "r386", "r847" ] }, "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillImpairedAccumulatedImpairmentLoss", "crdr": "credit", "presentation": [ "http://www.zoetis.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated goodwill impairment losses", "label": "Goodwill, Impaired, Accumulated Impairment Loss", "documentation": "Amount of accumulated impairment loss for asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r379", "r386", "r847" ] }, "us-gaap_GoodwillLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillLineItems", "presentation": [ "http://www.zoetis.com/role/GoodwillandOtherIntangibleAssetsGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Line Items]", "label": "Goodwill [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r847" ] }, "us-gaap_GoodwillOtherIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillOtherIncreaseDecrease", "crdr": "debit", "presentation": [ "http://www.zoetis.com/role/GoodwillandOtherIntangibleAssetsGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Goodwill, Other Increase (Decrease)", "documentation": "Amount of increase (decrease) of asset representing future economic benefit from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized, classified as other." } } }, "auth_ref": [ "r385" ] }, "us-gaap_GoodwillRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillRollForward", "presentation": [ "http://www.zoetis.com/role/GoodwillandOtherIntangibleAssetsGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Roll Forward]", "label": "Goodwill [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_GoodwillTransfers": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillTransfers", "crdr": "debit", "presentation": [ "http://www.zoetis.com/role/GoodwillandOtherIntangibleAssetsGoodwillDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Reclassification of goodwill to assets held for sale", "label": "Goodwill, Transfers", "documentation": "Amount of increase (decrease) from transfer into (out of) asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r1040" ] }, "zts_GrossMargin": { "xbrltype": "percentItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "GrossMargin", "presentation": [ "http://www.zoetis.com/role/SegmentInformationSelectedStatementofIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross margin, percentage", "label": "Gross Margin", "documentation": "Gross Margin" } } }, "auth_ref": [] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://www.zoetis.com/role/SegmentInformationSelectedStatementofIncomeDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.zoetis.com/role/SegmentInformationSelectedStatementofIncomeDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Gross profit", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r134", "r138", "r190", "r291", "r370", "r424", "r425", "r427", "r428", "r429", "r430", "r431", "r433", "r434", "r584", "r834", "r840", "r1023", "r1025", "r1027", "r1028", "r1029", "r1072" ] }, "us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GuaranteesIndemnificationsAndWarrantiesPolicies", "presentation": [ "http://www.zoetis.com/role/AccountingStandardsPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Guarantees and Indemnifications", "label": "Guarantees, Indemnifications and Warranties Policies [Policy Text Block]", "documentation": "Disclosure of accounting policy for guarantees, indemnifications and product warranties, and methodologies used in determining the amount of such liabilities." } } }, "auth_ref": [ "r421" ] }, "us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease", "crdr": "credit", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cumulative fair value adjustment for interest rate swap contracts", "label": "Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease)", "documentation": "Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk." } } }, "auth_ref": [ "r563" ] }, "us-gaap_HedgingDesignationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgingDesignationAxis", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsCreditFacilitiesDetails", "http://www.zoetis.com/role/FinancialInstrumentsCrosscurrencyforwardexchangecontractsDetails", "http://www.zoetis.com/role/FinancialInstrumentsCrosscurrencyinterestrateswapcontractsDetails", "http://www.zoetis.com/role/FinancialInstrumentsDerivativeNotionalAmountsDetails", "http://www.zoetis.com/role/FinancialInstrumentsFairValueofDerivativeInstrumentsDetails", "http://www.zoetis.com/role/FinancialInstrumentsForeignExchangeRiskDetails", "http://www.zoetis.com/role/FinancialInstrumentsInterestRateRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation [Axis]", "label": "Hedging Designation [Axis]", "documentation": "Information by designation of purpose of derivative instrument." } } }, "auth_ref": [ "r25", "r562" ] }, "us-gaap_HedgingDesignationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgingDesignationDomain", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsCreditFacilitiesDetails", "http://www.zoetis.com/role/FinancialInstrumentsCrosscurrencyforwardexchangecontractsDetails", "http://www.zoetis.com/role/FinancialInstrumentsCrosscurrencyinterestrateswapcontractsDetails", "http://www.zoetis.com/role/FinancialInstrumentsDerivativeNotionalAmountsDetails", "http://www.zoetis.com/role/FinancialInstrumentsFairValueofDerivativeInstrumentsDetails", "http://www.zoetis.com/role/FinancialInstrumentsForeignExchangeRiskDetails", "http://www.zoetis.com/role/FinancialInstrumentsInterestRateRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation [Domain]", "label": "Hedging Designation [Domain]", "documentation": "Designation of purpose of derivative instrument." } } }, "auth_ref": [ "r25" ] }, "zts_HorsesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "HorsesMember", "presentation": [ "http://www.zoetis.com/role/RevenueRevenuebySpeciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Horses", "label": "Horses [Member]", "documentation": "Horses [Member]" } } }, "auth_ref": [] }, "country_IT": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "IT", "presentation": [ "http://www.zoetis.com/role/RevenueRevenuebyGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Italy", "label": "ITALY" } } }, "auth_ref": [] }, "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.zoetis.com/role/OtherIncomeDeductionsNetDetails": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.zoetis.com/role/OtherIncomeDeductionsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Identifiable intangible asset impairment charges(b)", "label": "Impairment of Intangible Assets (Excluding Goodwill)", "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value." } } }, "auth_ref": [ "r16", "r390", "r401" ] }, "us-gaap_InProcessResearchAndDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InProcessResearchAndDevelopmentMember", "presentation": [ "http://www.zoetis.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "In-process research and development", "label": "In Process Research and Development [Member]", "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process." } } }, "auth_ref": [ "r1045", "r1047", "r1048", "r1049", "r1050", "r1051", "r1052", "r1053", "r1054", "r1055" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 1.0 }, "http://www.zoetis.com/role/SegmentInformationSelectedStatementofIncomeDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED", "http://www.zoetis.com/role/SegmentInformationSelectedStatementofIncomeDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Income before provision for taxes on income", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r135", "r186", "r190", "r657", "r669", "r834", "r840", "r1023", "r1025", "r1027", "r1028", "r1029" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "presentation": [ "http://www.zoetis.com/role/AcquisitionsandDivestituresDivesturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Name [Axis]", "label": "Disposal Group Name [Axis]", "documentation": "Information by name of disposal group." } } }, "auth_ref": [ "r861", "r862" ] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "presentation": [ "http://www.zoetis.com/role/AcquisitionsandDivestituresDivesturesDetails", "http://www.zoetis.com/role/AcquisitionsandDivestituresScheduleofAssetsHeldforSaleDetails", "http://www.zoetis.com/role/OtherIncomeDeductionsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "presentation": [ "http://www.zoetis.com/role/AcquisitionsandDivestituresDivesturesDetails", "http://www.zoetis.com/role/AcquisitionsandDivestituresScheduleofAssetsHeldforSaleDetails", "http://www.zoetis.com/role/OtherIncomeDeductionsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]", "label": "Disposal Groups, Including Discontinued Operations [Table]", "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r19", "r26", "r31", "r97", "r98", "r99", "r100", "r101", "r102", "r104", "r105", "r106", "r158" ] }, "us-gaap_IncomeTaxAuthorityNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityNameAxis", "presentation": [ "http://www.zoetis.com/role/IncomeTaxesTaxContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Authority, Name [Axis]", "label": "Income Tax Authority, Name [Axis]", "documentation": "Information by name of taxing authority." } } }, "auth_ref": [ "r530", "r1085" ] }, "us-gaap_IncomeTaxAuthorityNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityNameDomain", "presentation": [ "http://www.zoetis.com/role/IncomeTaxesTaxContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Authority, Name [Domain]", "label": "Income Tax Authority, Name [Domain]", "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes." } } }, "auth_ref": [ "r530", "r1085" ] }, "us-gaap_IncomeTaxContingencyLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxContingencyLineItems", "presentation": [ "http://www.zoetis.com/role/IncomeTaxesTaxContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Contingency [Line Items]", "label": "Income Tax Contingency [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxContingencyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxContingencyTable", "presentation": [ "http://www.zoetis.com/role/IncomeTaxesTaxContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Contingency [Table]", "label": "Income Tax Contingency [Table]", "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months." } } }, "auth_ref": [ "r1082" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.zoetis.com/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": [ "r292", "r520", "r525", "r526", "r527", "r528", "r532", "r533", "r538", "r540", "r541", "r542", "r714", "r867" ] }, "us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExaminationEstimateOfPossibleLoss", "crdr": "debit", "presentation": [ "http://www.zoetis.com/role/IncomeTaxesDeferredTaxesDetails", "http://www.zoetis.com/role/IncomeTaxesTaxContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated additional tax liability", "label": "Income Tax Examination, Estimate of Possible Loss", "documentation": "Estimated amount of loss resulting from an adverse tax position." } } }, "auth_ref": [ "r1083" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "parentTag": "us-gaap_ProfitLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Provision for taxes on income", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r194", "r197", "r306", "r307", "r321", "r337", "r359", "r524", "r525", "r539", "r678", "r867" ] }, "us-gaap_IncomeTaxUncertaintiesPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxUncertaintiesPolicy", "presentation": [ "http://www.zoetis.com/role/AccountingStandardsPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Contingencies", "label": "Income Tax Uncertainties, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for tax positions taken in the tax return filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other types of contingencies related to income taxes." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Income taxes", "label": "Income Taxes Paid, Net", "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } }, "auth_ref": [ "r39", "r287", "r534", "r535" ] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r15" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accounts receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r15" ] }, "us-gaap_IncreaseDecreaseInAccruedTaxesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedTaxesPayable", "crdr": "debit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Other tax accounts, net", "label": "Increase (Decrease) in Accrued Taxes Payable", "documentation": "The increase (decrease) during the reporting period of all taxes owed but not paid, including income, property and other taxes." } } }, "auth_ref": [ "r1009" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 13.0 } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Inventories", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r15" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Other changes in assets and liabilities, net of acquisitions and divestitures:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherOperatingAssets", "crdr": "credit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 14.0 } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other assets", "label": "Increase (Decrease) in Other Operating Assets", "documentation": "Amount of increase (decrease) in operating assets classified as other." } } }, "auth_ref": [ "r15" ] }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "crdr": "debit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Other liabilities", "label": "Increase (Decrease) in Other Operating Liabilities", "documentation": "Amount of increase (decrease) in operating liabilities classified as other." } } }, "auth_ref": [ "r15" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.zoetis.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets [Axis]", "label": "Indefinite-Lived Intangible Assets [Axis]", "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": [ "r389", "r394", "r398", "r848" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "crdr": "debit", "presentation": [ "http://www.zoetis.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total indefinite-lived intangible assets", "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)", "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": [ "r376", "r398", "r848" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.zoetis.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company." } } }, "auth_ref": [ "r389", "r394", "r398", "r848" ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r919", "r929", "r939", "r963", "r971", "r975", "r983" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r981" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r911", "r987" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r911", "r987" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r911", "r987" ] }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsGrossExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.zoetis.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails": { "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.zoetis.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible Assets, gross carrying amount", "label": "Intangible Assets, Gross (Excluding Goodwill)", "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill." } } }, "auth_ref": [ "r247" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 }, "http://www.zoetis.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED", "http://www.zoetis.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Identifiable intangible assets, less accumulated amortization", "totalLabel": "Identifiable intangible assets, less accumulated amortization", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r389", "r1052", "r1053" ] }, "us-gaap_InterestCostsCapitalized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestCostsCapitalized", "crdr": "debit", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsLongtermDebtMaturityDetails", "http://www.zoetis.com/role/FinancialInstrumentsScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capitalized interest", "label": "Interest Costs Capitalized", "documentation": "Amount of interest capitalized during the period." } } }, "auth_ref": [ "r598" ] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED", "http://www.zoetis.com/role/FinancialInstrumentsLongtermDebtMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense, net of capitalized interest", "label": "Interest Expense, Operating and Nonoperating", "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense." } } }, "auth_ref": [ "r321", "r329", "r333", "r339", "r359", "r597", "r840", "r841" ] }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestIncomeExpenseNonoperatingNet", "crdr": "credit", "calculation": { "http://www.zoetis.com/role/OtherIncomeDeductionsNetDetails": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.zoetis.com/role/OtherIncomeDeductionsNetDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Interest income", "label": "Interest Income (Expense), Nonoperating", "documentation": "Amount of interest income (expense) classified as nonoperating." } } }, "auth_ref": [ "r840", "r1007", "r1025" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Interest, net of capitalized interest", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r282", "r285", "r286" ] }, "us-gaap_InterestRateSwapMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestRateSwapMember", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsDerivativeNotionalAmountsDetails", "http://www.zoetis.com/role/FinancialInstrumentsInterestRateRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forward-starting interest rate swaps", "label": "Interest Rate Swap [Member]", "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period." } } }, "auth_ref": [ "r824", "r901", "r902" ] }, "us-gaap_InternalRevenueServiceIRSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InternalRevenueServiceIRSMember", "presentation": [ "http://www.zoetis.com/role/IncomeTaxesTaxContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Internal Revenue Service (IRS)", "label": "Internal Revenue Service (IRS) [Member]", "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity." } } }, "auth_ref": [] }, "zts_InternationalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "InternationalMember", "presentation": [ "http://www.zoetis.com/role/GoodwillandOtherIntangibleAssetsGoodwillDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "International", "label": "International [Member]", "documentation": "International [Member]" } } }, "auth_ref": [] }, "zts_InternationalSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "InternationalSegmentMember", "presentation": [ "http://www.zoetis.com/role/RevenueRevenuebyMajorSpeciesDetails", "http://www.zoetis.com/role/SegmentInformationSelectedStatementofIncomeDetails", "http://www.zoetis.com/role/SegmentInformationSelectedStatementofIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "International", "label": "International Segment [Member]", "documentation": "International Segment [Member]" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Inventory Disclosure [Abstract]", "label": "Inventory Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureTextBlock", "presentation": [ "http://www.zoetis.com/role/Inventories" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "label": "Inventory Disclosure [Text Block]", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": [ "r374" ] }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryFinishedGoodsNetOfReserves", "crdr": "debit", "calculation": { "http://www.zoetis.com/role/InventoriesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.zoetis.com/role/InventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finished goods", "label": "Inventory, Finished Goods, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale." } } }, "auth_ref": [ "r155", "r829" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 }, "http://www.zoetis.com/role/InventoriesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED", "http://www.zoetis.com/role/InventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "totalLabel": "Inventories", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r257", "r828", "r878" ] }, "us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryRawMaterialsAndSuppliesNetOfReserves", "crdr": "debit", "calculation": { "http://www.zoetis.com/role/InventoriesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.zoetis.com/role/InventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Raw materials and supplies", "label": "Inventory, Raw Materials and Supplies, Net of Reserves", "documentation": "Aggregated amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. This amount is net of valuation reserves and adjustments." } } }, "auth_ref": [ "r155", "r1003" ] }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWorkInProcessNetOfReserves", "crdr": "debit", "calculation": { "http://www.zoetis.com/role/InventoriesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.zoetis.com/role/InventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Work-in-process", "label": "Inventory, Work in Process, Net of Reserves", "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing." } } }, "auth_ref": [ "r155", "r830" ] }, "us-gaap_InventoryWriteDown": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWriteDown", "crdr": "debit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Provision for losses on inventory", "label": "Inventory Write-down", "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels." } } }, "auth_ref": [ "r375" ] }, "country_JP": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "JP", "presentation": [ "http://www.zoetis.com/role/RevenueRevenuebyGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Japan", "label": "JAPAN" } } }, "auth_ref": [] }, "zts_KristinPeckMember": { "xbrltype": "domainItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "KristinPeckMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Kristin Peck [Member]", "documentation": "Kristin Peck" } } }, "auth_ref": [] }, "zts_LawsuitTemporarilySuspended": { "xbrltype": "durationItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "LawsuitTemporarilySuspended", "presentation": [ "http://www.zoetis.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Duration of suspension of lawsuit", "label": "Lawsuit Temporarily Suspended", "documentation": "The number of years lawsuit was temporarily suspended." } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": [ "http://www.zoetis.com/role/ShareBasedPaymentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legal Entity [Axis]", "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r30", "r110", "r111", "r112", "r115", "r116", "r117", "r118", "r291", "r370", "r424", "r425", "r427", "r428", "r429", "r430", "r431", "r433", "r434", "r554", "r559", "r560", "r584", "r741", "r833", "r906", "r1072", "r1111", "r1112" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r125", "r185", "r666", "r878", "r1014", "r1031", "r1104" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities and Equity", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r112", "r244", "r291", "r370", "r424", "r425", "r427", "r428", "r429", "r430", "r431", "r433", "r434", "r554", "r559", "r560", "r584", "r878", "r1072", "r1111", "r1112" ] }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "crdr": "credit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 }, "http://www.zoetis.com/role/AcquisitionsandDivestituresScheduleofAssetsHeldforSaleDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.zoetis.com/role/AcquisitionsandDivestituresScheduleofAssetsHeldforSaleDetails", "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities associated with assets held for sale", "totalLabel": "Total Liabilities Associated with Assets Held for Sale", "label": "Disposal Group, Including Discontinued Operation, Liabilities", "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r3", "r97", "r103", "r157", "r241", "r242" ] }, "us-gaap_LineOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCredit", "crdr": "credit", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsCreditFacilitiesDetails", "http://www.zoetis.com/role/FinancialInstrumentsLongtermDebtMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of credit facility", "label": "Long-Term Line of Credit", "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": [ "r30", "r182", "r1120" ] }, "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityCurrentBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsCreditFacilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revolving credit facility, current borrowing capacity", "label": "Line of Credit Facility, Current Borrowing Capacity", "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility." } } }, "auth_ref": [ "r109", "r114" ] }, "us-gaap_LineOfCreditFacilityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityLineItems", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsCreditFacilitiesDetails", "http://www.zoetis.com/role/FinancialInstrumentsLongtermDebtMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit Facility [Line Items]", "label": "Line of Credit Facility [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r423", "r1013", "r1070" ] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsCreditFacilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of credit facility, maximum borrowing capacity", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r109", "r114" ] }, "us-gaap_LineOfCreditFacilityTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityTable", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsCreditFacilitiesDetails", "http://www.zoetis.com/role/FinancialInstrumentsLongtermDebtMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit Facility [Table]", "label": "Line of Credit Facility [Table]", "documentation": "Disclosure of information about short-term and long-term contractual arrangements with lender under which borrowing can occur up to maximum amount. Includes, but is not limited to, letter of credit, standby letter of credit, and revolving credit arrangement." } } }, "auth_ref": [ "r109", "r114", "r423", "r1013", "r1070" ] }, "zts_LineOfCreditForGeneralCorporatePurposeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "LineOfCreditForGeneralCorporatePurposeMember", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsLongtermDebtMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line Of Credit For General Corporate Purpose", "label": "Line Of Credit For General Corporate Purpose [Member]", "documentation": "Line Of Credit For General Corporate Purpose" } } }, "auth_ref": [] }, "zts_LineofCreditFacilityCovenantComplianceMaximumLeverageRatio": { "xbrltype": "pureItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "LineofCreditFacilityCovenantComplianceMaximumLeverageRatio", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsCreditFacilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum total leverage ratio", "label": "Line of Credit Facility, Covenant Compliance, Maximum Leverage Ratio", "documentation": "Line of Credit Facility, Covenant Compliance, Maximum Leverage Ratio" } } }, "auth_ref": [] }, "zts_LineofCreditFacilityCovenantComplianceMaximumLeverageRatioNextTwelveMonths": { "xbrltype": "pureItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "LineofCreditFacilityCovenantComplianceMaximumLeverageRatioNextTwelveMonths", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsCreditFacilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum total leverage ratio, next 12 months", "label": "Line of Credit Facility, Covenant Compliance, Maximum Leverage Ratio, Next Twelve Months", "documentation": "Line of Credit Facility, Covenant Compliance, Maximum Leverage Ratio, Next Twelve Months" } } }, "auth_ref": [] }, "srt_LitigationCaseAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "LitigationCaseAxis", "presentation": [ "http://www.zoetis.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Case [Axis]", "label": "Litigation Case [Axis]", "documentation": "Information by type of judicial proceeding, alternative dispute resolution or claim." } } }, "auth_ref": [] }, "srt_LitigationCaseTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "LitigationCaseTypeDomain", "presentation": [ "http://www.zoetis.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Case [Domain]", "label": "Litigation Case [Domain]", "documentation": "Judicial proceeding, alternative dispute resolution or claim. For example, but not limited to, name of case, category of litigation, or other differentiating information." } } }, "auth_ref": [] }, "zts_LivestockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "LivestockMember", "presentation": [ "http://www.zoetis.com/role/RevenueRevenuebyMajorSpeciesDetails", "http://www.zoetis.com/role/RevenueRevenuebySpeciesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Livestock", "label": "Livestock [Member]", "documentation": "Livestock [Member]" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://www.zoetis.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.zoetis.com/role/FinancialInstrumentsLongtermDebtMaturityDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsLongtermDebtMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Long-Term Debt, Maturity, Year One", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r18", "r293", "r446" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "crdr": "credit", "calculation": { "http://www.zoetis.com/role/FinancialInstrumentsLongtermDebtMaturityDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsLongtermDebtMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Long-Term Debt, Maturity, Year Four", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r18", "r293", "r446" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "crdr": "credit", "calculation": { "http://www.zoetis.com/role/FinancialInstrumentsLongtermDebtMaturityDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsLongtermDebtMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Long-Term Debt, Maturity, Year Three", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r18", "r293", "r446" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "calculation": { "http://www.zoetis.com/role/FinancialInstrumentsLongtermDebtMaturityDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsLongtermDebtMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Long-Term Debt, Maturity, Year Two", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r18", "r293", "r446" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.zoetis.com/role/FinancialInstrumentsLongtermDebtMaturityDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsLongtermDebtMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year." } } }, "auth_ref": [ "r1016" ] }, "zts_LongTermDebtMaturityAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "LongTermDebtMaturityAfterYearFour", "crdr": "credit", "calculation": { "http://www.zoetis.com/role/FinancialInstrumentsLongtermDebtMaturityDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsLongtermDebtMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "After 2025", "label": "Long-Term Debt Maturity, After Year Four", "documentation": "Long-Term Debt Maturity, After Year Four" } } }, "auth_ref": [] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED", "http://www.zoetis.com/role/FinancialInstrumentsScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt, net of discount and issuance costs", "label": "Long-Term Debt, Excluding Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": [ "r251" ] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsFairValueofDebtDetails", "http://www.zoetis.com/role/FinancialInstrumentsInterestRateRiskDetails", "http://www.zoetis.com/role/FinancialInstrumentsScheduleofLongtermDebtDetails", "http://www.zoetis.com/role/FinancialInstrumentsSeniorNotesOfferingandOtherLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r30", "r1058", "r1059", "r1060" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsFairValueofDebtDetails", "http://www.zoetis.com/role/FinancialInstrumentsInterestRateRiskDetails", "http://www.zoetis.com/role/FinancialInstrumentsScheduleofLongtermDebtDetails", "http://www.zoetis.com/role/FinancialInstrumentsSeniorNotesOfferingandOtherLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r30", "r51", "r1058", "r1059", "r1060" ] }, "us-gaap_LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesLineItems", "presentation": [ "http://www.zoetis.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Line Items]", "label": "Loss Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r416", "r417", "r418", "r422", "r519", "r849", "r1066", "r1067" ] }, "us-gaap_LossContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesTable", "presentation": [ "http://www.zoetis.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Table]", "label": "Loss Contingencies [Table]", "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation." } } }, "auth_ref": [ "r416", "r417", "r418", "r422", "r519", "r849", "r1066", "r1067" ] }, "zts_LossContingencyAdditionalNumberOfDefendants": { "xbrltype": "integerItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "LossContingencyAdditionalNumberOfDefendants", "presentation": [ "http://www.zoetis.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of additional defendants", "label": "Loss Contingency, Additional Number of Defendants", "documentation": "Loss Contingency, Additional Number of Defendants" } } }, "auth_ref": [] }, "us-gaap_LossContingencyPendingClaimsNumber": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyPendingClaimsNumber", "presentation": [ "http://www.zoetis.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of claims seeking damages", "label": "Loss Contingency, Pending Claims, Number", "documentation": "Number of pending claims pertaining to a loss contingency." } } }, "auth_ref": [ "r1066", "r1067" ] }, "country_MX": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "MX", "presentation": [ "http://www.zoetis.com/role/RevenueRevenuebyGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Mexico", "label": "MEXICO" } } }, "auth_ref": [] }, "us-gaap_ManufacturedProductOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ManufacturedProductOtherMember", "presentation": [ "http://www.zoetis.com/role/RevenueRevenuebySpeciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sheep and other", "label": "Manufactured Product, Other [Member]", "documentation": "Article or substance produced by labor or machinery, classified as other." } } }, "auth_ref": [ "r1078" ] }, "us-gaap_MaterialReconcilingItemsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MaterialReconcilingItemsMember", "presentation": [ "http://www.zoetis.com/role/SegmentInformationSelectedStatementofIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciling Items", "label": "Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment [Member]", "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity." } } }, "auth_ref": [ "r354", "r357", "r360", "r840", "r841" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsForeignExchangeRiskDetails", "http://www.zoetis.com/role/ShareBasedPaymentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]", "documentation": "Upper limit of the provided range." } } }, "auth_ref": [ "r201", "r203", "r205", "r206", "r208", "r236", "r237", "r417", "r418", "r419", "r420", "r481", "r519", "r579", "r617", "r697", "r698", "r705", "r733", "r734", "r787", "r789", "r791", "r792", "r800", "r821", "r822", "r846", "r855", "r863", "r872", "r873", "r874", "r875", "r888", "r1074", "r1113", "r1114", "r1115", "r1116", "r1117", "r1118" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r955" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r955" ] }, "zts_MedicatedFeedAdditivesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "MedicatedFeedAdditivesMember", "presentation": [ "http://www.zoetis.com/role/RevenueRevenuebyProductDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Medicated feed additives", "label": "Medicated Feed Additives [Member]", "documentation": "Medicated Feed Additives [Member]" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [ "http://www.zoetis.com/role/ShareBasedPaymentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]", "documentation": "Lower limit of the provided range." } } }, "auth_ref": [ "r201", "r203", "r205", "r206", "r208", "r236", "r237", "r417", "r418", "r419", "r420", "r481", "r519", "r579", "r617", "r697", "r698", "r705", "r733", "r734", "r787", "r789", "r791", "r792", "r800", "r821", "r822", "r846", "r855", "r863", "r872", "r873", "r874", "r888", "r1074", "r1113", "r1114", "r1115", "r1116", "r1117", "r1118" ] }, "us-gaap_MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterest", "crdr": "credit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Equity attributable to noncontrolling interests", "label": "Equity, Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r124", "r184", "r291", "r370", "r424", "r427", "r428", "r429", "r433", "r434", "r584", "r665", "r745" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r974" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r982" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r956" ] }, "us-gaap_NatureOfOperations": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NatureOfOperations", "presentation": [ "http://www.zoetis.com/role/Organization" ], "lang": { "en-us": { "role": { "terseLabel": "Organization", "label": "Nature of Operations [Text Block]", "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward." } } }, "auth_ref": [ "r195", "r198" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r284" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Financing Activities", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r284" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Investing Activities", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r149", "r150", "r151" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Activities", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED", "http://www.zoetis.com/role/EarningsperShareDetails", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net income attributable to Zoetis Inc.", "terseLabel": "Net Income (Loss) Attributable to Parent", "label": "Net Income (Loss) Attributable to Parent", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r139", "r151", "r187", "r242", "r268", "r271", "r275", "r291", "r297", "r299", "r300", "r301", "r302", "r303", "r306", "r307", "r313", "r370", "r424", "r425", "r427", "r428", "r429", "r430", "r431", "r433", "r434", "r546", "r551", "r574", "r584", "r672", "r763", "r780", "r781", "r904", "r1072" ] }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED", "http://www.zoetis.com/role/EarningsperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Less: Net income/(loss) attributable to noncontrolling interests", "verboseLabel": "Less: Net income/(loss) attributable to noncontrolling interests", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r74", "r172", "r268", "r271", "r303", "r306", "r307", "r671", "r1006" ] }, "us-gaap_NetInvestmentHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetInvestmentHedgingMember", "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEParentheticalUNAUDITED", "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Net Investment Hedging", "label": "Net Investment Hedging [Member]", "documentation": "Hedges of a net investment in a foreign operation." } } }, "auth_ref": [ "r80" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.zoetis.com/role/AccountingStandardsPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Recently Issued Accounting Standards", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r955" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r919", "r929", "r939", "r963", "r971" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r946" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r945" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r963" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r982" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r982" ] }, "us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncontrollingInterestDecreaseFromDeconsolidation", "crdr": "debit", "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Deconsolidation of noncontrolling interests", "label": "Noncontrolling Interest, Decrease from Deconsolidation", "documentation": "The amount of the reduction or elimination during the period of a noncontrolling interest resulting from the parent's loss of control and deconsolidation of the entity in which one or more outside parties had a noncontrolling interest." } } }, "auth_ref": [ "r22", "r58" ] }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncontrollingInterestMember", "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Attributable to Noncontrolling Interests", "label": "Noncontrolling Interest [Member]", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": [ "r70", "r469", "r1017", "r1018", "r1019", "r1020", "r1154" ] }, "us-gaap_NondesignatedMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NondesignatedMember", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsDerivativeNotionalAmountsDetails", "http://www.zoetis.com/role/FinancialInstrumentsFairValueofDerivativeInstrumentsDetails", "http://www.zoetis.com/role/FinancialInstrumentsForeignExchangeRiskDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Derivatives Not Designated as Hedging Instruments", "terseLabel": "Derivatives Not Designated as Hedging Instruments:", "label": "Not Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": [ "r25" ] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.zoetis.com/role/SegmentInformationSelectedStatementofIncomeDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 }, "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 3.0 }, "http://www.zoetis.com/role/OtherIncomeDeductionsNetDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED", "http://www.zoetis.com/role/OtherIncomeDeductionsNetDetails", "http://www.zoetis.com/role/SegmentInformationSelectedStatementofIncomeDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Other (income)/deductions\u2014net", "negatedTotalLabel": "Other (income)/deductions\u2014net", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r142" ] }, "zts_NumberOfCoreAnimalSpeciesMarketed": { "xbrltype": "integerItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "NumberOfCoreAnimalSpeciesMarketed", "presentation": [ "http://www.zoetis.com/role/OrganizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of core animal species", "label": "Number of Core Animal Species Marketed", "documentation": "Number of Core Animal Species Marketed" } } }, "auth_ref": [] }, "us-gaap_NumberOfCountriesInWhichEntityOperates": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfCountriesInWhichEntityOperates", "presentation": [ "http://www.zoetis.com/role/OrganizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of countries in which entity markets products", "label": "Number of Countries in which Entity Operates", "documentation": "The number of countries in which the entity operates as of balance sheet date." } } }, "auth_ref": [] }, "zts_NumberOfMajorProductCategories": { "xbrltype": "integerItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "NumberOfMajorProductCategories", "presentation": [ "http://www.zoetis.com/role/OrganizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of major product categories", "label": "Number of Major Product Categories", "documentation": "Number of Major Product Categories" } } }, "auth_ref": [] }, "zts_NumberOfMajorProductLines": { "xbrltype": "integerItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "NumberOfMajorProductLines", "presentation": [ "http://www.zoetis.com/role/RevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of major product lines", "label": "Number of Major Product Lines", "documentation": "Number of Major Product Lines" } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfOperatingSegments", "presentation": [ "http://www.zoetis.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of operating segments", "label": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r841", "r1024" ] }, "zts_NumberofRegionalSegments": { "xbrltype": "integerItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "NumberofRegionalSegments", "presentation": [ "http://www.zoetis.com/role/OrganizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of regional segments", "label": "Number of Regional Segments", "documentation": "Number of Regional Segments" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://www.zoetis.com/role/SegmentInformationSelectedStatementofIncomeDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.zoetis.com/role/SegmentInformationSelectedStatementofIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r603" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Amounts included in the measurement of lease liabilities:", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r605", "r606" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of-use assets", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r602" ] }, "us-gaap_OperatingSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingSegmentsMember", "presentation": [ "http://www.zoetis.com/role/RevenueRevenuebyMajorSpeciesDetails", "http://www.zoetis.com/role/SegmentInformationSelectedStatementofIncomeDetails", "http://www.zoetis.com/role/SegmentInformationSelectedStatementofIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Operating Segments", "terseLabel": "Operating Segments", "label": "Operating Segments [Member]", "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r353", "r354", "r355", "r356", "r357", "r360", "r840", "r841" ] }, "zts_OperationalEfficiencyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "OperationalEfficiencyMember", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsCreditFacilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operational Efficiency", "label": "Operational Efficiency [Member]", "documentation": "Operational Efficiency [Member]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://www.zoetis.com/role/BasisofPresentation" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r96", "r170", "r706", "r707" ] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses", "label": "Other Accrued Liabilities, Current", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r111" ] }, "us-gaap_OtherAssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetImpairmentCharges", "crdr": "debit", "calculation": { "http://www.zoetis.com/role/OtherIncomeDeductionsNetDetails": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.zoetis.com/role/OtherIncomeDeductionsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other asset impairment charges", "label": "Other Asset Impairment Charges", "documentation": "The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value." } } }, "auth_ref": [ "r1010", "r1056" ] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Other current assets", "label": "Other Assets, Current", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r258", "r878" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Other noncurrent assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r249" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "crdr": "credit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gains (losses) on derivatives for cash flow hedges, net and net investment hedges", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax", "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r261", "r265", "r673" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax", "crdr": "debit", "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEParentheticalUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax", "documentation": "Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r266" ] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation adjustments", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": [ "r5", "r673" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED", "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED", "http://www.zoetis.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Other comprehensive loss, net of tax", "terseLabel": "Other comprehensive loss, net of tax", "label": "Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r24", "r29", "r269", "r272", "r277", "r303", "r590", "r591", "r596", "r652", "r673", "r1004", "r1005" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive (loss)/income, net of tax(a):", "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax", "crdr": "debit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Benefit plans: Actuarial gains, net of tax of $0 and $0 for the three months ended September 30, 2024 and 2023, respectively, and $0 and $1 for the nine months ended September 30, 2024 and 2023, respectively", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax", "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan." } } }, "auth_ref": [ "r7", "r8", "r132", "r133", "r673" ] }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax", "crdr": "credit", "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEParentheticalUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, Tax", "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, Tax", "documentation": "Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan." } } }, "auth_ref": [ "r10" ] }, "us-gaap_OtherCurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCurrentAssetsMember", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsFairValueofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other current assets", "label": "Other Current Assets [Member]", "documentation": "Primary financial statement caption encompassing other current assets." } } }, "auth_ref": [ "r82", "r93" ] }, "us-gaap_OtherCurrentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCurrentLiabilitiesMember", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsFairValueofDerivativeInstrumentsDetails", "http://www.zoetis.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandDivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other current liabilities", "label": "Other Current Liabilities [Member]", "documentation": "Primary financial statement caption encompassing other current liabilities." } } }, "auth_ref": [] }, "zts_OtherDevelopedMarketsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "OtherDevelopedMarketsMember", "presentation": [ "http://www.zoetis.com/role/RevenueRevenuebyGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other developed markets", "label": "Other Developed Markets [Member]", "documentation": "Other Developed Markets [Member]" } } }, "auth_ref": [] }, "zts_OtherEmergingMarketsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "OtherEmergingMarketsMember", "presentation": [ "http://www.zoetis.com/role/RevenueRevenuebyGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other emerging markets", "label": "Other Emerging Markets [Member]", "documentation": "Other Emerging Markets [Member]" } } }, "auth_ref": [] }, "us-gaap_OtherIncomeAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherIncomeAndExpensesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Other Income and Expenses [Abstract]", "label": "Other Income and Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock", "presentation": [ "http://www.zoetis.com/role/OtherIncomeDeductionsNet" ], "lang": { "en-us": { "role": { "terseLabel": "Other (Income)/Deductions - Net", "label": "Other Income and Other Expense Disclosure [Text Block]", "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions." } } }, "auth_ref": [ "r996", "r1080" ] }, "us-gaap_OtherIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherIntangibleAssetsMember", "presentation": [ "http://www.zoetis.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Intangible Assets [Member]", "documentation": "Intangible assets classified as other." } } }, "auth_ref": [ "r848", "r1045", "r1047", "r1048", "r1049", "r1050", "r1051", "r1052", "r1053", "r1054", "r1055" ] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Other current liabilities", "label": "Other Liabilities, Current", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r111", "r878" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Other noncurrent liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r116" ] }, "zts_OtherNonPharmaceuticalsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "OtherNonPharmaceuticalsMember", "presentation": [ "http://www.zoetis.com/role/RevenueRevenuebyProductDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Other non-pharmaceutical", "label": "Other Non Pharmaceuticals [Member]", "documentation": "Other Non Pharmaceuticals [Member]" } } }, "auth_ref": [] }, "us-gaap_OtherNoncashIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncashIncomeExpense", "crdr": "credit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "negatedLabel": "Other non-cash adjustments", "label": "Other Noncash Income (Expense)", "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other." } } }, "auth_ref": [ "r151" ] }, "us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncashInvestingAndFinancingItemsAbstract", "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash transactions:", "label": "Other Noncash Investing and Financing Items [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherNoncurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncurrentAssetsMember", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsFairValueofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other noncurrent assets", "label": "Other Noncurrent Assets [Member]", "documentation": "Primary financial statement caption encompassing other noncurrent assets." } } }, "auth_ref": [] }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncurrentLiabilitiesMember", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsFairValueofDerivativeInstrumentsDetails", "http://www.zoetis.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandDivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other noncurrent liabilities", "label": "Other Noncurrent Liabilities [Member]", "documentation": "Primary financial statement caption encompassing other noncurrent liabilities." } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.zoetis.com/role/OtherIncomeDeductionsNetDetails": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.zoetis.com/role/OtherIncomeDeductionsNetDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other, net", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r143" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r955" ] }, "zts_OtherPharmaceuticalsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "OtherPharmaceuticalsMember", "presentation": [ "http://www.zoetis.com/role/RevenueRevenuebyProductDetails", "http://www.zoetis.com/role/RevenueRevenuebySpeciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other pharmaceutical", "label": "Other Pharmaceuticals [Member]", "documentation": "Other Pharmaceuticals [Member]" } } }, "auth_ref": [] }, "zts_OtherUnallocatedItemsIncludedinDepreciationDepletionandAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "OtherUnallocatedItemsIncludedinDepreciationDepletionandAmortization", "crdr": "debit", "presentation": [ "http://www.zoetis.com/role/SegmentInformationSelectedStatementofIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other unallocated, Depreciation and Amortization", "label": "Other Unallocated Items Included in Depreciation, Depletion and Amortization", "documentation": "Other Unallocated Items Included in Depreciation, Depletion and Amortization" } } }, "auth_ref": [] }, "zts_OtherUnallocatedItemsIncludedinIncomeLossfromContinuingOperationsbeforeIncomeTaxesNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "OtherUnallocatedItemsIncludedinIncomeLossfromContinuingOperationsbeforeIncomeTaxesNoncontrollingInterest", "crdr": "credit", "presentation": [ "http://www.zoetis.com/role/SegmentInformationSelectedStatementofIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other unallocated", "label": "Other Unallocated Items Included in Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Other Unallocated Items Included in Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest" } } }, "auth_ref": [] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r917", "r927", "r937", "r969" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r920", "r930", "r940", "r972" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r920", "r930", "r940", "r972" ] }, "zts_PainSedationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "PainSedationMember", "presentation": [ "http://www.zoetis.com/role/RevenueRevenuebyProductDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pain and sedation", "label": "Pain & Sedation [Member]", "documentation": "Pain & Sedation" } } }, "auth_ref": [] }, "zts_ParasiticidesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "ParasiticidesMember", "presentation": [ "http://www.zoetis.com/role/RevenueRevenuebyProductDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Parasiticides", "label": "Parasiticides [Member]", "documentation": "Parasiticides [Member]" } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r944" ] }, "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities", "crdr": "credit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payment of consideration related to previous acquisitions", "label": "Payment for Contingent Consideration Liability, Financing Activities", "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date." } } }, "auth_ref": [ "r12" ] }, "us-gaap_PaymentsForProceedsFromHedgeInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForProceedsFromHedgeInvestingActivities", "crdr": "credit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Proceeds from derivative instrument activity, net", "label": "Payments for (Proceeds from) Hedge, Investing Activities", "documentation": "The cash outflow or inflow for a financial contract that meets the hedge criteria as either a cash flow hedge, fair value hedge, or hedge of a net investment in a foreign operation." } } }, "auth_ref": [] }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForProceedsFromOtherInvestingActivities", "crdr": "credit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other investing activities", "label": "Payments for (Proceeds from) Other Investing Activities", "documentation": "Amount of cash (inflow) outflow from investing activities classified as other." } } }, "auth_ref": [ "r994", "r1008" ] }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchases of treasury stock, including excise taxes paid", "label": "Payments for Repurchase of Common Stock", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": [ "r147" ] }, "us-gaap_PaymentsOfOrdinaryDividends": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfOrdinaryDividends", "crdr": "credit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "negatedLabel": "Cash dividends paid", "label": "Payments of Ordinary Dividends", "documentation": "Cash outflow in the form of ordinary dividends to common shareholders, preferred shareholders and noncontrolling interests, generally out of earnings." } } }, "auth_ref": [ "r147" ] }, "us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireBusinessTwoNetOfCashAcquired", "crdr": "credit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "negatedLabel": "Acquisitions, net of cash acquired", "label": "Payments to Acquire Business Two, Net of Cash Acquired", "documentation": "The cash outflow associated with a second acquisition of a business, net of the cash acquired from the purchase." } } }, "auth_ref": [ "r1008" ] }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "crdr": "credit", "presentation": [ "http://www.zoetis.com/role/AcquisitionsandDivestituresConsiderationTransferredDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisition of a noncontrolling interest, net of cash acquired", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase." } } }, "auth_ref": [ "r37" ] }, "us-gaap_PaymentsToAcquireInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireInvestments", "crdr": "credit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchase of investments", "label": "Payments to Acquire Investments", "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period." } } }, "auth_ref": [ "r145" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "negatedLabel": "Capital expenditures", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r146" ] }, "zts_PeerCompaniesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "PeerCompaniesMember", "presentation": [ "http://www.zoetis.com/role/ShareBasedPaymentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "PeerCompanies", "label": "Peer Companies [Member]", "documentation": "Peer Companies [Member]" } } }, "auth_ref": [] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r954" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r954" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r946" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r963" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r956" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r945" ] }, "us-gaap_PerformanceSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PerformanceSharesMember", "presentation": [ "http://www.zoetis.com/role/ShareBasedPaymentsComponentsofShareBasedCompensationExpenseDetails", "http://www.zoetis.com/role/ShareBasedPaymentsNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "verboseLabel": "PSUs", "terseLabel": "Performance Shares", "label": "Performance Shares [Member]", "documentation": "Share-based payment arrangement awarded for meeting performance target." } } }, "auth_ref": [] }, "zts_PetMedixLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "PetMedixLtdMember", "presentation": [ "http://www.zoetis.com/role/AcquisitionsandDivestituresConsiderationTransferredDetails", "http://www.zoetis.com/role/AcquisitionsandDivestituresDivesturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "PetMedix Ltd.", "label": "PetMedix Ltd. [Member]", "documentation": "PetMedix Ltd." } } }, "auth_ref": [] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Prior Service Cost", "label": "Pension Adjustments Prior Service Cost [Member]" } } }, "auth_ref": [ "r947" ] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Service Cost", "label": "Pension Adjustments Service Cost [Member]" } } }, "auth_ref": [ "r991" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Benefits Adjustments, Footnote", "label": "Pension Benefits Adjustments, Footnote [Text Block]" } } }, "auth_ref": [ "r946" ] }, "zts_PoultryMember": { "xbrltype": "domainItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "PoultryMember", "presentation": [ "http://www.zoetis.com/role/RevenueRevenuebySpeciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Poultry", "label": "Poultry [Member]", "documentation": "Poultry [Member]" } } }, "auth_ref": [] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.zoetis.com/role/StockholdersEquityChangesinCommonSharesandTreasuryStockDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Preferred stock, shares authorized", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r119", "r743" ] }, "us-gaap_ProceedsFromDivestitureOfBusinesses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromDivestitureOfBusinesses", "crdr": "debit", "presentation": [ "http://www.zoetis.com/role/AcquisitionsandDivestituresDivesturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale proceeds", "label": "Proceeds from Divestiture of Businesses", "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period." } } }, "auth_ref": [ "r36" ] }, "us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromDivestitureOfBusinessesNetOfCashDivested", "crdr": "debit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.zoetis.com/role/AcquisitionsandDivestituresDivesturesDetails", "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of businesses, net of cash sold", "label": "Proceeds from Divestiture of Businesses, Net of Cash Divested", "documentation": "This element represents the cash inflow during the period from the sale of a component of the entity." } } }, "auth_ref": [ "r36" ] }, "us-gaap_ProceedsFromRepaymentsOfShortTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromRepaymentsOfShortTermDebt", "crdr": "debit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Decrease in short-term borrowings, net", "label": "Proceeds from (Repayments of) Short-Term Debt", "documentation": "The net cash inflow or outflow for borrowing having initial term of repayment within one year or the normal operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Net proceeds from sale of assets", "label": "Proceeds from Sale of Property, Plant, and Equipment", "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r144" ] }, "us-gaap_ProductInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductInformationLineItems", "presentation": [ "http://www.zoetis.com/role/OrganizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product Information [Line Items]", "label": "Product Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ProductMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductMember", "presentation": [ "http://www.zoetis.com/role/OrganizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product", "label": "Product [Member]", "documentation": "Article or substance produced by nature, labor or machinery." } } }, "auth_ref": [ "r856" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.zoetis.com/role/OrganizationDetails", "http://www.zoetis.com/role/RevenueRevenuebyMajorSpeciesDetails", "http://www.zoetis.com/role/RevenueRevenuebyProductDetails", "http://www.zoetis.com/role/RevenueRevenuebySpeciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]", "documentation": "Information by product and service, or group of similar products and similar services." } } }, "auth_ref": [ "r210", "r211", "r212", "r213", "r214", "r215", "r235", "r363", "r618", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r825", "r856", "r887", "r888", "r889", "r892", "r893", "r999", "r1068", "r1069", "r1077", "r1121", "r1124", "r1125", "r1126", "r1127", "r1128", "r1129", "r1130", "r1131", "r1132", "r1133", "r1134", "r1135", "r1136", "r1137", "r1138", "r1139", "r1140", "r1141", "r1142", "r1143", "r1144", "r1145", "r1146", "r1147", "r1148", "r1149", "r1150", "r1151" ] }, "zts_ProductRightsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "ProductRightsMember", "presentation": [ "http://www.zoetis.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product rights", "label": "Product Rights [Member]", "documentation": "Product Rights [Member]" } } }, "auth_ref": [] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.zoetis.com/role/OrganizationDetails", "http://www.zoetis.com/role/RevenueRevenuebyMajorSpeciesDetails", "http://www.zoetis.com/role/RevenueRevenuebyProductDetails", "http://www.zoetis.com/role/RevenueRevenuebySpeciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]", "documentation": "Product or service, or a group of similar products or similar services." } } }, "auth_ref": [ "r210", "r211", "r212", "r213", "r214", "r215", "r235", "r363", "r618", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r825", "r856", "r887", "r888", "r889", "r892", "r893", "r999", "r1068", "r1069", "r1077", "r1121", "r1124", "r1125", "r1126", "r1127", "r1128", "r1129", "r1130", "r1131", "r1132", "r1133", "r1134", "r1135", "r1136", "r1137", "r1138", "r1139", "r1140", "r1141", "r1142", "r1143", "r1144", "r1145", "r1146", "r1147", "r1148", "r1149", "r1150", "r1151" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 }, "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 }, "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED", "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED", "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED", "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED", "http://www.zoetis.com/role/EarningsperShareDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net income before allocation to noncontrolling interests", "verboseLabel": "Net income before allocation to noncontrolling interests", "terseLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r242", "r268", "r271", "r283", "r291", "r297", "r303", "r306", "r307", "r370", "r424", "r425", "r427", "r428", "r429", "r430", "r431", "r433", "r434", "r546", "r551", "r552", "r555", "r556", "r574", "r584", "r657", "r670", "r716", "r763", "r780", "r781", "r868", "r869", "r905", "r1006", "r1072" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment, less accumulated depreciation of $2,657 in 2024 and $2,594 in 2023", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r17", "r608", "r658", "r668", "r878" ] }, "zts_PumpkinInsuranceServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "PumpkinInsuranceServicesMember", "presentation": [ "http://www.zoetis.com/role/AcquisitionsandDivestituresDivesturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pumpkin Insurance Services", "label": "Pumpkin Insurance Services [Member]", "documentation": "Pumpkin Insurance Services" } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r944" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r944" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsForeignExchangeRiskDetails", "http://www.zoetis.com/role/ShareBasedPaymentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]", "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r201", "r203", "r205", "r206", "r208", "r236", "r237", "r417", "r418", "r419", "r420", "r474", "r481", "r509", "r510", "r511", "r519", "r579", "r615", "r616", "r617", "r697", "r698", "r705", "r733", "r734", "r787", "r789", "r791", "r792", "r800", "r821", "r822", "r846", "r855", "r863", "r872", "r873", "r874", "r875", "r888", "r896", "r1061", "r1074", "r1093", "r1114", "r1115", "r1116", "r1117", "r1118" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsForeignExchangeRiskDetails", "http://www.zoetis.com/role/ShareBasedPaymentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]", "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r201", "r203", "r205", "r206", "r208", "r236", "r237", "r417", "r418", "r419", "r420", "r474", "r481", "r509", "r510", "r511", "r519", "r579", "r615", "r616", "r617", "r697", "r698", "r705", "r733", "r734", "r787", "r789", "r791", "r792", "r800", "r821", "r822", "r846", "r855", "r863", "r872", "r873", "r874", "r875", "r888", "r896", "r1061", "r1074", "r1093", "r1114", "r1115", "r1116", "r1117", "r1118" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r912", "r922", "r932", "r964" ] }, "us-gaap_RepaymentsOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfLongTermDebt", "crdr": "credit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED", "http://www.zoetis.com/role/FinancialInstrumentsSeniorNotesOfferingandOtherLongTermDebtDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Principal payments on long-term debt", "terseLabel": "Repayments of long-term debt", "label": "Repayments of Long-Term Debt", "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r148", "r712" ] }, "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "crdr": "debit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" ], "lang": { "en-us": { "role": { "verboseLabel": "Research and development expenses", "label": "Research and Development Expense (Excluding Acquired in Process Cost)", "documentation": "Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r1081" ] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r913", "r923", "r933", "r965" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r914", "r924", "r934", "r966" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r921", "r931", "r941", "r973" ] }, "us-gaap_RestrictedCashCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashCurrent", "crdr": "debit", "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDPARENTHETICAL" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash", "label": "Restricted Cash, Current", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r1000", "r1011" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://www.zoetis.com/role/ShareBasedPaymentsComponentsofShareBasedCompensationExpenseDetails", "http://www.zoetis.com/role/ShareBasedPaymentsNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "verboseLabel": "RSUs / DSUs", "terseLabel": "Restricted Stock Units (RSUs)", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedActivitiesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Restructuring and Related Activities [Abstract]", "label": "Restructuring and Related Activities [Abstract]" } } }, "auth_ref": [] }, "zts_RestructuringAndRelatedActivitiesDivestitureRelatedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "RestructuringAndRelatedActivitiesDivestitureRelatedCost", "crdr": "debit", "presentation": [ "http://www.zoetis.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandDivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Divestiture-related costs", "label": "Restructuring And Related Activities, Divestiture Related Cost", "documentation": "Restructuring And Related Activities, Divestiture Related Cost" } } }, "auth_ref": [] }, "us-gaap_RestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCharges", "crdr": "debit", "presentation": [ "http://www.zoetis.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandDivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Provision", "label": "Restructuring Charges", "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r16", "r410", "r411", "r1062" ] }, "zts_RestructuringChargesAndAcquisitionAndDivestitureRelatedCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "RestructuringChargesAndAcquisitionAndDivestitureRelatedCosts", "crdr": "debit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED", "http://www.zoetis.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandDivestituresDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Restructuring charges and certain acquisition and divestiture-related costs", "terseLabel": "Total Restructuring charges and certain acquisition and divestiture-related costs", "label": "Restructuring Charges And Acquisition And Divestiture Related Costs", "documentation": "This element represents (i) restructuring charges, which are amounts charged against earnings in the period for incurred and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a program that is planned and controlled by management, and materially changes either the scope of a business undertaken by an entity, or the manner in which that business is conducted; and (ii) acquisition-related costs, which are costs incurred to effect a business combination which costs have been expensed during the period. Such costs can include transaction costs such as banking, legal, accounting and other costs directly related to effect a business combination as well as external, incremental costs of integration planning that are directly related to a business combination, including costs associated with preparing for systems and other integration activities." } } }, "auth_ref": [] }, "us-gaap_RestructuringCostAndReserveAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCostAndReserveAxis", "presentation": [ "http://www.zoetis.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandDivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Type [Axis]", "label": "Restructuring Type [Axis]", "documentation": "Information by type of restructuring cost." } } }, "auth_ref": [ "r406", "r407", "r411", "r412" ] }, "us-gaap_RestructuringCostAndReserveLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCostAndReserveLineItems", "presentation": [ "http://www.zoetis.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandDivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Cost and Reserve [Line Items]", "label": "Restructuring Cost and Reserve [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r406", "r407", "r408", "r409", "r411", "r412", "r413" ] }, "us-gaap_RestructuringPlanAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringPlanAxis", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsCreditFacilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Plan [Axis]", "label": "Restructuring Plan [Axis]", "documentation": "Information by individual restructuring plan." } } }, "auth_ref": [] }, "us-gaap_RestructuringPlanDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringPlanDomain", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsCreditFacilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Plan [Domain]", "label": "Restructuring Plan [Domain]", "documentation": "Identification of the individual restructuring plans." } } }, "auth_ref": [] }, "us-gaap_RestructuringReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserve", "crdr": "credit", "presentation": [ "http://www.zoetis.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandDivestituresDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Restructuring accrual balance", "periodEndLabel": "Restructuring accrual balance", "label": "Restructuring Reserve", "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan." } } }, "auth_ref": [ "r407", "r412" ] }, "us-gaap_RestructuringReserveAccrualAdjustment1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserveAccrualAdjustment1", "crdr": "debit", "presentation": [ "http://www.zoetis.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandDivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reserve adjustment", "label": "Restructuring Reserve, Accrual Adjustment", "documentation": "Amount of expense (reversal of expense) which increases (decreases) the restructuring reserve from an adjustment to a previously accrued restructuring liability." } } }, "auth_ref": [ "r407", "r412" ] }, "us-gaap_RestructuringReserveCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserveCurrent", "crdr": "credit", "presentation": [ "http://www.zoetis.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandDivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses", "label": "Restructuring Reserve, Current", "documentation": "Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset." } } }, "auth_ref": [ "r1001", "r1063", "r1064" ] }, "us-gaap_RestructuringReserveNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserveNoncurrent", "crdr": "credit", "presentation": [ "http://www.zoetis.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandDivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other noncurrent liabilities", "label": "Restructuring Reserve, Noncurrent", "documentation": "Carrying amount as of the balance sheet date of known and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid after one year or beyond the next operating cycle, if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset." } } }, "auth_ref": [ "r1002", "r1063", "r1064" ] }, "us-gaap_RestructuringReserveRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserveRollForward", "presentation": [ "http://www.zoetis.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandDivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Reserve [Roll Forward]", "label": "Restructuring Reserve [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "zts_RestructuringReserveUtilizationAndOther": { "xbrltype": "monetaryItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "RestructuringReserveUtilizationAndOther", "crdr": "debit", "presentation": [ "http://www.zoetis.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandDivestituresDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Utilization and other", "label": "Restructuring Reserve, Utilization And Other", "documentation": "Adjustment to restructuring reserve resulting from utilization and foreign currency translation." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Retained earnings", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r122", "r167", "r664", "r702", "r704", "r713", "r744", "r878" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Retained Earnings", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r238", "r294", "r295", "r296", "r298", "r303", "r305", "r307", "r371", "r372", "r403", "r536", "r537", "r543", "r544", "r545", "r547", "r550", "r551", "r564", "r566", "r567", "r569", "r572", "r599", "r601", "r699", "r701", "r717", "r1154" ] }, "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "presentation": [ "http://www.zoetis.com/role/RevenueRevenueRecognitionandDeferredRevenueTables" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue from External Customers by Geographic Areas", "label": "Revenue from External Customers by Geographic Areas [Table Text Block]", "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue." } } }, "auth_ref": [ "r153" ] }, "us-gaap_RevenueRecognitionAndDeferredRevenueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRecognitionAndDeferredRevenueAbstract", "lang": { "en-us": { "role": { "terseLabel": "Revenue Recognition and Deferred Revenue [Abstract]", "label": "Revenue Recognition and Deferred Revenue [Abstract]" } } }, "auth_ref": [] }, "zts_RevenuefromExternalCustomersbyMajorSpeciesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "RevenuefromExternalCustomersbyMajorSpeciesTableTextBlock", "presentation": [ "http://www.zoetis.com/role/RevenueRevenueRecognitionandDeferredRevenueTables" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue from External Customers by Major Species", "label": "Revenue from External Customers by Major Species [Table Text Block]", "documentation": "Revenue from External Customers by Major Species" } } }, "auth_ref": [] }, "zts_RevenuefromExternalCustomersbySpeciesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "RevenuefromExternalCustomersbySpeciesTableTextBlock", "presentation": [ "http://www.zoetis.com/role/RevenueRevenueRecognitionandDeferredRevenueTables" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue from External Customers by Species", "label": "Revenue from External Customers by Species [Table Text Block]", "documentation": "Revenue from External Customers by Species" } } }, "auth_ref": [] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Revenues", "crdr": "credit", "calculation": { "http://www.zoetis.com/role/SegmentInformationSelectedStatementofIncomeDetails": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 }, "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED", "http://www.zoetis.com/role/RevenueRevenuebyGeographicAreaDetails", "http://www.zoetis.com/role/RevenueRevenuebyMajorSpeciesDetails", "http://www.zoetis.com/role/RevenueRevenuebyProductDetails", "http://www.zoetis.com/role/RevenueRevenuebySpeciesDetails", "http://www.zoetis.com/role/SegmentInformationSelectedStatementofIncomeDetails", "http://www.zoetis.com/role/SegmentInformationSelectedStatementofIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue", "label": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": [ "r188", "r189", "r276", "r291", "r321", "r330", "r331", "r353", "r359", "r363", "r365", "r367", "r370", "r424", "r425", "r427", "r428", "r429", "r430", "r431", "r433", "r434", "r584", "r657", "r840", "r1072" ] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevolvingCreditFacilityMember", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsCreditFacilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revolving Credit Facility", "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Lease obligations obtained in exchange for right-of-use assets - operating", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r607", "r877" ] }, "zts_RoxanneLaganoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "RoxanneLaganoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Roxanne Lagano [Member]", "documentation": "Roxanne Lagano" } } }, "auth_ref": [] }, "zts_RoxanneLaganoTradingArrangementCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "RoxanneLaganoTradingArrangementCommonStockMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Roxanne Lagano Trading Arrangement, Common Stock [Member]", "documentation": "Roxanne Lagano Trading Arrangement, Common Stock" } } }, "auth_ref": [] }, "zts_RoxanneLaganoTradingArrangementEquityAwardsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "RoxanneLaganoTradingArrangementEquityAwardsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Roxanne Lagano Trading Arrangement, Equity Awards [Member]", "documentation": "Roxanne Lagano Trading Arrangement, Equity Awards" } } }, "auth_ref": [] }, "us-gaap_RoyaltyIncomeNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RoyaltyIncomeNonoperating", "crdr": "credit", "calculation": { "http://www.zoetis.com/role/OtherIncomeDeductionsNetDetails": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.zoetis.com/role/OtherIncomeDeductionsNetDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Royalty-related income", "label": "Royalty Income, Nonoperating", "documentation": "Ancillary revenue earned during the period from the consideration paid to the entity for the use of its rights and property by another party. Examples include licensing the use of copyrighted materials and leasing the extraction of natural resources." } } }, "auth_ref": [ "r142" ] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r982" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r982" ] }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": [ "http://www.zoetis.com/role/StockholdersEquityTables" ], "lang": { "en-us": { "role": { "terseLabel": "Changes, Net of Tax, in Accumulated Other Comprehensive Loss", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r34", "r1105", "r1106" ] }, "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "presentation": [ "http://www.zoetis.com/role/GoodwillandOtherIntangibleAssetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Components of Identifiable Intangible Assets", "label": "Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block]", "documentation": "Tabular disclosure of the characteristics, including initial carrying value, residual amount, weighted average useful life, of finite-lived intangible assets acquired during the period by major class. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company." } } }, "auth_ref": [ "r1046", "r1051" ] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": [ "http://www.zoetis.com/role/AcquisitionsandDivestituresConsiderationTransferredDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability." } } }, "auth_ref": [ "r65", "r67", "r548" ] }, "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "presentation": [ "http://www.zoetis.com/role/ShareBasedPaymentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Components of Share-based Compensation Expense", "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]", "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit." } } }, "auth_ref": [ "r61" ] }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDebtInstrumentsTextBlock", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer." } } }, "auth_ref": [ "r30", "r54", "r57", "r95", "r165", "r166", "r851", "r853", "r1016", "r1109" ] }, "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value", "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]", "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position." } } }, "auth_ref": [ "r84" ] }, "us-gaap_ScheduleOfDerivativeInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDerivativeInstrumentsTextBlock", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Derivative Instruments", "label": "Schedule of Derivative Instruments [Table Text Block]", "documentation": "Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item." } } }, "auth_ref": [ "r25", "r76", "r77", "r78", "r81", "r84", "r86", "r91", "r92" ] }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "presentation": [ "http://www.zoetis.com/role/AcquisitionsandDivestituresTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Groups, Including Discontinued Operations", "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]", "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r19", "r26", "r31", "r97", "r98", "r99", "r100", "r101", "r102", "r104", "r105", "r106", "r158" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://www.zoetis.com/role/EarningsperShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Basic and Diluted Earnings Per Share", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r1022" ] }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable", "presentation": [ "http://www.zoetis.com/role/RevenueRevenuebyGeographicAreaDetails", "http://www.zoetis.com/role/RevenueRevenuebyMajorSpeciesDetails", "http://www.zoetis.com/role/RevenueRevenuebyProductDetails", "http://www.zoetis.com/role/RevenueRevenuebySpeciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue from External Customers by Products and Services [Table]", "label": "Segment Reporting, Revenue from External Customer, Product and Service [Table]", "documentation": "Disclosure of information about revenue from external customer by product and service when not provided as part of reportable operating segment information." } } }, "auth_ref": [ "r46" ] }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "presentation": [ "http://www.zoetis.com/role/RevenueRevenueRecognitionandDeferredRevenueTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Significant Product Revenues", "label": "Revenue from External Customers by Products and Services [Table Text Block]", "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information." } } }, "auth_ref": [ "r46" ] }, "us-gaap_ScheduleOfGoodwillTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfGoodwillTable", "presentation": [ "http://www.zoetis.com/role/GoodwillandOtherIntangibleAssetsGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Goodwill [Table]", "label": "Goodwill [Table]", "documentation": "Disclosure of information about goodwill, including, but not limited to, change from acquisition, sale, impairment, and other reason." } } }, "auth_ref": [ "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r847" ] }, "us-gaap_ScheduleOfGoodwillTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfGoodwillTextBlock", "presentation": [ "http://www.zoetis.com/role/GoodwillandOtherIntangibleAssetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in the Carrying Amount of Goodwill", "label": "Schedule of Goodwill [Table Text Block]", "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule." } } }, "auth_ref": [ "r847", "r1033", "r1034", "r1035", "r1036", "r1037", "r1038", "r1039", "r1040", "r1041", "r1042", "r1043" ] }, "zts_ScheduleOfIndefinitelivedAndFinitelivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "ScheduleOfIndefinitelivedAndFinitelivedIntangibleAssetsTable", "presentation": [ "http://www.zoetis.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Indefinite-lived and Finite-lived Intangible Assets [Table]", "label": "Schedule Of Indefinitelived And Finitelived Intangible Assets [Table]", "documentation": "Schedule of Indefinite-lived and Finite-lived Intangible Assets [Table]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://www.zoetis.com/role/InventoriesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Components of Inventory", "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r32", "r126", "r127", "r128" ] }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Maturities of Long-term Debt", "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt." } } }, "auth_ref": [ "r18" ] }, "us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss)", "label": "Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period." } } }, "auth_ref": [ "r1088" ] }, "us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Net Investment Hedges, Statements of Financial Performance and Financial Position, Location", "label": "Schedule of Net Investment Hedges, Statements of Financial Performance and Financial Position, Location [Table Text Block]", "documentation": "Tabular disclosure for net investment hedges of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position." } } }, "auth_ref": [ "r176" ] }, "us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Other Derivatives Not Designated as Hedging Instruments, Statements of Financial Performance and Financial Position, Location", "label": "Derivatives Not Designated as Hedging Instruments [Table Text Block]", "documentation": "Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument." } } }, "auth_ref": [ "r87", "r995" ] }, "us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock", "presentation": [ "http://www.zoetis.com/role/OtherIncomeDeductionsNetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Components of Other (Income)/Deductions\u2014Net", "label": "Schedule of Other Operating Cost and Expense, by Component [Table Text Block]", "documentation": "Tabular disclosure of each detailed component of other operating costs and expenses that are applicable to sales and revenues, but not included in the cost of sales in the income statement." } } }, "auth_ref": [ "r140" ] }, "us-gaap_ScheduleOfProductInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfProductInformationTable", "presentation": [ "http://www.zoetis.com/role/OrganizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Product Information [Table]", "label": "Nature of Operation, Product Information, Concentration of Risk [Table]", "documentation": "Disclosure of information about concentration risk of product within nature of operation." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "presentation": [ "http://www.zoetis.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandDivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restructuring and Related Costs [Table]", "label": "Restructuring Cost [Table]", "documentation": "Disclosure of information about restructuring cost. Includes, but is not limited to, expected cost, cost incurred, statement of income caption that includes restructuring cost recognized, and amount of restructuring reserve." } } }, "auth_ref": [ "r406", "r407", "r408", "r409", "r411", "r412", "r413" ] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "presentation": [ "http://www.zoetis.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandDivestituresTables" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring and Related Costs", "label": "Restructuring and Related Costs [Table Text Block]", "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets." } } }, "auth_ref": [ "r49", "r159", "r160" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": [ "http://www.zoetis.com/role/SegmentInformationSelectedStatementofIncomeDetails", "http://www.zoetis.com/role/SegmentInformationSelectedStatementofIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment." } } }, "auth_ref": [ "r43", "r44", "r45" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": [ "http://www.zoetis.com/role/SegmentInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Selected Income Statement Information by Segment", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r43", "r44", "r45" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.zoetis.com/role/ShareBasedPaymentsComponentsofShareBasedCompensationExpenseDetails", "http://www.zoetis.com/role/ShareBasedPaymentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r483", "r485", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512" ] }, "us-gaap_ScheduleOfShortTermDebtTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShortTermDebtTable", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsCommercialPaperProgramDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Short-term Debt [Table]", "label": "Short-Term Debt [Table]", "documentation": "Disclosure of information about short-term debt arrangement. Includes, but is not limited to, description of arrangement, lender, repayment term, weighted-average interest rate, borrowed amount, and description and amount of refinancing of short-term obligation when obligation is excluded from current liability." } } }, "auth_ref": [ "r110" ] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://www.zoetis.com/role/StockholdersEquityChangesinCommonSharesandTreasuryStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock by Class [Table]", "label": "Stock, Class of Stock [Table]", "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks." } } }, "auth_ref": [ "r52", "r53", "r54", "r55", "r56", "r57", "r163", "r165", "r166", "r167", "r252", "r253", "r254", "r323", "r454", "r455", "r456", "r458", "r461", "r466", "r468", "r709", "r710", "r711", "r712", "r855", "r993", "r1012" ] }, "us-gaap_SecuritiesReceivedAsCollateral": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuritiesReceivedAsCollateral", "crdr": "debit", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsFairValueofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collateral received", "label": "Securities Received as Collateral", "documentation": "The carrying value as of the balance sheet date of the assets received as collateral against securities loaned to other broker-dealers. Borrowers of securities generally are required to provide collateral to the lenders of securities, commonly cash but sometimes other securities or standby letters of credit, with a value slightly higher than that of the securities borrowed. In instances where the entity is permitted to sell or re-pledge these securities, the entity reports the fair value of the collateral received and the related obligation to return the collateral as a liability." } } }, "auth_ref": [ "r21" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://www.zoetis.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r907" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://www.zoetis.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r909" ] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentDomain", "presentation": [ "http://www.zoetis.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails", "http://www.zoetis.com/role/RevenueRevenuebyMajorSpeciesDetails", "http://www.zoetis.com/role/SegmentInformationSelectedStatementofIncomeDetails", "http://www.zoetis.com/role/SegmentInformationSelectedStatementofIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Domain]", "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r188", "r189", "r190", "r191", "r321", "r326", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r340", "r341", "r343", "r344", "r345", "r353", "r354", "r355", "r356", "r357", "r359", "r360", "r361", "r367", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r402", "r409", "r413", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r837", "r840", "r841", "r847", "r891", "r1121", "r1124", "r1125", "r1126", "r1127", "r1128", "r1129", "r1130", "r1131", "r1132", "r1133", "r1134", "r1135", "r1136", "r1137", "r1138", "r1139", "r1140", "r1141", "r1142", "r1143", "r1144", "r1145", "r1146", "r1147", "r1148", "r1149", "r1150", "r1151" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.zoetis.com/role/GoodwillandOtherIntangibleAssetsGoodwillDetails", "http://www.zoetis.com/role/RevenueRevenuebyGeographicAreaDetails", "http://www.zoetis.com/role/RevenueRevenuebyMajorSpeciesDetails", "http://www.zoetis.com/role/RevenueRevenuebyProductDetails", "http://www.zoetis.com/role/RevenueRevenuebySpeciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Domain]", "verboseLabel": "Geographical [Domain]", "label": "Geographical [Domain]", "documentation": "Geographical area." } } }, "auth_ref": [ "r202", "r204", "r207", "r209", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r365", "r366", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r729", "r730", "r731", "r788", "r790", "r793", "r801", "r809", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r826", "r857", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r890", "r896", "r1077", "r1121", "r1124", "r1125", "r1127", "r1128", "r1129", "r1130", "r1131", "r1132", "r1133", "r1134", "r1135", "r1136", "r1137", "r1138", "r1139", "r1140", "r1141", "r1142", "r1143", "r1144", "r1145", "r1146", "r1147", "r1148", "r1149", "r1150", "r1151" ] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting [Abstract]", "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://www.zoetis.com/role/SegmentInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Information", "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r191", "r321", "r325", "r326", "r327", "r328", "r329", "r342", "r344", "r345", "r357", "r358", "r359", "r360", "r361", "r363", "r364", "r367", "r835", "r838", "r839", "r840", "r842", "r844", "r845" ] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingInformationLineItems", "presentation": [ "http://www.zoetis.com/role/SegmentInformationSelectedStatementofIncomeDetails", "http://www.zoetis.com/role/SegmentInformationSelectedStatementofIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting Information [Line Items]", "label": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": [ "http://www.zoetis.com/role/AccountingStandardsPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Information", "label": "Segment Reporting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": [ "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r362", "r365", "r836", "r837", "r843" ] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative expenses", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r141" ] }, "zts_SeniorNotes2000Due2030Member": { "xbrltype": "domainItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "SeniorNotes2000Due2030Member", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsInterestRateRiskDetails", "http://www.zoetis.com/role/FinancialInstrumentsScheduleofLongtermDebtDetails", "http://www.zoetis.com/role/FinancialInstrumentsSeniorNotesOfferingandOtherLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2.000% 2020 senior notes due 2030", "label": "Senior notes 2.000% due 2030 [Member]", "documentation": "Senior notes 2.000% due 2030" } } }, "auth_ref": [] }, "zts_SeniorNotes3.000Due2027Member": { "xbrltype": "domainItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "SeniorNotes3.000Due2027Member", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "3.000% 2017 senior notes due 2027", "label": "Senior Notes 3.000% Due 2027 [Member]", "documentation": "Senior Notes 3.000% Due 2027" } } }, "auth_ref": [] }, "zts_SeniorNotes3.900Due2028Member": { "xbrltype": "domainItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "SeniorNotes3.900Due2028Member", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsInterestRateRiskDetails", "http://www.zoetis.com/role/FinancialInstrumentsScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "3.900% 2018 senior notes due 2028", "label": "Senior Notes 3.900% Due 2028 [Member]", "documentation": "Senior Notes 3.900% Due 2028 [Member]" } } }, "auth_ref": [] }, "zts_SeniorNotes3.950Due2047Member": { "xbrltype": "domainItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "SeniorNotes3.950Due2047Member", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "3.950% 2017 senior notes due 2047", "label": "Senior Notes 3.950% Due 2047 [Member]", "documentation": "Senior Notes 3.950% Due 2047 [Member]" } } }, "auth_ref": [] }, "zts_SeniorNotes3000Due2050Member": { "xbrltype": "domainItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "SeniorNotes3000Due2050Member", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsScheduleofLongtermDebtDetails", "http://www.zoetis.com/role/FinancialInstrumentsSeniorNotesOfferingandOtherLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "3.000% 2020 senior notes due 2050", "label": "Senior Notes 3.000% due 2050 [Member]", "documentation": "Senior Notes 3.000% due 2050" } } }, "auth_ref": [] }, "zts_SeniorNotes4.450Due2048Member": { "xbrltype": "domainItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "SeniorNotes4.450Due2048Member", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "4.450% 2018 senior notes due 2048", "label": "Senior Notes 4.450% Due 2048 [Member]", "documentation": "Senior Notes 4.450% Due 2048 [Member]" } } }, "auth_ref": [] }, "zts_SeniorNotes4.500Due2025Member": { "xbrltype": "domainItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "SeniorNotes4.500Due2025Member", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsInterestRateRiskDetails", "http://www.zoetis.com/role/FinancialInstrumentsScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "4.500% 2015 senior notes due 2025", "label": "Senior Notes 4.500% Due 2025 [Member]", "documentation": "Senior Notes Due 2025 [Member]" } } }, "auth_ref": [] }, "zts_SeniorNotesDue2023Member": { "xbrltype": "domainItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "SeniorNotesDue2023Member", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsInterestRateRiskDetails", "http://www.zoetis.com/role/FinancialInstrumentsScheduleofLongtermDebtDetails", "http://www.zoetis.com/role/FinancialInstrumentsSeniorNotesOfferingandOtherLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Notes Due 2023", "label": "Senior Notes Due 2023 [Member]", "documentation": "Senior Notes Due 2023 [Member]" } } }, "auth_ref": [] }, "zts_SeniorNotesDue2043Member": { "xbrltype": "domainItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "SeniorNotesDue2043Member", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "4.700% 2013 senior notes due 2043", "label": "Senior Notes Due 2043 [Member]", "documentation": "Senior Notes Due 2043 [Member]" } } }, "auth_ref": [] }, "us-gaap_SeniorNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeniorNotesMember", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsFairValueofDebtDetails", "http://www.zoetis.com/role/FinancialInstrumentsInterestRateRiskDetails", "http://www.zoetis.com/role/FinancialInstrumentsScheduleofLongtermDebtDetails", "http://www.zoetis.com/role/FinancialInstrumentsSeniorNotesOfferingandOtherLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Notes", "label": "Senior Notes [Member]", "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors." } } }, "auth_ref": [] }, "us-gaap_SeveranceCosts1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeveranceCosts1", "crdr": "debit", "presentation": [ "http://www.zoetis.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandDivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee termination costs, net", "label": "Severance Costs", "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r16" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation expense", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r15" ] }, "zts_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGradedVestingPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGradedVestingPeriod", "presentation": [ "http://www.zoetis.com/role/ShareBasedPaymentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation, award graded vesting period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Graded Vesting Period", "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Graded Vesting Period" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://www.zoetis.com/role/ShareBasedPaymentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation, award vesting period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r864" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.zoetis.com/role/ShareBasedPaymentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation, granted, shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r501" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.zoetis.com/role/ShareBasedPaymentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation, weighted average grant date fair value (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r501" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://www.zoetis.com/role/ShareBasedPaymentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation, expected dividend rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r510" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://www.zoetis.com/role/ShareBasedPaymentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation, expected volatility rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r509" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://www.zoetis.com/role/ShareBasedPaymentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation, risk free interest rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r511" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.zoetis.com/role/ShareBasedPaymentsComponentsofShareBasedCompensationExpenseDetails", "http://www.zoetis.com/role/ShareBasedPaymentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r483", "r485", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://www.zoetis.com/role/ShareBasedPaymentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation, options granted, shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r494" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.zoetis.com/role/ShareBasedPaymentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation, Options, weighted average grant date fair value (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r504" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.zoetis.com/role/ShareBasedPaymentsComponentsofShareBasedCompensationExpenseDetails", "http://www.zoetis.com/role/ShareBasedPaymentsNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.zoetis.com/role/ShareBasedPaymentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation, weighted average exercise price (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r494" ] }, "zts_ShareBasedCompensationRelatedProceedsNetOfTaxesPaidOnWithholdingShares": { "xbrltype": "monetaryItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "ShareBasedCompensationRelatedProceedsNetOfTaxesPaidOnWithholdingShares", "crdr": "debit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation-related proceeds, net of taxes paid on withholding shares", "label": "Share-based compensation-related proceeds, net of taxes paid on withholding shares", "documentation": "Share-based compensation-related proceeds, net of taxes paid on withholding shares" } } }, "auth_ref": [] }, "srt_ShareRepurchaseProgramAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ShareRepurchaseProgramAxis", "presentation": [ "http://www.zoetis.com/role/StockholdersEquityChangesinCommonSharesandTreasuryStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share Repurchase Program [Axis]", "label": "Share Repurchase Program [Axis]", "documentation": "Information by share repurchase program." } } }, "auth_ref": [ "r1076" ] }, "srt_ShareRepurchaseProgramDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ShareRepurchaseProgramDomain", "presentation": [ "http://www.zoetis.com/role/StockholdersEquityChangesinCommonSharesandTreasuryStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share Repurchase Program [Domain]", "label": "Share Repurchase Program [Domain]", "documentation": "Name of share repurchase program." } } }, "auth_ref": [ "r1076" ] }, "zts_ShareRepurchaseProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "ShareRepurchaseProgramMember", "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Share Repurchase Program", "label": "Share Repurchase Program [Member]", "documentation": "Share Repurchase Program" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": [ "http://www.zoetis.com/role/ShareBasedPaymentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation, award expiration period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r865" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://www.zoetis.com/role/ShareBasedPaymentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation, expected term", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r508" ] }, "zts_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsTargetNumberofUnitsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsTargetNumberofUnitsPercentage", "presentation": [ "http://www.zoetis.com/role/ShareBasedPaymentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation, target number of units percentage", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Target Number of Units, Percentage", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Target Number of Units, Percentage" } } }, "auth_ref": [] }, "us-gaap_ShortTermBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermBorrowings", "crdr": "credit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term borrowings", "label": "Short-Term Debt", "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r108", "r180", "r878", "r1119" ] }, "us-gaap_ShortTermDebtLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtLineItems", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsCommercialPaperProgramDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term Debt [Line Items]", "label": "Short-Term Debt [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "zts_ShortTermDebtMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "ShortTermDebtMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsCommercialPaperProgramDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capacity of commercial paper program", "label": "Short-term Debt, Maximum Borrowing Capacity", "documentation": "Short-term Debt, Maximum Borrowing Capacity" } } }, "auth_ref": [] }, "us-gaap_ShortTermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtTypeAxis", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsCommercialPaperProgramDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term Debt, Type [Axis]", "label": "Short-Term Debt, Type [Axis]", "documentation": "Information by type of short-term debt arrangement." } } }, "auth_ref": [ "r110", "r1058", "r1059", "r1060" ] }, "us-gaap_ShortTermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtTypeDomain", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsCommercialPaperProgramDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term Debt, Type [Domain]", "label": "Short-Term Debt, Type [Domain]", "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing." } } }, "auth_ref": [ "r108", "r1058", "r1059", "r1060" ] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.zoetis.com/role/AccountingStandards" ], "lang": { "en-us": { "role": { "terseLabel": "Accounting Standards", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r152", "r289" ] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementBusinessSegmentsAxis", "presentation": [ "http://www.zoetis.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails", "http://www.zoetis.com/role/RevenueRevenuebyMajorSpeciesDetails", "http://www.zoetis.com/role/SegmentInformationSelectedStatementofIncomeDetails", "http://www.zoetis.com/role/SegmentInformationSelectedStatementofIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Axis]", "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": [ "r188", "r189", "r190", "r191", "r240", "r321", "r326", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r340", "r341", "r343", "r344", "r345", "r353", "r354", "r355", "r356", "r357", "r359", "r360", "r361", "r367", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r402", "r404", "r409", "r413", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r837", "r840", "r841", "r847", "r891", "r1121", "r1124", "r1125", "r1126", "r1127", "r1128", "r1129", "r1130", "r1131", "r1132", "r1133", "r1134", "r1135", "r1136", "r1137", "r1138", "r1139", "r1140", "r1141", "r1142", "r1143", "r1144", "r1145", "r1146", "r1147", "r1148", "r1149", "r1150", "r1151" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Axis]", "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r199", "r252", "r253", "r254", "r291", "r311", "r312", "r314", "r316", "r323", "r324", "r370", "r424", "r427", "r428", "r429", "r433", "r434", "r454", "r455", "r458", "r461", "r468", "r584", "r709", "r710", "r711", "r712", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r743", "r764", "r782", "r802", "r803", "r804", "r805", "r806", "r993", "r1012", "r1021" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED", "http://www.zoetis.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r24", "r120", "r123", "r124", "r238", "r273", "r274", "r275", "r294", "r295", "r296", "r298", "r303", "r305", "r307", "r322", "r371", "r372", "r403", "r469", "r536", "r537", "r543", "r544", "r545", "r547", "r550", "r551", "r564", "r565", "r566", "r567", "r568", "r569", "r572", "r590", "r592", "r593", "r594", "r595", "r596", "r599", "r601", "r609", "r673", "r699", "r700", "r701", "r717", "r782" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.zoetis.com/role/GoodwillandOtherIntangibleAssetsGoodwillDetails", "http://www.zoetis.com/role/RevenueRevenuebyGeographicAreaDetails", "http://www.zoetis.com/role/RevenueRevenuebyMajorSpeciesDetails", "http://www.zoetis.com/role/RevenueRevenuebyProductDetails", "http://www.zoetis.com/role/RevenueRevenuebySpeciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]", "documentation": "Information by geographical components." } } }, "auth_ref": [ "r202", "r204", "r207", "r209", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r365", "r366", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r729", "r730", "r731", "r788", "r790", "r793", "r801", "r809", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r826", "r857", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r890", "r896", "r1077", "r1121", "r1124", "r1125", "r1127", "r1128", "r1129", "r1130", "r1131", "r1132", "r1133", "r1134", "r1135", "r1136", "r1137", "r1138", "r1139", "r1140", "r1141", "r1142", "r1143", "r1144", "r1145", "r1146", "r1147", "r1148", "r1149", "r1150", "r1151" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED", "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEParentheticalUNAUDITED", "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED", "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r294", "r295", "r296", "r322", "r601", "r618", "r708", "r728", "r735", "r736", "r737", "r738", "r739", "r740", "r743", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r756", "r757", "r758", "r759", "r760", "r762", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r782", "r897" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Comprehensive Income [Abstract]", "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED", "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEParentheticalUNAUDITED", "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED", "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r294", "r295", "r296", "r322", "r368", "r601", "r618", "r708", "r728", "r735", "r736", "r737", "r738", "r739", "r740", "r743", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r756", "r757", "r758", "r759", "r760", "r762", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r782", "r897" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r916", "r926", "r936", "r968" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "srt_StockRepurchaseProgramAuthorizedAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StockRepurchaseProgramAuthorizedAmount1", "crdr": "credit", "presentation": [ "http://www.zoetis.com/role/StockholdersEquityChangesinCommonSharesandTreasuryStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock repurchase program, authorized amount", "label": "Share Repurchase Program, Authorized, Amount", "documentation": "Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership." } } }, "auth_ref": [ "r1076" ] }, "us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased", "presentation": [ "http://www.zoetis.com/role/StockholdersEquityChangesinCommonSharesandTreasuryStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock repurchase program, remaining number of shares authorized to be repurchased", "label": "Share Repurchase Program, Remaining Authorized, Number of Shares", "documentation": "Number of shares remaining authorized to be purchased under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "totalLabel": "Total Zoetis Inc. equity", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r120", "r123", "r124", "r154", "r745", "r761", "r783", "r784", "r878", "r906", "r1014", "r1031", "r1104", "r1154" ] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED", "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED", "http://www.zoetis.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total equity", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r70", "r71", "r73", "r238", "r239", "r274", "r294", "r295", "r296", "r298", "r303", "r305", "r371", "r372", "r403", "r469", "r536", "r537", "r543", "r544", "r545", "r547", "r550", "r551", "r564", "r565", "r566", "r567", "r568", "r569", "r572", "r590", "r592", "r596", "r600", "r609", "r700", "r701", "r715", "r745", "r761", "r783", "r784", "r807", "r905", "r1014", "r1031", "r1104", "r1154" ] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders\u2019 equity:", "label": "Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.zoetis.com/role/StockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders' Equity", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r164", "r290", "r453", "r455", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r467", "r469", "r571", "r785", "r786", "r808" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events [Abstract]", "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://www.zoetis.com/role/SubsequentEvent" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event", "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r610", "r611" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid during the period for:", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "zts_SwineMember": { "xbrltype": "domainItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "SwineMember", "presentation": [ "http://www.zoetis.com/role/RevenueRevenuebySpeciesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Swine", "label": "Swine [Member]", "documentation": "Swine [Member]" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r962" ] }, "us-gaap_TaxesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxesPayableCurrent", "crdr": "credit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Income taxes payable", "label": "Taxes Payable, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r110", "r111" ] }, "zts_TotalGeographicalAreaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "TotalGeographicalAreaMember", "presentation": [ "http://www.zoetis.com/role/RevenueRevenuebyGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total geographical area", "label": "Total Geographical Area [Member]", "documentation": "Total by Geographical Area [Member]" } } }, "auth_ref": [] }, "zts_TotalProductsandServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "TotalProductsandServicesMember", "presentation": [ "http://www.zoetis.com/role/RevenueRevenuebyProductDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total products and services", "label": "Total Products and Services [Member]", "documentation": "Total Products and Services [Member]" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r954" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r961" ] }, "us-gaap_TrademarksAndTradeNamesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TrademarksAndTradeNamesMember", "presentation": [ "http://www.zoetis.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Brands and tradenames", "label": "Trademarks and Trade Names [Member]", "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, or rights either acquired through registration of a business name to gain or protect exclusive use thereof." } } }, "auth_ref": [ "r69", "r1045", "r1047", "r1048", "r1049", "r1050", "r1051", "r1052", "r1053", "r1054", "r1055" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r981" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r983" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://www.zoetis.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TranslationAdjustmentForNetInvestmentHedgeIncreaseDecreaseNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TranslationAdjustmentForNetInvestmentHedgeIncreaseDecreaseNetOfTax", "crdr": "credit", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsCrosscurrencyforwardexchangecontractsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized net (losses)/gains on interest swap contracts, net of tax", "label": "Gain (Loss) on Derivative Used in Net Investment Hedge, after Tax", "documentation": "Amount, after tax, of reclassification from accumulated other comprehensive income (AOCI) of gain (loss) from increase (decrease) in fair value of net investment hedge." } } }, "auth_ref": [ "r193", "r561" ] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r984" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r985" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Expiration Date", "label": "Trading Arrangement Expiration Date" } } }, "auth_ref": [ "r985" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r983" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r983" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r986" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r984" ] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonMember", "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury Stock", "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r59" ] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonShares", "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDPARENTHETICAL", "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "verboseLabel": "Treasury stock, shares", "periodStartLabel": "Treasury stock, beginning balance (in shares)", "periodEndLabel": "Treasury stock, ending balance (in shares)", "label": "Treasury Stock, Common, Shares", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r59" ] }, "us-gaap_TreasuryStockSharesAcquired": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockSharesAcquired", "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury stock acquired, shares", "label": "Treasury Stock, Shares, Acquired", "documentation": "Number of shares that have been repurchased during the period and are being held in treasury." } } }, "auth_ref": [ "r24", "r120", "r167" ] }, "us-gaap_TreasuryStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockValue", "crdr": "debit", "calculation": { "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Treasury stock, at cost, 50,341,454 and 43,523,885 shares of common stock at September\u00a030, 2024 and December\u00a031, 2023, respectively", "label": "Treasury Stock, Value", "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury." } } }, "auth_ref": [ "r59", "r60", "r120", "r123" ] }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockValueAcquiredCostMethod", "crdr": "debit", "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Treasury stock acquired", "label": "Treasury Stock, Value, Acquired, Cost Method", "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method." } } }, "auth_ref": [ "r24", "r59", "r167" ] }, "us-gaap_TypeOfRestructuringDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfRestructuringDomain", "presentation": [ "http://www.zoetis.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandDivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Type of Restructuring [Domain]", "label": "Type of Restructuring [Domain]", "documentation": "Identification of the types of restructuring costs." } } }, "auth_ref": [ "r406", "r407", "r411", "r412" ] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "US", "presentation": [ "http://www.zoetis.com/role/GoodwillandOtherIntangibleAssetsGoodwillDetails", "http://www.zoetis.com/role/RevenueRevenuebyGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "United States", "verboseLabel": "United States (U.S.)", "label": "UNITED STATES" } } }, "auth_ref": [] }, "zts_UlianopolisBrazilMember": { "xbrltype": "domainItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "UlianopolisBrazilMember", "presentation": [ "http://www.zoetis.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ulianopolis, Brazil", "label": "Ulianopolis, Brazil [Member]", "documentation": "Ulianopolis, Brazil [Member]" } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r980" ] }, "zts_UnitedStatesSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "UnitedStatesSegmentMember", "presentation": [ "http://www.zoetis.com/role/RevenueRevenuebyMajorSpeciesDetails", "http://www.zoetis.com/role/SegmentInformationSelectedStatementofIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S.", "label": "United States Segment [Member]", "documentation": "United States Segment [Member]" } } }, "auth_ref": [] }, "us-gaap_UnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefits", "crdr": "credit", "presentation": [ "http://www.zoetis.com/role/IncomeTaxesTaxContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities associated with uncertain tax positions", "label": "Unrecognized Tax Benefits", "documentation": "Amount of unrecognized tax benefits." } } }, "auth_ref": [ "r521", "r531", "r866" ] }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "crdr": "credit", "presentation": [ "http://www.zoetis.com/role/IncomeTaxesTaxContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized tax benefits, income tax penalties and interest accrued", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return." } } }, "auth_ref": [ "r529", "r866" ] }, "zts_VaccinesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "VaccinesMember", "presentation": [ "http://www.zoetis.com/role/RevenueRevenuebyProductDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vaccines", "label": "Vaccines [Member]", "documentation": "Vaccines [Member]" } } }, "auth_ref": [] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year", "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]" } } }, "auth_ref": [ "r950" ] }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "calculation": { "http://www.zoetis.com/role/EarningsperShareDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.zoetis.com/role/EarningsperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock equivalents: stock options, RSUs, PSUs and DSUs", "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment", "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation." } } }, "auth_ref": [ "r1022" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://www.zoetis.com/role/EarningsperShareDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED", "http://www.zoetis.com/role/EarningsperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in shares)", "totalLabel": "Weighted-average common and potential dilutive shares outstanding", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r310", "r316" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://www.zoetis.com/role/EarningsperShareDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED", "http://www.zoetis.com/role/EarningsperShareDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Basic (in shares)", "terseLabel": "Weighted-average common shares outstanding", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r309", "r316" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "presentation": [ "http://www.zoetis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average common shares outstanding:", "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]" } } }, "auth_ref": [] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested", "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]" } } }, "auth_ref": [ "r948" ] }, "zts_Zts_FixedtoFloatInterestRateSwapMember": { "xbrltype": "domainItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "Zts_FixedtoFloatInterestRateSwapMember", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsFairValueofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fixed-to-floating interest rate swap contracts", "label": "zts_FixedtoFloatInterestRateSwap [Member]", "documentation": "zts_FixedtoFloatInterestRateSwap" } } }, "auth_ref": [] }, "zts_Zts_ForwardStartingInterestRateSwapMember": { "xbrltype": "domainItemType", "nsuri": "http://www.zoetis.com/20240930", "localname": "Zts_ForwardStartingInterestRateSwapMember", "presentation": [ "http://www.zoetis.com/role/FinancialInstrumentsCrosscurrencyforwardexchangecontractsDetails", "http://www.zoetis.com/role/FinancialInstrumentsFairValueofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forward-starting interest rate swap contracts", "label": "zts_ForwardStartingInterestRateSwap [Member]", "documentation": "zts_ForwardStartingInterestRateSwap" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "7", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-7" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "8", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-8" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-10" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(j)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(k)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-11" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-12" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-14" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(f)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477787/942-405-45-2" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)(1)", "SubTopic": "30", "Topic": "860", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-1A" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(2)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "SubTopic": "10", "Topic": "280", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-4" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(c)(2)", "SubTopic": "20", "Topic": "860", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4D" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "460", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "25", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479405/805-10-25-23" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "4A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-21" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4H", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4H" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4H", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4H" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-5" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "55", "Paragraph": "182", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "25", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480238/815-25-50-1" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-11" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3A" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4A" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4B" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5A" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5D" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-7" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-9" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A" }, "r159": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1" }, "r160": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r161": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r162": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-12A" }, "r163": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r164": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r165": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r166": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r167": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r168": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/805/tableOfContent" }, "r169": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38" }, "r170": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r171": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r172": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r173": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r174": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r175": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r176": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r177": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "25", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480238/815-25-50-1" }, "r178": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r179": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r180": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r181": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r182": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r183": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r184": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r185": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r186": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r187": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r188": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r189": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r190": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r191": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r192": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "430", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/430/tableOfContent" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "04", "Paragraph": "a", "Publisher": "SEC" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12", "Paragraph": "Column C", "Footnote": "5", "Publisher": "SEC" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12A", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12A", "Paragraph": "Column C", "Footnote": "4", "Publisher": "SEC" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(a)", "Footnote": "4", "Publisher": "SEC" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(b)", "Footnote": "4", "Publisher": "SEC" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column C", "Footnote": "2", "Publisher": "SEC" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "14", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "14", "Paragraph": "Column F", "Footnote": "7", "Publisher": "SEC" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column A", "Publisher": "SEC" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column B", "Publisher": "SEC" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column C", "Publisher": "SEC" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column D", "Publisher": "SEC" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column E", "Publisher": "SEC" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column F", "Publisher": "SEC" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column B", "Publisher": "SEC" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column C", "Publisher": "SEC" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column D", "Publisher": "SEC" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column E", "Publisher": "SEC" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column F", "Publisher": "SEC" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column G", "Publisher": "SEC" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column H", "Publisher": "SEC" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column I", "Publisher": "SEC" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "29", "Paragraph": "Column A", "Footnote": "4", "Publisher": "SEC" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(i)", "Publisher": "SEC" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(iii)(A)", "Publisher": "SEC" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(iii)(B)", "Publisher": "SEC" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(iv)", "Publisher": "SEC" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(i)", "Publisher": "SEC" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(iii)(A)", "Publisher": "SEC" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(iii)(B)", "Publisher": "SEC" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(iii)(C)", "Publisher": "SEC" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(iv)", "Publisher": "SEC" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 11", "Section": "L", "Publisher": "SEC" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 2", "Publisher": "SEC" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 4", "Publisher": "SEC" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-12" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/280/tableOfContent" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "36", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/330/tableOfContent" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-2" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/460/tableOfContent" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1B" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CCC", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4E" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4EE", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EE" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r769": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r770": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r772": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r773": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r774": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r775": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r776": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r777": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r778": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r779": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r780": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r781": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r782": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r783": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r784": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r785": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r786": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r787": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r788": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r789": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r790": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r791": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r792": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r793": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r794": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r795": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r796": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r797": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r798": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r799": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r800": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r801": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r802": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r803": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r804": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r805": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r806": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r807": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3" }, "r808": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r809": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r810": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r811": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "450", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477850/954-450-50-1" }, "r812": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r813": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r814": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r815": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r816": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r817": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r818": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r819": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r820": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r821": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r822": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r823": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r824": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(1)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r825": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r826": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r827": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r828": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r829": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r830": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r831": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r832": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r833": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r834": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r835": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r836": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r837": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r838": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r839": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r840": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r841": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r842": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r843": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r844": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r845": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r846": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r847": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r848": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r849": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27" }, "r850": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r851": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r852": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r853": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r854": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r855": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r856": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r857": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r858": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r859": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r860": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r861": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r862": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r863": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r864": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r865": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r866": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "217", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217" }, "r867": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r868": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r869": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r870": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r871": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r872": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r873": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r874": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r875": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r876": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r877": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r878": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r879": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r880": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r881": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r882": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r883": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r884": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r885": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r886": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r887": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r888": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r889": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r890": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r891": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r892": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r893": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r894": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r895": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r896": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r897": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r898": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r899": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r900": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r901": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r902": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column B)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r903": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r904": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r905": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r906": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r907": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r908": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r909": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r910": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r911": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r912": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r913": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r914": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r915": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r916": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r917": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r918": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r919": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r920": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r921": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r922": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r923": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r924": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r925": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r926": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r927": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r928": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r929": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r930": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r931": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r932": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r933": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r934": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r935": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r936": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r937": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r938": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r939": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r940": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r941": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r942": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r943": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r944": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r945": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r946": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r947": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r948": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r949": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r950": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r951": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r952": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r953": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r954": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r955": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r956": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r957": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r958": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r959": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r960": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r961": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r962": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r963": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r964": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r965": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r966": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r967": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r968": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r969": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r970": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r971": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r972": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r973": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r974": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r975": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r976": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r977": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r978": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r979": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r980": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r981": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r982": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r983": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r984": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r985": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r986": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r987": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r988": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r989": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r990": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r991": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r992": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r993": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r994": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r995": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CC", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CC" }, "r996": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Topic": "610", "Publisher": "FASB", "URI": "https://asc.fasb.org/610/tableOfContent" }, "r997": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(ii)", "Publisher": "SEC" }, "r998": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(iii)", "Publisher": "SEC" }, "r999": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 2", "Publisher": "SEC" }, "r1000": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1001": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1002": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1003": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1004": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r1005": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r1006": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r1007": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1008": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r1009": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r1010": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r1011": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r1012": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1013": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1014": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1015": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1016": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r1017": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r1018": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r1019": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r1020": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r1021": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r1022": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r1023": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r1024": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r1025": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r1026": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r1027": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r1028": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1029": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1030": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r1031": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r1032": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-20/tableOfContent" }, "r1033": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1034": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1035": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1036": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1037": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1038": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1039": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1040": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1041": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1042": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A" }, "r1043": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r1044": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r1045": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r1046": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1047": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1048": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1049": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1050": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1051": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1052": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1053": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1054": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1055": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1056": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2" }, "r1057": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r1058": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1059": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1060": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1061": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r1062": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3" }, "r1063": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r1064": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r1065": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r1066": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r1067": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r1068": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r1069": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r1070": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r1071": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r1072": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1073": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1074": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r1075": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r1076": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r1077": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r1078": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1079": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1080": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "720", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/720/tableOfContent" }, "r1081": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r1082": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r1083": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r1084": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r1085": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3" }, "r1086": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r1087": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B" }, "r1088": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CCC", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC" }, "r1089": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r1090": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r1091": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1092": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1093": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1094": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1095": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1096": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1097": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1098": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1099": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1100": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1101": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r1102": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r1103": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r1104": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r1105": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r1106": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r1107": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479424/830-30-S99-1" }, "r1108": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A" }, "r1109": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r1110": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r1111": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1112": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1113": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1114": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1115": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1116": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1117": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1118": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1119": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1120": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1121": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r1122": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1123": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1124": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1125": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1126": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r1127": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r1128": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r1129": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1130": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1131": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1132": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1133": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1134": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1135": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1136": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1137": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1138": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1139": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1140": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1141": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1142": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1143": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1144": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1145": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1146": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1147": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1148": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1149": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1150": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1151": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1152": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1153": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1154": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1155": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" } } } ZIP 98 0001555280-24-000332-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001555280-24-000332-xbrl.zip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‰B M^(E'H=C!K_!BD:&>^D'L_.3$Q$.+^P63FK1,%8V!>8@N5]E7@Y2BQJ.^<17: M1H9>U%J7F=(E27J349\2G(Y/CI?Z*!2W:$Z,W\)L57=NFU%+4A<\FR%U$QF[/-944U:J!DOC$EWLMIR)ZNN[F2U$]*>>">K@PBS M,'N&2FDJH\\&@\%6?4BI)H@Z_9'F&ZIB,;&C)>)5,%MR>+R2S_AR_[ M3,G@7D#$&:BHH F7T&X7:<7K@88ONA-*O(\.8' ?9 M^QDHR[!;(8RHBLUC5)0_Z0R*FTP6^F1' M"I"04=SY<+ #A31EZJWJ11M)@52&O=2W4%7(: E5.T8F1Y:Y%I\D*?.%VKWXP$\MQJ('9' MS=\=\E7*FXF_*,?LM!'NAKPZ J#$R6@?/(#QN M] #-Q!TQ,3Y$2.21B.;@W%/F)Q[0]4(TI30?=L6'1!Q#9. (FB-7\#>'BRP* MBC(ZPNBWQL+%T-O8+CFC(FI/N(LY[A.+3ZI9_XFZ "/7L+.]2?Q W\E4@!O< M'#DP>(S!:0[MB$/8<3D,*&"#&@QV?@JMASXN(XZYNVS\30B NT(MUEWR<<,_DL&IH*^.8_,4I7<*'I>G\$#%)PC%I]<5$LWNS]J1*_69,\J? MC.,H$<2;3+D7<4K@D,."T!/Q;EB3IMX8=QH34?EZ \.T*:]''E*KB'(B*3EB M6/Q5I@M.1_P6I1%'H;**S*IGXXF-)S88O.;]M.#7S1;*S1XK# M .O;L#'10N8_RZ]'(+J4&?NB!7%7.[M,$+%9Z)@C4/PVFY+TX&F>ZTT%[B28 MT#ZE-H-($/_3L75*AQ%'9N0[P4A#/%,3=33PBI[-QT(23 9"CT)FC65!A%8R MNW:QI*J0R4L5X6*)E!*9NX3N%;)*IOW@OBZ,KX!3O5GJ<"L2&0M,P*EII^(= MFID["R_A:176_4DGEE9J% >,L]1DCJ%$T9.EAK2[)QBIV;0KB]H6IQJSVRN6 M_*A:J%E_!QDXMGSRASVX8' &1AFWE8.L#R'WP#?!-9D(DCQHC+6=,I1%(9;( M6@P\+-[%$ZUAG&*3\IEF8:IF+#J1KE!VHK")(@\M&1KI MLX")FE9S6DG"!*LG)^K)XN\HE[CGP4_HTN.096J#3( 01$AEX:A<&BX2'RP:DR1:2;Y*//)9Y0,KG3,9(F+ M)45:-)CD2B<)NUR>*\8OH1)1N#( ]RX@PT(6Y?Q:?:B*\Q-*?.;,PU(;Q!2P M^CR^(JJL$HEN,D].H0)X<2:62I7S7/A*1X3V@<*6CL8F!6; ^*02&+ C4OD=:%QH1NU^-4:^MA_*RIK ,)D_ MHL-14H"$/2PQIIT9Z=H+>)^RGE"%:S[M+E0KEHE*$_=Y@+LNF-"B1$P6 M!'ZW_!_&9W&-*@L$.^LVX&.C?D5;YC?F!<:M6EX(&&!<4<%\)3E'CI4I$';#U61"APA MRZ?&,:H.0=Q',<9$40"]8,6D?-B>?#J3#!!\@R*5F-B17W=8-?[EAJHQ#6%' MP/8&/ X)+(02")!#^76+"ZL?_ DEGCCH$46X&WW:5E4R(WPS)5(ARA)5%I.$ M!8CHX;@)HXV(&,*?)CPMG-!3\H>%H$.'42OU'!="@HNO@16-?GA=((?)288BK#FVQ7,0&PGC(JF^2OQ;;X/V-J7IY)0J26 M9$1VIKF2+44@%YA4@*9[X.[6[IP[Z)Q$.&1*F4@?C*=B4%)J"+@5 M'F$Y&X"/=5X!'RO#AMC*W1"OY8D+"=PW3*SLDXP51$=DSRE>#$;.^(N]63NJ M&2TA+C$_J@AQ121 >FE^.,&PG*].?",G4L ;85I4#/XD:['B;K])H.0$3C$L MT^N1Q0?$;HVZYQW"@[/8J?OL<[3CRMXIZB\C(AKLH.*_""YQZ"9/KJ[:T M*+H;\\I,\FH2R]H[H$"?#Q26VG?R[NM-=E9OO^/OZ>IZNR__BLGS"F3:^ZKQ M"V4,AA,J!0#G.D'UA8"(E4R"KD$V.F''D^Q^C+$X^]@E"$3FFB(\M4$V,!O2 M%9$N2FF4Z+>A1^$CH"*S$<5>G):,Z0N*?]F4-^?09I@ =4SHSB0,:X^KX0G6 M4)((8::"8:$B'@/+YOV9"$>AU<=U;(=2;W0TOZ0>(4LSP4>QE5F);G-%5"@2 M2ARY,W8)(@310($Q/M8 _AZ"NHACJ",FXDNTHV((3"X=R5Y+4<1,4B2)YR(I M0LN6 E#4#=3*7\.#U!H>K+*&Q;+!(2?"KN+T&*-ZA*00KX6I $B;)F4[NKZR MVO1T9&O;D:UZV2-;71W9.NK(5NU@1OJWJ^^/QNTMG?'5&Q^,^\>_W'PW;N\^ MWW__>O5X>W^WMOO2:KR.G5QT[Z6>Z[U\H7S*;PEBPJUPE9B13.HJMP!*G *HJ5YQSIQ/ 5.(*E8V 7$0RD#J5 M-L&M%6@,J;-IE?\2Q_!D]8E,@+D'*_X^0C6^B1/:538,Z@YYK#%1S)]B[2LBK@HOXIHY&J(7QT$H?-%2>T#06>#_-R \1!,DRXT9!84305).HB1-7 M?>]RXMQ)(J3:XO7C!GO8"BKJK4<'3\5H59 CD1$VKR!4%$&BQJ8P-)M-?'ZI M/GS @BN;32\MA]Y -WU(AX%0VLVK(].RPK&@;O7:72&KU%"&$OW4MUSB38 MB5O8IISU5X>8$1Q'GIPUJ_4,=83XZB+Z^(Z]GPG:1?V.\R5GV:[1IR$;CR[6 M]]V%9%BAY2-V4"4K_5**12]+++:M1S87E7TV$5].&JXP>V[(P2? $I]OV*GR M&\@%"<4RG=PU,5=86IA90)$ =,)4[02XO"[FS5.*"EKXOJ;[JD*,I8,O L'J M$UJ^GO$_JKFIY$&@PCC_XH'Q"T_PY%?RW[ZIEEV93'C--&'FCZ$'7.R?R1F; MX& /!FOO&@>@X5]#D,6Z<6;0!YELU\H5Q<;KDU]:OFI&!GWH-+I(!.ITZY7: M13>=3ZGHLC5:X*]$DV5ID;^\7Q/*U]3#-N92:(Z^K9^?5R^ZRZC;M6AY@FOD MO%-IU%MZC1S/&FG7&I5VMUWIUBXVVQ(']%^9MD09PL5-47[<:%O,($ Y5G6W M>5XY;S967-79_-[9PIUYW)_U*G/IOX8>5;H^AJM=NKKM%LKA?= M4BS5&JUW:]5VYY .4QF%N5;I=BZT,!>,+[#AU+O=2KO9J5QT6UOU;=:UIJ37 M*,_EF\#OOAOB*;\BQI&%"QJ59J-6:9ZONCBV3BYMRVW;,6E66^L%UO126G2L7FZVN[U$^4T;4BYB(B+.X><[%=;2R%>9A]Y-^H7BR9"++5 M05\L"129G8Q[-09Q"WQ$&"&,\C26#'QK^0+2V'4,AP=S29X+,-..G9^]0_+3 MR&/H8YQ4FLH?K<.R;'55]NEL-ND999/*:G@)9I*3SJG@*3TN@/UD=@ A.:@, M 19E""S*#U;)Q)0KJQ" Y #I^0BY*VO**"4?(2G=*1>%8C[B+I (#1E4>OR+JQ0-W+-?+R =)VHC"\C9[?C]; M+Y>.Z]QARUV!0X>4_X[U_.89F/ .&\-@N-F_!"E P)!ZK=>N7WG>HS=V@OYG MFPW?&&+V( XOP>7 >N%]&*KM\SJ-;V^!-5WT7=NRE7U5?Y57KSZCQ MYB/>;.#=9W7CT6.T3<-SL-AN+) -4N/X^/K?"\M=-A(QOW/PQ2^.*L=9+'JW 3KZEC0!%F4A3F[UP!;DGDL4CZF";5[IA M=@0&=H7B9TQ(9M\(I*A.;) MU%@K$X1&!LKN$PN20SA/'9\UU('9+#T$A+8O MNHSV!8959/4B[C40DK3I$X*6#:C=.UBXB=7VSEP!GJA"2.=C>E75^ KV+\K% M?_MB_E%]&\(>OK/>BUHVV9U-E/=)^GPF#$^@5^A8@CK"T'XS1['V&^R:3"V- M__3F]N[S/ 'C(5\-AU?8>O=J'*29[(3CL[Y+B"OXI 29+]Y\;#^J4@]9T9P(V,+VS(''=E M?9G]FK2";M9@>XY5\_]0206L#,+EKQA_%MWDC6N@I<]M"60B"^Q1GW@\8-YT MLZ&MJ\J;M>:N5'D&Z3)5>;/62JGR9F%5N9"AJ,QX7J4GU3FJ]WGET%E>!UXL MK0.;M79"!\IWS.G RKH[3'>7.TRS!K9$J])L=E?=8"*5KJC\F?>\$%:249?* M=@DJMVHK4/E\*2IC!%\%\Z)HKV^\P\_X=3K4]EZ"<.#"BB S$J&V5;G5JN^6 M6Q?(K8OVQ3RW8+/P_5=X)H+#U9;10Q@DK27QXA7(>XY3/!,AG71D-Q;@Q M%&.CY%",G=K.H!C5=3!!\PRXA1)_Z8=CX.4TGUN'QFE,C9:_C*R>%7PX]/AV M#MZ8Q:,/"X-A90!K[^2&!&\$8Z,@[W[A0;J=:@=Q/E9#!ZDWJYWNQ5:0*NK5 M=J.U%:2*BT:U>;YX4$OB#:R!%;!O)5(KN!)9/#ZI1%B]]CM_:=;KOS?1I*Z. M@C&Z831&\+>K]0QUD9^2M&1V28F2RW-"AN2^U#]-=)7-2KXS#K(Q&SLIHZ)61U9I!KXQ3 M61F-[#VCH?>,W>T9W5I'KXSBKXSL/:.A]XS=[1E[6AD'(-K-/\_JM7KU]NYA MB:* XY.96W*OC7_^\OV+ 31XO+J[OC$^W5__^O7F[E$KP^(JPS\"_PRU8*W; MK%5?_'XDR0_7?SEQ/9B4Z<>K?][?W7_]EW'SS\>;NX?;^SL#"'3S]4H+>K!ZW;2R?V-NNEQ/[+ MU2]:[!>)/1#HYHL6^-(*_,3C*8'_]OU&"_PB@0<"/8" :T5?;KGO\T%*[C_= M?-9ROTCN@4"W=[>'D_I#12OR,9>.61BNJ>?M-X0$I_['3/25_L0"9GRV;"Z2 M#=Z)%+% 0%HG!0@3[3 1C5FRVZ^*',):>V_,R\LR]>N=5PL^]YWRE9E<4I#\ MK6;9\[>:NI7NT65CI5.**--JY^TPELRK>KC]\]W5XZ]@W2V9JTFC3U>2'F:I M?TN<+E!_O52M_F"YU'9Q(W:0\_!1V$Z]CPCP)@NQ>)_ZFHG&Y_B:'C=\X!C\ MX#J&!:_I\1&S!Z))+1U[;3":IY7V[7%?9DV:8G3*9;A\OHZ)@4OL\QO';.:99;.V BX MB-]LR:Q;];+C,93OP%JD(HC6*S"E6W%^9QXA 4+JU<9 M9"E:K/ST\)/QM^^W#X^W=\9UU?AV<_VW=9R_[:RH77?J2@E8N]I))H:3::^^ MG&=9,<10E:)?5V4U^IQ([I5?FB6Y"56B.%AVA,WGT^SNU=*[E]Z]].ZURN[U MCYO'QYN[?QE_O7^X^?:7$FQ>G6456I$H_0\>!-R9&G]U?3X9'8[*I2=D'HR M*&66=#U ;^I%.9!Y^]=7[3GGDI"$I).<2>^A@73G7))P(9G9W9<]PA:@;2,QDIR$_NMO M2;;!X _90+H]U_1#&HRJ2E6_TE>I)/_V][>9:[U@+@BC-[63HT;-PM1F#J&3 MF]KSTVW]LO;W3[_\\MM_U>O_^#SH61UF>S-,I=7F&$GL6*]$3BTYQ=8?C'\C M+\CJNTB.&9_5ZY\T69O-%YQ,IM(Z;9PVPV+AK_S:_GAQ]G$T&M7 M9Q<7)\XEUDS?Q+6PIWB&+%"-BNLW<5.;2CF_/CY^?7T]>CT[8GQR?-IHG!S_ MX[XWU$5K05F7T&]KI=]&W W+GQVKGT=(X+#X=[G.^SO#DH@CF\V.E:Z-J[-& M6%0Q(AFL"14247O)VI&\+A=S+$Z2B>#W8_6[$M2H-T[JIR2')41I?>O"D2 VRW"BI&HDD MZEL]I*NK1_634W"*K>NP:B7%ZA#2[5B'Q):1!HJ)4G\7NU9CVVYV[B\(G^"WRWBW-3"U0"B M3I=*(A=W5$W]-=^:I8H^#^[2YG>Z(ID<0LFA[)6K?FKH?R=6?;4BB7P$;I;/ MSHKP^^UXD\L&?T]@YY%^TI\W>X6 ."B20;AAVMQTZ^TPD2QX&$*0 4S[\:'3 M?1AV._!A^-B[Z[2>NIWA$_R][SX\#1]O[Q[:C_?=YX?6<^<.?LH'5F&N&0!> M79V?GIPK (=@9!P@N)1@1458*QG6XZWE2[$^+.7\>D!VA0'8IC_H?H4R=[]W MWP?F3!%&S$^WP7Q-Y,$#BL+31S"EE5/ &53X >Z0(L_H&V?[\XVU*OQZ\)65 M^3ZW>JV'=G?XM=M]&N[#&5(8&M%NYD,[8&_Y_ ](F@S?;PV@:7SM/MVU6[V] MP[K.W8CQ^:X80TN.2JP\YM&>M_N_SW=/_]QW?[[)U8CQQ3:]MB_ET)I3QM36 M\.MM[_&/O?3/!L9&?#]N-2J#($M+JBC&CWR"*/E>8#&\1F%$Y5*M>(FP728\ MCN%+E+Q"=OZ,!!%LW(\HD<_<281&JU]M6EUSL=C8BO*ID/E;M@[9$SH9JB@. MXH[(9_XD0I/Y+QJ;YE]QL99L*F3] 7[!U,/Y+!X6-EKY9-/* 66%#-NR__2( MT-P$N%6'O& AB01SY';O= 9& $[C;K[BIL.;47X5@F4 2G//!K6AQ;>G*I- M6?<1%OJ\S804+2&8351JBLI,V1G%/LC" AY^ ZB0U=ML-B-2MW/H?MM,1X8P3$;R#L59 M#(Q8Q);M$6YZ.%CC5R%8AGBBC% X/2R!S@A";!D=,*EH*MC0&PG\IP<*=-4T M,:?=-XB,1H\M>E<<+,VB0A9/"&SWF4OR]T%9#+*1:#;CXT%2A-SZ$#*LTHY< M$,5>_F>SB<];A>KP&'..G>#')P23]=PQPJ)LC2#&!I* /O+_4HH?XPOD+ M\ M\$55"=Z,X&L1.,ULC/#%AJ#,F&P5L=I?7+U82]VS5*,GQ,;%=XCI5]%_TL+S M1;S!P,.(;2S>; CT5Q&GI(AR$8PRZ(WXY(M+5Q&52,2X"!AQ,B,&6<'J*EK> M%&\N D=.7D:,MHI@5Q&\>$BZ"%RIU$: :O.!"&*01&W%(6/_[\3E8$8;,J@Q'\-]H M\06S"4?S*;%;'*-MP#&P,D(56\ZOH H_C1;6BKFEN!^P X/?H_\P/IQCM9^P M$W))C(RXQ9;YB;AIUE; ^X :&'L?@!7%*A8.2,3J@-+*PGW.5!1Q)Y0V>!A1 MB@4$$E$*N%82I8R=@38\(K .]"?-'%'A[\P50G '_D9T8]&$[,T%E<02D6A% M1!Z@7X?&_ZP_[0GL.$<3O%<))^2RX5W).."Y;GUU.:SCN9B-_9CG5^PZL(8= M(K?8ZF$W$4;$$S(^LA$/A:I3JT$T5\FUQFJ&!)(KZ0?[VQLN.%;O6ZS17Q*2 M2]YA3[J"+I2VH5PLW&-@8H0W'OHQ;4M7$*K(P3+]A]'0Y 6@,C$Q0A6+#D5/ MK,%7_W^8= 7/*XY4F.06?-D.J40F1J0RSQ:JW\+\._]!Q8&"/VN9[CNTJD0^ M1KAB,:%XPUK/Q:\D8DG)-6UP8B)OD4U<(HM"5X2A$<-8K"@Y?:=N^1*LE8@# MF*'MV6R&N7K81W/,^US%KF>[0YK)U@AL++R4"NQ2CJ4%68&D [Z!C8:8$L8? MF,3B<0P#$'1GX=JAQ^CD":L7<(R*S3_W(,?H ;$05)H'^((M+=D*14=6)DIZ M78FWE/R#7X1X+:,*RD!R;VZ0R=: ^GDC%IE*13T2G] (RP/"&U#<(L)_1ZX' M6.P%VA1^1DQCL:@).6-@6F@]E&H%8NNA M7&LI^. ,23"18&SD,#2*5S1_)V\PBC&Z0\[(V88[A'(M)=A2DBON$)$SB 5W M)F)T1LABH:ZU Y 5-+[IU&+X>R%DBC(UP782BU7E.A,9*7: -H["=F_ MJJ>8"EW;[IOZ6*S-[T&.T1_B]\0EG:K6NY"!9+7(BA:*2K<"\0>WT';;KJO/ MP<<(:_PFNF18J]V9Q\^^M_5241"J=MT9U593*:9/'".PY$)3%$-S-QE&I&.Q ML<13^'4KD KK(,N7Z[N$G[0:BO:)#[ZPCE/+MKV9JB .,Y)GH.L4.CIH.#U8 M9>[+(7(+,GI%+'AF]HJ(\&7&17TC,VKV0HA'8:L1'!6- KZ4*'"J*1 M<35Q(6!R\#%B%(M$9=YT7$FXXE=H%.LL4\F-X,3O"TJZ@N, "3 =8A?;T.\O M7V_)QEL$-4J%3PL40&++)D,L."-OZ',A[ M0AR+.0;>">#9&#OJF.;C6)\QZB,"/9AJ[&KEJ6[RUR&'5"OMBWU)&P@ 3H0Z MTP5+;:@7U!UTV6@!#O232J]4&Q5C4E9'4GX^"(_@0E\77*-"7HA\)O\[#+[6ZK)WD?8>W9.,A1CMF12PD4KL$-:KYM-LW?%_"? M'IIHG@%77ZXSYFS6?9.84^2V/2%A7L?%^N58^OI$,_S;,RP)Q-D*[-,8Y;;# M@Z>F!6P\P!.BDCN#=4'Z>)).8-:(0-- M%C_IW*,)ICGU>1QW&8,[CLB>IV>2E&&:KBO8A5YL H-,?I52*,J@T1,LXMW519O(53=M M9JN425(&G=I!QN4]HMX8!>M?1)VOW@S1KQBYKK9:YDB^R:[U1J SUOB5BFEWI:(DRU%C/]/I3Q&?( MQL =)D9YYH8I%&702$_T@C6%2E\88OY";%-O8Z(J@V9]Q)$*P-G$,:F36+0, M.OR.;%LM]+*KOUFJ##7O8+6_REPV,?1+"07+4/\6E>2.CK$*[N+0T[,UR20I M@TY]*#7$CI9B:A#QDN^G00%0U,*EX.K.0%0&8.ZQ P,#+ IN,79:CD/T+D*V M6MDT9=!*#WT/C!8?+].)RJ!7'TME_+>>= RM*%ZP!(THW#1NL]F(^*NVM#OP MVTA,]:8H=IU;QOO0' M,E&5P%54KH%*UGZD'2+FS-_.7*4=#*"T2O;71(_C@4J0HFK+F.KST,QUU38= M53$;52(SI6&?8@H$Q7^@E_BZ(5EMSZ*GF[0]Q#UES>JUFC5G:R<;O6F@%O_30'[L&L1:7]YTW9G MY.]:S)*2D^F,0^/Q[9A>7[Y$W,H8&]IRD>\)M\>L7N M"[Z'D7*:OO3:IXB?::KAE''YM+QV55?W,^.&Q3*)BJ'7A?Q*IZ=FO3*)"J#7C&KG^5N2QOERZ"-ZJA7 MF>3]Y5D>8N,^YC8\@TH_L0Y[I1..'*P.AX5QGR_J0?J:??LP_+B00E4ZOJ["*EP7TBA.53"]=NV;! M;J=9JFYGW>#GOL&;1;PO3E0RO9I'S;"*^;TOB:@,>D5?DA.^(Z$UEIC_$R-^ MR[STT$ .RI(N!]22[C%94#Z7RI- MS+]^>0AVDGJG9W6W__ 5S;-5+L"@-/J2-^Q(=NLR)+=0-@=U&31=2QHND%]< M)AW"%RNIR6)P\0)VR0MV6M2Y77W;O,! 'XI+[7YWXKD'JSCR>KI0$U)OI",T MVYV]#/*?](:B:2,\J6@9X/7-W0N,OX*CEP2 ZEL52Y&FYK;?\KG90Z*2O*U[PWH&= M)+T3_B%13NN-,G0:+59%HCHM7^ !/NW-YHH*^BD^P3(\3JN.PHA@_8TFZ:OW M'UF%]W38W.O\#K9U^X%UW\DVMZ'DIR]#^VQY$T](J&MS&UWS4I<@H>I9;;RP M.7.)^,S1=V*8^*06+P-H:C=^=2OAPD]!53.T\+BR>H@:$])* MDVZ[RGN!UK;L2IH[D'KQ5P?/.59WIA%U\^7R[<:UI+9J8ZY2 M28=D0LF8V-!S#-0[I=1VN3\S%GYR&G94FJZZ#U#U5^K"$[_/\J#8,O%"C/"8 M<>R7TY=*;2:H^FOQ]+N%?DYMRIHD5<0^%=4M?]'T[4FKB/33=$)!0LP;1_P-X0I;B')C"= MSU8@L6C95'CB2&5L1];?P0LHS%=X%.=3?N7]=R#H>(,A0K8%HQ^JOK[U5]A3 M/$.??OD_4$L#!!0 ( (-N9%G:<'I\(2, )9< 0 4 >G1S+3(P,C0P M.3,P7V-A;"YX;6SE?5ES6SF2[GO_"M^ZKS?;V)>.Z9[P6N4(5\EAN;KF/C&P M)"Q.4Z3FD+*M_O63("659$D6%QSRN.K!LD11/!^0'Q*9B43F?_SGE]/)DT_8 MS<>SZ=]_X']E/SS!:9KE\?3CWW_X]<-K<#_\YS_^\I?_^#\ __7\_=LG+V?I M_!2GBRO\:?PY-TD+,JL.P7XQ_+/7LS.+KKQ MQY/%$\&$NGK;U6^[OR5KI(VQ@.,A@S(!P16F0&)*S"9OC&+_[^/?&/-6:>4@ M!95 J6 @YI# I>*<-(9GA\L/G8RG__I;_1+#')_0\*;SY8]__^%DL3C[V].G MGS]__NN7V$W^.NL^/A6,R:=7[_[A\NU?[KS_LUR^FWOOGRY_>_W6^?B^-]+' M\J?_]?/;XW2"IP'&T_DB3%-]P'S\M_GRQ;>S%!;+67\4UY,'WU%_@JNW07T) MN #)__IEGG_XQU^>/%E-1S>;X'LL3^K_O[Y_<^N1_Y[A8CS_:YJ=/JV_?OKB MZ)>7KWXY?O62OCD^>OOFY;,/KUX>?Z"O/[_ZYLWO[PX^OG5K[\\^_7E M&_H5C6GYC,7%&?[]A_GX]&R"5Z^==%C^_L._%W.HLF=>L@KL_V[\B*>_#R6% M23J?+&?N+?U\^:"*O,=1X9<%3C.NIO0*R626;KUI4@4ZZZ[^S^7R$J2C+2P$3G 3800A>1"690AWI[%.K@YC6Y) M@!+F<$,:XA3K)[WN9J'I.&N/H#+NE9.;/D50 KM[W(7S!^:LOBR[,.M(KH;MXL\#3^2\S^NUT0=*A MQWQ\,UU@A_/%R+F(0;( ,5D-"E, %Z.&(J60HTRUG5 M6*\]"&8=YLD]&:%#(UY;238CUGN<(WW,R;-I?HF?<#([JT&72TBOOJ3)>8W0 M/$O_*^Z=",O_7)1^7'V2S/"?,Q=I_&!.AX-LDCJU7P(B;PPA,>$4A1 M*V] 9:Z*%ZH$+(WI^3":==BG_^SL:R3,9N0ZQN78?B2/L0L3@O0LGXZGX_FB MSM*G:\4M+//&D'G*$T>R")B"&&G(IJ247%:&V]:1I/60K4,Z\V=.=I<=X1NA]\O)0B*6E".%^,Z4WX'B?58JUK:#ZRR3H; M44-*(8+RG(%/1@(K,7%G5++ZL=CYKAC6(9_]LY)OKP)N:"Q^PNDYSD?>!!V= M=\"+#Z!4,N"-C2",,UYQ'I)N;_FMGKT.K=R?W,?82D[M?%5<_#XQ(QNTD69) M3TGN_//5'M(>OOF\/>1 K#_>1@D11XL3[%[,3L\Z/"%SGHRJWYE$M#HJ MM#F/R+!GVF4/FM< 7"!',TI))E:P41K--9EL9KLD[&'ZF\Y N;<_E3Y>*(__W^7Q18T'7LV6<#D4D!QBB)([W&VMA_)D';6YCS]6H<.@ S--N]OC>5%F)^\GLP^_X3Y(_X8QM/E MGE%H7WB/:1+F\W$9K]+BZMAH!%EZH5/FH*(F\\,Q#;[H!-HI6;A3QG*]1SIO MBG_#+?^/2^)>!;\7ZKZK+RSA+=_UCOS]CO;7#NN*N\Q>>3>AU7C/.@S,EU)T MABPTF5>6>8B,D=>'(AC&0B*S:X\LWF$H&YXE]FO#'I31^^)#PS.9.^.X!J24 M9LD%"8'V!5!(_IXWV4")I41.'H"-K=7L-^#T.%+Z:758]JXF&Y#XUO%7F$84 M3$LH(I(NXCP1A;0"EF+P5A2>6.L(0^,A#,F8:L7#N\=4AY/Z/A;I6J"=LM[R MZE"C1U ^"HC&DY.-F+W.J&)*^Z/J=Q<5.0 WFXMU'US<:D&AL38P-( \$W1% MWH@3*8!%VO.85B;H_#VIT9VBUL&+FGUA0)80R 2(!4*HT; 869).HN6M%^HP MH]:'9-DWXMZ;R&U'O*A!.M3!J61]B4R;L$[1T!M42DR&BMOG5JX>3SL ML*[ND#C57*;[CH@_?_;VV2\O7AW_].K5A^/F\>\'/KVG:/ T2=;8&$F/E 1&59'%+5#9%GRQJMU]>1==='J4U91QP6I0^*GR X$C^2Q M"DO&L'$<9*K7?E34UK8^7[L%8$@[UA:2_5HI;#^YS?8:VNO.L%MT5KYU[MRW\ QI;VD@_693 MWXP,-;GS\W@R&:5 XV*%G!Q5PZZA('@N AB.W*,TA3/:1K"@V$O-64 M-KS1^-7U&5QB8NAB=*[U6>$ZN#:\$C!T M(C0715MWX^IZU31=[D8J)UVTEZ 5(\]')@%.60E>F229U]SE7L[;OP:R86[^ MT&FP^V2WD_O53:>W&.;XOL[?4?EUON+GR*;BH\@:;,X)%-:,+ZYI S)6<\Y3 M%J'U!8UO MHP77[P/&@V^*:E306>N5!YOJ[:%$/G!, M9)<8ARF[E!0/K97!PV@VS%T?.A,:37LS&MQV2@HSJK",$%G4H!Q]\<()X*S0 MAB2M=+9U@/(;'M\V%M G^I19=U'G,S'%,E,1N"%[6IG(:%EYI/84)0YL\6 M+T+77="V^\\P.<>1L<+'* 4(B8Z@A0PA&@/H#2_2*.93ZP#'6L"&YP2W8$E[ MF?3A UV-5)68A#>3VHR8S7 M3$46E6I=LF\+F,/SFIML,SW+J]W=],4L_>MD-J%YGE=5M[C8[L 1N4S)63+X M [F!L69^:'(('0MD7VD94+:V5]L@;S]_(Y.]<3XIP%P#XI:^EX>2.FCFY5H.,C3E,%1#L)>I8%F%P05"D,7,@9>#T) M8TQ'^F7[).&'X PI'-,K)UJ)I ^]<.5 1A.MJS]XTS\&P3*R2^FM(0R()P(1@0Q4O&BXHF]9+_ MM1TA]G4&T@M S./HQI2"*8Q/QJ+I*5U=(5CK1O_P4G:GX,$ MLN]-O14HZWEX .MMTL;[:$7S]/K-( XI'--:R?0HK'9>>8=A?MY=+,>^RI!E MG@E/"A"$"8J8S0(X&1@XA36&J!.IQ-9.^1T4@^K8U)@8.\YYTQ/2V?0&"HW. MJV@U^7GU;$]&3Z8^6?XQH DY^U*XZ>%8]":&(<5B&HM]I^GN)17"$;FB)3,^ M&DD N _@9="5A!B]=,&;UD'8!U,AFAS>!G)&0RD:D F$6DJM]@H6P S)1GE5 MC&A]JW2[H-$!CC@WDO8WSJ2VF>MV[)U-/]8CUI<8%S,^[$AD9SWU/)B2M@%S@320$\@=R)'2RDMJ>5@)7#BE?'(^Q=9%\QY'M:&OVWNWN3[(=*>P8EM9-3Q'.KM$=E1N M^FRCDKCSQAN(61":1+A\*DLT)O@0)&)K[_@A+(.JP[\GOC212[N*K-=8CBX[ MT5X?]X]JV)$;80%#S1 E%QXBR@3):&5Y8CZJUO'?;\ 95!>@/>N67:73I OY M\4GH\#DIMUR/KG Z7T[49<(8S41"S-?'5S7-<)R/IK^-%R$]<^I (FQ9.WH)K_;7OJE# MK^_9+)5H1".SL@ER[2>KL#8MD<4#K13)&3"A)TZ*1*I JSC6FZFK>9;;< MMC;AUT?74M&3N5,_?G'>D4OU_'P^GN)\CJLMJL)9_1[SB$D9F*$I$%Y94-Y; MDIC.4*PC:UHHM*YU1O@V.(=T&-P3W[ZU#?0BSEXLC.,P(8@/-DT@$T@7##R M#LOJ-/5 PS!'WY'&*A83CZWS -Z1SYP/0K*7PFGO:'V;/$B$A._R2_Q\^ MSZX7P.6O\H@0<*:X!&TD+8!@ D2>?>T,IGS2(CILG;JR$<#OP1MO3K'>)-B< M9&3WW%P0RY/9^Z9#^GK-3W% K#EGNEI7.6@(3EA>O)2,-U=CFT$<5.;GGHG6 MAQ3[TVM_?70;>N9_*((UEEW? M:NPGS!_QOKG02;)L5 17.,V%, @^<0&<=O4H,23O>SP,6P?B]^"#[TF--9%B M?VILA6SYVB@QD:/D'&*L?3*%R[4OFH(HI-71:NE+-T8^ \Q!1%#" 9JY7N-*]N;"UD6GNPV2!5\ZKNZZ-K4L_\S>E9&'=5 M&B].0O>1QJQ84%BK2)02:]]:X2#J), 6+74RFFO6NJCI_4B^@UC+KIRYMV3Y M;B)IV TPU8M-^!)7_[^9WNW;,4++LZP9?\'( "II!XX6+MD9-HC,@U"E?3? MQW%]#WD)K;G37%[],JGFG=\L9S,2Y )%&VA_T5(0R1617%@$DK^7M?<+P]9[ M]5K AI3W?T@J[22P'KFT]*I_3U"^D=0J"OD\FI--X3Q1/#%%9DLAUR<'IFTA M@Z;YF<(&\+Z#U(7^>=5&>"U/$,IX4:]QCTQPJ *QVY=:+LEE#J%ZT$Y:7Y3S M6J@>#J0NG_X=9!NTYL:64]]0L5PVIONMH_EX.?L\':$QPH02(2"YLDI8PN&* M)1ZR4I"33QM;A[WNHAC2C8&]J8F=1+$'"_AJ"RQ1>"M< E,4[8-)(@V0#"L3 M,\_&<\F:G^,_"FI()CK)E,K-@0*JL MR7[B$AQI-N#:9UU88,:TYLV#8#:L?/:'\)7:2*9=4;1[TSI'P83$BB@@,6R M;OB'+A"P5)&]F,WIW5ZEXFL9V"C]-S=[HX>N M%:9C?Q %TJ](^KL8>ZG>GN,4RV5"XUM$#0S*BE&6%AEXK04;!.!.!Q^:= M 1Z!M!:+_F#1WI92:DB=LP[3>#E-]/T$ET*8YF>GM2O4OU=J,!?%4*?:ZZGF MUQ9<7B6PX)Q+(7"AC6Z=0;T.KK5(=."\N?8D:BRO'MVG*\=N.>:2,,2B0%I+ MD'A9NOL64+',:1JR%/V?'-P M!9W#IT1U[_CM*V(]A;@777U'4D7'6M4Z8V0]9&OQZ- );_L.[&XAM&:$JN9:#2L>35?-=Y:5 M@H_*"A(?F: T*]%!\@Q!!:\A%@*FG2@!?<'2_(C_VXC6(M"A$]I:$ZBAD-K5 MTZ1QUW\UE^X36?O+D]3YHANG!7F%-55XFF^_<..=[[ ;S_+==7'I)I"_&B> [??$>XQ;T=XC%K1 MSA53+5TFG890E &=LDC*D!/O6M>\W39OY[!Y+0/F^-^4R)15D+H":65H^C-5^$0IR$ RC,$F5UOIXVZ)EATTH^O[IN:OX>ZQDN$RD M7[E(\S#--RYESX_3">;S"?<)++K*N'%2]K$Y3)_#:^M6H:[O:\W:L; M-AQOHSJ'6_?T14TNLLH,.",MI[2BG3@[#U*76FTY%)>:5S9OTI)YBX.$]1]U M?1R_*B9[,PU0D\.OC$P@?0T9U4/YH$H!X9RRP3D=L+57W 3XD)R\O;#U;M>Y M?8N_8;?"M:$_W)XY6U&*=$@&3,Z@.'+PEE5+6[%HH/64T(?R!WTO)8DU":#TX0]!J:SC1A=;%U.?6?00W+*O@/"[BKV M)DE-&T#^JJ_Q]0*310@M$0I3\;)=7PWS">.YXXF66$Z/6+5-@ S)Y]HK^_8O MQG9-9Y:>PF93Q&62+I@(NM2NR<'7)J(ZTHK![&06'&-KQW\+F'O<01XL.'&C M)X2(K'!/UEK(]=1.KXAF_9TS\'OEZO8I\C8*KTR0R&(N2%ENTM*%;#SHP+!E93/*QF%]O MX(9DK^^+G\.0]+X)>[MIU/LJSZ/RZQR7H[BQ-7@NLLB1 6;I0%EEH,;20?/$ MK'-1EZ^ON>S*UC61#%90-"\)8V M!F6M9&@C;U[R;@>X0[HO/N!-?R%.6L-DFD!RM2V M#;5X5@Y<^Y ::= _I_OJ J;FCI _F,KVX93\O]V2,')C/!136N'>, M$9*R4:7 I1.']I=>;.HL[>NN_(#)N:.D#T'.J[MU'\*72\3*\9!TD8!8;[,( M5WM"& \V94Z&I/%DA1R.FW?P;G@M_\]*S=WD?!A30/>6#\RVR!\V?3_'86 MIC?J"M8VOS[YHGP48$.J.7A"@;/"0\Y&QE2LR+EU:E/3 6Q:Q^#/RN+&5.@Q M3_*RWGZ]7/\2\_FR*$/M5;-])N1CG[A[KN-&F%MU;9Y-9U=QG-O5<$Q$;HV@ MO93[#(I)VDN9<<"S1F,R%F.:-VE^"$S/]T"U*II;YTGO"DO>5DV"J.=5==5H MET,TMO5]] ;W0/=5RZ )0S:\]+F)1!I>/U]@A_/%K5'>''[5;\;0\)C-8'BD M06>;($0G(7!34HG!<]/:E5@'UY"._OIA3'/IM.O6/;L(D\7%"MA-1".IJCJF6&'W!D-'[UK'=C0 .JY=3/QJF-X$U+ROYP.A1 M:\L\F=P8G2!,M?28E!RTTES7:W3>MH[!?AO1D ZG^B%-0XFT9BN+)& M) -Z>RD'^;T M):L>HW&7%ZK#Y,UTONC.EPW WLZF'\FC.WV)[1N MIS$UBM[5Y_S^^!>AZR[JK?73&J0=I6"S]APARWICW6M+IH>WP%CP,7)6'95475N/]R>VS'.W^/999.YVC1Z3 (YJQ+YA2;XPV> _?B M6:'U_O\Q=*]GY]U(<:E#L0:R15MO.D0(ECDHJ*7*C$MKUDF^?O1!0XKV-6=' M^ZEN9B9M1-AKJ#X+IF.]3X":B.H3A]ILK=:_9,E9(6WST]&M@ XI0C@,G;.5 M" _'M@^?9R/ME)6%G(8BJTOIR-@+7I=J^Y%=J;A@I757^&UP#BF_?CASPE-X,$=%1>C^[ M8AY2;'((%-Q=L ?4?,0I'&DI:9H(ILL\ 2V7!-X2X*2L98AH@XT'UWT5Z9 2 MXX= O6V%N.>0Q>LP[OX9)N^A%)\MEIXFM[FP8W'4.W>?^6;3U@> M(HP48@XL(XB4;0T=!G#2LWICV1EG; JJ>:&>-7 -*V#1E#]WVZXT%E/#!C[? M1'95)>9B9!)G.9$7HSWSH)3W-/RBR9GF,FA2L8$UOQ"Q)K9!]6\_+).VDU>/ MF^*-#C';[W7W?,CN6]ACR!KM3->W2*OD"[>L&#)-R/VGA6T%F<8L9.#)!O0A M:N5:FYLWG]^LZS%M_^/Y">::VE+SC8_*>YQC]ZG68,Q$8"81F"*;7PER1F.2 M#$1!(Z0@'Z!Y,X4U8 UIK]F:$0]V/FXDCAZZ8\^Z?[VI%7\2SK\"5KA#E8P" M[PL!TX@050G C/ .@W<\]+84'H8UI#!Y>YXT$D=[GKP/G\G?HUTL3.HED>/S ML[,)Z>7;$#%&*2R/M9PK!R51D7T4;*W=73RB3+&Y ;\1P"$%P]MSI[F(>C0Z MKC(NPS1?WI"YG9IY[XO;FR<[/6YW0Z;=:)N9/%_=7,3%W638DGCFEHQ@)QF1 M4J !QY*"%!QW2M3AW5P-;@12]@U>@';2A&R8T:9YFMW&* ?EK/?.L)ZEN ^V M50N"(_D0)FO@D8<:8>?@G36,;R/J<;Q+)4!"EPI]Y*!YKCFU MQH/3]6(A)T/8BFM!W-S[ [/@G=#IV9'OJDW5V0 MM3 V\BY^6U*19/4)N_ 1?SD_C34!X>5XVBC:$N*MN>N!Q=Y[S/,S':61CD464FBBD:[D- M%. LK2=I<[ V%ZZ:NQX; 1S2-M"_$AR;C]Y+$(X7%68,) MBBFZ!A<->"4B,*TY39+1CIE]4.YQJ$.*_QZ>8P?*YPWTS+K5G-[ MC!.LS2*/%[2OU]_-RE6=G&VWSRT>LOO.NNO(&FVZ2\O[730W/%:LZK!> M:WU-8WZQJDE'^]9U4;K+ZZZK]WT(7W#^ZLNB"S3_XVGH+M[0K"W++=)?TH1. MEG=Q5Z6$1K2/BF7'8'(X/2AN%$3,"J3W/+C,(KKF15?Z&\[.92.N[BI?WE*> MCQ*J(I@.P$(MIR2,@*!= C)+#?KDG(VMO8L[(#94KWV'F(=!QCM%)G827;MV MZ@]?>.=)<"]KYZ=:Y-1G#\&4#)+ES+-V(K?OGKY+49K]I84,DU!M)-FN9LF- MS4U*;91'!\)4C]G'>D$*$5C4U@9KF%=[LU@/G1&UL[+U9=UO)D2[ZWK^BKN_K#5?.@U>[SU)IL'662M*55.T^3U@Y M1%)HDX : %4E__H3B8$C0&(3N0$*HI=+)0Z%_67$MS,C(F/X]__UQ]GI3U]Q M,AV.1W_]$_\S^]-/.$KC/!R=_/5/OWUZ!>Y/_^L__NW?_OW_ ?BO7SZ\^>G% M.)V?X6CVT_,)AAGFGWX?SC[_-/N,/_UC//GG\&OXZ?UIF)7QY S@/^;_V?/Q MEV^3XOW?Y?SW^;>^Y_G/[WX MU>EPW2_2Q_*?_^O7-Q_39SP+,!Q-9V&4+A] C\^SB__P*AK]\^*']*O3X5^F M\__^S3B%V5Q!]R[AIXV_4;^"U:]!_19P 9+_^8]I_M-__-M//RTD%R9I,C[% M#UA^6O[UMP^O;R,=CF8_Y^'9S\O?^3F M8-F(?K7D"DI7./]O_;2?=\;TF8!,TGE$H._BJ%*\(<9UG[X[YHO/@HPEG)_. M&B*^_=E-\8[/PK"E@&]]= .T\P^",SR+.&D)]=KG7L&Y GD38?W(?XUQ-IS^ M.8W/?IZ#>_[N[8N7;S^^?$%_^?CNS>L7SSZ]?/'Q$_WYZ\NWGSZ^>_7\W:_O M/[S\._W.Z_]\^?HM??GRM[?/?GOQFG[O_L7\:S:%N@,S+]D<]&[/N[)(8M-P M-*P;U!OZ'+X..,3K1ZN-$R\#7]=3HHD6LG4@ 3=015<@3O8X3(/&,F:T["O,V9Z8J# M)4SCG#7+1_Q<%? SGLZFJ^_,53)7QV84"UDW6->G$$]QD&P6-@8!D?, 2D<- MP08%6D=O++(KYKW^:3<[Q\IOCT8Q8_?)T_D!ZH?&D_F57)KS M"=E>L^%7?$T6R61NR7T83O_Y[(_A=$"&5A$1.8@B'*AH$P1T$K(1S&>GLW*Y M,2_NPM.0)7<8 G>PY@%J'OO- : MHB_DL6/"C(&C+[8Q'=8":1_ H\Z TFFM&0:I2F,*;$9S1#QH)/(>MH+WDW$9SMZ, MI]-![V6>< M/!^??9G@YWH*UJ.-W':LV(B([\JG\,=[8OHXT_^LUG M98:3#YA.PW0Z+,-%G/S9*--*!S)83R>E!H-&@4HQ@=.R #EM3/K ';=ICR3L MBG__=-PW?SK0MU?E[YG(K\83')Z,GI]/)CA*WSY-PFA*LEMBKU^=+E:2__M\ M<>*OA#^P/FJN+3D4.FBR(3AM#-YJ"$:'K)CB*K6VK_I9R1.Y]T^(VS07?=+\ M_<*#IB7,?^O]F*2(L^%D?N#]@B/2^>S]*2UNS;(4+Y(\9 ^R! DJ% T^T*$H M.*W(BJA4Z019QD!RHY/')4U_>(-1,*F+ M]@

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end XML 99 zts-20240930_htm.xml IDEA: XBRL DOCUMENT 0001555280 2024-01-01 2024-09-30 0001555280 2024-10-31 0001555280 2024-07-01 2024-09-30 0001555280 2023-07-01 2023-09-30 0001555280 2023-01-01 2023-09-30 0001555280 us-gaap:CashFlowHedgingMember 2024-07-01 2024-09-30 0001555280 us-gaap:CashFlowHedgingMember 2023-07-01 2023-09-30 0001555280 us-gaap:CashFlowHedgingMember 2024-01-01 2024-09-30 0001555280 us-gaap:CashFlowHedgingMember 2023-01-01 2023-09-30 0001555280 us-gaap:NetInvestmentHedgingMember 2024-07-01 2024-09-30 0001555280 us-gaap:NetInvestmentHedgingMember 2023-07-01 2023-09-30 0001555280 us-gaap:NetInvestmentHedgingMember 2024-01-01 2024-09-30 0001555280 us-gaap:NetInvestmentHedgingMember 2023-01-01 2023-09-30 0001555280 2024-09-30 0001555280 2023-12-31 0001555280 us-gaap:CommonStockMember 2024-06-30 0001555280 us-gaap:TreasuryStockCommonMember 2024-06-30 0001555280 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001555280 us-gaap:RetainedEarningsMember 2024-06-30 0001555280 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001555280 us-gaap:NoncontrollingInterestMember 2024-06-30 0001555280 2024-06-30 0001555280 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001555280 us-gaap:NoncontrollingInterestMember 2024-07-01 2024-09-30 0001555280 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-01 2024-09-30 0001555280 zts:ShareRepurchaseProgramMember us-gaap:TreasuryStockCommonMember 2024-07-01 2024-09-30 0001555280 us-gaap:TreasuryStockCommonMember 2024-07-01 2024-09-30 0001555280 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001555280 us-gaap:CommonStockMember 2024-09-30 0001555280 us-gaap:TreasuryStockCommonMember 2024-09-30 0001555280 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001555280 us-gaap:RetainedEarningsMember 2024-09-30 0001555280 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0001555280 us-gaap:NoncontrollingInterestMember 2024-09-30 0001555280 us-gaap:CommonStockMember 2023-06-30 0001555280 us-gaap:TreasuryStockCommonMember 2023-06-30 0001555280 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001555280 us-gaap:RetainedEarningsMember 2023-06-30 0001555280 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001555280 us-gaap:NoncontrollingInterestMember 2023-06-30 0001555280 2023-06-30 0001555280 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001555280 us-gaap:NoncontrollingInterestMember 2023-07-01 2023-09-30 0001555280 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2023-09-30 0001555280 zts:ShareRepurchaseProgramMember us-gaap:TreasuryStockCommonMember 2023-07-01 2023-09-30 0001555280 us-gaap:TreasuryStockCommonMember 2023-07-01 2023-09-30 0001555280 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001555280 us-gaap:CommonStockMember 2023-09-30 0001555280 us-gaap:TreasuryStockCommonMember 2023-09-30 0001555280 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001555280 us-gaap:RetainedEarningsMember 2023-09-30 0001555280 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001555280 us-gaap:NoncontrollingInterestMember 2023-09-30 0001555280 2023-09-30 0001555280 us-gaap:CommonStockMember 2023-12-31 0001555280 us-gaap:TreasuryStockCommonMember 2023-12-31 0001555280 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001555280 us-gaap:RetainedEarningsMember 2023-12-31 0001555280 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001555280 us-gaap:NoncontrollingInterestMember 2023-12-31 0001555280 us-gaap:RetainedEarningsMember 2024-01-01 2024-09-30 0001555280 us-gaap:NoncontrollingInterestMember 2024-01-01 2024-09-30 0001555280 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-09-30 0001555280 zts:ShareRepurchaseProgramMember us-gaap:TreasuryStockCommonMember 2024-01-01 2024-09-30 0001555280 us-gaap:TreasuryStockCommonMember 2024-01-01 2024-09-30 0001555280 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-09-30 0001555280 us-gaap:CommonStockMember 2022-12-31 0001555280 us-gaap:TreasuryStockCommonMember 2022-12-31 0001555280 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001555280 us-gaap:RetainedEarningsMember 2022-12-31 0001555280 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001555280 us-gaap:NoncontrollingInterestMember 2022-12-31 0001555280 2022-12-31 0001555280 us-gaap:RetainedEarningsMember 2023-01-01 2023-09-30 0001555280 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-09-30 0001555280 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-09-30 0001555280 zts:ShareRepurchaseProgramMember us-gaap:TreasuryStockCommonMember 2023-01-01 2023-09-30 0001555280 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-09-30 0001555280 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-09-30 0001555280 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember 2024-01-01 2024-09-30 0001555280 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember 2023-01-01 2023-09-30 0001555280 us-gaap:ProductMember 2024-09-30 0001555280 country:US 2024-07-01 2024-09-30 0001555280 country:US 2023-07-01 2023-09-30 0001555280 country:US 2024-01-01 2024-09-30 0001555280 country:US 2023-01-01 2023-09-30 0001555280 country:AU 2024-07-01 2024-09-30 0001555280 country:AU 2023-07-01 2023-09-30 0001555280 country:AU 2024-01-01 2024-09-30 0001555280 country:AU 2023-01-01 2023-09-30 0001555280 country:BR 2024-07-01 2024-09-30 0001555280 country:BR 2023-07-01 2023-09-30 0001555280 country:BR 2024-01-01 2024-09-30 0001555280 country:BR 2023-01-01 2023-09-30 0001555280 country:CA 2024-07-01 2024-09-30 0001555280 country:CA 2023-07-01 2023-09-30 0001555280 country:CA 2024-01-01 2024-09-30 0001555280 country:CA 2023-01-01 2023-09-30 0001555280 country:CL 2024-07-01 2024-09-30 0001555280 country:CL 2023-07-01 2023-09-30 0001555280 country:CL 2024-01-01 2024-09-30 0001555280 country:CL 2023-01-01 2023-09-30 0001555280 country:CN 2024-07-01 2024-09-30 0001555280 country:CN 2023-07-01 2023-09-30 0001555280 country:CN 2024-01-01 2024-09-30 0001555280 country:CN 2023-01-01 2023-09-30 0001555280 country:FR 2024-07-01 2024-09-30 0001555280 country:FR 2023-07-01 2023-09-30 0001555280 country:FR 2024-01-01 2024-09-30 0001555280 country:FR 2023-01-01 2023-09-30 0001555280 country:DE 2024-07-01 2024-09-30 0001555280 country:DE 2023-07-01 2023-09-30 0001555280 country:DE 2024-01-01 2024-09-30 0001555280 country:DE 2023-01-01 2023-09-30 0001555280 country:IT 2024-07-01 2024-09-30 0001555280 country:IT 2023-07-01 2023-09-30 0001555280 country:IT 2024-01-01 2024-09-30 0001555280 country:IT 2023-01-01 2023-09-30 0001555280 country:JP 2024-07-01 2024-09-30 0001555280 country:JP 2023-07-01 2023-09-30 0001555280 country:JP 2024-01-01 2024-09-30 0001555280 country:JP 2023-01-01 2023-09-30 0001555280 country:MX 2024-07-01 2024-09-30 0001555280 country:MX 2023-07-01 2023-09-30 0001555280 country:MX 2024-01-01 2024-09-30 0001555280 country:MX 2023-01-01 2023-09-30 0001555280 country:ES 2024-07-01 2024-09-30 0001555280 country:ES 2023-07-01 2023-09-30 0001555280 country:ES 2024-01-01 2024-09-30 0001555280 country:ES 2023-01-01 2023-09-30 0001555280 country:GB 2024-07-01 2024-09-30 0001555280 country:GB 2023-07-01 2023-09-30 0001555280 country:GB 2024-01-01 2024-09-30 0001555280 country:GB 2023-01-01 2023-09-30 0001555280 zts:OtherDevelopedMarketsMember 2024-07-01 2024-09-30 0001555280 zts:OtherDevelopedMarketsMember 2023-07-01 2023-09-30 0001555280 zts:OtherDevelopedMarketsMember 2024-01-01 2024-09-30 0001555280 zts:OtherDevelopedMarketsMember 2023-01-01 2023-09-30 0001555280 zts:OtherEmergingMarketsMember 2024-07-01 2024-09-30 0001555280 zts:OtherEmergingMarketsMember 2023-07-01 2023-09-30 0001555280 zts:OtherEmergingMarketsMember 2024-01-01 2024-09-30 0001555280 zts:OtherEmergingMarketsMember 2023-01-01 2023-09-30 0001555280 zts:TotalGeographicalAreaMember 2024-07-01 2024-09-30 0001555280 zts:TotalGeographicalAreaMember 2023-07-01 2023-09-30 0001555280 zts:TotalGeographicalAreaMember 2024-01-01 2024-09-30 0001555280 zts:TotalGeographicalAreaMember 2023-01-01 2023-09-30 0001555280 zts:ContractManufacturingandHumanHealthDiagnosticsMember 2024-07-01 2024-09-30 0001555280 zts:ContractManufacturingandHumanHealthDiagnosticsMember 2023-07-01 2023-09-30 0001555280 zts:ContractManufacturingandHumanHealthDiagnosticsMember 2024-01-01 2024-09-30 0001555280 zts:ContractManufacturingandHumanHealthDiagnosticsMember 2023-01-01 2023-09-30 0001555280 zts:CompanionAnimalMember zts:UnitedStatesSegmentMember 2024-07-01 2024-09-30 0001555280 zts:CompanionAnimalMember zts:UnitedStatesSegmentMember 2023-07-01 2023-09-30 0001555280 zts:CompanionAnimalMember zts:UnitedStatesSegmentMember 2024-01-01 2024-09-30 0001555280 zts:CompanionAnimalMember zts:UnitedStatesSegmentMember 2023-01-01 2023-09-30 0001555280 zts:LivestockMember zts:UnitedStatesSegmentMember 2024-07-01 2024-09-30 0001555280 zts:LivestockMember zts:UnitedStatesSegmentMember 2023-07-01 2023-09-30 0001555280 zts:LivestockMember zts:UnitedStatesSegmentMember 2024-01-01 2024-09-30 0001555280 zts:LivestockMember zts:UnitedStatesSegmentMember 2023-01-01 2023-09-30 0001555280 us-gaap:OperatingSegmentsMember zts:UnitedStatesSegmentMember 2024-07-01 2024-09-30 0001555280 us-gaap:OperatingSegmentsMember zts:UnitedStatesSegmentMember 2023-07-01 2023-09-30 0001555280 us-gaap:OperatingSegmentsMember zts:UnitedStatesSegmentMember 2024-01-01 2024-09-30 0001555280 us-gaap:OperatingSegmentsMember zts:UnitedStatesSegmentMember 2023-01-01 2023-09-30 0001555280 zts:CompanionAnimalMember zts:InternationalSegmentMember 2024-07-01 2024-09-30 0001555280 zts:CompanionAnimalMember zts:InternationalSegmentMember 2023-07-01 2023-09-30 0001555280 zts:CompanionAnimalMember zts:InternationalSegmentMember 2024-01-01 2024-09-30 0001555280 zts:CompanionAnimalMember zts:InternationalSegmentMember 2023-01-01 2023-09-30 0001555280 zts:LivestockMember zts:InternationalSegmentMember 2024-07-01 2024-09-30 0001555280 zts:LivestockMember zts:InternationalSegmentMember 2023-07-01 2023-09-30 0001555280 zts:LivestockMember zts:InternationalSegmentMember 2024-01-01 2024-09-30 0001555280 zts:LivestockMember zts:InternationalSegmentMember 2023-01-01 2023-09-30 0001555280 us-gaap:OperatingSegmentsMember zts:InternationalSegmentMember 2024-07-01 2024-09-30 0001555280 us-gaap:OperatingSegmentsMember zts:InternationalSegmentMember 2023-07-01 2023-09-30 0001555280 us-gaap:OperatingSegmentsMember zts:InternationalSegmentMember 2024-01-01 2024-09-30 0001555280 us-gaap:OperatingSegmentsMember zts:InternationalSegmentMember 2023-01-01 2023-09-30 0001555280 zts:CompanionAnimalMember 2024-07-01 2024-09-30 0001555280 zts:CompanionAnimalMember 2023-07-01 2023-09-30 0001555280 zts:CompanionAnimalMember 2024-01-01 2024-09-30 0001555280 zts:CompanionAnimalMember 2023-01-01 2023-09-30 0001555280 zts:LivestockMember 2024-07-01 2024-09-30 0001555280 zts:LivestockMember 2023-07-01 2023-09-30 0001555280 zts:LivestockMember 2024-01-01 2024-09-30 0001555280 zts:LivestockMember 2023-01-01 2023-09-30 0001555280 zts:DogsAndCatsMember 2024-07-01 2024-09-30 0001555280 zts:DogsAndCatsMember 2023-07-01 2023-09-30 0001555280 zts:DogsAndCatsMember 2024-01-01 2024-09-30 0001555280 zts:DogsAndCatsMember 2023-01-01 2023-09-30 0001555280 zts:HorsesMember 2024-07-01 2024-09-30 0001555280 zts:HorsesMember 2023-07-01 2023-09-30 0001555280 zts:HorsesMember 2024-01-01 2024-09-30 0001555280 zts:HorsesMember 2023-01-01 2023-09-30 0001555280 zts:CattleMember 2024-07-01 2024-09-30 0001555280 zts:CattleMember 2023-07-01 2023-09-30 0001555280 zts:CattleMember 2024-01-01 2024-09-30 0001555280 zts:CattleMember 2023-01-01 2023-09-30 0001555280 zts:PoultryMember 2024-07-01 2024-09-30 0001555280 zts:PoultryMember 2023-07-01 2023-09-30 0001555280 zts:PoultryMember 2024-01-01 2024-09-30 0001555280 zts:PoultryMember 2023-01-01 2023-09-30 0001555280 zts:SwineMember 2024-07-01 2024-09-30 0001555280 zts:SwineMember 2023-07-01 2023-09-30 0001555280 zts:SwineMember 2024-01-01 2024-09-30 0001555280 zts:SwineMember 2023-01-01 2023-09-30 0001555280 zts:FishMember 2024-07-01 2024-09-30 0001555280 zts:FishMember 2023-07-01 2023-09-30 0001555280 zts:FishMember 2024-01-01 2024-09-30 0001555280 zts:FishMember 2023-01-01 2023-09-30 0001555280 us-gaap:ManufacturedProductOtherMember 2024-07-01 2024-09-30 0001555280 us-gaap:ManufacturedProductOtherMember 2023-07-01 2023-09-30 0001555280 us-gaap:ManufacturedProductOtherMember 2024-01-01 2024-09-30 0001555280 us-gaap:ManufacturedProductOtherMember 2023-01-01 2023-09-30 0001555280 zts:ParasiticidesMember 2024-07-01 2024-09-30 0001555280 zts:ParasiticidesMember 2023-07-01 2023-09-30 0001555280 zts:ParasiticidesMember 2024-01-01 2024-09-30 0001555280 zts:ParasiticidesMember 2023-01-01 2023-09-30 0001555280 zts:VaccinesMember 2024-07-01 2024-09-30 0001555280 zts:VaccinesMember 2023-07-01 2023-09-30 0001555280 zts:VaccinesMember 2024-01-01 2024-09-30 0001555280 zts:VaccinesMember 2023-01-01 2023-09-30 0001555280 zts:DermatologyMember 2024-07-01 2024-09-30 0001555280 zts:DermatologyMember 2023-07-01 2023-09-30 0001555280 zts:DermatologyMember 2024-01-01 2024-09-30 0001555280 zts:DermatologyMember 2023-01-01 2023-09-30 0001555280 zts:AntiInfectiveProductsMember 2024-07-01 2024-09-30 0001555280 zts:AntiInfectiveProductsMember 2023-07-01 2023-09-30 0001555280 zts:AntiInfectiveProductsMember 2024-01-01 2024-09-30 0001555280 zts:AntiInfectiveProductsMember 2023-01-01 2023-09-30 0001555280 zts:PainSedationMember 2024-07-01 2024-09-30 0001555280 zts:PainSedationMember 2023-07-01 2023-09-30 0001555280 zts:PainSedationMember 2024-01-01 2024-09-30 0001555280 zts:PainSedationMember 2023-01-01 2023-09-30 0001555280 zts:OtherPharmaceuticalsMember 2024-07-01 2024-09-30 0001555280 zts:OtherPharmaceuticalsMember 2023-07-01 2023-09-30 0001555280 zts:OtherPharmaceuticalsMember 2024-01-01 2024-09-30 0001555280 zts:OtherPharmaceuticalsMember 2023-01-01 2023-09-30 0001555280 zts:AnimalHealthDiagnosticsMember 2024-07-01 2024-09-30 0001555280 zts:AnimalHealthDiagnosticsMember 2023-07-01 2023-09-30 0001555280 zts:AnimalHealthDiagnosticsMember 2024-01-01 2024-09-30 0001555280 zts:AnimalHealthDiagnosticsMember 2023-01-01 2023-09-30 0001555280 zts:MedicatedFeedAdditivesMember 2024-07-01 2024-09-30 0001555280 zts:MedicatedFeedAdditivesMember 2023-07-01 2023-09-30 0001555280 zts:MedicatedFeedAdditivesMember 2024-01-01 2024-09-30 0001555280 zts:MedicatedFeedAdditivesMember 2023-01-01 2023-09-30 0001555280 zts:OtherNonPharmaceuticalsMember 2024-07-01 2024-09-30 0001555280 zts:OtherNonPharmaceuticalsMember 2023-07-01 2023-09-30 0001555280 zts:OtherNonPharmaceuticalsMember 2024-01-01 2024-09-30 0001555280 zts:OtherNonPharmaceuticalsMember 2023-01-01 2023-09-30 0001555280 zts:TotalProductsandServicesMember 2024-07-01 2024-09-30 0001555280 zts:TotalProductsandServicesMember 2023-07-01 2023-09-30 0001555280 zts:TotalProductsandServicesMember 2024-01-01 2024-09-30 0001555280 zts:TotalProductsandServicesMember 2023-01-01 2023-09-30 0001555280 zts:PetMedixLtdMember 2024-09-30 0001555280 zts:PetMedixLtdMember 2023-08-03 2023-08-03 0001555280 2024-04-28 0001555280 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember 2024-09-30 0001555280 zts:PumpkinInsuranceServicesMember 2024-01-01 2024-06-30 0001555280 zts:PumpkinInsuranceServicesMember 2024-04-01 2024-06-30 0001555280 us-gaap:AcquisitionRelatedCostsMember 2024-07-01 2024-09-30 0001555280 us-gaap:AcquisitionRelatedCostsMember 2023-07-01 2023-09-30 0001555280 us-gaap:AcquisitionRelatedCostsMember 2024-01-01 2024-09-30 0001555280 us-gaap:AcquisitionRelatedCostsMember 2023-01-01 2023-09-30 0001555280 us-gaap:EmployeeSeveranceMember 2024-07-01 2024-09-30 0001555280 us-gaap:EmployeeSeveranceMember 2023-07-01 2023-09-30 0001555280 us-gaap:EmployeeSeveranceMember 2024-01-01 2024-09-30 0001555280 us-gaap:EmployeeSeveranceMember 2023-01-01 2023-09-30 0001555280 us-gaap:FacilityClosingMember 2024-07-01 2024-09-30 0001555280 us-gaap:FacilityClosingMember 2023-07-01 2023-09-30 0001555280 us-gaap:FacilityClosingMember 2024-01-01 2024-09-30 0001555280 us-gaap:FacilityClosingMember 2023-01-01 2023-09-30 0001555280 us-gaap:OtherCurrentLiabilitiesMember 2024-09-30 0001555280 us-gaap:OtherCurrentLiabilitiesMember 2023-12-31 0001555280 us-gaap:OtherNoncurrentLiabilitiesMember 2024-09-30 0001555280 us-gaap:OtherNoncurrentLiabilitiesMember 2023-12-31 0001555280 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember 2024-07-01 2024-09-30 0001555280 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember 2023-07-01 2023-09-30 0001555280 us-gaap:InternalRevenueServiceIRSMember 2024-07-01 2024-07-31 0001555280 us-gaap:RevolvingCreditFacilityMember 2024-09-30 0001555280 zts:OperationalEfficiencyMember 2024-09-30 0001555280 us-gaap:RevolvingCreditFacilityMember 2023-12-31 0001555280 zts:LineOfCreditForGeneralCorporatePurposeMember 2024-09-30 0001555280 zts:LineOfCreditForGeneralCorporatePurposeMember 2023-12-31 0001555280 us-gaap:CommercialPaperMember 2013-02-28 0001555280 zts:A2022SeniorNotesMember us-gaap:SeniorNotesMember 2022-11-08 0001555280 zts:A5400SeniorNotesDue2025Member us-gaap:SeniorNotesMember 2024-09-30 0001555280 zts:A5400SeniorNotesDue2025Member us-gaap:SeniorNotesMember 2022-11-08 0001555280 zts:A5600SeniorNotesDue2032Member us-gaap:SeniorNotesMember 2024-09-30 0001555280 zts:A5600SeniorNotesDue2032Member us-gaap:SeniorNotesMember 2022-11-08 0001555280 zts:SeniorNotesDue2023Member us-gaap:SeniorNotesMember 2023-02-01 0001555280 zts:SeniorNotesDue2023Member us-gaap:SeniorNotesMember 2024-09-30 0001555280 us-gaap:SeniorNotesMember 2013-01-28 0001555280 zts:SeniorNotes4.500Due2025Member us-gaap:SeniorNotesMember 2024-09-30 0001555280 zts:SeniorNotes4.500Due2025Member us-gaap:SeniorNotesMember 2023-12-31 0001555280 zts:A5400SeniorNotesDue2025Member us-gaap:SeniorNotesMember 2023-12-31 0001555280 zts:SeniorNotes3.000Due2027Member us-gaap:SeniorNotesMember 2024-09-30 0001555280 zts:SeniorNotes3.000Due2027Member us-gaap:SeniorNotesMember 2023-12-31 0001555280 zts:SeniorNotes3.900Due2028Member us-gaap:SeniorNotesMember 2024-09-30 0001555280 zts:SeniorNotes3.900Due2028Member us-gaap:SeniorNotesMember 2023-12-31 0001555280 zts:SeniorNotes2000Due2030Member us-gaap:SeniorNotesMember 2024-09-30 0001555280 zts:SeniorNotes2000Due2030Member us-gaap:SeniorNotesMember 2023-12-31 0001555280 zts:A5600SeniorNotesDue2032Member us-gaap:SeniorNotesMember 2023-12-31 0001555280 zts:SeniorNotesDue2043Member us-gaap:SeniorNotesMember 2024-09-30 0001555280 zts:SeniorNotesDue2043Member us-gaap:SeniorNotesMember 2023-12-31 0001555280 zts:SeniorNotes3.950Due2047Member us-gaap:SeniorNotesMember 2024-09-30 0001555280 zts:SeniorNotes3.950Due2047Member us-gaap:SeniorNotesMember 2023-12-31 0001555280 zts:SeniorNotes4.450Due2048Member us-gaap:SeniorNotesMember 2024-09-30 0001555280 zts:SeniorNotes4.450Due2048Member us-gaap:SeniorNotesMember 2023-12-31 0001555280 zts:SeniorNotes3000Due2050Member us-gaap:SeniorNotesMember 2024-09-30 0001555280 zts:SeniorNotes3000Due2050Member us-gaap:SeniorNotesMember 2023-12-31 0001555280 us-gaap:FairValueInputsLevel2Member us-gaap:SeniorNotesMember 2024-09-30 0001555280 us-gaap:FairValueInputsLevel2Member us-gaap:SeniorNotesMember 2023-12-31 0001555280 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2024-01-01 2024-09-30 0001555280 srt:MaximumMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2024-01-01 2024-09-30 0001555280 srt:MaximumMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-01-01 2024-09-30 0001555280 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:SeniorNotesMember 2023-12-31 0001555280 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2024-09-30 0001555280 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2023-12-31 0001555280 us-gaap:CrossCurrencyInterestRateContractMember 2024-09-30 0001555280 us-gaap:CrossCurrencyInterestRateContractMember 2023-12-31 0001555280 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0001555280 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0001555280 us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2024-09-30 0001555280 us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2023-12-31 0001555280 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2024-09-30 0001555280 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2023-12-31 0001555280 us-gaap:OtherNoncurrentAssetsMember zts:Zts_ForwardStartingInterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0001555280 us-gaap:OtherNoncurrentAssetsMember zts:Zts_ForwardStartingInterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0001555280 us-gaap:OtherCurrentAssetsMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0001555280 us-gaap:OtherCurrentAssetsMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0001555280 us-gaap:OtherNoncurrentAssetsMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0001555280 us-gaap:OtherNoncurrentAssetsMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0001555280 us-gaap:OtherCurrentLiabilitiesMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0001555280 us-gaap:OtherCurrentLiabilitiesMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0001555280 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0001555280 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0001555280 us-gaap:OtherNoncurrentLiabilitiesMember zts:Zts_FixedtoFloatInterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0001555280 us-gaap:OtherNoncurrentLiabilitiesMember zts:Zts_FixedtoFloatInterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0001555280 us-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0001555280 us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0001555280 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0001555280 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0001555280 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2024-07-01 2024-09-30 0001555280 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2023-07-01 2023-09-30 0001555280 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2023-01-01 2023-09-30 0001555280 zts:Zts_ForwardStartingInterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-07-01 2024-09-30 0001555280 zts:Zts_ForwardStartingInterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-07-01 2023-09-30 0001555280 zts:Zts_ForwardStartingInterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-01-01 2024-09-30 0001555280 zts:Zts_ForwardStartingInterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-01-01 2023-09-30 0001555280 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-07-01 2024-09-30 0001555280 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-07-01 2023-09-30 0001555280 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-01-01 2024-09-30 0001555280 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-01-01 2023-09-30 0001555280 country:US 2023-12-31 0001555280 zts:InternationalMember 2023-12-31 0001555280 zts:InternationalMember 2024-01-01 2024-09-30 0001555280 country:US 2024-09-30 0001555280 zts:InternationalMember 2024-09-30 0001555280 us-gaap:DevelopedTechnologyRightsMember 2024-09-30 0001555280 us-gaap:DevelopedTechnologyRightsMember 2023-12-31 0001555280 us-gaap:TrademarksAndTradeNamesMember 2024-09-30 0001555280 us-gaap:TrademarksAndTradeNamesMember 2023-12-31 0001555280 us-gaap:OtherIntangibleAssetsMember 2024-09-30 0001555280 us-gaap:OtherIntangibleAssetsMember 2023-12-31 0001555280 us-gaap:TrademarksAndTradeNamesMember 2024-09-30 0001555280 us-gaap:TrademarksAndTradeNamesMember 2023-12-31 0001555280 us-gaap:InProcessResearchAndDevelopmentMember 2024-09-30 0001555280 us-gaap:InProcessResearchAndDevelopmentMember 2023-12-31 0001555280 zts:ProductRightsMember 2024-09-30 0001555280 zts:ProductRightsMember 2023-12-31 0001555280 us-gaap:EmployeeStockOptionMember 2024-07-01 2024-09-30 0001555280 us-gaap:EmployeeStockOptionMember 2023-07-01 2023-09-30 0001555280 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-09-30 0001555280 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-09-30 0001555280 us-gaap:RestrictedStockUnitsRSUMember 2024-07-01 2024-09-30 0001555280 us-gaap:RestrictedStockUnitsRSUMember 2023-07-01 2023-09-30 0001555280 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-09-30 0001555280 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-09-30 0001555280 us-gaap:PerformanceSharesMember 2024-07-01 2024-09-30 0001555280 us-gaap:PerformanceSharesMember 2023-07-01 2023-09-30 0001555280 us-gaap:PerformanceSharesMember 2024-01-01 2024-09-30 0001555280 us-gaap:PerformanceSharesMember 2023-01-01 2023-09-30 0001555280 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-12-31 0001555280 us-gaap:PerformanceSharesMember zts:PeerCompaniesMember 2024-01-01 2024-09-30 0001555280 srt:MinimumMember us-gaap:PerformanceSharesMember 2024-01-01 2024-09-30 0001555280 srt:MaximumMember us-gaap:PerformanceSharesMember 2024-01-01 2024-09-30 0001555280 zts:December2021ShareRepurchaseProgramMember 2022-12-31 0001555280 zts:December2021ShareRepurchaseProgramMember 2024-09-30 0001555280 zts:August2024ShareRepurchaseProgramMember 2024-09-30 0001555280 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2023-12-31 0001555280 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-12-31 0001555280 us-gaap:AccumulatedTranslationAdjustmentMember 2023-12-31 0001555280 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-12-31 0001555280 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2024-01-01 2024-09-30 0001555280 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2024-01-01 2024-09-30 0001555280 us-gaap:AccumulatedTranslationAdjustmentMember 2024-01-01 2024-09-30 0001555280 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-01-01 2024-09-30 0001555280 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2024-09-30 0001555280 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2024-09-30 0001555280 us-gaap:AccumulatedTranslationAdjustmentMember 2024-09-30 0001555280 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-09-30 0001555280 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2022-12-31 0001555280 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-12-31 0001555280 us-gaap:AccumulatedTranslationAdjustmentMember 2022-12-31 0001555280 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-12-31 0001555280 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2023-01-01 2023-09-30 0001555280 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-01-01 2023-09-30 0001555280 us-gaap:AccumulatedTranslationAdjustmentMember 2023-01-01 2023-09-30 0001555280 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-01-01 2023-09-30 0001555280 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2023-09-30 0001555280 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-09-30 0001555280 us-gaap:AccumulatedTranslationAdjustmentMember 2023-09-30 0001555280 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-09-30 0001555280 zts:UlianopolisBrazilMember 2012-02-29 0001555280 zts:UlianopolisBrazilMember 2012-04-01 2012-04-30 0001555280 us-gaap:OperatingSegmentsMember 2024-07-01 2024-09-30 0001555280 us-gaap:OperatingSegmentsMember 2023-07-01 2023-09-30 0001555280 us-gaap:AllOtherSegmentsMember 2024-07-01 2024-09-30 0001555280 us-gaap:AllOtherSegmentsMember 2023-07-01 2023-09-30 0001555280 us-gaap:CorporateNonSegmentMember 2024-07-01 2024-09-30 0001555280 us-gaap:CorporateNonSegmentMember 2023-07-01 2023-09-30 0001555280 us-gaap:MaterialReconcilingItemsMember 2024-07-01 2024-09-30 0001555280 us-gaap:MaterialReconcilingItemsMember 2023-07-01 2023-09-30 0001555280 us-gaap:OperatingSegmentsMember currency:EUR zts:InternationalSegmentMember 2024-07-01 2024-09-30 0001555280 us-gaap:OperatingSegmentsMember currency:EUR zts:InternationalSegmentMember 2023-07-01 2023-09-30 0001555280 us-gaap:OperatingSegmentsMember 2024-01-01 2024-09-30 0001555280 us-gaap:OperatingSegmentsMember 2023-01-01 2023-09-30 0001555280 us-gaap:AllOtherSegmentsMember 2024-01-01 2024-09-30 0001555280 us-gaap:AllOtherSegmentsMember 2023-01-01 2023-09-30 0001555280 us-gaap:CorporateNonSegmentMember 2024-01-01 2024-09-30 0001555280 us-gaap:CorporateNonSegmentMember 2023-01-01 2023-09-30 0001555280 us-gaap:MaterialReconcilingItemsMember 2024-01-01 2024-09-30 0001555280 us-gaap:MaterialReconcilingItemsMember 2023-01-01 2023-09-30 0001555280 us-gaap:OperatingSegmentsMember currency:EUR zts:InternationalSegmentMember 2024-01-01 2024-09-30 0001555280 us-gaap:OperatingSegmentsMember currency:EUR zts:InternationalSegmentMember 2023-01-01 2023-09-30 0001555280 zts:KristinPeckMember 2024-01-01 2024-09-30 0001555280 zts:KristinPeckMember 2024-07-01 2024-09-30 0001555280 zts:KristinPeckMember 2024-09-30 0001555280 zts:RoxanneLaganoMember 2024-01-01 2024-09-30 0001555280 zts:RoxanneLaganoMember 2024-07-01 2024-09-30 0001555280 zts:RoxanneLaganoMember zts:RoxanneLaganoTradingArrangementCommonStockMember 2024-07-01 2024-09-30 0001555280 zts:RoxanneLaganoMember zts:RoxanneLaganoTradingArrangementCommonStockMember 2024-09-30 0001555280 zts:RoxanneLaganoMember zts:RoxanneLaganoTradingArrangementEquityAwardsMember 2024-07-01 2024-09-30 0001555280 zts:RoxanneLaganoMember zts:RoxanneLaganoTradingArrangementEquityAwardsMember 2024-09-30 shares iso4217:USD iso4217:USD shares zts:geographicRegion zts:country zts:specie zts:productCategory zts:product_category pure iso4217:EUR iso4217:DKK iso4217:CHF zts:defendant zts:segment false 2024 Q3 0001555280 --12-31 P383D P365D P308D 10-Q true 2024-09-30 false 001-35797 Zoetis Inc. DE 46-0696167 10 Sylvan Way, Parsippany, NJ 07054 973 822-7000 Common Stock, par value $0.01 per share ZTS NYSE Yes Yes Large Accelerated Filer false false false 451165011 2388000000 2151000000 6939000000 6331000000 701000000 638000000 2012000000 1833000000 565000000 525000000 1693000000 1586000000 167000000 152000000 500000000 440000000 35000000 38000000 107000000 112000000 5000000 16000000 51000000 45000000 57000000 59000000 174000000 180000000 16000000 -6000000 -1000000 151000000 874000000 717000000 2401000000 2286000000 182000000 121000000 486000000 469000000 692000000 596000000 1915000000 1817000000 10000000 0 10000000 -2000000 682000000 596000000 1905000000 1819000000 1.51 1.29 4.18 3.94 1.50 1.29 4.18 3.93 452900000 460300000 455400000 461900000 453500000 461400000 456100000 463000000.0 0 0 0.864 0.750 692000000 596000000 1915000000 1817000000 -1000000 1000000 -1000000 0 -4000000 3000000 -5000000 0 -7000000 5000000 -2000000 1000000 -23000000 18000000 -5000000 5000000 21000000 60000000 -2000000 -6000000 0 0 0 1000000 0 0 0 -4000000 -6000000 81000000 -12000000 3000000 686000000 677000000 1903000000 1820000000 10000000 0 10000000 -2000000 676000000 677000000 1893000000 1822000000 1714000000 2041000000 19000000 18000000 1411000000 1304000000 2416000000 2564000000 314000000 0 427000000 434000000 6282000000 6343000000 2657000000 2594000000 3298000000 3204000000 223000000 230000000 2744000000 2759000000 1186000000 1338000000 409000000 206000000 215000000 206000000 14357000000 14286000000 0 3000000 404000000 411000000 0 198000000 725000000 683000000 335000000 382000000 97000000 110000000 26000000 0 115000000 102000000 1702000000 1889000000 6574000000 6564000000 172000000 146000000 181000000 188000000 274000000 271000000 220000000 237000000 9123000000 9295000000 0.01 6000000000 501891243 501891243 451549789 458367358 5000000 5000000 50341454 43523885 6889000000 5597000000 1163000000 1133000000 11806000000 10295000000 -851000000 -839000000 5234000000 4997000000 0 -6000000 5234000000 4991000000 14357000000 14286000000 4000000 2000000 501900000 5000000 48000000.0 -6464000000 1146000000 11124000000 -845000000 -6000000 4960000000 682000000 10000000 692000000 -6000000 -6000000 4000000 4000000 0 2000000 17000000 0 19000000 2300000 427000000 427000000 501900000 5000000 50300000 -6889000000 1163000000 11806000000 -851000000 0 5234000000 501900000 5000000 41200000 -5126000000 1098000000 9543000000 -895000000 -4000000 4621000000 596000000 0 596000000 81000000 81000000 200000 9000000 18000000 1000000 28000000 1400000 252000000 252000000 501900000 5000000 42400000 -5369000000 1116000000 10140000000 -814000000 -4000000 5074000000 501900000 5000000 43500000 -5597000000 1133000000 10295000000 -839000000 -6000000 4991000000 1905000000 10000000 1915000000 -12000000 -12000000 4000000 4000000 500000 15000000 30000000 0 45000000 7300000 1307000000 1307000000 394000000 394000000 501900000 5000000 50300000 -6889000000 1163000000 11806000000 -851000000 0 5234000000 501900000 5000000 38100000 -4539000000 1088000000 8668000000 -817000000 -2000000 4403000000 1819000000 -2000000 1817000000 3000000 3000000 700000 34000000 28000000 -1000000 61000000 5000000.0 864000000 864000000 346000000 346000000 501900000 5000000 42400000 -5369000000 1116000000 10140000000 -814000000 -4000000 5074000000 1915000000 1817000000 374000000 365000000 55000000 43000000 16000000 27000000 -22000000 0 0 118000000 71000000 82000000 -186000000 -40000000 -11000000 6000000 134000000 54000000 113000000 497000000 14000000 119000000 5000000 -9000000 36000000 -27000000 -10000000 -8000000 2048000000 1456000000 439000000 534000000 8000000 155000000 4000000 3000000 -11000000 -23000000 0 96000000 1000000 4000000 2000000 -2000000 -441000000 -567000000 -3000000 0 0 1350000000 5000000 3000000 -10000000 18000000 1305000000 857000000 592000000 520000000 -1915000000 -2712000000 -19000000 -4000000 -327000000 -1827000000 2041000000 3581000000 1714000000 1754000000 657000000 586000000 205000000 225000000 46000000 42000000 1000000 0 4000000 4000000 12000000 7000000 39000000 74000000 <div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1. Organization </span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Zoetis Inc. (including its subsidiaries, collectively, Zoetis, the company, we, us or our) is a global leader in the animal health industry, focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. We organize and operate our business in two geographic regions: the United States (U.S.) and International. </span></div>We directly market our products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. Our products are sold in more than 100 countries, including developed and emerging markets. We have a diversified business, commercializing products across eight core species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock); and within eight major product categories: parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, animal health diagnostics and medicated feed additives. 2 45 100 8 8 <div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2. Basis of Presentation </span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements were prepared following the requirements of the Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by accounting principles generally accepted in the United States of America (U.S. GAAP) can be condensed or omitted. Balance sheet amounts and operating results for subsidiaries operating outside the U.S. are as of and for the three and nine months ended August 31, 2024 and August 31, 2023. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Revenue, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain reclassifications of prior year information have been made to conform to the current year's presentation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We are responsible for the unaudited condensed consolidated financial statements included in this Form 10-Q. The condensed consolidated financial statements include all normal and recurring adjustments that are considered necessary for the fair presentation of our financial position and operating results. The information included in this interim report should be read in conjunction with the financial statements and accompanying notes included in our 2023 Annual Report on Form 10-K. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In the third quarter of 2024, we concluded that we were no longer the primary beneficiary of a variable interest entity (VIE) that was previously consolidated. The effects of the deconsolidation were not material to the condensed consolidated financial statements.</span></div> <div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements were prepared following the requirements of the Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by accounting principles generally accepted in the United States of America (U.S. GAAP) can be condensed or omitted. Balance sheet amounts and operating results for subsidiaries operating outside the U.S. are as of and for the three and nine months ended August 31, 2024 and August 31, 2023. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Revenue, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain reclassifications of prior year information have been made to conform to the current year's presentation.</span></div>We are responsible for the unaudited condensed consolidated financial statements included in this Form 10-Q. The condensed consolidated financial statements include all normal and recurring adjustments that are considered necessary for the fair presentation of our financial position and operating results. The information included in this interim report should be read in conjunction with the financial statements and accompanying notes included in our 2023 Annual Report on Form 10-K. <div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">3. Accounting Standards </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Recently Issued Accounting Standards</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The new guidance requires expanded annual and interim disclosures for significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss. This update is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. The update is to be applied retrospectively to all periods presented in the financial statements. Early adoption is permitted. The adoption of this guidance will impact our disclosures only and we do not expect it to have an impact on our consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax disclosures. The new guidance requires standardized categories for the effective tax rate reconciliation, disaggregation of income taxes paid and other income tax-related disclosures. This update is effective for fiscal years beginning after December 15, 2024. We are currently evaluating the impact that the new guidance will have on our notes to the consolidated financial statements.</span></div> <div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Recently Issued Accounting Standards</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The new guidance requires expanded annual and interim disclosures for significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss. This update is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. The update is to be applied retrospectively to all periods presented in the financial statements. Early adoption is permitted. The adoption of this guidance will impact our disclosures only and we do not expect it to have an impact on our consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax disclosures. The new guidance requires standardized categories for the effective tax rate reconciliation, disaggregation of income taxes paid and other income tax-related disclosures. This update is effective for fiscal years beginning after December 15, 2024. We are currently evaluating the impact that the new guidance will have on our notes to the consolidated financial statements.</span></div> <div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4. Revenue </span></div><div style="margin-top:6pt;padding-left:18pt;padding-right:4.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">A. Revenue from Product Sales</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We offer a diversified portfolio of products which allows us to capitalize on local and regional customer needs. Generally, our products are promoted to veterinarians and livestock producers by our sales organization which includes sales representatives and technical and veterinary operations specialists, and then sold directly by us or through distributors, retailers or e-commerce outlets. The depth of our product portfolio enables us to address the varying needs of customers in different species and geographies. Many of our top-selling product lines are distributed across both of our operating segments, leveraging our research and development (R&amp;D) operations and manufacturing and supply chain network.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Over the course of our history, we have focused on developing a diverse portfolio of animal health products, including medicines, vaccines and diagnostics, complemented by biodevices, genetic tests and a range of services. We refer to all different brands of a particular product, or its dosage forms for all species, as a product line. We have approximately 300 comprehensive product lines, including products for both companion animals and livestock, within our major product categories.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In the first quarter of 2024, we modified the list of major product categories to include a category for pain and sedation products, which were previously included within other pharmaceutical products. The prior period presentation has been revised to reflect the new product category.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our major product categories are:</span></div><div style="margin-top:3pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;padding-left:14.85pt">parasiticides:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> products that prevent or eliminate external and internal parasites such as fleas, ticks and worms;</span></div><div style="margin-top:3pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;padding-left:14.85pt">vaccines:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> biological preparations that help prevent diseases of the respiratory, gastrointestinal and reproductive tracts or induce a specific immune response;</span></div><div style="margin-top:3pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;padding-left:14.85pt">dermatology:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> products that relieve itch associated with allergic conditions and atopic dermatitis;</span></div><div style="margin-top:3pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;padding-left:14.85pt">anti-infectives:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> products that prevent, kill or slow the growth of bacteria, fungi or protozoa;</span></div><div style="margin-top:3pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;padding-left:14.85pt">pain and sedation:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> products that alleviate pain, primarily associated with osteoarthritis and postoperative pain;</span></div><div style="margin-top:3pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;padding-left:14.85pt">other pharmaceutical:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> antiemetic, reproductive and oncology products;</span></div><div style="margin-top:3pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;padding-left:14.85pt">animal health diagnostics:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> testing and analysis of blood, urine and other animal samples and related products and services, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services and blood glucose monitors; and</span></div><div style="margin-top:3pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;padding-left:14.85pt">medicated feed additives: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">products added to animal feed that provide medicines to livestock.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our remaining revenue is derived from other non-pharmaceutical product categories, such as nutritionals, as well as products and services in biodevices, genetic tests and precision animal health. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our companion animal products help extend and improve the quality of life for pets; increase convenience and compliance for pet owners; and help veterinarians improve the quality of their care and the efficiency of their businesses. Growth in the companion animal medicines, vaccines and diagnostics sector is driven by economic development, related increases in disposable income and increases in pet ownership and spending on pet care. Companion animals are also living longer, deepening the human-animal bond, receiving increased medical treatment and benefiting from advances in animal health medicine, vaccines and diagnostics.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our livestock products primarily help prevent or treat diseases and conditions to allow veterinarians and producers to care for their animals and to enable the cost-effective production of safe, high-quality animal protein. Human population growth and increasing standards of living are important long-term growth drivers for our livestock products in three major ways. First, population growth and increasing standards of living drive demand for improved nutrition, particularly through increased consumption of animal protein. Second, population growth leads to greater natural resource constraints driving a need for enhanced productivity. Finally, as standards of living improve and the global food chain faces increased scrutiny, there is more focus on food quality, safety and reliability of supply. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following tables present our revenue disaggregated by geographic area, species and major product category:</span></div><div style="margin-top:6pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Revenue by geographic area</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.014%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(MILLIONS OF DOLLARS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,346</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,174 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,817</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,344 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">83</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">239</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">248 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brazil</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">101</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">301</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">276 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">66</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">202</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">183 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chile</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">31</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">93</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">61</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">205</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">255 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">France</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">36</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">111</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">57</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">166</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">148 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Italy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">31</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">95</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">33</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">109</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">39</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">129</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">119 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Spain</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">35</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">80</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">230</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">209 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other developed markets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">148</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">413</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">374 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other emerging markets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">220</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">670</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">605 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,367</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,130 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6,880</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,273 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract manufacturing &amp; human health</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">21</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">59</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Revenue</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,388</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,151 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6,939</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,331 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Revenue by major species</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.014%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(MILLIONS OF DOLLARS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Companion animal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,068</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">908 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,046</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,588 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Livestock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">278</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">266 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">771</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">756 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,346</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,174 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,817</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,344 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Companion animal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">541</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">506 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,662</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,540 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Livestock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">480</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">450 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,401</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,389 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">956 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,063</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,929 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Companion animal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,609</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,414 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,708</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,128 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Livestock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">758</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">716 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,172</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,145 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract manufacturing &amp; human health</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">21</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">59</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,388</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,151 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6,939</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,331 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Revenue by species</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.014%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(MILLIONS OF DOLLARS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Companion Animal:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dogs and Cats</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,551</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,354 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,516</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,931 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Horses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">58</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">192</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">197 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,609</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,414 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,708</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,128 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Livestock:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cattle</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">391</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">374 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,132</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,102 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Poultry</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">139</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">410</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">397 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Swine</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">131</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">129 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">388</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">404 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fish</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">70</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">177</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">158 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sheep and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">27</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">65</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">758</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">716 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,172</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,145 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract manufacturing &amp; human health</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">21</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">59</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,388</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,151 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6,939</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,331 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Revenue by major product category</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.014%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(MILLIONS OF DOLLARS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Parasiticides</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">530</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">465 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,634</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,465 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vaccines</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">468</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">449 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,365</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,308 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dermatology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">453</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">397 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,234</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,048 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Anti-infectives</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">274</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">264 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">819</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">796 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pain and sedation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">219</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">634</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">408 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other pharmaceutical</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">169</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">166 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">478</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">514 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Animal health diagnostics</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">101</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">286</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">284 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicated feed additives</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">91</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">242</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">257 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other non-pharmaceutical</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">62</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">188</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">193 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,367</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,130 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6,880</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,273 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract manufacturing &amp; human health</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">21</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">59</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Revenue</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,388</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,151 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6,939</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,331 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">B. Revenue from Contracts with Customers</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Contract liabilities reflected within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> as of December 31, 2023 and 2022, and subsequently recognized as revenue during each of the first nine months of 2024 and 2023 were $4 million. Contract liabilities as of September 30, 2024 and December 31, 2023 were $21 million and $11 million, respectively.</span></div>Estimated future revenue expected to be generated from long-term contracts with unsatisfied performance obligations as of September 30, 2024 is not material. 300 <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following tables present our revenue disaggregated by geographic area, species and major product category:</span></div><div style="margin-top:6pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Revenue by geographic area</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.014%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(MILLIONS OF DOLLARS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,346</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,174 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,817</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,344 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">83</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">239</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">248 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brazil</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">101</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">301</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">276 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">66</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">202</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">183 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chile</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">31</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">93</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">61</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">205</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">255 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">France</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">36</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">111</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">57</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">166</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">148 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Italy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">31</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">95</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">33</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">109</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">39</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">129</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">119 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Spain</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">35</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">80</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">230</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">209 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other developed markets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">148</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">413</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">374 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other emerging markets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">220</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">670</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">605 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,367</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,130 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6,880</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,273 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract manufacturing &amp; human health</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">21</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">59</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Revenue</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,388</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,151 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6,939</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,331 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1346000000 1174000000 3817000000 3344000000 83000000 84000000 239000000 248000000 101000000 101000000 301000000 276000000 66000000 63000000 202000000 183000000 31000000 31000000 93000000 109000000 61000000 69000000 205000000 255000000 36000000 34000000 111000000 102000000 57000000 50000000 166000000 148000000 31000000 26000000 95000000 87000000 33000000 34000000 109000000 120000000 39000000 42000000 129000000 119000000 35000000 30000000 100000000 94000000 80000000 78000000 230000000 209000000 148000000 127000000 413000000 374000000 220000000 187000000 670000000 605000000 2367000000 2130000000 6880000000 6273000000 21000000 21000000 59000000 58000000 2388000000 2151000000 6939000000 6331000000 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Revenue by major species</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.014%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(MILLIONS OF DOLLARS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Companion animal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,068</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">908 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,046</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,588 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Livestock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">278</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">266 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">771</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">756 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,346</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,174 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,817</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,344 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Companion animal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">541</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">506 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,662</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,540 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Livestock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">480</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">450 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,401</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,389 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">956 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,063</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,929 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Companion animal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,609</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,414 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,708</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,128 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Livestock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">758</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">716 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,172</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,145 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract manufacturing &amp; human health</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">21</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">59</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,388</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,151 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6,939</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,331 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1068000000 908000000 3046000000 2588000000 278000000 266000000 771000000 756000000 1346000000 1174000000 3817000000 3344000000 541000000 506000000 1662000000 1540000000 480000000 450000000 1401000000 1389000000 1021000000 956000000 3063000000 2929000000 1609000000 1414000000 4708000000 4128000000 758000000 716000000 2172000000 2145000000 21000000 21000000 59000000 58000000 2388000000 2151000000 6939000000 6331000000 <div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Revenue by species</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.014%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(MILLIONS OF DOLLARS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Companion Animal:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dogs and Cats</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,551</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,354 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,516</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,931 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Horses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">58</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">192</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">197 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,609</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,414 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,708</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,128 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Livestock:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cattle</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">391</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">374 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,132</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,102 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Poultry</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">139</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">410</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">397 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Swine</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">131</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">129 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">388</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">404 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fish</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">70</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">177</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">158 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sheep and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">27</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">65</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">758</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">716 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,172</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,145 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract manufacturing &amp; human health</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">21</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">59</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,388</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,151 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6,939</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,331 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1551000000 1354000000 4516000000 3931000000 58000000 60000000 192000000 197000000 1609000000 1414000000 4708000000 4128000000 391000000 374000000 1132000000 1102000000 139000000 127000000 410000000 397000000 131000000 129000000 388000000 404000000 70000000 57000000 177000000 158000000 27000000 29000000 65000000 84000000 758000000 716000000 2172000000 2145000000 21000000 21000000 59000000 58000000 2388000000 2151000000 6939000000 6331000000 <div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Revenue by major product category</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.014%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(MILLIONS OF DOLLARS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Parasiticides</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">530</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">465 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,634</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,465 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vaccines</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">468</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">449 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,365</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,308 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dermatology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">453</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">397 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,234</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,048 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Anti-infectives</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">274</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">264 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">819</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">796 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pain and sedation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">219</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">634</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">408 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other pharmaceutical</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">169</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">166 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">478</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">514 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Animal health diagnostics</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">101</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">286</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">284 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicated feed additives</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">91</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">242</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">257 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other non-pharmaceutical</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">62</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">188</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">193 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,367</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,130 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6,880</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,273 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract manufacturing &amp; human health</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">21</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">59</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Revenue</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,388</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,151 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6,939</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,331 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 530000000 465000000 1634000000 1465000000 468000000 449000000 1365000000 1308000000 453000000 397000000 1234000000 1048000000 274000000 264000000 819000000 796000000 219000000 147000000 634000000 408000000 169000000 166000000 478000000 514000000 101000000 95000000 286000000 284000000 91000000 86000000 242000000 257000000 62000000 61000000 188000000 193000000 2367000000 2130000000 6880000000 6273000000 21000000 21000000 59000000 58000000 2388000000 2151000000 6939000000 6331000000 4000000 4000000 21000000 11000000 <div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">5. Acquisitions and Divestitures </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">A. Acquisitions</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the third quarter of 2023, we acquired 100% of the issued share capital of PetMedix Ltd. (PetMedix), a privately held research and development stage animal health biopharmaceutical company based in the United Kingdom, which develops antibody-based therapeutics for companion animals. The purchase price included upfront cash consideration of $111 million, excluding $19 million of cash acquired, $5 million in cash withheld for customary post-closing adjustments, and contingent consideration up to $100 million based on the achievement of certain milestones. There are additional contingent payments to be made to the seller upon receipt of payments from a third party related to a preexisting collaboration arrangement between PetMedix and the third party. The initial fair value assessment of the contingent consideration and additional contingent payments is not material and the transaction did not have a material impact on our condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the third quarter of 2023, we also completed the acquisition of adivo GmbH (adivo), a privately held research and development stage animal health biopharmaceutical company based in Germany. The transaction did not have a material impact on our condensed consolidated financial statements. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">B. Divestitures</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the second quarter of 2024, we entered into a definitive agreement where Phibro Animal Health will acquire Zoetis’ medicated feed additive product portfolio, certain water soluble products and related assets for $350 million, subject to customary closing adjustments. Net assets and liabilities related to the sale met all the criteria to be classified as held for sale during the second quarter of 2024. We have determined that this future divestiture does not qualify for reporting as a discontinued operation, as it does not represent a strategic shift that has or will have a major effect on our operations and/or financial results. Proceeds upon the closing of this transaction were received in the fourth quarter of 2024. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Note 17. Subsequent Event</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> for additional information.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of September 30, 2024, major classes of assets held for sale and liabilities associated with assets held for sale are summarized below:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.123%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(MILLIONS OF DOLLARS)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Assets held for sale</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable, less allowance for doubtful accounts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">162</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, plant and equipment, less accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">108</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Identifiable intangible assets, less accumulated amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">26</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on assets held for sale</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">  Total Assets Held for Sale</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">314</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Liabilities associated with assets held for sale</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued compensation and related items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">  Total Liabilities Associated with Assets Held for Sale</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">26</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> We recorded a loss on assets held for sale of $22 million in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Condensed Consolidated Statements of Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> during the nine months ended September 30, 2024. Of the loss on assets held for sale, $12 million is allocated to goodwill and the remaining $10 million relates to selling costs to be recognized upon closing and foreign currency translation losses to be reclassified out of accumulated other comprehensive income into earnings upon closing of the transaction.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the second quarter of 2023, we received net cash proceeds of $93 million ($99 million sales proceeds, net of cash sold of $6 million) for the sale of a majority interest in our pet insurance business, Pumpkin Insurance Services. We recorded a net pre-tax gain of $101 million within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions—net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, which includes $24 million related to the remeasurement of our retained noncontrolling investment to fair value. We also completed the divestiture of Performance Livestock Analytics, part of our precision animal health business in the third quarter of 2023. The transaction did not have a material impact on our condensed consolidated financial statements.</span></div> 1 111000000 19000000 5000000 100000000 350000000 <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of September 30, 2024, major classes of assets held for sale and liabilities associated with assets held for sale are summarized below:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.123%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(MILLIONS OF DOLLARS)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Assets held for sale</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable, less allowance for doubtful accounts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">162</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, plant and equipment, less accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">108</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Identifiable intangible assets, less accumulated amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">26</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on assets held for sale</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">  Total Assets Held for Sale</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">314</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Liabilities associated with assets held for sale</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued compensation and related items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">  Total Liabilities Associated with Assets Held for Sale</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">26</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> We recorded a loss on assets held for sale of $22 million in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Condensed Consolidated Statements of Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> during the nine months ended September 30, 2024. Of the loss on assets held for sale, $12 million is allocated to goodwill and the remaining $10 million relates to selling costs to be recognized upon closing and foreign currency translation losses to be reclassified out of accumulated other comprehensive income into earnings upon closing of the transaction.</span></div> 1000000 162000000 2000000 108000000 2000000 12000000 26000000 2000000 9000000 -10000000 314000000 11000000 8000000 1000000 6000000 26000000 -22000000 -22000000 12000000 12000000 10000000 10000000 93000000 99000000 6000000 101000000 24000000 <div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">6. Restructuring Charges and Other Costs Associated with Acquisitions and Divestitures </span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In connection with our cost-reduction/productivity initiatives, we typically incur restructuring charges associated with workforce reductions and site closings. In connection with our acquisition and divestiture activities, we typically incur costs associated with executing the transactions. Acquisition activity may also include integrating the acquired operations, which may include expenditures for consulting and the integration of systems and processes, product transfers and restructuring the company, which may include charges related to employees, assets and activities that will not continue in the company. Divestiture activity may also include costs to separate the divested operations, which may include expenditures for consulting and the disintegration of systems and processes, transfer costs, and restructuring charges which may include charges related to employees, assets and activities that will not continue in the company's ongoing operations. All operating functions can be impacted by these actions, including sales and marketing, manufacturing and R&amp;D, as well as functions such as business technology, shared services and corporate operations. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The components of costs incurred in connection with restructuring initiatives, acquisitions and divestitures are as follows: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.066%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.066%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.066%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.071%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(MILLIONS OF DOLLARS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring charges and certain acquisition and divestiture-related costs:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition-related costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Divestiture-related costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt;padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring charges, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employee termination costs, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">39</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset impairment charges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exit costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt;padding-left:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Total Restructuring charges and certain acquisition and divestiture-related costs</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">51</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">    Divestiture-related costs consisted of costs related to the planned sale of our medicated feed additive product portfolio, certain water soluble products and related assets. </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> The restructuring charges for the nine months ended September 30, 2024 primarily consisted of employee termination costs related to organizational structure refinements, partially offset by a reversal of certain employee termination costs as a result of a change in strategy from our 2015 operational efficiency initiative.</span></div><div style="margin-top:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The restructuring charges for the three and nine months ended September 30, 2023 primarily consisted of employee termination and exit costs related to organizational structure refinements and other cost-reduction and productivity initiatives.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The change in our restructuring accrual is as follows:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.677%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.123%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(MILLIONS OF DOLLARS)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrual</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, December 31, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Provision</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">46</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Reserve adjustment</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Utilization and other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, September 30, 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">46</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">    At September 30, 2024 and December 31, 2023, included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Accrued expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> ($44 million and $26 million, respectively) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other noncurrent liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> ($2 million and $9 million, respectively). </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)     </span>Includes adjustments for foreign currency translation. <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The components of costs incurred in connection with restructuring initiatives, acquisitions and divestitures are as follows: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.066%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.066%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.066%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.071%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(MILLIONS OF DOLLARS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring charges and certain acquisition and divestiture-related costs:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition-related costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Divestiture-related costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt;padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring charges, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employee termination costs, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">39</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset impairment charges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exit costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt;padding-left:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Total Restructuring charges and certain acquisition and divestiture-related costs</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">51</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">    Divestiture-related costs consisted of costs related to the planned sale of our medicated feed additive product portfolio, certain water soluble products and related assets. </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> The restructuring charges for the nine months ended September 30, 2024 primarily consisted of employee termination costs related to organizational structure refinements, partially offset by a reversal of certain employee termination costs as a result of a change in strategy from our 2015 operational efficiency initiative.</span></div><div style="margin-top:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The restructuring charges for the three and nine months ended September 30, 2023 primarily consisted of employee termination and exit costs related to organizational structure refinements and other cost-reduction and productivity initiatives.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The change in our restructuring accrual is as follows:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.677%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.123%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(MILLIONS OF DOLLARS)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrual</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, December 31, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Provision</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">46</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Reserve adjustment</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Utilization and other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, September 30, 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">46</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">    At September 30, 2024 and December 31, 2023, included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Accrued expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> ($44 million and $26 million, respectively) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other noncurrent liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> ($2 million and $9 million, respectively). </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)     </span>Includes adjustments for foreign currency translation. 0 3000000 1000000 7000000 7000000 0 11000000 0 -2000000 8000000 39000000 33000000 0 1000000 0 1000000 0 4000000 0 4000000 5000000 16000000 51000000 45000000 35000000 46000000 -7000000 28000000 46000000 44000000 26000000 2000000 9000000 <div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">7. Other (Income)/Deductions—Net</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The components of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions—net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> are as follows: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.014%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(MILLIONS OF DOLLARS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Royalty-related income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(79)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(79)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Identifiable intangible asset impairment charges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on assets held for sale</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">22</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other asset impairment charges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net gain on sale of business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">42</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Other (income)/deductions—net</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(16)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(151)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">     For the nine months ended September 30, 2023, predominantly associated with a settlement for underpayment of royalties in prior periods.</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">    For the nine months ended September 30, 2024, represents asset impairment charges related to our aquaculture business. </span></div><div style="margin-top:4pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For the three months ended September 30, 2023, primarily represents asset impairment charges related to our diagnostics business. </span></div><div style="margin-top:1pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2023, primarily represents asset impairment charges related to our precision animal health and diagnostics businesses.</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">    Represents a loss on assets held for sale related to the planned sale of our medicated feed additive product portfolio, certain water soluble products and related assets. For additional information, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 5. Acquisitions and Divestitures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">    Relates to the gain on sale of a majority interest in our pet insurance business. For additional information, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 5. Acquisitions and Divestitures.</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">    Primarily driven by costs related to hedging and exposures to certain emerging and developed market currencies.</span></div> <div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The components of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions—net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> are as follows: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.014%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(MILLIONS OF DOLLARS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Royalty-related income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(79)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(79)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Identifiable intangible asset impairment charges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on assets held for sale</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">22</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other asset impairment charges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net gain on sale of business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">42</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Other (income)/deductions—net</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(16)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(151)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">     For the nine months ended September 30, 2023, predominantly associated with a settlement for underpayment of royalties in prior periods.</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">    For the nine months ended September 30, 2024, represents asset impairment charges related to our aquaculture business. </span></div><div style="margin-top:4pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For the three months ended September 30, 2023, primarily represents asset impairment charges related to our diagnostics business. </span></div><div style="margin-top:1pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2023, primarily represents asset impairment charges related to our precision animal health and diagnostics businesses.</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">    Represents a loss on assets held for sale related to the planned sale of our medicated feed additive product portfolio, certain water soluble products and related assets. For additional information, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 5. Acquisitions and Divestitures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">    Relates to the gain on sale of a majority interest in our pet insurance business. For additional information, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 5. Acquisitions and Divestitures.</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">    Primarily driven by costs related to hedging and exposures to certain emerging and developed market currencies.</span></div> 2000000 1000000 5000000 36000000 23000000 23000000 79000000 79000000 0 6000000 11000000 17000000 0 0 -22000000 0 0 1000000 0 1000000 0 0 0 101000000 -5000000 -19000000 -42000000 -41000000 -4000000 -4000000 -10000000 -6000000 16000000 -6000000 -1000000 151000000 <div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">8. Income Taxes </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">A. Taxes on Income</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our effective tax rate was 20.8% and 16.9% for the three months ended September 30, 2024 and 2023, respectively. The higher effective tax rate for the three months ended September 30, 2024, compared with the three months ended September 30, 2023, was primarily attributable to a benefit from the tax loss on the divestiture of Performance Livestock Analytics recorded in the third quarter of 2023, higher net discrete tax expenses and a less favorable jurisdictional mix of earnings (which includes the impact of the location of earnings and repatriation costs), partially offset by a higher benefit in the U.S. related to foreign-derived intangible income. Jurisdictional mix of earnings can vary depending on repatriation decisions, operating fluctuations in the normal course of business and the impact of non-deductible items and non-taxable items.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our effective tax rate was 20.2% and 20.5% for the nine months ended September 30, 2024 and 2023, respectively. The lower effective tax rate for the nine months ended September 30, 2024, compared with the nine months ended September 30, 2023, was primarily attributable to a higher benefit in the U.S. related to foreign-derived intangible income, lower net discrete tax expenses and a more favorable jurisdictional mix of earnings (which includes the impact of the location of earnings and repatriation costs), partially offset by a benefit from the tax loss on the divestiture of Performance Livestock Analytics recorded in the third quarter of 2023. Jurisdictional mix of earnings can vary depending on repatriation decisions, operating fluctuations in the normal course of business and the impact of non-deductible items and non-taxable items.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2022, the company implemented an initiative to maximize its cash position in the U.S. This initiative resulted in a tax benefit in the U.S. in connection with a prepayment from a related foreign entity in Belgium which qualifies as foreign-derived intangible income; however, this income tax benefit was deferred to 2023 and 2024. A portion of this benefit was recognized during the three and nine months ended September 30, 2024 and 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The global minimum tax provisions (Pillar Two) resulting from the Organisation for Economic Co-operation and Development (OECD) Base Erosion and Profit Shifting project are effective beginning in 2024 and the impact of these provisions is included in our effective tax rate for the three and nine months ended September 30, 2024.</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">B. Deferred Taxes</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of September 30, 2024, the total net deferred income tax asset of $237 million is included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent deferred tax assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">($409 million) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent deferred tax liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">($172 million). </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December 31, 2023, the total net deferred income tax asset of $60 million is included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent deferred tax assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">($206 million) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent deferred tax liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">($146 million).</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">C. Tax Contingencies</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Uncertain Tax Positions</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of September 30, 2024, the net tax liabilities associated with uncertain tax positions of $217 million (exclusive of interest and penalties related to uncertain tax positions of $36 million) are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other taxes payable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December 31, 2023, the net tax liabilities associated with uncertain tax positions of $209 million (exclusive of interest and penalties related to uncertain tax positions of $27 million) are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other taxes payable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our tax liabilities for uncertain tax positions relate primarily to issues common among multinational corporations. Any settlements or statute of limitations expirations could result in a significant decrease in our uncertain tax positions. Substantially all of these unrecognized tax benefits, if recognized, would impact our effective income tax rate. We do not expect that within the next twelve months any of our uncertain tax positions could significantly decrease as a result of settlements with taxing authorities or the expiration of the statutes of limitations. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but our estimates of uncertain tax positions and potential tax benefits may not be representative of actual outcomes, and any variation from such estimates could materially affect our financial statements in the period of settlement or when the statutes of limitations expire, as we treat these events as discrete items in the period of resolution. Finalizing audits with the relevant taxing authorities can include formal administrative and legal proceedings, and, as a result, it is difficult to estimate the timing and range of possible changes related to our uncertain tax positions, and such changes could be significant. </span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Status of Tax Audits and Potential Impact on Accrual for Uncertain Tax Positions</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We are currently under income tax audit by the U.S. Internal Revenue Service (IRS) for tax years 2017 and 2018. In July 2024, the IRS issued Notices of Proposed Adjustment (NOPA) related to the one-time mandatory deemed repatriation tax incurred on the 2018 U.S. Federal Income Tax return. In September 2024, the IRS issued a Revenue Agent Report for the adjustments identified in the NOPA. As of September 30, 2024, the additional tax liability, based on the income adjustment proposed by the IRS under the NOPA, is approximately $450 million, excluding interest and penalties.</span></div>Based on current facts and circumstances, we disagree with the IRS’ position and will defend our position taken on the 2018 U.S. Federal Income Tax return. We believe the amount previously accrued related to this uncertain tax position remains appropriate, but we will continue to evaluate the adequacy of our tax reserve as the audit progresses. However, the outcome of tax audits cannot be predicted with certainty. If any issues addressed in our tax audits are not consistent with management’s expectations, we could be required to adjust our provision for income taxes and this amount could be material to our financial statements. 0.208 0.169 0.202 0.205 237000000 409000000 172000000 60000000 206000000 146000000 217000000 36000000 209000000 27000000 <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our tax liabilities for uncertain tax positions relate primarily to issues common among multinational corporations. Any settlements or statute of limitations expirations could result in a significant decrease in our uncertain tax positions. Substantially all of these unrecognized tax benefits, if recognized, would impact our effective income tax rate. We do not expect that within the next twelve months any of our uncertain tax positions could significantly decrease as a result of settlements with taxing authorities or the expiration of the statutes of limitations. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but our estimates of uncertain tax positions and potential tax benefits may not be representative of actual outcomes, and any variation from such estimates could materially affect our financial statements in the period of settlement or when the statutes of limitations expire, as we treat these events as discrete items in the period of resolution. Finalizing audits with the relevant taxing authorities can include formal administrative and legal proceedings, and, as a result, it is difficult to estimate the timing and range of possible changes related to our uncertain tax positions, and such changes could be significant. </span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Status of Tax Audits and Potential Impact on Accrual for Uncertain Tax Positions</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We are currently under income tax audit by the U.S. Internal Revenue Service (IRS) for tax years 2017 and 2018. In July 2024, the IRS issued Notices of Proposed Adjustment (NOPA) related to the one-time mandatory deemed repatriation tax incurred on the 2018 U.S. Federal Income Tax return. In September 2024, the IRS issued a Revenue Agent Report for the adjustments identified in the NOPA. As of September 30, 2024, the additional tax liability, based on the income adjustment proposed by the IRS under the NOPA, is approximately $450 million, excluding interest and penalties.</span></div>Based on current facts and circumstances, we disagree with the IRS’ position and will defend our position taken on the 2018 U.S. Federal Income Tax return. We believe the amount previously accrued related to this uncertain tax position remains appropriate, but we will continue to evaluate the adequacy of our tax reserve as the audit progresses. However, the outcome of tax audits cannot be predicted with certainty. If any issues addressed in our tax audits are not consistent with management’s expectations, we could be required to adjust our provision for income taxes and this amount could be material to our financial statements. 450000000 <div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">9. Financial Instruments </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">A. Debt</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Credit Facilities</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In December 2022, we entered into an amended and restated revolving credit agreement with a syndicate of banks providing for a multi-year $1.0 billion senior unsecured revolving credit facility (the credit facility), which expires in December 2027. Subject to certain conditions, we have the right to increase the credit facility to up to $1.5 billion. The credit facility contains a financial covenant requiring us to not exceed a maximum total leverage ratio (the ratio of consolidated net debt as of the end of the period to consolidated Earnings Before Interest, Income Taxes, Depreciation and Amortization (EBITDA) for such period) of 3.50:1. Upon entering into a material acquisition, the maximum total leverage ratio increases to 4.00:1, and extends until the fourth full consecutive fiscal quarter ended immediately following the consummation of a material acquisition. In addition, the credit facility contains other customary covenants. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We were in compliance with all financial covenants as of September 30, 2024 and December 31, 2023. There were no amounts drawn under the credit facility as of September 30, 2024 or December 31, 2023. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We have additional lines of credit and other credit arrangements with a group of banks and other financial intermediaries for general corporate purposes. We maintain cash and cash equivalent balances in excess of our outstanding short-term borrowings. As of September 30, 2024, we had access to $56 million of lines of credit which expire at various times and are generally renewed annually. There were no borrowings outstanding related to these facilities as of September 30, 2024 and $3 million of borrowings outstanding related to these facilities as of December 31, 2023. </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Commercial Paper Program</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In February 2013, we entered into a commercial paper program with a capacity of up to $1.0 billion. As of September 30, 2024 and December 31, 2023, there was no commercial paper outstanding under this program. </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Senior Notes and Other Long-Term Debt</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On November 8, 2022, we issued $1.35 billion aggregate principal amount of our senior notes (2022 senior notes), with an original issue discount of $2 million. These notes are comprised of $600 million aggregate principal amount of 5.400% senior notes due 2025 and $750 million aggregate principal amount of 5.600% senior notes due 2032. On February 1, 2023, the net proceeds were used to redeem in full, upon maturity, the $1.35 billion aggregate principal amount of our 3.250% 2013 senior notes due 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our senior notes are governed by an indenture and supplemental indentures (collectively, the indenture) between us and Deutsche Bank Trust Company Americas, as trustee. The indenture contains certain covenants, including limitations on our and certain of our subsidiaries’ ability to incur liens or engage in sale-leaseback transactions. The indenture also contains restrictions on our ability to consolidate, merge or sell substantially all of our assets. In addition, the indenture contains other customary terms, including certain events of default, upon the occurrence of which the senior notes may be declared immediately due and payable.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pursuant to the indenture, we are able to redeem the senior notes of any series, in whole or in part, at any time by paying a “make whole” premium, plus accrued and unpaid interest to, but excluding, the date of redemption. Upon the occurrence of a change of control of us and a downgrade of the senior notes below an investment grade rating by each of Moody’s Investors Service, Inc. and Standard &amp; Poor’s Ratings Services, we are, in certain circumstances, required to make an offer to repurchase all of the outstanding senior notes at a price equal to 101% of the aggregate principal amount of the senior notes together with accrued and unpaid interest to, but excluding, the date of repurchase.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The components of our long-term debt are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.066%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.124%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(MILLIONS OF DOLLARS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.500% 2015 senior notes due 2025</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">750</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.400% 2022 senior notes due 2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">600</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.000% 2017 senior notes due 2027</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">750</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.900% 2018 senior notes due 2028</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">500</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.000% 2020 senior notes due 2030</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">750</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.600% 2022 senior notes due 2032</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">750</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.700% 2013 senior notes due 2043</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,150</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,150 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.950% 2017 senior notes due 2047</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">500</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.450% 2018 senior notes due 2048</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.000% 2020 senior notes due 2050</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">500</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6,650</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,650 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized debt discount / debt issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(56)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cumulative fair value adjustment for interest rate swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Long-term debt, net of discount and issuance costs</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6,574</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,564 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair value of our long-term debt was $6,334 million and $6,319 million as of September 30, 2024 and December 31, 2023, respectively, and has been determined using a third-party model that uses significant inputs derived from, or corroborated by, observable market data, including benchmark security prices and Zoetis’ credit spreads (Level 2 inputs). </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table provides the principal amount of debt outstanding, as of September 30, 2024, by scheduled maturity date:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.022%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.377%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">After</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(MILLIONS OF DOLLARS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Maturities</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,350 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,050 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,650 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Interest Expense</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest expense, net of capitalized interest, was $57 million and $174 million for the three and nine months ended September 30, 2024, respectively, and $59 million and $180 million for the three and nine months ended September 30, 2023, respectively. Capitalized interest expense was $9 million and $26 million for the three and nine months ended September 30, 2024, respectively, and $7 million and $19 million for the three and nine months ended September 30, 2023, respectively.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">B. Derivative Financial Instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Foreign Exchange Risk</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A significant portion of our revenue, earnings and net investment in foreign affiliates is exposed to changes in foreign exchange rates. We seek to manage our foreign exchange risk, in part, through operational means, including managing same-currency revenue in relation to same-currency costs and same-currency assets in relation to same-currency liabilities. Depending on market conditions, foreign exchange risk is also managed through the use of various derivative financial instruments. These derivative financial instruments serve to manage the exposure of our net investment in certain foreign operations to changes in foreign exchange rates and protect net income against the impact of translation into U.S. dollars of certain foreign exchange-denominated transactions. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">All derivative financial instruments used to manage foreign currency risk are measured at fair value and are reported as assets or liabilities on the Condensed Consolidated Balance Sheets. The derivative financial instruments primarily offset exposures in the Australian dollar, British pound, Canadian dollar, Chinese renminbi, euro and Norwegian krone. Changes in fair value are reported in earnings or in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive loss, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">depending on the nature and purpose of the financial instrument, as follows: </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">For foreign currency forward-exchange contracts not designated as hedging instruments, we recognize the gains and losses that are used to offset the same foreign currency assets or liabilities immediately into earnings along with the earnings impact of the items they generally offset. These contracts essentially take the opposite currency position of that reflected in the month-end balance sheet to counterbalance the effect of any currency movement. The vast majority of the foreign currency forward-exchange contracts mature within 60 days and all mature within four years.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">For foreign exchange derivative instruments that are designated as hedging instruments against our net investment in foreign operations, changes in the fair value are recorded as a component of cumulative translation adjustment within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive loss </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">and reclassified into earnings when the foreign investment is sold or substantially liquidated. These instruments include cross-currency interest rate swaps and foreign currency forward-exchange contracts. Gains and losses excluded from the assessment of hedge effectiveness are recognized in earnings (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Interest expense, net of capitalized interest</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">). The cash flows from these contracts are reflected within the investing section of our Condensed Consolidated Statements of Cash Flows</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> These contracts have varying maturities and all mature within one year.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Interest Rate Risk</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The company may use interest rate swap contracts on certain investing and borrowing transactions to manage its net exposure to interest rates and to reduce its overall cost of borrowing. </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">In anticipation of issuing fixed-rate debt, we may use forward-starting interest rate swaps that are designated as cash flow hedges to hedge against changes in interest rates that could impact expected future issuances of debt. Unrealized gains or losses on the forward-starting interest rate swaps are reported in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and are recognized in earnings over the life of the future fixed rate notes. When the company discontinues hedge accounting because it is no longer probable that an anticipated transaction will occur within the originally expected period of execution, or within an additional two-month period thereafter, changes to fair value accumulated in other comprehensive income are recognized immediately in earnings.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">During the period from 2019 to 2022, we entered into forward-starting interest rate swaps with an aggregate notional value of $650 million. We designated these swaps as cash flow hedges against interest rate exposure related principally to the issuance of fixed-rate debt to refinance our 3.250% 2013 senior notes due 2023. Upon issuance of our 2022 senior notes, we terminated these contracts and received $114 million in cash from the counterparties for settlement. The settlement amount, which represented the fair value of the contracts at the time of termination, was recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, and will be amortized into income (offset to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Interest expense, net of capitalized interest</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">) over the life of the 5.600% 2022 senior notes due 2032. </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">As of September 30, 2024, we had outstanding forward-starting interest rate swaps, having an effective date and mandatory termination date in March 2026, to hedge against interest rate exposure related principally to the anticipated future issuance of fixed-rate debt to be used primarily to refinance our 4.500% 2015 senior notes due 2025.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">We may use fixed-to-floating interest rate swaps that are designated as fair value hedges to hedge against changes in the fair value of certain fixed-rate debt attributable to changes in the benchmark of the Secured Overnight Financing Rate (SOFR). These derivative instruments effectively convert a portion of the company’s long-term debt from fixed-rate to floating-rate debt based on the daily SOFR rate plus a spread. Gains or losses on the fixed-to-floating interest rate swaps due to changes in SOFR are recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Interest expense, net of capitalized interest.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Changes in the fair value of the fixed-to-floating interest rate swaps are offset by changes in the fair value of the underlying fixed-rate debt. As of September 30, 2024, we had outstanding fixed-to-floating interest rate swaps that correspond to a portion of the 3.900% 2018 senior notes due 2028 and the 2.000% 2020 senior notes due 2030. The amounts recorded during the three and nine </span></div><div style="margin-top:3pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">months ended September 30, 2024 for changes in the fair value of these hedges are not material to our condensed consolidated financial statements.</span></div><div style="margin-top:3pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the first quarter of 2023, we executed amendments to certain of our interest rate swap contracts, which changed the floating rate index from LIBOR to SOFR. These amendments did not have a material impact on our condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Outstanding Positions</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The aggregate notional amount of derivative instruments are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.124%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Notional </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivatives not Designated as Hedging Instruments: </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">     Foreign currency forward-exchange contracts </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,965</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,948 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivatives Designated as Hedging Instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">     Foreign exchange derivative instruments (in foreign currency):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">          Euro </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">750</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">650 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">          Danish krone</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">475</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">          Swiss franc</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">25</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">     Forward-starting interest rate swaps </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">200</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">     Fixed-to-floating interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">250</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">250 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Fair Value of Derivative Instruments</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The classification and fair values of derivative instruments are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.124%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair Value of Derivatives</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(MILLIONS OF DOLLARS)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance Sheet Location</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivatives Not Designated as Hedging Instruments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">   Foreign currency forward-exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">17</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">   Foreign currency forward-exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total derivatives not designated as hedging instruments</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivatives Designated as Hedging Instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">   Forward-starting interest rate swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">   Foreign exchange derivative instruments </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">17</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">   Foreign exchange derivative instruments </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">   Foreign exchange derivative instruments </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">   Foreign exchange derivative instruments </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">   Fixed-to-floating interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total derivatives designated as hedging instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total derivatives</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(5)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The company’s derivative transactions are subject to master netting agreements that mitigate credit risk by permitting net settlement of transactions with the same counterparty. The company also has collateral security agreements with certain of its counterparties. Under these collateral security agreements each party is required to post cash collateral when the net fair value of derivative instruments covered by the collateral agreement exceeds contractually established thresholds. At September 30, 2024, there was $12 million of collateral received and $22 million of collateral posted related to derivative instruments recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, respectively. At December 31, 2023, there was $13 million of collateral received and $33 million of collateral posted related to derivative instruments recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We use a market approach in valuing financial instruments on a recurring basis. Our derivative financial instruments are measured at fair value on a recurring basis using Level 2 inputs in the calculation of fair value.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The amounts of net gains/(losses) on derivative instruments not designated as hedging instruments, recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions—net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.014%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(MILLIONS OF DOLLARS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency forward-exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">These amounts were substantially offset in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions—net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> by the effect of changing exchange rates on the underlying foreign currency exposures.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The amounts of unrecognized net (losses)/gains on interest rate swap contracts, recorded, net of tax, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.955%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.014%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(MILLIONS OF DOLLARS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forward-starting interest rate swap contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange derivative instruments</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(23)</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 </span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(5)</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Gains on interest rate swap contracts, recognized within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Interest expense, net of capitalized interest, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.014%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(MILLIONS OF DOLLARS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange derivative instruments</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The net amount of deferred gains related to derivative instruments designated as cash flow hedges that is expected to be reclassified from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> into earnings over the next 12 months is not material.</span></div> 1000000000.0 1500000000 3.50 4.00 0 0 56000000 0 3000000 1000000000.0 0 0 1350000000 2000000 600000000 0.05400 750000000 0.05600 1350000000 0.03250 1.01 <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The components of our long-term debt are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.066%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.124%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(MILLIONS OF DOLLARS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.500% 2015 senior notes due 2025</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">750</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.400% 2022 senior notes due 2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">600</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.000% 2017 senior notes due 2027</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">750</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.900% 2018 senior notes due 2028</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">500</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.000% 2020 senior notes due 2030</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">750</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.600% 2022 senior notes due 2032</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">750</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.700% 2013 senior notes due 2043</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,150</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,150 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.950% 2017 senior notes due 2047</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">500</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.450% 2018 senior notes due 2048</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.000% 2020 senior notes due 2050</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">500</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6,650</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,650 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized debt discount / debt issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(56)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cumulative fair value adjustment for interest rate swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Long-term debt, net of discount and issuance costs</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6,574</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,564 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 0.04500 750000000 750000000 0.05400 600000000 600000000 0.03000 750000000 750000000 0.03900 500000000 500000000 0.02000 750000000 750000000 0.05600 750000000 750000000 0.04700 1150000000 1150000000 0.03950 500000000 500000000 0.04450 400000000 400000000 0.03000 500000000 500000000 6650000000 6650000000 -56000000 -60000000 -20000000 -26000000 6574000000 6564000000 6334000000 6319000000 <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table provides the principal amount of debt outstanding, as of September 30, 2024, by scheduled maturity date:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.022%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.377%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">After</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(MILLIONS OF DOLLARS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Maturities</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,350 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,050 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,650 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 0 1350000000 0 750000000 500000000 4050000000 6650000000 57000000 174000000 59000000 180000000 9000000 26000000 7000000 19000000 P60D P4Y P1Y 650000000 0.03250 114000000 0.05600 0.04500 0.03900 0.02000 <div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The aggregate notional amount of derivative instruments are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.124%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Notional </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivatives not Designated as Hedging Instruments: </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">     Foreign currency forward-exchange contracts </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,965</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,948 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivatives Designated as Hedging Instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">     Foreign exchange derivative instruments (in foreign currency):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">          Euro </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">750</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">650 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">          Danish krone</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">475</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">          Swiss franc</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">25</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">     Forward-starting interest rate swaps </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">200</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">     Fixed-to-floating interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">250</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">250 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 1965000000 1948000000 750000000 650000000 475000000 600000000 25000000 25000000 200000000 100000000 250000000 250000000 <div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The classification and fair values of derivative instruments are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.124%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair Value of Derivatives</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(MILLIONS OF DOLLARS)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance Sheet Location</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivatives Not Designated as Hedging Instruments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">   Foreign currency forward-exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">17</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">   Foreign currency forward-exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total derivatives not designated as hedging instruments</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivatives Designated as Hedging Instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">   Forward-starting interest rate swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">   Foreign exchange derivative instruments </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">17</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">   Foreign exchange derivative instruments </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">   Foreign exchange derivative instruments </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">   Foreign exchange derivative instruments </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">   Fixed-to-floating interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total derivatives designated as hedging instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total derivatives</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(5)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 17000000 11000000 14000000 11000000 3000000 0 12000000 12000000 17000000 5000000 0 11000000 17000000 20000000 0 1000000 20000000 26000000 -8000000 -19000000 -5000000 -19000000 12000000 22000000 13000000 33000000 <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The amounts of net gains/(losses) on derivative instruments not designated as hedging instruments, recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions—net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.014%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(MILLIONS OF DOLLARS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency forward-exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 11000000 16000000 12000000 -20000000 <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The amounts of unrecognized net (losses)/gains on interest rate swap contracts, recorded, net of tax, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.955%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.014%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(MILLIONS OF DOLLARS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forward-starting interest rate swap contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange derivative instruments</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(23)</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 </span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(5)</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> -3000000 5000000 0 5000000 -23000000 18000000 -5000000 5000000 <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Gains on interest rate swap contracts, recognized within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Interest expense, net of capitalized interest, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.014%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(MILLIONS OF DOLLARS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange derivative instruments</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 4000000 4000000 12000000 14000000 <div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">10. Inventories </span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The components of inventory are as follows: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.124%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(MILLIONS OF DOLLARS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,049</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,147 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">951</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">966 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials and supplies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">416</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">451 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,416</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,564 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The components of inventory are as follows: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.124%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(MILLIONS OF DOLLARS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,049</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,147 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">951</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">966 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials and supplies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">416</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">451 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,416</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,564 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1049000000 1147000000 951000000 966000000 416000000 451000000 2416000000 2564000000 <div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">11. Goodwill and Other Intangible Assets </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">A. Goodwill </span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The components of, and changes in, the carrying amount of goodwill are as follows: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.124%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(MILLIONS OF DOLLARS)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,532 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,227 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,759 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, September 30, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,515</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,229</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,744</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Includes adjustments for the reclassification of goodwill of $24 million to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Assets held for sale</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> related to the planned sale of our medicated feed additive product portfolio, certain water soluble products and related assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">as well as</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">foreign currency translation. For additional information, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 5. Acquisitions and Divestitures: B. Divestitures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The gross goodwill balance was $3,280 million and $3,295 million as of September 30, 2024 and December 31, 2023, respectively. Accumulated goodwill impairment losses were $536 million as of September 30, 2024 and December 31, 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">B. Other Intangible Assets</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The components of identifiable intangible assets are as follows: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.594%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of September 30, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Identifiable</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Identifiable</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intangible Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intangible Assets</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less Accumulated</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less Accumulated</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(MILLIONS OF DOLLARS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finite-lived intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Developed technology rights</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,931</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,164)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">767</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,986 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,101)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">885 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brands and tradenames</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">370</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(245)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">125</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">383 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(246)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">276</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(196)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">80</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">270 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(190)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,577</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,605)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">972</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,639 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,537)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,102 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indefinite-lived intangible assets:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brands and tradenames</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">66</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">66</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">141</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">141</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">141 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">141 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product rights</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total indefinite-lived intangible assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">214</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">214</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">236 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">236 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Identifiable intangible assets</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,791</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,605)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,186</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,875 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,537)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,338 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">C. Amortization</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization expense related to finite-lived acquired intangible assets that contribute to our ability to sell, manufacture, research, market and distribute products, compounds and intellectual property is included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Amortization of intangible assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> as it benefits multiple business functions. Amortization expense related to finite-lived acquired intangible assets that are associated with a single function is included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales, Selling, general and administrative expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, as appropriate. Total amortization expense for finite-lived intangible assets was $42 million and $128 million for the three and nine months ended September 30, 2024, respectively, and $46 million and $141 million for the three and nine months ended September 30, 2023, respectively.</span></div> <div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The components of, and changes in, the carrying amount of goodwill are as follows: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.124%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(MILLIONS OF DOLLARS)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,532 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,227 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,759 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, September 30, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,515</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,229</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,744</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Includes adjustments for the reclassification of goodwill of $24 million to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Assets held for sale</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> related to the planned sale of our medicated feed additive product portfolio, certain water soluble products and related assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">as well as</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">foreign currency translation. For additional information, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 5. Acquisitions and Divestitures: B. Divestitures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div> 1532000000 1227000000 2759000000 -17000000 2000000 -15000000 1515000000 1229000000 2744000000 -24000000 3280000000 3295000000 536000000 536000000 <div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The components of identifiable intangible assets are as follows: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.594%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of September 30, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Identifiable</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Identifiable</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intangible Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intangible Assets</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less Accumulated</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less Accumulated</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(MILLIONS OF DOLLARS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finite-lived intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Developed technology rights</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,931</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,164)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">767</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,986 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,101)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">885 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brands and tradenames</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">370</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(245)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">125</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">383 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(246)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">276</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(196)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">80</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">270 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(190)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,577</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,605)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">972</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,639 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,537)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,102 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indefinite-lived intangible assets:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brands and tradenames</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">66</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">66</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">141</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">141</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">141 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">141 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product rights</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total indefinite-lived intangible assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">214</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">214</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">236 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">236 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Identifiable intangible assets</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,791</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,605)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,186</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,875 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,537)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,338 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div> 1931000000 1164000000 767000000 1986000000 1101000000 885000000 370000000 245000000 125000000 383000000 246000000 137000000 276000000 196000000 80000000 270000000 190000000 80000000 2577000000 1605000000 972000000 2639000000 1537000000 1102000000 66000000 66000000 88000000 88000000 141000000 141000000 141000000 141000000 7000000 7000000 7000000 7000000 214000000 214000000 236000000 236000000 2791000000 1605000000 1186000000 2875000000 1537000000 1338000000 42000000 128000000 46000000 141000000 <div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">12. Share-based Payments </span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Zoetis 2013 Equity and Incentive Plan, Amended and Restated as of May 19, 2022 (Equity Plan), provides long-term incentives to our employees and non-employee directors. The principal types of share-based awards available under the Equity Plan may include, but are not limited to, stock options, restricted stock and restricted stock units (RSUs), deferred stock units (DSUs), performance-vesting restricted stock units (PSUs) and other equity-based or cash-based awards. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The components of share-based compensation expense are as follows: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.014%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(MILLIONS OF DOLLARS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options / stock appreciation rights</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">RSUs / DSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">31</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">16</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation expense—total</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">55</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2024 and 2023, we capitalized less than $1 million of share-based compensation expense to inventory.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2024, the company granted 270,450 stock options with a weighted-average exercise price of $195.84 per stock option and a weighted-average fair value of $50.90 per stock option. The fair-value based method for valuing each Zoetis stock option grant on the grant date uses the Black-Scholes-Merton option-pricing model, which incorporates a number of valuation assumptions. The weighted-average fair value was estimated based on the following assumptions: risk-free interest rate of 4.06%; expected dividend yield of 0.88%; expected stock price volatility of 27.02%; and expected term of 4.1 years. Stock options granted prior to 2023 generally vest after three years of continuous service from the date of grant and have a contractual term of 10 years. Beginning in 2023, stock options granted are subject to graded vesting over three years from the date of grant and have a contractual term of 10 years. The values determined through this fair-value based method generally are amortized on a straight-line basis over the vesting term into </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales, Selling, general and administrative expenses, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">as appropriate.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2024, the company granted 246,112 RSUs, with a weighted-average grant date fair value of $195.10 per RSU. RSUs are accounted for using a fair-value-based method that utilizes the closing price of Zoetis common stock on the date of grant. RSUs granted prior to 2023 generally vest after three years of continuous service from the date of grant. Beginning in 2023, RSUs granted are subject to graded vesting over three years from the date of grant. The values generally are amortized on a straight-line basis over the vesting term into </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales, Selling, general and administrative expenses, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">as appropriate. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2024, the company granted 101,099 PSUs with a weighted-average grant date fair value of $268.71 per PSU. PSUs are accounted for using a Monte Carlo simulation model. The units underlying the PSUs will be earned and vested over a three-year performance period, based upon the total shareholder return of the company in comparison to the total shareholder return of the companies </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">comprising the S&amp;P 500 stock market index at the start of the performance period, excluding companies that during the performance period are acquired or no longer publicly traded (Relative TSR). The weighted-average fair value was estimated based on volatility assumptions of Zoetis common stock and an average of the S&amp;P 500 companies, which were 26.2% and 30.6%, respectively. Depending on the company’s Relative TSR performance at the end of the performance period, the recipient may earn from 0% to 200% of the target number of units. Vested units are settled in shares of the company’s common stock. PSU values are amortized on a straight-line basis over the vesting term into </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales, Selling, general and administrative expenses, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">as appropriate.</span></div> <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The components of share-based compensation expense are as follows: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.014%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(MILLIONS OF DOLLARS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options / stock appreciation rights</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">RSUs / DSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">31</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">16</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation expense—total</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">55</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2024 and 2023, we capitalized less than $1 million of share-based compensation expense to inventory.</span></div> 2000000 3000000 8000000 6000000 10000000 10000000 31000000 27000000 6000000 4000000 16000000 10000000 18000000 17000000 55000000 43000000 1000000 1000000 1000000 1000000 270450 195.84 50.90 0.0406 0.0088 0.2702 P4Y1M6D P3Y P10Y P3Y P10Y 246112 195.10 P3Y P3Y 101099 268.71 P3Y 0.262 0.306 0 2 <div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">13. Stockholders’ Equity </span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Zoetis is authorized to issue 6 billion shares of common stock and 1 billion shares of preferred stock. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In December 2021, our Board of Directors authorized a $3.5 billion multi-year share repurchase program. As of September 30, 2024, there was $200 million remaining under this authorization. In August 2024, our Board of Directors authorized a new multi-year share repurchase program of up to $6 billion of our outstanding common stock. Purchases of Zoetis shares may be made at the discretion of management, depending on market conditions, business needs and available liquidity.</span></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Accumulated other comprehensive loss</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Changes, net of tax, in accumulated other comprehensive loss, were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.210%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency Translation Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Currency</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated Other</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash Flow</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Investment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Translation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actuarial</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(MILLIONS OF DOLLARS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hedges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hedges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gains/(Losses)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(944)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(839)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;text-align:center"><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, September 30, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">80</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">13</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(946)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(851)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(944)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(817)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income/(loss), net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, September 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(950)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(814)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 6000000000 1000000000 3500000000 200000000 6000000000 <div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Changes, net of tax, in accumulated other comprehensive loss, were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.210%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency Translation Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Currency</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated Other</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash Flow</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Investment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Translation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actuarial</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(MILLIONS OF DOLLARS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hedges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hedges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gains/(Losses)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(944)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(839)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;text-align:center"><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, September 30, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">80</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">13</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(946)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(851)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(944)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(817)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income/(loss), net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, September 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(950)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(814)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 85000000 18000000 -944000000 2000000 -839000000 -5000000 -5000000 -2000000 0 -12000000 80000000 13000000 -946000000 2000000 -851000000 90000000 41000000 -944000000 -4000000 -817000000 0 5000000 -6000000 4000000 3000000 90000000 46000000 -950000000 0 -814000000 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">14. Earnings per Share</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table presents the calculation of basic and diluted earnings per share:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.955%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.014%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(MILLIONS OF DOLLARS AND SHARES, EXCEPT PER SHARE DATA)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Numerator</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income before allocation to noncontrolling interests</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">692</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">596 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,915</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,817 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Net income/(loss) attributable to noncontrolling interests</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to Zoetis Inc.</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">682</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">596 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,905</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,819 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Denominator</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">452.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">460.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">455.4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">461.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock equivalents: stock options, RSUs, PSUs and DSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average common and potential dilutive shares outstanding</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">453.5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">461.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">456.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">463.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per share attributable to Zoetis Inc. stockholders—basic</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1.51</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.29 </span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4.18</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.94 </span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per share attributable to Zoetis Inc. stockholders—diluted</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1.50</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.29 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4.18</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.93 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The number of stock options outstanding under the company’s Equity Plan that were excluded from the computation of diluted earnings per share, as the effect would have been antidilutive, were not material for the three and nine months ended September 30, 2024 and 2023.</span></div> <div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table presents the calculation of basic and diluted earnings per share:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.955%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.014%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(MILLIONS OF DOLLARS AND SHARES, EXCEPT PER SHARE DATA)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Numerator</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income before allocation to noncontrolling interests</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">692</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">596 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,915</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,817 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Net income/(loss) attributable to noncontrolling interests</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to Zoetis Inc.</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">682</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">596 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,905</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,819 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Denominator</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">452.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">460.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">455.4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">461.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock equivalents: stock options, RSUs, PSUs and DSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average common and potential dilutive shares outstanding</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">453.5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">461.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">456.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">463.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per share attributable to Zoetis Inc. stockholders—basic</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1.51</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.29 </span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4.18</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.94 </span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per share attributable to Zoetis Inc. stockholders—diluted</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1.50</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.29 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4.18</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.93 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 692000000 596000000 1915000000 1817000000 10000000 0 10000000 -2000000 682000000 596000000 1905000000 1819000000 452900000 460300000 455400000 461900000 600000 1100000 700000 1100000 453500000 461400000 456100000 463000000.0 1.51 1.29 4.18 3.94 1.50 1.29 4.18 3.93 <div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">15. Commitments and Contingencies</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business. For a discussion of our tax contingencies, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Note 8. Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">A. Legal Proceedings</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our non-tax contingencies include, among others, the following: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•    Product liability and other product-related litigation, which can include injury, consumer, off-label promotion, antitrust and breach of contract claims. </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•    Commercial and other matters, which can include product-pricing claims and environmental claims and proceedings. </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•    Patent litigation, which typically involves challenges to the coverage and/or validity of our patents or those of third parties on various products or processes. </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•    Government investigations, which can involve regulation by national, state and local government agencies in the U.S. and in other countries. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain of these contingencies could result in losses, including damages, fines and/or civil penalties, and/or criminal charges, which could be substantial. </span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We believe that we have strong defenses in these types of matters, but litigation is inherently unpredictable and excessive verdicts do occur. We do not believe that any of these matters will have a material adverse effect on our financial position. However, we could incur judgments, enter into settlements or revise our expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on our results of operations or cash flows in the period in which the amounts are paid.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We have accrued for losses that are both probable and reasonably estimable. Substantially all of these contingencies are subject to significant uncertainties and, therefore, determining the likelihood of a loss and/or the measurement of any loss can be complex. Consequently, we are unable to estimate the range of reasonably possible loss in excess of amounts accrued. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but the assessment process relies on estimates and assumptions that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions. </span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amounts recorded for legal and environmental contingencies can result from a complex series of judgments about future events and uncertainties and can rely on estimates and assumptions.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The principal matters to which we are a party are discussed below. In determining whether a pending matter is significant for financial reporting and disclosure purposes, we consider both quantitative and qualitative factors in order to assess materiality, such as, among other things, the amount of damages and the nature of any other relief sought in the proceeding, if such damages and other relief are specified; our view of the merits of the claims and of the strength of our defenses; whether the action purports to be a class action and our view of the likelihood that a class will be certified by the court; the jurisdiction in which the proceeding is pending; any experience that we or, to our knowledge, other companies have had in similar proceedings; whether disclosure of the action would be important to a reader of our financial statements, including whether disclosure might change a reader’s judgment about our financial statements in light of all of the information about the company that is available to the reader; the potential impact of the proceeding on our reputation; and the extent of public interest in the matter. In addition, with respect to patent matters, we consider, among other things, the financial significance of the product protected by the patent. </span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Ulianopolis, Brazil</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In February 2012, the Municipality of Ulianopolis (State of Para, Brazil) filed a complaint against Fort Dodge Saúde Animal Ltda. (FDSAL), a Zoetis entity, and five other large companies alleging that waste sent to a local waste incineration facility for destruction, but that was not ultimately destroyed as the facility lost its operating permit, caused environmental impacts requiring cleanup. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Municipality is seeking recovery of cleanup costs purportedly related to FDSAL’s share of all waste accumulated at the incineration facility awaiting destruction, and compensatory damages to be allocated among the six defendants. We believe we have strong arguments against the claim, including defense strategies against any claim of joint and several liability. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At the request of the Municipal prosecutor, in April 2012, the lawsuit was suspended for one year. Since that time, the prosecutor has initiated investigations into the Municipality's actions in the matter as well as the efforts undertaken by the six defendants to remove and dispose of their individual waste from the incineration facility. On October 3, 2014, the Municipal prosecutor announced that the investigation remained ongoing and outlined the terms of a proposed Term of Reference (a document that establishes the minimum elements to be addressed in the preparation of an Environmental Impact Assessment), under which the companies would be liable to withdraw the waste and remediate the area. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On March 5, 2015, we presented our response to the prosecutor’s proposed Term of Reference, arguing that the proposed terms were overly general in nature and expressing our interest in discussing alternatives to address the matter. The prosecutor agreed to consider our request to engage a technical consultant to conduct an environmental diagnostic of the contaminated area. On May 29, 2015, we, in conjunction with the other defendant companies, submitted a draft cooperation agreement to the prosecutor, which outlined the proposed terms and conditions for the engagement of a technical consultant to conduct the environmental diagnostic. On August 19, 2016, the parties and the prosecutor agreed to engage the services of a third-party consultant to conduct a limited environmental assessment of the site. The site assessment was conducted during June 2017, and a written report summarizing the results of the assessment was provided to the parties and the prosecutor in November 2017. The report noted that waste is still present on the site and that further (Phase II) environmental assessments are needed before a plan to manage that remaining waste can be prepared. On April 1, 2019, the defendants met with the Prosecutor to discuss the conclusions set forth in the written report. Following that discussion, on April 10, 2019, the Prosecutor issued a procedural order requesting that the defendants prepare and submit a technical proposal outlining the steps needed to conduct the additional Phase II environmental assessments. The defendants presented the technical proposal to the Prosecutor on October 21, 2019. On March 3, 2020, the Prosecutor notified the defendants that he submitted the proposal to the Ministry of the Environment for its review and consideration by the Prosecutor. On July 15, 2020, the Prosecutor recommended certain amendments to the proposal for the Phase II testing. On September 28, 2020, the parties and the Prosecutor agreed to the final terms and conditions concerning the cooperation agreement with respect to the Phase II testing. Phase II testing began the week of October 14, 2024. The consultant will provide a report upon completion of the testing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">B. Guarantees and Indemnifications</span></div>In the ordinary course of business and in connection with the sale of assets and businesses, we indemnify our counterparties against certain liabilities that may arise in connection with the transaction or related to activities prior to the transaction. These indemnifications typically pertain to environmental, tax, employee and/or product-related matters and patent-infringement claims. If the indemnified party were to make a successful claim pursuant to the terms of the indemnification, we would be required to reimburse the loss. These indemnifications are generally subject to threshold amounts, specified claim periods and other restrictions and limitations. Historically, we have not paid significant amounts under these provisions and, as of September 30, 2024, recorded amounts for the estimated fair value of these indemnifications were not material. <div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">A. Legal Proceedings</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our non-tax contingencies include, among others, the following: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•    Product liability and other product-related litigation, which can include injury, consumer, off-label promotion, antitrust and breach of contract claims. </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•    Commercial and other matters, which can include product-pricing claims and environmental claims and proceedings. </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•    Patent litigation, which typically involves challenges to the coverage and/or validity of our patents or those of third parties on various products or processes. </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•    Government investigations, which can involve regulation by national, state and local government agencies in the U.S. and in other countries. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain of these contingencies could result in losses, including damages, fines and/or civil penalties, and/or criminal charges, which could be substantial. </span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We believe that we have strong defenses in these types of matters, but litigation is inherently unpredictable and excessive verdicts do occur. We do not believe that any of these matters will have a material adverse effect on our financial position. However, we could incur judgments, enter into settlements or revise our expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on our results of operations or cash flows in the period in which the amounts are paid.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We have accrued for losses that are both probable and reasonably estimable. Substantially all of these contingencies are subject to significant uncertainties and, therefore, determining the likelihood of a loss and/or the measurement of any loss can be complex. Consequently, we are unable to estimate the range of reasonably possible loss in excess of amounts accrued. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but the assessment process relies on estimates and assumptions that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions. </span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amounts recorded for legal and environmental contingencies can result from a complex series of judgments about future events and uncertainties and can rely on estimates and assumptions.</span></div>The principal matters to which we are a party are discussed below. In determining whether a pending matter is significant for financial reporting and disclosure purposes, we consider both quantitative and qualitative factors in order to assess materiality, such as, among other things, the amount of damages and the nature of any other relief sought in the proceeding, if such damages and other relief are specified; our view of the merits of the claims and of the strength of our defenses; whether the action purports to be a class action and our view of the likelihood that a class will be certified by the court; the jurisdiction in which the proceeding is pending; any experience that we or, to our knowledge, other companies have had in similar proceedings; whether disclosure of the action would be important to a reader of our financial statements, including whether disclosure might change a reader’s judgment about our financial statements in light of all of the information about the company that is available to the reader; the potential impact of the proceeding on our reputation; and the extent of public interest in the matter. In addition, with respect to patent matters, we consider, among other things, the financial significance of the product protected by the patent. 5 6 P1Y 6 <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">B. Guarantees and Indemnifications</span></div>In the ordinary course of business and in connection with the sale of assets and businesses, we indemnify our counterparties against certain liabilities that may arise in connection with the transaction or related to activities prior to the transaction. These indemnifications typically pertain to environmental, tax, employee and/or product-related matters and patent-infringement claims. If the indemnified party were to make a successful claim pursuant to the terms of the indemnification, we would be required to reimburse the loss. These indemnifications are generally subject to threshold amounts, specified claim periods and other restrictions and limitations. Historically, we have not paid significant amounts under these provisions and, as of September 30, 2024, recorded amounts for the estimated fair value of these indemnifications were not material. <div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">16. Segment Information </span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Operating Segments</span></div><div style="margin-bottom:6pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We manage our operations through two geographic operating segments: the U.S. and International. Each operating segment has responsibility for its commercial activities. Within each of these operating segments, we offer a diversified product portfolio, including parasiticides, vaccines, dermatology, anti-infectives</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> pain and sedation, other pharmaceutical, animal health diagnostics and medicated feed additives, for both companion animal and livestock customers. Our chief operating decision maker uses the revenue and earnings of the two operating segments, among other factors, for performance evaluation and resource allocation. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Other Costs and Business Activities </span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain costs are not allocated to our operating segment results, such as costs associated with the following: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other business activities, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">includes our Client Supply Services contract manufacturing results, our human health business, and expenses associated with our dedicated veterinary medicine research and development organization, research alliances, U.S. regulatory affairs and other operations focused on the development of our products. Other R&amp;D-related costs associated with non-U.S. market and regulatory activities are generally included in the international commercial segment. </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Corporate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, includes enabling functions such as information technology, facilities, legal, finance, human resources, business development, certain diagnostic costs and communications, among others. These costs also include certain compensation costs, certain procurement costs and other miscellaneous operating expenses not charged to our operating segments, as well as interest income and expense. </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Certain transactions and events such as (i) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Purchase accounting adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, where we incur expenses associated with the amortization of fair value adjustments to inventory, intangible assets and property, plant and equipment; (ii) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Acquisition and divestiture-related costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, where we incur costs associated with acquiring and integrating newly acquired businesses, such as transaction costs and integration costs, as well as divestiture-related costs; and (iii) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Certain significant items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, which comprise substantive, unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis, such as restructuring charges and implementation costs associated with our cost-reduction/productivity initiatives that are not associated with an acquisition or divestiture, certain asset impairment charges, certain legal and commercial settlements and the impact of divestiture-related gains and losses. </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.85pt">Other unallocated</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> includes (i) certain overhead expenses associated with our global manufacturing operations not charged to our operating segments; (ii) certain costs associated with finance that specifically support our global manufacturing operations; (iii) certain supply chain and global logistics costs; and (iv) certain procurement costs. </span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Segment Assets </span></div><div style="margin-bottom:6pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We manage our assets on a total company basis, not by operating segment. Therefore, our chief operating decision maker does not regularly review any asset information by operating segment and, accordingly, we do not report asset information by operating segment.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Selected Statement of Income Information</span></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.125%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and Amortization</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(MILLIONS OF DOLLARS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">U.S.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,346</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,174 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">258</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">228 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,088</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">946 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">    Gross margin</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">80.8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">199</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">202 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other (income)/deductions-net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Earnings</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">889</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">744 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">20</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">956 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">321</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">306 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">700</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">650 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">    Gross margin</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">68.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">157</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">156 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other (income)/deductions-net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International Earnings</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">542</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">493 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">25</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total operating segments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,431</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,237 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">45</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other business activities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(137)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(124)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reconciling Items:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt;padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(306)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(258)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">31</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt;padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase accounting adjustments</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">35</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt;padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition and divestiture-related costs</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt;padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certain significant items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt;padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other unallocated</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(71)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Earnings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">874</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">717 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">121</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">124 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">    Certain production facilities are shared. Depreciation and amortization is allocated to the reportable operating segments based on estimates of where the benefits of the related assets are realized. </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">    Revenue denominated in euros was $234 million and $206 million for the three months ended September 30, 2024 and 2023, respectively. </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">    For the three months ended September 30, 2023, primarily consisted of employee termination and exit costs related to organizational structure refinements and other cost-reduction and productivity initiatives, as well as certain asset impairment charges related to our diagnostics and precision animal health businesses. </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Defined as income before provision for taxes on income. </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.125%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and Amortization</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nine Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(MILLIONS OF DOLLARS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">U.S.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,817</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,344 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">707</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">645 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,110</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,699 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">    Gross margin</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">81.5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">593</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">602 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other (income)/deductions-net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Earnings</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,517</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,097 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">65</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,063</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,929 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">976</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">912 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,087</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,017 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">    Gross margin</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">68.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">491</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">473 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other (income)/deductions-net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International Earnings</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,595</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,543 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">73</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total operating segments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,112</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,640 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">138</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">125 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other business activities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(411)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(354)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">29</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reconciling Items:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt;padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(893)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(722)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">96</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt;padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase accounting adjustments</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(107)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(124)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">107</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">118 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt;padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition and divestiture-related costs</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt;padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certain significant items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(77)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt;padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other unallocated</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(211)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(191)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Earnings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,401</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,286 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">374</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">365 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">    Certain production facilities are shared. Depreciation and amortization is allocated to the reportable operating segments based on estimates of where the benefits of the related assets are realized. </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">    Revenue denominated in euros was $694 million and $627 million for the nine months ended September 30, 2024 and 2023, respectively. </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">    For the nine months ended September 30, 2024, primarily consisted of employee termination costs related to organizational structure refinements, a loss on assets held for sale related to the planned sale of our medicated feed additive product portfolio, certain water soluble products and related assets, as well as asset impairment charges related to our aquaculture business, partially offset by a reversal of certain employee termination costs as a result of a change in strategy from our 2015 operational efficiency initiative.</span></div><div style="margin-top:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2023, primarily consisted of a gain on the sale of a majority interest in our pet insurance business, partially offset by employee termination costs related to organizational structure refinements and certain asset impairment charges related to our precision animal health and diagnostics businesses. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)    </span>Defined as income before provision for taxes on income. <div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Operating Segments</span></div><div style="margin-bottom:6pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We manage our operations through two geographic operating segments: the U.S. and International. Each operating segment has responsibility for its commercial activities. Within each of these operating segments, we offer a diversified product portfolio, including parasiticides, vaccines, dermatology, anti-infectives</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> pain and sedation, other pharmaceutical, animal health diagnostics and medicated feed additives, for both companion animal and livestock customers. Our chief operating decision maker uses the revenue and earnings of the two operating segments, among other factors, for performance evaluation and resource allocation. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Other Costs and Business Activities </span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain costs are not allocated to our operating segment results, such as costs associated with the following: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other business activities, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">includes our Client Supply Services contract manufacturing results, our human health business, and expenses associated with our dedicated veterinary medicine research and development organization, research alliances, U.S. regulatory affairs and other operations focused on the development of our products. Other R&amp;D-related costs associated with non-U.S. market and regulatory activities are generally included in the international commercial segment. </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Corporate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, includes enabling functions such as information technology, facilities, legal, finance, human resources, business development, certain diagnostic costs and communications, among others. These costs also include certain compensation costs, certain procurement costs and other miscellaneous operating expenses not charged to our operating segments, as well as interest income and expense. </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Certain transactions and events such as (i) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Purchase accounting adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, where we incur expenses associated with the amortization of fair value adjustments to inventory, intangible assets and property, plant and equipment; (ii) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Acquisition and divestiture-related costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, where we incur costs associated with acquiring and integrating newly acquired businesses, such as transaction costs and integration costs, as well as divestiture-related costs; and (iii) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Certain significant items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, which comprise substantive, unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis, such as restructuring charges and implementation costs associated with our cost-reduction/productivity initiatives that are not associated with an acquisition or divestiture, certain asset impairment charges, certain legal and commercial settlements and the impact of divestiture-related gains and losses. </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.85pt">Other unallocated</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> includes (i) certain overhead expenses associated with our global manufacturing operations not charged to our operating segments; (ii) certain costs associated with finance that specifically support our global manufacturing operations; (iii) certain supply chain and global logistics costs; and (iv) certain procurement costs. </span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Segment Assets </span></div><div style="margin-bottom:6pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We manage our assets on a total company basis, not by operating segment. Therefore, our chief operating decision maker does not regularly review any asset information by operating segment and, accordingly, we do not report asset information by operating segment.</span></div> 2 2 <div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.125%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and Amortization</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(MILLIONS OF DOLLARS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">U.S.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,346</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,174 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">258</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">228 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,088</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">946 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">    Gross margin</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">80.8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">199</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">202 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other (income)/deductions-net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Earnings</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">889</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">744 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">20</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">956 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">321</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">306 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">700</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">650 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">    Gross margin</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">68.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">157</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">156 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other (income)/deductions-net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International Earnings</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">542</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">493 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">25</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total operating segments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,431</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,237 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">45</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other business activities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(137)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(124)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reconciling Items:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt;padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(306)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(258)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">31</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt;padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase accounting adjustments</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">35</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt;padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition and divestiture-related costs</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt;padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certain significant items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt;padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other unallocated</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(71)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Earnings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">874</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">717 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">121</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">124 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">    Certain production facilities are shared. Depreciation and amortization is allocated to the reportable operating segments based on estimates of where the benefits of the related assets are realized. </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">    Revenue denominated in euros was $234 million and $206 million for the three months ended September 30, 2024 and 2023, respectively. </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">    For the three months ended September 30, 2023, primarily consisted of employee termination and exit costs related to organizational structure refinements and other cost-reduction and productivity initiatives, as well as certain asset impairment charges related to our diagnostics and precision animal health businesses. </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Defined as income before provision for taxes on income. </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.125%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and Amortization</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nine Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(MILLIONS OF DOLLARS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">U.S.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,817</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,344 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">707</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">645 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,110</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,699 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">    Gross margin</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">81.5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">593</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">602 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other (income)/deductions-net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Earnings</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,517</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,097 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">65</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,063</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,929 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">976</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">912 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,087</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,017 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">    Gross margin</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">68.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">491</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">473 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other (income)/deductions-net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International Earnings</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,595</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,543 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">73</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total operating segments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,112</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,640 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">138</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">125 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other business activities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(411)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(354)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">29</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reconciling Items:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt;padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(893)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(722)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">96</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt;padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase accounting adjustments</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(107)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(124)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">107</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">118 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt;padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition and divestiture-related costs</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt;padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certain significant items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(77)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt;padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other unallocated</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(211)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(191)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Earnings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,401</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,286 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">374</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">365 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">    Certain production facilities are shared. Depreciation and amortization is allocated to the reportable operating segments based on estimates of where the benefits of the related assets are realized. </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">    Revenue denominated in euros was $694 million and $627 million for the nine months ended September 30, 2024 and 2023, respectively. </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">    For the nine months ended September 30, 2024, primarily consisted of employee termination costs related to organizational structure refinements, a loss on assets held for sale related to the planned sale of our medicated feed additive product portfolio, certain water soluble products and related assets, as well as asset impairment charges related to our aquaculture business, partially offset by a reversal of certain employee termination costs as a result of a change in strategy from our 2015 operational efficiency initiative.</span></div><div style="margin-top:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2023, primarily consisted of a gain on the sale of a majority interest in our pet insurance business, partially offset by employee termination costs related to organizational structure refinements and certain asset impairment charges related to our precision animal health and diagnostics businesses. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)    </span>Defined as income before provision for taxes on income. 1346000000 1174000000 258000000 228000000 1088000000 946000000 0.808 0.806 199000000 202000000 0 0 889000000 744000000 20000000 19000000 1021000000 956000000 321000000 306000000 700000000 650000000 0.686 0.680 157000000 156000000 -1000000 -1000000 542000000 493000000 25000000 24000000 1431000000 1237000000 45000000 43000000 -137000000 -124000000 9000000 9000000 -306000000 -258000000 31000000 33000000 -35000000 -39000000 35000000 39000000 -7000000 -3000000 0 0 -1000000 -23000000 0 0 -71000000 -73000000 1000000 0 874000000 717000000 121000000 124000000 234000000 206000000 3817000000 3344000000 707000000 645000000 3110000000 2699000000 0.815 0.807 593000000 602000000 0 0 2517000000 2097000000 65000000 58000000 3063000000 2929000000 976000000 912000000 2087000000 2017000000 0.681 0.689 491000000 473000000 -1000000 -1000000 1595000000 1543000000 73000000 67000000 4112000000 3640000000 138000000 125000000 -411000000 -354000000 29000000 24000000 -893000000 -722000000 96000000 95000000 -107000000 -124000000 107000000 118000000 -12000000 -8000000 0 0 -77000000 45000000 0 0 -211000000 -191000000 4000000 3000000 2401000000 2286000000 374000000 365000000 694000000 627000000 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">17. Subsequent Event </span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On October 31, 2024, we completed the divestiture of our medicated feed additive product portfolio, certain water soluble products and related as</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">sets. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">do not expect the closing of the divestiture to have </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">a material impact to our consolidated financial statements.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> See </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">N</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">ote 5. Acquisitions and Divestitures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> for additional information regarding the transaction.</span></div> false false false Kristin Peck, Chief Executive Officer, adopted a pre-arranged trading plan on September 12, 2024, that is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. Ms. Peck's plan provides for (i) the sale of up to 52,000 shares of Zoetis common stock between December 13, 2024 and December 31, 2025 and (ii) the gifting of up to $300,000 worth of Zoetis common stock to a charitable fund between December 13, 2024 and December 31, 2025. Kristin Peck Chief Executive Officer true September 12, 2024 52000 December 31, 2025 <div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Roxanne Lagano, Executive Vice President, General Counsel and Corporate Secretary, adopted a pre-arranged trading plan on September 13, 2024, that is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. Ms. Lagano’s plan provides for the sale of (i) between December 16, 2024 and December 16, 2025, up to 4,339 shares of Zoetis common stock and (ii) between February 11, 2025 and December 16, 2025, 100% of the net shares (net of tax withholding) resulting from the vesting of 4,858 gross shares of Zoetis common stock relating to equity awards, subject to certain conditions.</span></div> Roxanne Lagano Executive Vice President, General Counsel and Corporate Secretary true September 13, 2024 December 16, 2025 4339 December 16, 2025 4858 Presented net of reclassification adjustments, which are not material in any period presented. As of September 30, 2024 and December 31, 2023, includes $4 million and $2 million of restricted cash, respectively. Includes the issuance of shares of Zoetis Inc. common stock and the reacquisition of shares of treasury stock associated with exercises of employee share-based awards. Also includes the reacquisition of shares of treasury stock associated with the vesting of employee share-based awards to satisfy tax withholding requirements. For additional information, see Note 12. Share-based Payments and Note 13. Stockholders’ Equity. Reflects the acquisition of treasury shares in connection with the share repurchase program and includes excise tax accrued on net share repurchases. For additional information, see Note 13. Stockholders’ Equity. Includes the issuance of shares of Zoetis Inc. common stock and the reacquisition of shares of treasury stock associated with exercises of employee share-based awards. Also includes the reacquisition of shares of treasury stock associated with the vesting of employee share-based awards to satisfy tax withholding requirements. For additional information, see Note 12. Share-based Payments and Note 13. Stockholders’ Equity. Reflects the acquisition of treasury shares in connection with the share repurchase program and includes excise tax accrued on net share repurchases. For additional information, see Note 13. Stockholders’ Equity. (3) At September 30, 2024 and December 31, 2023, included in Accrued expenses ($44 million and $26 million, respectively) and Other noncurrent liabilities ($2 million and $9 million, respectively). Includes adjustments for foreign currency translation. $24 million to Assets held for sale related to the planned sale of our medicated feed additive product portfolio, certain water soluble products and related assets, as well as foreign currency translation. For additional information, see Note 5. Acquisitions and Divestitures: B. Divestitures. For the three and nine months ended September 30, 2024 and 2023, we capitalized less than $1 million of share-based compensation expense to inventory Certain production facilities are shared. Depreciation and amortization is allocated to the reportable operating segments based on estimates of where the benefits of the related assets are realized. Revenue denominated in euros was $694 million and $627 million for the nine months ended September 30, 2024 and 2023, respectively. For the nine months ended September 30, 2023, primarily consisted of a gain on the sale of a majority interest in our pet insurance business, partially offset by employee termination costs related to organizational structure refinements and certain asset impairment charges related to our precision animal health and diagnostics businesses. Defined as income before provision for taxes on income.